ItemId_x,Title_x,Journal,ShortTitle_x,Year,Reference,Study_Author,Study_NR,Study_Unclear,Study_Year of publication,Study_NR,Study_Country,Study_NR,Study_Unclear,Study_Sponsorship Source,Study_NR,Study_Protocol or trial registration ID,Study_NR,Study_Unclear,Study_Parallel RCT,Study_2,Study_3,Study_4,Study_Double,Study_Blinding outcome assessor,Study_Blinding investigator,Study_NR,Study_Unclear,Study_Community,Study_Primary Care,Study_Secondary/Tertiary Care,Study_Inpatient,Study_Outpatient,Study_NR,Study_Unclear,Study_Inclusion Criteria,Study_Unclear,Study_Exclusion Criteria,Study_NR,Study_Unclear,Study_Mean Age,Study_NR,Study_Unclear,Study_N participants,Study_N females,Study_NR,Study_Unclear,Study_Race,Study_NR,Study_Unclear,Study_Condition of interest,Study_Comorbidities,Study_NR,Study_Unclear,Study_Other concomitant medications ,Study_NR,Study_Unclear,Study_Bupropion,Study_Isocarboxazid,Study_Minaprine,Study_Moclobemide,Study_Phenelzine,Study_Placebo,Study_Selegiline,Study_MADRS,Study_HRSD,Study_HAM-D,Study_Dropouts,Study_N dropouts (any reason),Study_NR,Study_Unclear,Study_N dropouts (adverse events),Study_NR,Study_Anhedonia,Study_Acceptability,Study_Tolerability,Study_Safety,Study_Dose flexible,Study_Oral,Study_*HAM-A,Study_*Sheehan Disability Scale,Study_*QLES-Q General Activities,Study_*Motivation and Energy Inventory,Study_*CSFQ Total,Study_*Bupropion XR,"Study_*Zung - ""anhedonia""",Study_*bupropion SR,Study_*Anxiety,Study_AE details,Study_Min,Study_Mean,Study_Max,Study_Treatment duration,Study_Min,Study_Max,Study_Year of study completion,Study_NR,Study_Unclear,Study_Study length,Study_NR,Study_Unclear,Study_NR,Study_NR,Study_NR,Study_Number of administration,Study_*CGIS,Study_*Dextromethorphan=Bupropion,Study_SAE details,Study_NR,Study_NR,Study_Unclear,Study_*CGI-C,Study_*CGI-I,Study_HSC - anxiety scale,Study_*5,Study_Study IDs,Study_Age (dispersion),Study_SD,Study_Range,Study_NR,Study_N reporting AEs,Study_NR,Study_Unclear,Study_N reporting SAEs,Study_NR,Study_*SRT Anxiety Subscale,Study_*NPRL - anxiety,ArmId,ArmTitle,Arm_Double,Arm_Blinding care provider,Arm_Blinding investigator,Arm_NR,Arm_Mean Age,Arm_NR,Arm_Unclear,Arm_N participants,Arm_NR,Arm_Unclear,Arm_N females,Arm_NR,Arm_Unclear,Arm_Race,Arm_NR,Arm_Condition of interest,Arm_Comorbidities,Arm_NR,Arm_Unclear,Arm_Other concomitant medications ,Arm_NR,Arm_Unclear,Arm_Bupropion,Arm_Isocarboxazid,Arm_Memantine,Arm_Methyphenidate,Arm_Minaprine,Arm_Moclobemide,Arm_Phenelzine,Arm_Placebo,Arm_Pramipexole,Arm_Ropinirole,Arm_Selegiline,Arm_Tranylcypromine,Arm_MADRS,Arm_BDI,Arm_HRSD,Arm_CDRS-R,Arm_HAM-D,Arm_Dropouts,Arm_N dropouts (any reason),Arm_NR,Arm_Unclear,Arm_N dropouts (adverse events),Arm_NR,Arm_Unclear,Arm_Anhedonia,Arm_Acceptability,Arm_Tolerability,Arm_Safety,Arm_Dose fixed,Arm_Dose flexible,Arm_Unclear,Arm_Oral,Arm_Transdermal,Arm_*HAM-A,Arm_*Motivation and Energy Inventory,Arm_*Bupropion XR,13685899,Arm_IDS-IVR-30 (energy/pleasure/interest),Arm_IDS-C-30 (energy/pleasure/interest),Arm_*bupropion SR,Arm_*MASQ Anhedonia,Arm_*MASQ - anxiety ,Arm_IDS-IVR-30 (anxiety),Arm_IDS-C-30 (anxiety),Arm_*Anxiety,Arm_AE details,Arm_*RX-10100,Arm_Min,Arm_Mean,Arm_Max,Arm_Treatment duration,Arm_Min,Arm_Max,Arm_NR,Arm_NR,Arm_NR,Arm_Unclear,Arm_NR,Arm_Unclear,Arm_NR,Arm_Unclear,Arm_NR,Arm_Unclear,Arm_NR,Arm_Unclear,Arm_Number of administration,Arm_Unclear,Arm_NR,Arm_Unclear,Arm_*CGIS,Arm_*SCL-58 Anxiety subscale,Arm_*SCL-90 Anxiety subscale,Arm_*Covi Anxiety Scale Total,Arm_*Dextromethorphan=Bupropion,Arm_*Motivation and Energy Inventory (MEI),Arm_SAE details,Arm_NR,Arm_Unclear,Arm_NR,Arm_Unclear,Arm_SHID - anxiety total subscale,Arm_SHID - psychic anxiety item,Arm_SHID - situational anxiety item,Arm_SHID - somatic anxiety item,Arm_*HRSD - psychic anxiety item,Arm_*GSK372475,Arm_*CGI-I,Arm_Zung SAS ,Arm_*HAMD-21 Anxiety/Somatization Item,Arm_Age (dispersion),Arm_SD,Arm_Range,Arm_NR,Arm_Unclear,Arm_N reporting AEs,Arm_NR,Arm_Unclear,Arm_N reporting SAEs,Arm_NR,Arm_Unclear,Arm_Amitifadine,Arm_MADRS Anhedonia factor,Arm_*Covi Anxiety Scale Verbal,Arm_*Covi Anxiety Scale Somatic,Arm_HAMD- Anxiety item,Arm_*Brofaromine,Arm_*HRSD - somatic anxiety item,Arm_MADRS anhedonia item,ItemId_y,OutcomeTypeName,OutcomeId,ItemSetId,OutcomeTypeId,ItemAttributeIdIntervention,ItemAttributeIdControl,ItemAttributeIdOutcome,Title_y,ItemTimepointId,ItemTimepointMetric,ItemTimepointValue,TimepointDisplayValue,ItemArmIdGrp1,ItemArmIdGrp2,grp1ArmName,grp2ArmName,ShortTitle_y,OutcomeDescription,Participant_N,Mean,SD / SE / CI lower,CI upper,InterventionText,OutcomeText
87999335,Monoamine oxidase inhibitors in the treatment of atypical depression.,Journal of clinical psychopharmacology,Zisook (1985),1985,"Zisook S, Braff D L, and Click M A (1985) Monoamine oxidase inhibitors in the treatment of atypical depression.. Journal of clinical psychopharmacology 5(3), 131-7",Zisook,na,na,1985,na,tick,na,tick,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,tick,na,na,na,na,tick,na,tick,na,tick,"First, patients were clinically diagnosed by the principal investigator as suffering from nonmelancholic depression with concomitant anxiety and somatic symptoms. Additionally patients met Research Diagnostic Critiera (RDC) for major or minor depression/ The depression, lasting at least 1 month, was of moderate or greater severity as reflected by a minimum baseline score of 20 on the Hamilton DEpression Scale. The anxiety was also of moderate or greater severity as reflected by a minium baseline score of 8 on the covi anxiety scale (a three dimensional clinical rating of verbal report behaviour and somatic complaints on 5 point scale), with a score of at least 3 on it's somatic factor. Patients diagnosed as suffering from panic attacks were considered suitable for inclusion provided they also met the depression criteria.",na,tick,na,tick,tick,tick,na,69.00,55.00,na,na,"White 37.00
Black 27.00
Mexican-American 6.00",na,na,"First, patients were clinically diagnosed by the principal investigator as suffering from nonmelancholic depression with concomitant anxiety and somatic symptoms. Additionally patients met Research Diagnostic Critiera (RDC) for major or minor depression/ The depression, lasting at least 1 month",tick,na,tick,tick,na,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,6 weeks,na,na,tick,tick,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Zisook, 1985",na,na,na,na,na,na,na,na,na,na,na,37200,isocarboxazid,na,tick,tick,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,39.00mg,tick,6 weeks,tick,80mg,na,na,na,tick,na,na,tick,na,na,na,tick,na,2 per day,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999335,Monoamine oxidase inhibitors in the treatment of atypical depression.,Journal of clinical psychopharmacology,Zisook (1985),1985,"Zisook S, Braff D L, and Click M A (1985) Monoamine oxidase inhibitors in the treatment of atypical depression.. Journal of clinical psychopharmacology 5(3), 131-7",Zisook,na,na,1985,na,tick,na,tick,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,tick,na,na,na,na,tick,na,tick,na,tick,"First, patients were clinically diagnosed by the principal investigator as suffering from nonmelancholic depression with concomitant anxiety and somatic symptoms. Additionally patients met Research Diagnostic Critiera (RDC) for major or minor depression/ The depression, lasting at least 1 month, was of moderate or greater severity as reflected by a minimum baseline score of 20 on the Hamilton DEpression Scale. The anxiety was also of moderate or greater severity as reflected by a minium baseline score of 8 on the covi anxiety scale (a three dimensional clinical rating of verbal report behaviour and somatic complaints on 5 point scale), with a score of at least 3 on it's somatic factor. Patients diagnosed as suffering from panic attacks were considered suitable for inclusion provided they also met the depression criteria.",na,tick,na,tick,tick,tick,na,69.00,55.00,na,na,"White 37.00
Black 27.00
Mexican-American 6.00",na,na,"First, patients were clinically diagnosed by the principal investigator as suffering from nonmelancholic depression with concomitant anxiety and somatic symptoms. Additionally patients met Research Diagnostic Critiera (RDC) for major or minor depression/ The depression, lasting at least 1 month",tick,na,tick,tick,na,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,6 weeks,na,na,tick,tick,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Zisook, 1985",na,na,na,na,na,na,na,na,na,na,na,37201,Placebo ,na,na,tick,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87998230,"A double-blind, placebo-controlled study of memantine in the treatment of major depression.",The American journal of psychiatry,Zarate (2006),2006,"Zarate Carlos A Jr, Singh Jaskaran B, Quiroz Jorge A, De Jesus Georgette, Denicoff Kirk K, Luckenbaugh David A, Manji Husseini K, and Charney Dennis S (2006) A double-blind, placebo-controlled study of memantine in the treatment of major depression.. The American journal of psychiatry 163(1), 153-5","[{'ItemDocumentId': 1081951, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Zarate[¬e]""', 'IsFromPDF': True, 'DocTitle': 'zarate-et-al-2006-a-double-blind-placebo-controlled-study-of-memantine-in-the-treatment-of-major-depression (1).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1081951, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'zarate-et-al-2006-a-double-blind-placebo-controlled-study-of-memantine-in-the-treatment-of-major-depression (1).pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1081951, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Men and women 18 to 80 years old who were outpatients with a diagnosis of\nmajor depressive disorder, recurrent, without psychotic features, diagnosed\naccording to the Structured Clinical Interview for DSM-IV Axis I Disorders,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'zarate-et-al-2006-a-double-blind-placebo-controlled-study-of-memantine-in-the-treatment-of-major-depression (1).pdf', 'ItemArm': ''}, {'ItemDocumentId': 1081951, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""free of comorbid substance\nabuse or dependence for 3 months, were free of acute medical illnesses[¬e]""', 'IsFromPDF': True, 'DocTitle': 'zarate-et-al-2006-a-double-blind-placebo-controlled-study-of-memantine-in-the-treatment-of-major-depression (1).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1081951, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""judged clinically not to be at serious risk for suicide[¬e]""', 'IsFromPDF': True, 'DocTitle': 'zarate-et-al-2006-a-double-blind-placebo-controlled-study-of-memantine-in-the-treatment-of-major-depression (1).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,Comorbid anxiety disorder diagnosis were permitted,na,na,Zolpidem 5-10mg/day max 3x/week,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Zarate, 2006",na,na,na,na,na,na,na,na,na,na,na,37448,Memantine,na,na,na,na,47.1,na,na,16,na,na,9,na,na,tick,tick,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,3,na,na,1,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,tick,na,5mg,19.4mg,20mg,8 weeks,5mg,20mg,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,12.3,na,na,na,tick,na,na,tick,tick,na,na,na,na,na,na,na,na,na,87998230.0,Continuous,109606.0,114138687.0,5.0,13669965.0,0.0,13671957.0,HAM-A,1979.0,weeks,8,8 weeks,37448.0,37449.0,Memantine,Placebo,Zarate (2006),P value reported;F not T,13.0,0.42,0.0,0.0,Memantine,*HAM-A
87998230,"A double-blind, placebo-controlled study of memantine in the treatment of major depression.",The American journal of psychiatry,Zarate (2006),2006,"Zarate Carlos A Jr, Singh Jaskaran B, Quiroz Jorge A, De Jesus Georgette, Denicoff Kirk K, Luckenbaugh David A, Manji Husseini K, and Charney Dennis S (2006) A double-blind, placebo-controlled study of memantine in the treatment of major depression.. The American journal of psychiatry 163(1), 153-5","[{'ItemDocumentId': 1081951, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Zarate[¬e]""', 'IsFromPDF': True, 'DocTitle': 'zarate-et-al-2006-a-double-blind-placebo-controlled-study-of-memantine-in-the-treatment-of-major-depression (1).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1081951, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'zarate-et-al-2006-a-double-blind-placebo-controlled-study-of-memantine-in-the-treatment-of-major-depression (1).pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1081951, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Men and women 18 to 80 years old who were outpatients with a diagnosis of\nmajor depressive disorder, recurrent, without psychotic features, diagnosed\naccording to the Structured Clinical Interview for DSM-IV Axis I Disorders,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'zarate-et-al-2006-a-double-blind-placebo-controlled-study-of-memantine-in-the-treatment-of-major-depression (1).pdf', 'ItemArm': ''}, {'ItemDocumentId': 1081951, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""free of comorbid substance\nabuse or dependence for 3 months, were free of acute medical illnesses[¬e]""', 'IsFromPDF': True, 'DocTitle': 'zarate-et-al-2006-a-double-blind-placebo-controlled-study-of-memantine-in-the-treatment-of-major-depression (1).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1081951, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""judged clinically not to be at serious risk for suicide[¬e]""', 'IsFromPDF': True, 'DocTitle': 'zarate-et-al-2006-a-double-blind-placebo-controlled-study-of-memantine-in-the-treatment-of-major-depression (1).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,Comorbid anxiety disorder diagnosis were permitted,na,na,Zolpidem 5-10mg/day max 3x/week,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Zarate, 2006",na,na,na,na,na,na,na,na,na,na,na,37449,Placebo,na,na,na,na,46.1,na,na,16,na,na,7,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,3,na,na,1,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,9.4,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999366,Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.,Psychopharmacology,White (1984),1984,"White K, Razani J, Cadow B, Gelfand R, Palmer R, Simpson G, and Sloane R B (1984) Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.. Psychopharmacology 82(3), 258-62","[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""White[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""For inclusion, such patients were required to\nmeet Research Diagnostic Criteria (Spitzer et al. 1977) for\nmajor depressive disorder, confirmed in independent in-\nterviews by two clinicians, generally a psychologist and a\npsychiatrist.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included history of schizo-\nphrenia, cerebral dysfunction, glaucoma, urinary retention,\nhyperthyroidism, diabetes, asthma, cardiovascular disease,\nhypertension, pheochromocytoma, or liver disease.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,37,na,na,183,55,na,na,tick,tick,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depressive disorder,""\n""Patients were classified as ""endogenous"" or ""nonen-\ndogenous"" according to whether or not they met Research\nDiagnostic Criteria for the endogenous subtype of major\ndepressive disorder.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",Exclude majority,tick,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""At the point of starting\ntreatment with study medications, all patients were free of\nother psychotherapeutic drugs for at least 1 week; only\nhypnotics, analgesics, or antihistamines could be concur-\nrently administered during the trial.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,White 1984,tick,na,na,tick,na,na,na,na,na,na,tick,37176,tranylcypromine,na,na,na,na,38,na,na,63,na,na,14,na,na,tick,tick,"Depression: 
Endogenous=10
Nonendogenous=27",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,26,na,na,12,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Dizziness=24;
Sedation=14;
Insomnia=20;
Dry Mouth=26;
Constipation=5;
Blurred vision=5;
Confusion=1;
Headache=11;
Overexcitement=9;
Tremor=4",na,tick,44.4mg,tick,4,30mg,60mg,na,na,na,na,na,na,tick,na,na,na,tick,na,between 2 to 6 capsules per day,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,37,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999366.0,Continuous,109195.0,113308475.0,1.0,13669985.0,0.0,13687027.0,Zung anhedonia,1803.0,weeks,0,0 weeks,37176.0,0.0,tranylcypromine,,White (1984),,37.0,99999.0,99999.0,0.0,Tranylcypromine,"*Zung - ""anhedonia"""
87999366,Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.,Psychopharmacology,White (1984),1984,"White K, Razani J, Cadow B, Gelfand R, Palmer R, Simpson G, and Sloane R B (1984) Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.. Psychopharmacology 82(3), 258-62","[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""White[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""For inclusion, such patients were required to\nmeet Research Diagnostic Criteria (Spitzer et al. 1977) for\nmajor depressive disorder, confirmed in independent in-\nterviews by two clinicians, generally a psychologist and a\npsychiatrist.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included history of schizo-\nphrenia, cerebral dysfunction, glaucoma, urinary retention,\nhyperthyroidism, diabetes, asthma, cardiovascular disease,\nhypertension, pheochromocytoma, or liver disease.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,37,na,na,183,55,na,na,tick,tick,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depressive disorder,""\n""Patients were classified as ""endogenous"" or ""nonen-\ndogenous"" according to whether or not they met Research\nDiagnostic Criteria for the endogenous subtype of major\ndepressive disorder.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",Exclude majority,tick,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""At the point of starting\ntreatment with study medications, all patients were free of\nother psychotherapeutic drugs for at least 1 week; only\nhypnotics, analgesics, or antihistamines could be concur-\nrently administered during the trial.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,White 1984,tick,na,na,tick,na,na,na,na,na,na,tick,37176,tranylcypromine,na,na,na,na,38,na,na,63,na,na,14,na,na,tick,tick,"Depression: 
Endogenous=10
Nonendogenous=27",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,26,na,na,12,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Dizziness=24;
Sedation=14;
Insomnia=20;
Dry Mouth=26;
Constipation=5;
Blurred vision=5;
Confusion=1;
Headache=11;
Overexcitement=9;
Tremor=4",na,tick,44.4mg,tick,4,30mg,60mg,na,na,na,na,na,na,tick,na,na,na,tick,na,between 2 to 6 capsules per day,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,37,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999366.0,Continuous,109196.0,113308475.0,1.0,13669985.0,0.0,13687027.0,Zung anhedonia,1804.0,weeks,4,4 weeks,37176.0,0.0,tranylcypromine,,White (1984),,37.0,99999.0,99999.0,0.0,Tranylcypromine,"*Zung - ""anhedonia"""
87999366,Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.,Psychopharmacology,White (1984),1984,"White K, Razani J, Cadow B, Gelfand R, Palmer R, Simpson G, and Sloane R B (1984) Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.. Psychopharmacology 82(3), 258-62","[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""White[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""For inclusion, such patients were required to\nmeet Research Diagnostic Criteria (Spitzer et al. 1977) for\nmajor depressive disorder, confirmed in independent in-\nterviews by two clinicians, generally a psychologist and a\npsychiatrist.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included history of schizo-\nphrenia, cerebral dysfunction, glaucoma, urinary retention,\nhyperthyroidism, diabetes, asthma, cardiovascular disease,\nhypertension, pheochromocytoma, or liver disease.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,37,na,na,183,55,na,na,tick,tick,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depressive disorder,""\n""Patients were classified as ""endogenous"" or ""nonen-\ndogenous"" according to whether or not they met Research\nDiagnostic Criteria for the endogenous subtype of major\ndepressive disorder.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",Exclude majority,tick,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""At the point of starting\ntreatment with study medications, all patients were free of\nother psychotherapeutic drugs for at least 1 week; only\nhypnotics, analgesics, or antihistamines could be concur-\nrently administered during the trial.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,White 1984,tick,na,na,tick,na,na,na,na,na,na,tick,37176,tranylcypromine,na,na,na,na,38,na,na,63,na,na,14,na,na,tick,tick,"Depression: 
Endogenous=10
Nonendogenous=27",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,26,na,na,12,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Dizziness=24;
Sedation=14;
Insomnia=20;
Dry Mouth=26;
Constipation=5;
Blurred vision=5;
Confusion=1;
Headache=11;
Overexcitement=9;
Tremor=4",na,tick,44.4mg,tick,4,30mg,60mg,na,na,na,na,na,na,tick,na,na,na,tick,na,between 2 to 6 capsules per day,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,37,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999366.0,Continuous,109202.0,113308475.0,1.0,13669985.0,0.0,13794252.0,NPRL anxiety,1803.0,weeks,0,0 weeks,37176.0,0.0,tranylcypromine,,White (1984),,37.0,99999.0,99999.0,0.0,Tranylcypromine,*NPRL - anxiety
87999366,Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.,Psychopharmacology,White (1984),1984,"White K, Razani J, Cadow B, Gelfand R, Palmer R, Simpson G, and Sloane R B (1984) Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.. Psychopharmacology 82(3), 258-62","[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""White[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""For inclusion, such patients were required to\nmeet Research Diagnostic Criteria (Spitzer et al. 1977) for\nmajor depressive disorder, confirmed in independent in-\nterviews by two clinicians, generally a psychologist and a\npsychiatrist.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included history of schizo-\nphrenia, cerebral dysfunction, glaucoma, urinary retention,\nhyperthyroidism, diabetes, asthma, cardiovascular disease,\nhypertension, pheochromocytoma, or liver disease.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,37,na,na,183,55,na,na,tick,tick,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depressive disorder,""\n""Patients were classified as ""endogenous"" or ""nonen-\ndogenous"" according to whether or not they met Research\nDiagnostic Criteria for the endogenous subtype of major\ndepressive disorder.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",Exclude majority,tick,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""At the point of starting\ntreatment with study medications, all patients were free of\nother psychotherapeutic drugs for at least 1 week; only\nhypnotics, analgesics, or antihistamines could be concur-\nrently administered during the trial.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,White 1984,tick,na,na,tick,na,na,na,na,na,na,tick,37176,tranylcypromine,na,na,na,na,38,na,na,63,na,na,14,na,na,tick,tick,"Depression: 
Endogenous=10
Nonendogenous=27",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,26,na,na,12,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Dizziness=24;
Sedation=14;
Insomnia=20;
Dry Mouth=26;
Constipation=5;
Blurred vision=5;
Confusion=1;
Headache=11;
Overexcitement=9;
Tremor=4",na,tick,44.4mg,tick,4,30mg,60mg,na,na,na,na,na,na,tick,na,na,na,tick,na,between 2 to 6 capsules per day,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,37,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999366.0,Continuous,109203.0,113308475.0,1.0,13669985.0,0.0,13794252.0,NPRL anxiety,1804.0,weeks,4,4 weeks,37176.0,0.0,tranylcypromine,,White (1984),,37.0,99999.0,99999.0,0.0,Tranylcypromine,*NPRL - anxiety
87999366,Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.,Psychopharmacology,White (1984),1984,"White K, Razani J, Cadow B, Gelfand R, Palmer R, Simpson G, and Sloane R B (1984) Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.. Psychopharmacology 82(3), 258-62","[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""White[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""For inclusion, such patients were required to\nmeet Research Diagnostic Criteria (Spitzer et al. 1977) for\nmajor depressive disorder, confirmed in independent in-\nterviews by two clinicians, generally a psychologist and a\npsychiatrist.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included history of schizo-\nphrenia, cerebral dysfunction, glaucoma, urinary retention,\nhyperthyroidism, diabetes, asthma, cardiovascular disease,\nhypertension, pheochromocytoma, or liver disease.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,37,na,na,183,55,na,na,tick,tick,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depressive disorder,""\n""Patients were classified as ""endogenous"" or ""nonen-\ndogenous"" according to whether or not they met Research\nDiagnostic Criteria for the endogenous subtype of major\ndepressive disorder.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",Exclude majority,tick,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""At the point of starting\ntreatment with study medications, all patients were free of\nother psychotherapeutic drugs for at least 1 week; only\nhypnotics, analgesics, or antihistamines could be concur-\nrently administered during the trial.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,White 1984,tick,na,na,tick,na,na,na,na,na,na,tick,37177,nortriptyline,na,na,na,na,35,na,na,61,na,na,20,na,na,tick,tick,"Depression: 
Endogenous=6
Nonendogenous=34",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999366,Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.,Psychopharmacology,White (1984),1984,"White K, Razani J, Cadow B, Gelfand R, Palmer R, Simpson G, and Sloane R B (1984) Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.. Psychopharmacology 82(3), 258-62","[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""White[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""For inclusion, such patients were required to\nmeet Research Diagnostic Criteria (Spitzer et al. 1977) for\nmajor depressive disorder, confirmed in independent in-\nterviews by two clinicians, generally a psychologist and a\npsychiatrist.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included history of schizo-\nphrenia, cerebral dysfunction, glaucoma, urinary retention,\nhyperthyroidism, diabetes, asthma, cardiovascular disease,\nhypertension, pheochromocytoma, or liver disease.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,37,na,na,183,55,na,na,tick,tick,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depressive disorder,""\n""Patients were classified as ""endogenous"" or ""nonen-\ndogenous"" according to whether or not they met Research\nDiagnostic Criteria for the endogenous subtype of major\ndepressive disorder.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",Exclude majority,tick,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""At the point of starting\ntreatment with study medications, all patients were free of\nother psychotherapeutic drugs for at least 1 week; only\nhypnotics, analgesics, or antihistamines could be concur-\nrently administered during the trial.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,White 1984,tick,na,na,tick,na,na,na,na,na,na,tick,37178,placebo,na,na,na,na,39,na,na,59,na,na,21,na,na,tick,tick,"Depression: 
Endogenous=8
Nonendogenous=37",na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,14,na,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Dizziness=6;
Sedation=11;
Insomnia=4;
Dry Mouth=9;
Constipation=3;
Blurred vision=3;
Confusion=1;
Headache=8;
Overexcitement=3;
Tremor=1",na,na,na,na,4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,between 2 to 6 capsules per day,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999366.0,Continuous,109192.0,113308475.0,1.0,13669974.0,0.0,13687027.0,Zung anhedonia,1803.0,weeks,0,0 weeks,37178.0,0.0,placebo,,White (1984),,40.0,99999.0,99999.0,0.0,Placebo,"*Zung - ""anhedonia"""
87999366,Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.,Psychopharmacology,White (1984),1984,"White K, Razani J, Cadow B, Gelfand R, Palmer R, Simpson G, and Sloane R B (1984) Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.. Psychopharmacology 82(3), 258-62","[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""White[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""For inclusion, such patients were required to\nmeet Research Diagnostic Criteria (Spitzer et al. 1977) for\nmajor depressive disorder, confirmed in independent in-\nterviews by two clinicians, generally a psychologist and a\npsychiatrist.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included history of schizo-\nphrenia, cerebral dysfunction, glaucoma, urinary retention,\nhyperthyroidism, diabetes, asthma, cardiovascular disease,\nhypertension, pheochromocytoma, or liver disease.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,37,na,na,183,55,na,na,tick,tick,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depressive disorder,""\n""Patients were classified as ""endogenous"" or ""nonen-\ndogenous"" according to whether or not they met Research\nDiagnostic Criteria for the endogenous subtype of major\ndepressive disorder.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",Exclude majority,tick,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""At the point of starting\ntreatment with study medications, all patients were free of\nother psychotherapeutic drugs for at least 1 week; only\nhypnotics, analgesics, or antihistamines could be concur-\nrently administered during the trial.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,White 1984,tick,na,na,tick,na,na,na,na,na,na,tick,37178,placebo,na,na,na,na,39,na,na,59,na,na,21,na,na,tick,tick,"Depression: 
Endogenous=8
Nonendogenous=37",na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,14,na,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Dizziness=6;
Sedation=11;
Insomnia=4;
Dry Mouth=9;
Constipation=3;
Blurred vision=3;
Confusion=1;
Headache=8;
Overexcitement=3;
Tremor=1",na,na,na,na,4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,between 2 to 6 capsules per day,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999366.0,Continuous,109193.0,113308475.0,1.0,13669974.0,0.0,13687027.0,Zung anhedonia,1804.0,weeks,4,4 weeks,37178.0,0.0,placebo,,White (1984),,40.0,99999.0,99999.0,0.0,Placebo,"*Zung - ""anhedonia"""
87999366,Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.,Psychopharmacology,White (1984),1984,"White K, Razani J, Cadow B, Gelfand R, Palmer R, Simpson G, and Sloane R B (1984) Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.. Psychopharmacology 82(3), 258-62","[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""White[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""For inclusion, such patients were required to\nmeet Research Diagnostic Criteria (Spitzer et al. 1977) for\nmajor depressive disorder, confirmed in independent in-\nterviews by two clinicians, generally a psychologist and a\npsychiatrist.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included history of schizo-\nphrenia, cerebral dysfunction, glaucoma, urinary retention,\nhyperthyroidism, diabetes, asthma, cardiovascular disease,\nhypertension, pheochromocytoma, or liver disease.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,37,na,na,183,55,na,na,tick,tick,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depressive disorder,""\n""Patients were classified as ""endogenous"" or ""nonen-\ndogenous"" according to whether or not they met Research\nDiagnostic Criteria for the endogenous subtype of major\ndepressive disorder.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",Exclude majority,tick,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""At the point of starting\ntreatment with study medications, all patients were free of\nother psychotherapeutic drugs for at least 1 week; only\nhypnotics, analgesics, or antihistamines could be concur-\nrently administered during the trial.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,White 1984,tick,na,na,tick,na,na,na,na,na,na,tick,37178,placebo,na,na,na,na,39,na,na,59,na,na,21,na,na,tick,tick,"Depression: 
Endogenous=8
Nonendogenous=37",na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,14,na,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Dizziness=6;
Sedation=11;
Insomnia=4;
Dry Mouth=9;
Constipation=3;
Blurred vision=3;
Confusion=1;
Headache=8;
Overexcitement=3;
Tremor=1",na,na,na,na,4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,between 2 to 6 capsules per day,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999366.0,Continuous,109198.0,113308475.0,1.0,13669974.0,0.0,13794252.0,NPRL anxiety,1803.0,weeks,0,0 weeks,37178.0,0.0,placebo,,White (1984),,40.0,99999.0,99999.0,0.0,Placebo,*NPRL - anxiety
87999366,Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.,Psychopharmacology,White (1984),1984,"White K, Razani J, Cadow B, Gelfand R, Palmer R, Simpson G, and Sloane R B (1984) Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial.. Psychopharmacology 82(3), 258-62","[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""White[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""For inclusion, such patients were required to\nmeet Research Diagnostic Criteria (Spitzer et al. 1977) for\nmajor depressive disorder, confirmed in independent in-\nterviews by two clinicians, generally a psychologist and a\npsychiatrist.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included history of schizo-\nphrenia, cerebral dysfunction, glaucoma, urinary retention,\nhyperthyroidism, diabetes, asthma, cardiovascular disease,\nhypertension, pheochromocytoma, or liver disease.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",na,na,37,na,na,183,55,na,na,tick,tick,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depressive disorder,""\n""Patients were classified as ""endogenous"" or ""nonen-\ndogenous"" according to whether or not they met Research\nDiagnostic Criteria for the endogenous subtype of major\ndepressive disorder.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",Exclude majority,tick,na,"[{'ItemDocumentId': 1050792, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""At the point of starting\ntreatment with study medications, all patients were free of\nother psychotherapeutic drugs for at least 1 week; only\nhypnotics, analgesics, or antihistamines could be concur-\nrently administered during the trial.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'White K et al. - 1984 - Tranylcypromine vs nortriptyline vs placebo in dep.pdf', 'ItemArm': ''}]",tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,White 1984,tick,na,na,tick,na,na,na,na,na,na,tick,37178,placebo,na,na,na,na,39,na,na,59,na,na,21,na,na,tick,tick,"Depression: 
Endogenous=8
Nonendogenous=37",na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,14,na,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Dizziness=6;
Sedation=11;
Insomnia=4;
Dry Mouth=9;
Constipation=3;
Blurred vision=3;
Confusion=1;
Headache=8;
Overexcitement=3;
Tremor=1",na,na,na,na,4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,between 2 to 6 capsules per day,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999366.0,Continuous,109199.0,113308475.0,1.0,13669974.0,0.0,13794252.0,NPRL anxiety,1804.0,weeks,4,4 weeks,37178.0,0.0,placebo,,White (1984),,40.0,99999.0,99999.0,0.0,Placebo,*NPRL - anxiety
87998762,"Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group.",International clinical psychopharmacology,Versiani (1997),1997,"Versiani M, Amrein R, and Stabl M (1997) Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group.. International clinical psychopharmacology 12(4), 183-93",Versiani,na,na,1997,na,tick,na,tick,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,Male and female aged 18-65 with DSM-III-R criteria for dysthymia. Baseline CGI at least moderate.,na,"Patients previously treated with imipramine or moclobemide, suicidal patients, concomitant psychiatric disorders or organic diseases.",na,na,na,na,na,na,na,na,na,na,na,na,Dysthimia,tick,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Versiani, 1997",na,na,na,na,na,na,na,na,na,na,na,37203,Moclobemide,na,na,na,na,41,na,na,108,na,na,73,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Dry mouth=38;Tremor=8;Constipation=11;Sweating=5;Blurred vision=5;Sleepiness=12;Dizziness=19;Headache=21;Insomnia=19;Nausea=19,na,75mg,633mg,750mg,6weeks,75mg,750mg,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,12,na,na,na,73,na,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87998762,"Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group.",International clinical psychopharmacology,Versiani (1997),1997,"Versiani M, Amrein R, and Stabl M (1997) Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group.. International clinical psychopharmacology 12(4), 183-93",Versiani,na,na,1997,na,tick,na,tick,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,Male and female aged 18-65 with DSM-III-R criteria for dysthymia. Baseline CGI at least moderate.,na,"Patients previously treated with imipramine or moclobemide, suicidal patients, concomitant psychiatric disorders or organic diseases.",na,na,na,na,na,na,na,na,na,na,na,na,Dysthimia,tick,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Versiani, 1997",na,na,na,na,na,na,na,na,na,na,na,37204,Placebo ,na,na,na,na,40,na,na,104,na,na,71,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Dry mouth=21;Tremor=7;Constipation=15;Sweating=1;Blurred vision=4;Sleepiness=12;Dizziness=10;Headache=12;Insomnia=21;Nausea=20,na,na,na,na,6weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,11,na,na,na,61,na,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999137,"Moclobemide, imipramine and placebo in the treatment of major depression.",Acta psychiatrica Scandinavica. Supplementum,Versiani (1990),1990,"Versiani M, Nardi A E, Mundim F D, Alves A, and Schmid-Burgk W (1990) Moclobemide, imipramine and placebo in the treatment of major depression.. Acta psychiatrica Scandinavica. Supplementum 360, 57-8","[{'ItemDocumentId': 1053848, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Versiani[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - September 1990 - Versiani.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1053848, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1990[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - September 1990 - Versiani.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1053848, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Brazil[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - September 1990 - Versiani.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1053848, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Patients were diagnosed according to the Struc-\ntured Clinical Interview for DSM-111-R (1, 2).\nInclusion criteria were a diagnosis of major de-\npression (DSM-111-R) and a minimum score of 17\npoints on the Hamilton Rating Scale for De-\npression (HRSD, 21-item version).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - September 1990 - Versiani.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,75,tick,tick,na,tick,tick,na,"[{'ItemDocumentId': 1053848, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""major de-\npression (DSM-111-R)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - September 1990 - Versiani.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,Versiani 1990,tick,na,na,tick,na,na,na,na,na,na,na,37205,Moclobemide,na,na,na,na,tick,tick,na,25,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,5,na,na,1,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,600mg,600mg,600mg,6 weeks,600mg,600mg,na,na,tick,na,na,na,na,na,na,na,na,na,6 capsules per day,na,na,na,na,na,na,na,na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999137,"Moclobemide, imipramine and placebo in the treatment of major depression.",Acta psychiatrica Scandinavica. Supplementum,Versiani (1990),1990,"Versiani M, Nardi A E, Mundim F D, Alves A, and Schmid-Burgk W (1990) Moclobemide, imipramine and placebo in the treatment of major depression.. Acta psychiatrica Scandinavica. Supplementum 360, 57-8","[{'ItemDocumentId': 1053848, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Versiani[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - September 1990 - Versiani.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1053848, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1990[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - September 1990 - Versiani.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1053848, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Brazil[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - September 1990 - Versiani.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1053848, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Patients were diagnosed according to the Struc-\ntured Clinical Interview for DSM-111-R (1, 2).\nInclusion criteria were a diagnosis of major de-\npression (DSM-111-R) and a minimum score of 17\npoints on the Hamilton Rating Scale for De-\npression (HRSD, 21-item version).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - September 1990 - Versiani.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,75,tick,tick,na,tick,tick,na,"[{'ItemDocumentId': 1053848, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""major de-\npression (DSM-111-R)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - September 1990 - Versiani.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,Versiani 1990,tick,na,na,tick,na,na,na,na,na,na,na,37206,Placebo ,na,na,na,na,tick,tick,na,25,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,3,na,na,0,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,6 capsules per day,na,na,na,na,na,na,na,na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
89956243,A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes.,"Journal of Mental Science, The Asylum Journal, The Asylum Journal of Mental Science",Versiani (1989),1989,"Versiani Marcio, Oggero U, Alterwain Paulo, Capponi R, and et al (1989) A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes.. Journal of Mental Science, The Asylum Journal, and The Asylum Journal of Mental Science 155(Suppl 6), 72-77","[{'ItemDocumentId': 1063654, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""VERSIANI[¬e]""', 'IsFromPDF': True, 'DocTitle': 'a-double-blind-comparative-trial-of-moclobemide-v-imipramine-and-placebo-in-major-depressive-episodes.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1063654, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1989)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'a-double-blind-comparative-trial-of-moclobemide-v-imipramine-and-placebo-in-major-depressive-episodes.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1063654, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""men or non-pregnant and non-\nlactating women, aged 18 to 65 years. Patients were required\nto meet the DSM-III criteria for a major depressive episode\nand to have a minimum baseline score of 17 on the 21-item\nHamilton Rating Scale for Depression (HRSD).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'a-double-blind-comparative-trial-of-moclobemide-v-imipramine-and-placebo-in-major-depressive-episodes.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063654, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""marked suicidal intent\n(since out-patients could be enrolled in the study), other\npsychiatric illness, severe organic disease, alcoholism, and drug\nabuse. In addition, patients were required not to have the usual\ncontraindications to treatment with TCAs.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'a-double-blind-comparative-trial-of-moclobemide-v-imipramine-and-placebo-in-major-depressive-episodes.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063654, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""major depressive episode according to DSM-III criteria w[¬e]""', 'IsFromPDF': True, 'DocTitle': 'a-double-blind-comparative-trial-of-moclobemide-v-imipramine-and-placebo-in-major-depressive-episodes.pdf', 'ItemArm': ''}]","[{'ItemDocumentId': 1063654, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""depressive subtype did\nnot affect either inclusion in or exclusion from the study.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'a-double-blind-comparative-trial-of-moclobemide-v-imipramine-and-placebo-in-major-depressive-episodes.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1063654, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Patients receiving lithium could be enrolled in the study,\nproviding treatment had been stabilised for at least 4 weeks[¬e]""', 'IsFromPDF': True, 'DocTitle': 'a-double-blind-comparative-trial-of-moclobemide-v-imipramine-and-placebo-in-major-depressive-episodes.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Versiani, 1989",na,na,na,na,na,na,na,na,na,na,na,37441,Moclobemide,na,na,na,na,44,na,na,164,na,na,124,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,43,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,tick,6 weeks,300mg,600mg,na,na,na,na,na,na,tick,na,tick,na,tick,na,3x daily,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,12,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
89956243,A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes.,"Journal of Mental Science, The Asylum Journal, The Asylum Journal of Mental Science",Versiani (1989),1989,"Versiani Marcio, Oggero U, Alterwain Paulo, Capponi R, and et al (1989) A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes.. Journal of Mental Science, The Asylum Journal, and The Asylum Journal of Mental Science 155(Suppl 6), 72-77","[{'ItemDocumentId': 1063654, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""VERSIANI[¬e]""', 'IsFromPDF': True, 'DocTitle': 'a-double-blind-comparative-trial-of-moclobemide-v-imipramine-and-placebo-in-major-depressive-episodes.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1063654, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1989)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'a-double-blind-comparative-trial-of-moclobemide-v-imipramine-and-placebo-in-major-depressive-episodes.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1063654, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""men or non-pregnant and non-\nlactating women, aged 18 to 65 years. Patients were required\nto meet the DSM-III criteria for a major depressive episode\nand to have a minimum baseline score of 17 on the 21-item\nHamilton Rating Scale for Depression (HRSD).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'a-double-blind-comparative-trial-of-moclobemide-v-imipramine-and-placebo-in-major-depressive-episodes.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063654, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""marked suicidal intent\n(since out-patients could be enrolled in the study), other\npsychiatric illness, severe organic disease, alcoholism, and drug\nabuse. In addition, patients were required not to have the usual\ncontraindications to treatment with TCAs.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'a-double-blind-comparative-trial-of-moclobemide-v-imipramine-and-placebo-in-major-depressive-episodes.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063654, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""major depressive episode according to DSM-III criteria w[¬e]""', 'IsFromPDF': True, 'DocTitle': 'a-double-blind-comparative-trial-of-moclobemide-v-imipramine-and-placebo-in-major-depressive-episodes.pdf', 'ItemArm': ''}]","[{'ItemDocumentId': 1063654, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""depressive subtype did\nnot affect either inclusion in or exclusion from the study.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'a-double-blind-comparative-trial-of-moclobemide-v-imipramine-and-placebo-in-major-depressive-episodes.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1063654, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Patients receiving lithium could be enrolled in the study,\nproviding treatment had been stabilised for at least 4 weeks[¬e]""', 'IsFromPDF': True, 'DocTitle': 'a-double-blind-comparative-trial-of-moclobemide-v-imipramine-and-placebo-in-major-depressive-episodes.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Versiani, 1989",na,na,na,na,na,na,na,na,na,na,na,37443,Placebo ,na,na,na,na,42,na,na,162,na,na,123,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,58,na,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,12,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999157,"Double-blind comparison of moclobemide, imipramine and placebo in depressive patients.",Acta psychiatrica Scandinavica. Supplementum,Ucha (1990),1990,"Ucha Udabe, R , Marquez C A, Traballi C A, and Portes N (1990) Double-blind comparison of moclobemide, imipramine and placebo in depressive patients.. Acta psychiatrica Scandinavica. Supplementum 360, 54-6","[{'ItemDocumentId': 1053888, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ucha[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - September 1990 - Udabe.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1053888, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1990[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - September 1990 - Udabe.pdf', 'ItemArm': ''}]",na,tick,na,tick,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,'outpatients',"[{'ItemDocumentId': 1053888, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""outpatients, 44 females and 28 males,\nrange 18-65 years, scoring at least 17 points on the\nHamilton Rating Scale for Depression (HRSD, 21-\nitem version)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - September 1990 - Udabe.pdf', 'ItemArm': ''}]",na,tick,tick,na,na,na,na,72,na,na,na,na,na,na,"[{'ItemDocumentId': 1053888, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""major depressive episodes\n(DSM-111[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - September 1990 - Udabe.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,14,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,Ucha 1990,na,na,na,na,na,na,na,na,na,na,na,37207,Placebo ,na,na,na,na,42.2,na,na,24,na,na,13,na,na,tick,tick,"Endogenous depression (unipolar)=2
Endogenous depression (bipolar)=1
Neurotic depression=13
Reactive depression=5
Other=3",na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,na,tick,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,5.6 tabs per day,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,3 to 6 capsules per day,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,15.1,na,na,na,18,na,na,9,na,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999157,"Double-blind comparison of moclobemide, imipramine and placebo in depressive patients.",Acta psychiatrica Scandinavica. Supplementum,Ucha (1990),1990,"Ucha Udabe, R , Marquez C A, Traballi C A, and Portes N (1990) Double-blind comparison of moclobemide, imipramine and placebo in depressive patients.. Acta psychiatrica Scandinavica. Supplementum 360, 54-6","[{'ItemDocumentId': 1053888, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ucha[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - September 1990 - Udabe.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1053888, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1990[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - September 1990 - Udabe.pdf', 'ItemArm': ''}]",na,tick,na,tick,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,'outpatients',"[{'ItemDocumentId': 1053888, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""outpatients, 44 females and 28 males,\nrange 18-65 years, scoring at least 17 points on the\nHamilton Rating Scale for Depression (HRSD, 21-\nitem version)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - September 1990 - Udabe.pdf', 'ItemArm': ''}]",na,tick,tick,na,na,na,na,72,na,na,na,na,na,na,"[{'ItemDocumentId': 1053888, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""major depressive episodes\n(DSM-111[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - September 1990 - Udabe.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,14,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,Ucha 1990,na,na,na,na,na,na,na,na,na,na,na,37209,moclobemide,na,na,na,na,40.5,na,na,24,na,na,16,na,na,tick,tick,"Endogenous depression (unipolar)=3
Endogenous depression (bipolar)=3
Neurotic depression=12
Reactive depression=2
Other=4",na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,na,tick,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,508mg (day 14); 405mg (day 42),6 weeks,300mg,600mg,na,na,na,na,na,na,na,na,tick,na,tick,na,3 to 6 capsules per day,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,15.6,na,na,na,20,na,na,9,na,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87998395,Assessing the effects of bupropion SR on mood dimensions of depression.,Journal of affective disorders,Tomarken (2004),2004,"Tomarken Andrew J, Dichter Gabriel S, Freid Cathryn, Addington Stephanie, and Shelton Richard C (2004) Assessing the effects of bupropion SR on mood dimensions of depression.. Journal of affective disorders 78(3), 235-41","[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Tomarken[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 6:\n[¬s]""Glaxo Wellcome Inc""\n""d NIMH\ngrant MH01741[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""outpatients who met\nDSM-IV""\n""criteria for recurrent major depression as determined\nby the Structured Clinical Interview for DSM-IV""\n""(1) had\nscores on the 17-item version of the Hamilton Rating\nScale for Depression (HAM-D-17, Hamilton, 1960)\nthat were greater than 17, (2) were free ofpsychotropic\nmedications for at least 1 week[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""not have\natypical depression, psychotic disorders, bipolar dis-\norder, a history ofdrug or alcohol abuse in the previous\n6 months, a history of central nervous system (CNS)\ndisorders, antisocial, borderline, or schizotypal per-\nsonality disorders.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Tomarken, 2004",na,na,na,na,na,na,na,na,na,na,na,37179,bupropion SR,na,na,na,na,39.4,na,na,10,na,na,6,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1,na,na,tick,tick,na,tick,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,tick,tick,tick,na,na,tick,tick,na,100mg,tick,400mg,6 weeks,300mg,400mg,na,na,na,na,na,na,na,na,tick,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,9.8,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87998395.0,Continuous,109352.0,113822918.0,5.0,13687717.0,0.0,13687787.0,MASQ Anhedonia,1805.0,weeks,0,0 weeks,37179.0,0.0,bupropion SR,,Tomarken (2004),Random regression analysis; group x linear interaction,10.0,99999.0,0.0,0.0,*bupropion SR,*MASQ Anhedonia
87998395,Assessing the effects of bupropion SR on mood dimensions of depression.,Journal of affective disorders,Tomarken (2004),2004,"Tomarken Andrew J, Dichter Gabriel S, Freid Cathryn, Addington Stephanie, and Shelton Richard C (2004) Assessing the effects of bupropion SR on mood dimensions of depression.. Journal of affective disorders 78(3), 235-41","[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Tomarken[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 6:\n[¬s]""Glaxo Wellcome Inc""\n""d NIMH\ngrant MH01741[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""outpatients who met\nDSM-IV""\n""criteria for recurrent major depression as determined\nby the Structured Clinical Interview for DSM-IV""\n""(1) had\nscores on the 17-item version of the Hamilton Rating\nScale for Depression (HAM-D-17, Hamilton, 1960)\nthat were greater than 17, (2) were free ofpsychotropic\nmedications for at least 1 week[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""not have\natypical depression, psychotic disorders, bipolar dis-\norder, a history ofdrug or alcohol abuse in the previous\n6 months, a history of central nervous system (CNS)\ndisorders, antisocial, borderline, or schizotypal per-\nsonality disorders.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Tomarken, 2004",na,na,na,na,na,na,na,na,na,na,na,37179,bupropion SR,na,na,na,na,39.4,na,na,10,na,na,6,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1,na,na,tick,tick,na,tick,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,tick,tick,tick,na,na,tick,tick,na,100mg,tick,400mg,6 weeks,300mg,400mg,na,na,na,na,na,na,na,na,tick,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,9.8,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87998395.0,Continuous,109355.0,113822918.0,1.0,13687717.0,0.0,13687787.0,MASQ Anhedonia,1806.0,weeks,6,6 weeks,37179.0,0.0,bupropion SR,,Tomarken (2004),,10.0,99999.0,99999.0,0.0,*bupropion SR,*MASQ Anhedonia
87998395,Assessing the effects of bupropion SR on mood dimensions of depression.,Journal of affective disorders,Tomarken (2004),2004,"Tomarken Andrew J, Dichter Gabriel S, Freid Cathryn, Addington Stephanie, and Shelton Richard C (2004) Assessing the effects of bupropion SR on mood dimensions of depression.. Journal of affective disorders 78(3), 235-41","[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Tomarken[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 6:\n[¬s]""Glaxo Wellcome Inc""\n""d NIMH\ngrant MH01741[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""outpatients who met\nDSM-IV""\n""criteria for recurrent major depression as determined\nby the Structured Clinical Interview for DSM-IV""\n""(1) had\nscores on the 17-item version of the Hamilton Rating\nScale for Depression (HAM-D-17, Hamilton, 1960)\nthat were greater than 17, (2) were free ofpsychotropic\nmedications for at least 1 week[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""not have\natypical depression, psychotic disorders, bipolar dis-\norder, a history ofdrug or alcohol abuse in the previous\n6 months, a history of central nervous system (CNS)\ndisorders, antisocial, borderline, or schizotypal per-\nsonality disorders.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Tomarken, 2004",na,na,na,na,na,na,na,na,na,na,na,37179,bupropion SR,na,na,na,na,39.4,na,na,10,na,na,6,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1,na,na,tick,tick,na,tick,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,tick,tick,tick,na,na,tick,tick,na,100mg,tick,400mg,6 weeks,300mg,400mg,na,na,na,na,na,na,na,na,tick,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,9.8,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87998395.0,Continuous,109362.0,113822918.0,1.0,13687717.0,0.0,13688476.0,MASQ Anxiety,1805.0,weeks,0,0 weeks,37179.0,0.0,bupropion SR,,Tomarken (2004),,10.0,99999.0,99999.0,0.0,*bupropion SR,*MASQ - anxiety 
87998395,Assessing the effects of bupropion SR on mood dimensions of depression.,Journal of affective disorders,Tomarken (2004),2004,"Tomarken Andrew J, Dichter Gabriel S, Freid Cathryn, Addington Stephanie, and Shelton Richard C (2004) Assessing the effects of bupropion SR on mood dimensions of depression.. Journal of affective disorders 78(3), 235-41","[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Tomarken[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 6:\n[¬s]""Glaxo Wellcome Inc""\n""d NIMH\ngrant MH01741[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""outpatients who met\nDSM-IV""\n""criteria for recurrent major depression as determined\nby the Structured Clinical Interview for DSM-IV""\n""(1) had\nscores on the 17-item version of the Hamilton Rating\nScale for Depression (HAM-D-17, Hamilton, 1960)\nthat were greater than 17, (2) were free ofpsychotropic\nmedications for at least 1 week[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""not have\natypical depression, psychotic disorders, bipolar dis-\norder, a history ofdrug or alcohol abuse in the previous\n6 months, a history of central nervous system (CNS)\ndisorders, antisocial, borderline, or schizotypal per-\nsonality disorders.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Tomarken, 2004",na,na,na,na,na,na,na,na,na,na,na,37179,bupropion SR,na,na,na,na,39.4,na,na,10,na,na,6,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1,na,na,tick,tick,na,tick,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,tick,tick,tick,na,na,tick,tick,na,100mg,tick,400mg,6 weeks,300mg,400mg,na,na,na,na,na,na,na,na,tick,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,9.8,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87998395.0,Continuous,109363.0,113822918.0,1.0,13687717.0,0.0,13688476.0,MASQ Anxiety,1806.0,weeks,6,6 weeks,37179.0,0.0,bupropion SR,,Tomarken (2004),,10.0,99999.0,99999.0,0.0,*bupropion SR,*MASQ - anxiety 
87998395,Assessing the effects of bupropion SR on mood dimensions of depression.,Journal of affective disorders,Tomarken (2004),2004,"Tomarken Andrew J, Dichter Gabriel S, Freid Cathryn, Addington Stephanie, and Shelton Richard C (2004) Assessing the effects of bupropion SR on mood dimensions of depression.. Journal of affective disorders 78(3), 235-41","[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Tomarken[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 6:\n[¬s]""Glaxo Wellcome Inc""\n""d NIMH\ngrant MH01741[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""outpatients who met\nDSM-IV""\n""criteria for recurrent major depression as determined\nby the Structured Clinical Interview for DSM-IV""\n""(1) had\nscores on the 17-item version of the Hamilton Rating\nScale for Depression (HAM-D-17, Hamilton, 1960)\nthat were greater than 17, (2) were free ofpsychotropic\nmedications for at least 1 week[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""not have\natypical depression, psychotic disorders, bipolar dis-\norder, a history ofdrug or alcohol abuse in the previous\n6 months, a history of central nervous system (CNS)\ndisorders, antisocial, borderline, or schizotypal per-\nsonality disorders.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Tomarken, 2004",na,na,na,na,na,na,na,na,na,na,na,37180,Placebo ,na,na,na,na,37.5,na,na,9,na,na,6,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,0,na,na,tick,tick,na,tick,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,tick,tick,na,na,tick,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,7.80,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87998395.0,Continuous,109357.0,113822918.0,1.0,13669974.0,0.0,13687787.0,MASQ Anhedonia,1805.0,weeks,0,0 weeks,37180.0,0.0,Placebo ,,Tomarken (2004),,9.0,99999.0,99999.0,0.0,Placebo,*MASQ Anhedonia
87998395,Assessing the effects of bupropion SR on mood dimensions of depression.,Journal of affective disorders,Tomarken (2004),2004,"Tomarken Andrew J, Dichter Gabriel S, Freid Cathryn, Addington Stephanie, and Shelton Richard C (2004) Assessing the effects of bupropion SR on mood dimensions of depression.. Journal of affective disorders 78(3), 235-41","[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Tomarken[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 6:\n[¬s]""Glaxo Wellcome Inc""\n""d NIMH\ngrant MH01741[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""outpatients who met\nDSM-IV""\n""criteria for recurrent major depression as determined\nby the Structured Clinical Interview for DSM-IV""\n""(1) had\nscores on the 17-item version of the Hamilton Rating\nScale for Depression (HAM-D-17, Hamilton, 1960)\nthat were greater than 17, (2) were free ofpsychotropic\nmedications for at least 1 week[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""not have\natypical depression, psychotic disorders, bipolar dis-\norder, a history ofdrug or alcohol abuse in the previous\n6 months, a history of central nervous system (CNS)\ndisorders, antisocial, borderline, or schizotypal per-\nsonality disorders.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Tomarken, 2004",na,na,na,na,na,na,na,na,na,na,na,37180,Placebo ,na,na,na,na,37.5,na,na,9,na,na,6,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,0,na,na,tick,tick,na,tick,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,tick,tick,na,na,tick,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,7.80,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87998395.0,Continuous,109359.0,113822918.0,1.0,13669974.0,0.0,13687787.0,MASQ Anhedonia,1806.0,weeks,6,6 weeks,37180.0,0.0,Placebo ,,Tomarken (2004),,9.0,99999.0,99999.0,0.0,Placebo,*MASQ Anhedonia
87998395,Assessing the effects of bupropion SR on mood dimensions of depression.,Journal of affective disorders,Tomarken (2004),2004,"Tomarken Andrew J, Dichter Gabriel S, Freid Cathryn, Addington Stephanie, and Shelton Richard C (2004) Assessing the effects of bupropion SR on mood dimensions of depression.. Journal of affective disorders 78(3), 235-41","[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Tomarken[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 6:\n[¬s]""Glaxo Wellcome Inc""\n""d NIMH\ngrant MH01741[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""outpatients who met\nDSM-IV""\n""criteria for recurrent major depression as determined\nby the Structured Clinical Interview for DSM-IV""\n""(1) had\nscores on the 17-item version of the Hamilton Rating\nScale for Depression (HAM-D-17, Hamilton, 1960)\nthat were greater than 17, (2) were free ofpsychotropic\nmedications for at least 1 week[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""not have\natypical depression, psychotic disorders, bipolar dis-\norder, a history ofdrug or alcohol abuse in the previous\n6 months, a history of central nervous system (CNS)\ndisorders, antisocial, borderline, or schizotypal per-\nsonality disorders.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Tomarken, 2004",na,na,na,na,na,na,na,na,na,na,na,37180,Placebo ,na,na,na,na,37.5,na,na,9,na,na,6,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,0,na,na,tick,tick,na,tick,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,tick,tick,na,na,tick,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,7.80,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87998395.0,Continuous,109365.0,113822918.0,1.0,13669974.0,0.0,13688476.0,MASQ Anxiety,1805.0,weeks,0,0 weeks,37180.0,0.0,Placebo ,,Tomarken (2004),,9.0,99999.0,99999.0,0.0,Placebo,*MASQ - anxiety 
87998395,Assessing the effects of bupropion SR on mood dimensions of depression.,Journal of affective disorders,Tomarken (2004),2004,"Tomarken Andrew J, Dichter Gabriel S, Freid Cathryn, Addington Stephanie, and Shelton Richard C (2004) Assessing the effects of bupropion SR on mood dimensions of depression.. Journal of affective disorders 78(3), 235-41","[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Tomarken[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 6:\n[¬s]""Glaxo Wellcome Inc""\n""d NIMH\ngrant MH01741[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""outpatients who met\nDSM-IV""\n""criteria for recurrent major depression as determined\nby the Structured Clinical Interview for DSM-IV""\n""(1) had\nscores on the 17-item version of the Hamilton Rating\nScale for Depression (HAM-D-17, Hamilton, 1960)\nthat were greater than 17, (2) were free ofpsychotropic\nmedications for at least 1 week[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""not have\natypical depression, psychotic disorders, bipolar dis-\norder, a history ofdrug or alcohol abuse in the previous\n6 months, a history of central nervous system (CNS)\ndisorders, antisocial, borderline, or schizotypal per-\nsonality disorders.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050681, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Tomarken Andrew J et al. - 2004 - Assessing the effects of bupropion SR on mood dime.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Tomarken, 2004",na,na,na,na,na,na,na,na,na,na,na,37180,Placebo ,na,na,na,na,37.5,na,na,9,na,na,6,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,0,na,na,tick,tick,na,tick,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,tick,tick,na,na,tick,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,7.80,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87998395.0,Continuous,109366.0,113822918.0,1.0,13669974.0,0.0,13688476.0,MASQ Anxiety,1806.0,weeks,6,6 weeks,37180.0,0.0,Placebo ,,Tomarken (2004),,9.0,99999.0,99999.0,0.0,Placebo,*MASQ - anxiety 
87999511,Comparative effects of phenelzine and amitriptyline: a placebo controlled trial.,Neuropharmacology,Rowan (1980),1980,"Rowan P, Paykel E S, Parker P R, and West E (1980) Comparative effects of phenelzine and amitriptyline: a placebo controlled trial.. Neuropharmacology 19(12), 1223-5","[{'ItemDocumentId': 1050697, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""ROWAN,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Rowan P et al. - 1980 - Comparative effects of phenelzine and amitriptylin.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050697, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Rowan P et al. - 1980 - Comparative effects of phenelzine and amitriptylin.pdf', 'ItemArm': ''}]",na,tick,na,tick,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,Depression or mixed anxiety/depression of at least 2 weeks with a minimum score of 7 on the Raskin Three Area Scale.,na,Inpatients/severe typical endogenous depressives/bipolars/pure anxiety disorders without depressive symptoms.,na,na,na,na,na,176,na,na,na,na,na,na,Depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,45,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,tick,na,na,tick,tick,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,"Rowan, 1980; Paykel, 1982a; Paykel, 1982b; Bhat, 1984",na,na,na,na,na,na,na,na,na,na,na,37319,Phenelzine,na,na,na,na,tick,tick,na,99999,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,na,tick,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,tick,6 weeks,45mg,75mg,na,na,na,na,na,na,tick,na,tick,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999511,Comparative effects of phenelzine and amitriptyline: a placebo controlled trial.,Neuropharmacology,Rowan (1980),1980,"Rowan P, Paykel E S, Parker P R, and West E (1980) Comparative effects of phenelzine and amitriptyline: a placebo controlled trial.. Neuropharmacology 19(12), 1223-5","[{'ItemDocumentId': 1050697, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""ROWAN,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Rowan P et al. - 1980 - Comparative effects of phenelzine and amitriptylin.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050697, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Rowan P et al. - 1980 - Comparative effects of phenelzine and amitriptylin.pdf', 'ItemArm': ''}]",na,tick,na,tick,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,Depression or mixed anxiety/depression of at least 2 weeks with a minimum score of 7 on the Raskin Three Area Scale.,na,Inpatients/severe typical endogenous depressives/bipolars/pure anxiety disorders without depressive symptoms.,na,na,na,na,na,176,na,na,na,na,na,na,Depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,45,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,tick,na,na,tick,tick,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,"Rowan, 1980; Paykel, 1982a; Paykel, 1982b; Bhat, 1984",na,na,na,na,na,na,na,na,na,na,na,37321,Placebo,na,na,na,na,tick,tick,na,99999,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,na,tick,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999692,A controlled trial of methyl phenidate (ritalin) in the treatment of depressive states.,"Journal of neurology, neurosurgery, and psychiatry",ROBIN (1958),1958,"ROBIN A A, and WISEBERG S (1958) A controlled trial of methyl phenidate (ritalin) in the treatment of depressive states.. Journal of neurology, neurosurgery, and and psychiatry 21(1), 55-7","[{'ItemDocumentId': 1061803, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""ROBIN[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Robin 1958.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1061803, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1958,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Robin 1958.pdf', 'ItemArm': ''}]",na,UK,na,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1061803, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""(a) Complaint\nof depression as a prominent symptom; (b) evidence\nof depression at interview, e.g. sad, careworn ex-\npression, general bearing, and lack of spontaneity.""\n""(a) Sleep disturbance;\n(b) loss of appetite and weight; (c) impairment of\ninterests; (d) lack of confidence; (e) reduced alert-\nness; (f) retardation or agitation.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Robin 1958.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1061803, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""cases""\n""where the anxiety component was sufficiently large""\n""to contraindicate stimulant medication or where""\n""symptoms of a physical nature were prominent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Robin 1958.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Robin, 1958",na,na,na,na,na,na,na,na,na,na,na,37317,Placebo,na,na,na,na,39.5,na,na,23,na,na,13,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,0,na,na,0,na,na,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,4 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,13.9,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999692,A controlled trial of methyl phenidate (ritalin) in the treatment of depressive states.,"Journal of neurology, neurosurgery, and psychiatry",ROBIN (1958),1958,"ROBIN A A, and WISEBERG S (1958) A controlled trial of methyl phenidate (ritalin) in the treatment of depressive states.. Journal of neurology, neurosurgery, and and psychiatry 21(1), 55-7","[{'ItemDocumentId': 1061803, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""ROBIN[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Robin 1958.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1061803, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1958,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Robin 1958.pdf', 'ItemArm': ''}]",na,UK,na,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1061803, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""(a) Complaint\nof depression as a prominent symptom; (b) evidence\nof depression at interview, e.g. sad, careworn ex-\npression, general bearing, and lack of spontaneity.""\n""(a) Sleep disturbance;\n(b) loss of appetite and weight; (c) impairment of\ninterests; (d) lack of confidence; (e) reduced alert-\nness; (f) retardation or agitation.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Robin 1958.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1061803, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""cases""\n""where the anxiety component was sufficiently large""\n""to contraindicate stimulant medication or where""\n""symptoms of a physical nature were prominent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Robin 1958.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Robin, 1958",na,na,na,na,na,na,na,na,na,na,na,37318,Methylphenidate,na,na,na,na,37.5,na,na,22,na,na,16,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,5,na,na,2,na,na,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,4 weeks,20mg,40mg,na,na,na,na,na,na,na,tick,tick,na,na,tick,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,11.5,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
90051999,"Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of serdaxin in subjects with major depressive disorder","49th Annual Conference of the American College of Neuropsychopharmacology, ACNP 2010. Miami Beach, FL United States.",Riesenberg (2010),2010,"Riesenberg R, Rosenthal J, Moldauer L, and Peterson C (2010) Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of serdaxin in subjects with major depressive disorder. 49th Annual Conference of the American College of Neuropsychopharmacology, ACNP 2010. Miami Beach, and FL United States. 35(SUPPL. 1), S214-S215 DOI: https://dx.doi.org/10.1038/npp.2010.217","[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Riesenberg[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2012[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 10:\n[¬s]""Rexahn Pharmaceuticals[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 10:\n[¬s]""NCT00839176[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,na,tick,na,na,tick,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""male or female between 18 and 65 years old, diagnosis of\nMDD using DSM-IV criteria, Hamilton Rating Scale for\nDepression (HAM-D-17) score ≥20 at screening and before\nrandomization and Clinical Global Impressions Severity\n(CGI-S) score ≥4 at screening and before randomization.\nWomen had to test negative for pregnancy by serum preg-\nnancy test and use approved contraceptive methods during\nthe test period.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""exclusion criteria included other current nondepres-\nsive Axis I disorders; depressive episode duration of less\nthan 1 month or greater than 9 months; bipolar disorder,\ndysthymic disorder, borderline personality disorder, psy-\nchotic disorder, or other current psychotic features; use of\nany treatment for MDD within 7 days ofVisit 1 (14 days for[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""fluoxetine); use of antidepressants, anxiolytics, or other\npsychoactive drugs within 14 days; subjects who were non-\nresponsive to two or more trials of antidepressant medica-\ntions given an adequate duration for symptom treatment,\nuncontrolled atrial fibrillation/flutter at screening; hyper-\nor hypothyroidism unless on stable dose of thyroid medica-\ntion within 3 months of screening; AST and/or ALT >3\ntimes ULN; HBA1c >12%; body mass index (BMI) ≥30\nor ≤18; and unstable angina pectoris.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""MDD.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Riesenberg, 2012;Riesenberg, 2010",na,na,na,na,na,na,na,na,na,na,na,37187,Placebo ,na,na,na,na,42.5,na,na,21,na,na,11,na,na,Hispanic/Latino=2;Black or African American=10;White,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,13,na,na,3,na,na,na,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Gastrointestinal disorders=5; Constipation=0; Dyspepsia=0; General disorders and administration site conditions=2; pain=0; Injury, poisoning and procedural complications=1; Muscle strain=0; Investigations=2; Blood bilirubin increased=0; Blood creatine phosphokinase increased=0; Blood pressure increased=0; Musculoskeletal and connective tissue disorders=4; Myalgia=0; Nervous system disorders=3; Headache=0; Psychiatric disorders=3; Agitation=0",na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,6x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.8,na,na,na,tick,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
90051999,"Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of serdaxin in subjects with major depressive disorder","49th Annual Conference of the American College of Neuropsychopharmacology, ACNP 2010. Miami Beach, FL United States.",Riesenberg (2010),2010,"Riesenberg R, Rosenthal J, Moldauer L, and Peterson C (2010) Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of serdaxin in subjects with major depressive disorder. 49th Annual Conference of the American College of Neuropsychopharmacology, ACNP 2010. Miami Beach, and FL United States. 35(SUPPL. 1), S214-S215 DOI: https://dx.doi.org/10.1038/npp.2010.217","[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Riesenberg[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2012[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 10:\n[¬s]""Rexahn Pharmaceuticals[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 10:\n[¬s]""NCT00839176[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,na,tick,na,na,tick,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""male or female between 18 and 65 years old, diagnosis of\nMDD using DSM-IV criteria, Hamilton Rating Scale for\nDepression (HAM-D-17) score ≥20 at screening and before\nrandomization and Clinical Global Impressions Severity\n(CGI-S) score ≥4 at screening and before randomization.\nWomen had to test negative for pregnancy by serum preg-\nnancy test and use approved contraceptive methods during\nthe test period.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""exclusion criteria included other current nondepres-\nsive Axis I disorders; depressive episode duration of less\nthan 1 month or greater than 9 months; bipolar disorder,\ndysthymic disorder, borderline personality disorder, psy-\nchotic disorder, or other current psychotic features; use of\nany treatment for MDD within 7 days ofVisit 1 (14 days for[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""fluoxetine); use of antidepressants, anxiolytics, or other\npsychoactive drugs within 14 days; subjects who were non-\nresponsive to two or more trials of antidepressant medica-\ntions given an adequate duration for symptom treatment,\nuncontrolled atrial fibrillation/flutter at screening; hyper-\nor hypothyroidism unless on stable dose of thyroid medica-\ntion within 3 months of screening; AST and/or ALT >3\ntimes ULN; HBA1c >12%; body mass index (BMI) ≥30\nor ≤18; and unstable angina pectoris.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""MDD.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Riesenberg, 2012;Riesenberg, 2010",na,na,na,na,na,na,na,na,na,na,na,37188,RX-10100 5mg,na,na,na,na,44.8,na,na,21,na,na,11,na,na,Black or African American=12;White=9,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,3,na,na,0,na,na,na,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Gastrointestinal disorders=3; Constipation=2; Dyspepsia=1; General disorders and administration site conditions=2; pain=0; Injury, poisoning and procedural complications=1; Muscle strain=1; Investigations=4; Blood bilirubin increased=1; Blood creatine phosphokinase increased=1; Blood pressure increased=1; Musculoskeletal and connective tissue disorders=0; Myalgia=0; Nervous system disorders=4; Headache=3; Psychiatric disorders=1; Agitation=1",tick,5mg,tick,5mg,8 weeks,5mg,5mg,na,na,na,na,na,na,na,na,na,na,na,na,6x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.9,na,na,na,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
90051999,"Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of serdaxin in subjects with major depressive disorder","49th Annual Conference of the American College of Neuropsychopharmacology, ACNP 2010. Miami Beach, FL United States.",Riesenberg (2010),2010,"Riesenberg R, Rosenthal J, Moldauer L, and Peterson C (2010) Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of serdaxin in subjects with major depressive disorder. 49th Annual Conference of the American College of Neuropsychopharmacology, ACNP 2010. Miami Beach, and FL United States. 35(SUPPL. 1), S214-S215 DOI: https://dx.doi.org/10.1038/npp.2010.217","[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Riesenberg[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2012[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 10:\n[¬s]""Rexahn Pharmaceuticals[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 10:\n[¬s]""NCT00839176[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,na,tick,na,na,tick,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""male or female between 18 and 65 years old, diagnosis of\nMDD using DSM-IV criteria, Hamilton Rating Scale for\nDepression (HAM-D-17) score ≥20 at screening and before\nrandomization and Clinical Global Impressions Severity\n(CGI-S) score ≥4 at screening and before randomization.\nWomen had to test negative for pregnancy by serum preg-\nnancy test and use approved contraceptive methods during\nthe test period.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""exclusion criteria included other current nondepres-\nsive Axis I disorders; depressive episode duration of less\nthan 1 month or greater than 9 months; bipolar disorder,\ndysthymic disorder, borderline personality disorder, psy-\nchotic disorder, or other current psychotic features; use of\nany treatment for MDD within 7 days ofVisit 1 (14 days for[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""fluoxetine); use of antidepressants, anxiolytics, or other\npsychoactive drugs within 14 days; subjects who were non-\nresponsive to two or more trials of antidepressant medica-\ntions given an adequate duration for symptom treatment,\nuncontrolled atrial fibrillation/flutter at screening; hyper-\nor hypothyroidism unless on stable dose of thyroid medica-\ntion within 3 months of screening; AST and/or ALT >3\ntimes ULN; HBA1c >12%; body mass index (BMI) ≥30\nor ≤18; and unstable angina pectoris.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""MDD.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Riesenberg, 2012;Riesenberg, 2010",na,na,na,na,na,na,na,na,na,na,na,37189,RX-10100 10mg,na,na,na,na,42.6,na,na,16,na,na,7,na,na,Hispanic/Latino=2;Asian=1;Black or African American=9;White=4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,6,na,na,2,na,na,na,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Gastrointestinal disorders=5; Constipation=1; Dyspepsia=0; General disorders and administration site conditions=2; pain=2; Injury, poisoning and procedural complications=2; Muscle strain=1; Investigations=2; Blood bilirubin increased=0; Blood creatine phosphokinase increased=1; Blood pressure increased=1; Musculoskeletal and connective tissue disorders=2; Myalgia=0; Nervous system disorders=6; Headache=4; Psychiatric disorders=2; Agitation=1",tick,10mg,tick,10mg,8 weeks,10mg,10mg,na,na,na,na,na,na,na,na,tick,na,na,na,6x daily,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.97,na,na,na,tick,na,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
90051999,"Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of serdaxin in subjects with major depressive disorder","49th Annual Conference of the American College of Neuropsychopharmacology, ACNP 2010. Miami Beach, FL United States.",Riesenberg (2010),2010,"Riesenberg R, Rosenthal J, Moldauer L, and Peterson C (2010) Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of serdaxin in subjects with major depressive disorder. 49th Annual Conference of the American College of Neuropsychopharmacology, ACNP 2010. Miami Beach, and FL United States. 35(SUPPL. 1), S214-S215 DOI: https://dx.doi.org/10.1038/npp.2010.217","[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Riesenberg[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2012[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 10:\n[¬s]""Rexahn Pharmaceuticals[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 10:\n[¬s]""NCT00839176[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,na,tick,na,na,tick,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""male or female between 18 and 65 years old, diagnosis of\nMDD using DSM-IV criteria, Hamilton Rating Scale for\nDepression (HAM-D-17) score ≥20 at screening and before\nrandomization and Clinical Global Impressions Severity\n(CGI-S) score ≥4 at screening and before randomization.\nWomen had to test negative for pregnancy by serum preg-\nnancy test and use approved contraceptive methods during\nthe test period.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""exclusion criteria included other current nondepres-\nsive Axis I disorders; depressive episode duration of less\nthan 1 month or greater than 9 months; bipolar disorder,\ndysthymic disorder, borderline personality disorder, psy-\nchotic disorder, or other current psychotic features; use of\nany treatment for MDD within 7 days ofVisit 1 (14 days for[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""fluoxetine); use of antidepressants, anxiolytics, or other\npsychoactive drugs within 14 days; subjects who were non-\nresponsive to two or more trials of antidepressant medica-\ntions given an adequate duration for symptom treatment,\nuncontrolled atrial fibrillation/flutter at screening; hyper-\nor hypothyroidism unless on stable dose of thyroid medica-\ntion within 3 months of screening; AST and/or ALT >3\ntimes ULN; HBA1c >12%; body mass index (BMI) ≥30\nor ≤18; and unstable angina pectoris.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1061709, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""MDD.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Riesenberg 2010.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Riesenberg, 2012;Riesenberg, 2010",na,na,na,na,na,na,na,na,na,na,na,37190,RX-10100 15mg,na,na,na,na,39.4,na,na,17,na,na,9,na,na,Hispanic/Latino=0;Asian=0;Black or African American=10;White=7,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1,na,na,0,na,na,na,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Gastrointestinal disorders=3; Constipation=0; Dyspepsia=1; General disorders and administration site conditions=0; pain=0; Injury, poisoning and procedural complications=1; Muscle strain=0; Investigations=3; Blood bilirubin increased=1; Blood creatine phosphokinase increased=1; Blood pressure increased=0; Musculoskeletal and connective tissue disorders=2; Myalgia=2; Nervous system disorders=1; Headache=0; Psychiatric disorders=4; Agitation=0",tick,15,tick,15,8 weeks,15,15,na,na,na,na,na,na,na,na,tick,na,na,na,6x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.27,na,na,na,tick,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
89913734,Pemoline and methylphenidate in mildly depressed outpatients,Clinical pharmacology and therapeutics,Rickels (1970),1970,"Rickels K, Gordon PE, Gansman DH, Weise CC, Pereira-Ogan JA, and Hesbacher PT (1970) Pemoline and methylphenidate in mildly depressed outpatients. Clinical pharmacology and therapeutics 11(5), 698‐710 DOI: 10.1002/cpt1970115698","[{'ItemDocumentId': 1065005, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Rickels[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Clin Pharma and Therapeutics - September 1970 - Rickels.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1065005, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1970[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Clin Pharma and Therapeutics - September 1970 - Rickels.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1065005, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States Public Health Service Grants\nMH-08957 and MH-08958.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Clin Pharma and Therapeutics - September 1970 - Rickels.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,tick,tick,tick,na,tick,na,na,"[{'ItemDocumentId': 1065005, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""mildly\nto moderately depressed patients, all of\nwhom had target symptoms of fatigue,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Clin Pharma and Therapeutics - September 1970 - Rickels.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1065005, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""apathy, or anorexia[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Clin Pharma and Therapeutics - September 1970 - Rickels.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1065005, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients with evidence 6f sociopathy,\nalcoholism, marked organic brain syn-\ndrome, or psychosis were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Clin Pharma and Therapeutics - September 1970 - Rickels.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,120,94,na,na,caucasian=84,na,na,Depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Rickels, 1970",tick,na,na,tick,na,na,na,na,na,na,na,37233,methylphenidate,na,na,na,na,99999,na,na,99999,na,na,99999,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,stimulation=11; mild sedation=1;nausea=1;vomiting=1;dizziness=1;vertigo=1,na,15mg,tick,15mg,4 weeks,15mg,15mg,na,na,na,na,na,na,na,na,tick,na,na,na,3x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,13,na,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
89913734,Pemoline and methylphenidate in mildly depressed outpatients,Clinical pharmacology and therapeutics,Rickels (1970),1970,"Rickels K, Gordon PE, Gansman DH, Weise CC, Pereira-Ogan JA, and Hesbacher PT (1970) Pemoline and methylphenidate in mildly depressed outpatients. Clinical pharmacology and therapeutics 11(5), 698‐710 DOI: 10.1002/cpt1970115698","[{'ItemDocumentId': 1065005, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Rickels[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Clin Pharma and Therapeutics - September 1970 - Rickels.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1065005, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1970[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Clin Pharma and Therapeutics - September 1970 - Rickels.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1065005, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States Public Health Service Grants\nMH-08957 and MH-08958.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Clin Pharma and Therapeutics - September 1970 - Rickels.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,tick,tick,tick,na,tick,na,na,"[{'ItemDocumentId': 1065005, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""mildly\nto moderately depressed patients, all of\nwhom had target symptoms of fatigue,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Clin Pharma and Therapeutics - September 1970 - Rickels.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1065005, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""apathy, or anorexia[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Clin Pharma and Therapeutics - September 1970 - Rickels.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1065005, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients with evidence 6f sociopathy,\nalcoholism, marked organic brain syn-\ndrome, or psychosis were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Clin Pharma and Therapeutics - September 1970 - Rickels.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,120,94,na,na,caucasian=84,na,na,Depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Rickels, 1970",tick,na,na,tick,na,na,na,na,na,na,na,37234,Placebo ,na,na,na,na,99999,na,na,99999,na,na,99999,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Itching skin=1;nervousness=1;sedation=2;stimulation=4,na,na,na,na,4 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,3x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,6,na,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87998734,A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.,Clinical therapeutics,Reimherr (1998),1998,"Reimherr F W, Cunningham L A, Batey S R, Johnston J A, and Ascher J A (1998) A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.. Clinical therapeutics 20(3), 505-16",Reimherr,na,na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1998[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063703, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '848-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 10:\n[¬s]""Glaxo Wellcome Inc., Research Tri-\nangle Park, North Carolina.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063703, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 203[¬e]""', 'IsFromPDF': True, 'DocTitle': '848-v1.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""males and females\n218 years of age with a DSM III-R15 (Di-\nagnostic and Statistical Manual of Men-\ntal Disorders, 3rd edition, revised) diag-\nnosis of major depression\n(single\nrecurrent episode) and a minimum score\nof 20 on the 17-item Hamilton\nRating\nScale for Depression (HAM-D)16*17 who\npresented with a major depressive episode\nof at least 4 weeks’ but less than 2 years’\nduration.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""a known pre-\ndisposition\nto seizures (including\nfebrile\nseizure during childhood, epilepsy, brain\ntumor, significant head trauma, family his-\ntory of idiopathic seizure disorder, or cur-\nrent treatment with medications that lower\nthe seizure threshold), a history of unre-""\n""sponsiveness\nto pharmacotherapy\nof the SR\nor\nfor de-\npression, a history or current diagnosis of[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""anorexia nervosa or bulimia, a history of\nalcohol or substance abuse within 1 year\nprior to the study, or active suicidal be-\nhavior or ideation. Pregnant or lactating\nwomen and women not using an accept-\nable form of contraception were also ex-\ncluded. Patients could not have received\nany psychoactive\ndrug within 1 week of\nthe treatment phase (2 weeks for MAOIs\nor protriptyline, 4 weeks for fluoxetine or\nany investigational\ndrug).[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063703, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1992[¬e]""', 'IsFromPDF': True, 'DocTitle': '848-v1.pdf', 'ItemArm': ''}]",na,na,12,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Reimherr, 1998, Well203; Cunningham, 1998",na,na,na,na,na,na,na,na,na,na,na,37310,Placebo,na,na,na,na,40.2,na,na,121,na,na,69,na,na,white=100;black=9;other=8,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,60,na,na,4,na,na,na,tick,tick,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,Headache=21;Dry Mouth=7;Sweating=2;Constipation=8;Nausea=7;Infection=6;Insomnia=6;Tremor=0;Dizziness=2;Dyspepsia=4;Nervousness=4;Anxiety=5;Rash=2;Diarrhea=5;Rhinitis=6;Flu Syndrome=1;Myalgia=5,na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,Overdose=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,12.2,na,na,na,tick,tick,na,1,na,na,na,na,na,na,na,na,na,na,87998734.0,Continuous,108165.0,113800040.0,1.0,13669974.0,0.0,13671957.0,HAM-A,1898.0,weeks,0,0 weeks,37310.0,0.0,Placebo,,Reimherr (1998),,116.0,17.39,4.22,0.0,Placebo,*HAM-A
87998734,A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.,Clinical therapeutics,Reimherr (1998),1998,"Reimherr F W, Cunningham L A, Batey S R, Johnston J A, and Ascher J A (1998) A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.. Clinical therapeutics 20(3), 505-16",Reimherr,na,na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1998[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063703, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '848-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 10:\n[¬s]""Glaxo Wellcome Inc., Research Tri-\nangle Park, North Carolina.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063703, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 203[¬e]""', 'IsFromPDF': True, 'DocTitle': '848-v1.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""males and females\n218 years of age with a DSM III-R15 (Di-\nagnostic and Statistical Manual of Men-\ntal Disorders, 3rd edition, revised) diag-\nnosis of major depression\n(single\nrecurrent episode) and a minimum score\nof 20 on the 17-item Hamilton\nRating\nScale for Depression (HAM-D)16*17 who\npresented with a major depressive episode\nof at least 4 weeks’ but less than 2 years’\nduration.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""a known pre-\ndisposition\nto seizures (including\nfebrile\nseizure during childhood, epilepsy, brain\ntumor, significant head trauma, family his-\ntory of idiopathic seizure disorder, or cur-\nrent treatment with medications that lower\nthe seizure threshold), a history of unre-""\n""sponsiveness\nto pharmacotherapy\nof the SR\nor\nfor de-\npression, a history or current diagnosis of[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""anorexia nervosa or bulimia, a history of\nalcohol or substance abuse within 1 year\nprior to the study, or active suicidal be-\nhavior or ideation. Pregnant or lactating\nwomen and women not using an accept-\nable form of contraception were also ex-\ncluded. Patients could not have received\nany psychoactive\ndrug within 1 week of\nthe treatment phase (2 weeks for MAOIs\nor protriptyline, 4 weeks for fluoxetine or\nany investigational\ndrug).[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063703, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1992[¬e]""', 'IsFromPDF': True, 'DocTitle': '848-v1.pdf', 'ItemArm': ''}]",na,na,12,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Reimherr, 1998, Well203; Cunningham, 1998",na,na,na,na,na,na,na,na,na,na,na,37310,Placebo,na,na,na,na,40.2,na,na,121,na,na,69,na,na,white=100;black=9;other=8,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,60,na,na,4,na,na,na,tick,tick,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,Headache=21;Dry Mouth=7;Sweating=2;Constipation=8;Nausea=7;Infection=6;Insomnia=6;Tremor=0;Dizziness=2;Dyspepsia=4;Nervousness=4;Anxiety=5;Rash=2;Diarrhea=5;Rhinitis=6;Flu Syndrome=1;Myalgia=5,na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,Overdose=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,12.2,na,na,na,tick,tick,na,1,na,na,na,na,na,na,na,na,na,na,87998734.0,Continuous,108166.0,113800040.0,1.0,13669974.0,0.0,13671957.0,HAM-A,1899.0,weeks,8,8 weeks,37310.0,0.0,Placebo,,Reimherr (1998),Change from baseline;LOCF,116.0,-5.78,6.89,0.0,Placebo,*HAM-A
87998734,A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.,Clinical therapeutics,Reimherr (1998),1998,"Reimherr F W, Cunningham L A, Batey S R, Johnston J A, and Ascher J A (1998) A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.. Clinical therapeutics 20(3), 505-16",Reimherr,na,na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1998[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063703, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '848-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 10:\n[¬s]""Glaxo Wellcome Inc., Research Tri-\nangle Park, North Carolina.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063703, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 203[¬e]""', 'IsFromPDF': True, 'DocTitle': '848-v1.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""males and females\n218 years of age with a DSM III-R15 (Di-\nagnostic and Statistical Manual of Men-\ntal Disorders, 3rd edition, revised) diag-\nnosis of major depression\n(single\nrecurrent episode) and a minimum score\nof 20 on the 17-item Hamilton\nRating\nScale for Depression (HAM-D)16*17 who\npresented with a major depressive episode\nof at least 4 weeks’ but less than 2 years’\nduration.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""a known pre-\ndisposition\nto seizures (including\nfebrile\nseizure during childhood, epilepsy, brain\ntumor, significant head trauma, family his-\ntory of idiopathic seizure disorder, or cur-\nrent treatment with medications that lower\nthe seizure threshold), a history of unre-""\n""sponsiveness\nto pharmacotherapy\nof the SR\nor\nfor de-\npression, a history or current diagnosis of[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""anorexia nervosa or bulimia, a history of\nalcohol or substance abuse within 1 year\nprior to the study, or active suicidal be-\nhavior or ideation. Pregnant or lactating\nwomen and women not using an accept-\nable form of contraception were also ex-\ncluded. Patients could not have received\nany psychoactive\ndrug within 1 week of\nthe treatment phase (2 weeks for MAOIs\nor protriptyline, 4 weeks for fluoxetine or\nany investigational\ndrug).[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063703, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1992[¬e]""', 'IsFromPDF': True, 'DocTitle': '848-v1.pdf', 'ItemArm': ''}]",na,na,12,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Reimherr, 1998, Well203; Cunningham, 1998",na,na,na,na,na,na,na,na,na,na,na,37311,Bupropion SR 150mg,na,na,na,na,38.3,na,na,121,na,na,86,na,na,white=100;black=4;other=14,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,55,na,na,10,na,na,na,tick,tick,tick,tick,na,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,tick,Headache=26;Dry Mouth=16;Sweating=5;Constipation=6;Nausea=11;Infection=4;Insomnia=9;Tremor=4;Dizziness=7;Dyspepsia=3;Nervousness=5;Anxiety=8;Rash=5;Diarrhea=2;Rhinitis=9;Flu Syndrome=6;Myalgia=2,na,150mg,tick,150mg,8 weeks,150mg,150mg,na,na,na,na,na,na,na,na,tick,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.00,na,na,na,tick,tick,na,0,na,na,na,na,na,na,na,na,na,na,87998734.0,Continuous,108167.0,113800040.0,1.0,13687717.0,0.0,13671957.0,HAM-A,1898.0,weeks,0,0 weeks,37311.0,0.0,Bupropion SR 150mg,,Reimherr (1998),,120.0,16.88,4.81,0.0,*bupropion SR,*HAM-A
87998734,A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.,Clinical therapeutics,Reimherr (1998),1998,"Reimherr F W, Cunningham L A, Batey S R, Johnston J A, and Ascher J A (1998) A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.. Clinical therapeutics 20(3), 505-16",Reimherr,na,na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1998[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063703, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '848-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 10:\n[¬s]""Glaxo Wellcome Inc., Research Tri-\nangle Park, North Carolina.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063703, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 203[¬e]""', 'IsFromPDF': True, 'DocTitle': '848-v1.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""males and females\n218 years of age with a DSM III-R15 (Di-\nagnostic and Statistical Manual of Men-\ntal Disorders, 3rd edition, revised) diag-\nnosis of major depression\n(single\nrecurrent episode) and a minimum score\nof 20 on the 17-item Hamilton\nRating\nScale for Depression (HAM-D)16*17 who\npresented with a major depressive episode\nof at least 4 weeks’ but less than 2 years’\nduration.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""a known pre-\ndisposition\nto seizures (including\nfebrile\nseizure during childhood, epilepsy, brain\ntumor, significant head trauma, family his-\ntory of idiopathic seizure disorder, or cur-\nrent treatment with medications that lower\nthe seizure threshold), a history of unre-""\n""sponsiveness\nto pharmacotherapy\nof the SR\nor\nfor de-\npression, a history or current diagnosis of[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""anorexia nervosa or bulimia, a history of\nalcohol or substance abuse within 1 year\nprior to the study, or active suicidal be-\nhavior or ideation. Pregnant or lactating\nwomen and women not using an accept-\nable form of contraception were also ex-\ncluded. Patients could not have received\nany psychoactive\ndrug within 1 week of\nthe treatment phase (2 weeks for MAOIs\nor protriptyline, 4 weeks for fluoxetine or\nany investigational\ndrug).[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063703, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1992[¬e]""', 'IsFromPDF': True, 'DocTitle': '848-v1.pdf', 'ItemArm': ''}]",na,na,12,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Reimherr, 1998, Well203; Cunningham, 1998",na,na,na,na,na,na,na,na,na,na,na,37311,Bupropion SR 150mg,na,na,na,na,38.3,na,na,121,na,na,86,na,na,white=100;black=4;other=14,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,55,na,na,10,na,na,na,tick,tick,tick,tick,na,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,tick,Headache=26;Dry Mouth=16;Sweating=5;Constipation=6;Nausea=11;Infection=4;Insomnia=9;Tremor=4;Dizziness=7;Dyspepsia=3;Nervousness=5;Anxiety=8;Rash=5;Diarrhea=2;Rhinitis=9;Flu Syndrome=6;Myalgia=2,na,150mg,tick,150mg,8 weeks,150mg,150mg,na,na,na,na,na,na,na,na,tick,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.00,na,na,na,tick,tick,na,0,na,na,na,na,na,na,na,na,na,na,87998734.0,Continuous,108168.0,113800040.0,1.0,13687717.0,0.0,13671957.0,HAM-A,1899.0,weeks,8,8 weeks,37311.0,0.0,Bupropion SR 150mg,,Reimherr (1998),Change from baseline;LOCF,120.0,-6.8,6.5,0.0,*bupropion SR,*HAM-A
87998734,A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.,Clinical therapeutics,Reimherr (1998),1998,"Reimherr F W, Cunningham L A, Batey S R, Johnston J A, and Ascher J A (1998) A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.. Clinical therapeutics 20(3), 505-16",Reimherr,na,na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1998[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063703, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '848-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 10:\n[¬s]""Glaxo Wellcome Inc., Research Tri-\nangle Park, North Carolina.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063703, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 203[¬e]""', 'IsFromPDF': True, 'DocTitle': '848-v1.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""males and females\n218 years of age with a DSM III-R15 (Di-\nagnostic and Statistical Manual of Men-\ntal Disorders, 3rd edition, revised) diag-\nnosis of major depression\n(single\nrecurrent episode) and a minimum score\nof 20 on the 17-item Hamilton\nRating\nScale for Depression (HAM-D)16*17 who\npresented with a major depressive episode\nof at least 4 weeks’ but less than 2 years’\nduration.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""a known pre-\ndisposition\nto seizures (including\nfebrile\nseizure during childhood, epilepsy, brain\ntumor, significant head trauma, family his-\ntory of idiopathic seizure disorder, or cur-\nrent treatment with medications that lower\nthe seizure threshold), a history of unre-""\n""sponsiveness\nto pharmacotherapy\nof the SR\nor\nfor de-\npression, a history or current diagnosis of[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""anorexia nervosa or bulimia, a history of\nalcohol or substance abuse within 1 year\nprior to the study, or active suicidal be-\nhavior or ideation. Pregnant or lactating\nwomen and women not using an accept-\nable form of contraception were also ex-\ncluded. Patients could not have received\nany psychoactive\ndrug within 1 week of\nthe treatment phase (2 weeks for MAOIs\nor protriptyline, 4 weeks for fluoxetine or\nany investigational\ndrug).[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063703, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1992[¬e]""', 'IsFromPDF': True, 'DocTitle': '848-v1.pdf', 'ItemArm': ''}]",na,na,12,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Reimherr, 1998, Well203; Cunningham, 1998",na,na,na,na,na,na,na,na,na,na,na,37312,Bupropion SR 300mg,na,na,na,na,38.6,na,na,120,na,na,92,na,na,white=100;black=3;other=11,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,53,na,na,13,na,na,na,tick,tick,tick,tick,na,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,tick,Headache=28;Dry Mouth=19;Sweating=13;Constipation=12;Nausea=12 Infection=10;Insomnia=10;Tremor=10;Dizziness=8;Dyspepsia=6;Nervousness=6;Anxiety=5;Rash=5;Diarrhea=4;Rhinitis=4;Flu Syndrome=3;Myalgia=2,na,300mg,tick,300mg,8 weeks,300mg,300mg,na,na,na,na,na,na,na,na,tick,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,0,na,na,na,na,na,na,na,na,na,na,na,na,na,na,10.70,na,na,na,tick,tick,na,0,na,na,na,na,na,na,na,na,na,na,87998734.0,Continuous,108169.0,113800040.0,1.0,13687717.0,0.0,13671957.0,HAM-A,1898.0,weeks,0,0 weeks,37312.0,0.0,Bupropion SR 300mg,,Reimherr (1998),,113.0,17.89,5.07,0.0,*bupropion SR,*HAM-A
87998734,A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.,Clinical therapeutics,Reimherr (1998),1998,"Reimherr F W, Cunningham L A, Batey S R, Johnston J A, and Ascher J A (1998) A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.. Clinical therapeutics 20(3), 505-16",Reimherr,na,na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1998[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063703, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '848-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 10:\n[¬s]""Glaxo Wellcome Inc., Research Tri-\nangle Park, North Carolina.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063703, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 203[¬e]""', 'IsFromPDF': True, 'DocTitle': '848-v1.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""males and females\n218 years of age with a DSM III-R15 (Di-\nagnostic and Statistical Manual of Men-\ntal Disorders, 3rd edition, revised) diag-\nnosis of major depression\n(single\nrecurrent episode) and a minimum score\nof 20 on the 17-item Hamilton\nRating\nScale for Depression (HAM-D)16*17 who\npresented with a major depressive episode\nof at least 4 weeks’ but less than 2 years’\nduration.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""a known pre-\ndisposition\nto seizures (including\nfebrile\nseizure during childhood, epilepsy, brain\ntumor, significant head trauma, family his-\ntory of idiopathic seizure disorder, or cur-\nrent treatment with medications that lower\nthe seizure threshold), a history of unre-""\n""sponsiveness\nto pharmacotherapy\nof the SR\nor\nfor de-\npression, a history or current diagnosis of[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052936, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""anorexia nervosa or bulimia, a history of\nalcohol or substance abuse within 1 year\nprior to the study, or active suicidal be-\nhavior or ideation. Pregnant or lactating\nwomen and women not using an accept-\nable form of contraception were also ex-\ncluded. Patients could not have received\nany psychoactive\ndrug within 1 week of\nthe treatment phase (2 weeks for MAOIs\nor protriptyline, 4 weeks for fluoxetine or\nany investigational\ndrug).[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S014929189880060X-main.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063703, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1992[¬e]""', 'IsFromPDF': True, 'DocTitle': '848-v1.pdf', 'ItemArm': ''}]",na,na,12,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Reimherr, 1998, Well203; Cunningham, 1998",na,na,na,na,na,na,na,na,na,na,na,37312,Bupropion SR 300mg,na,na,na,na,38.6,na,na,120,na,na,92,na,na,white=100;black=3;other=11,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,53,na,na,13,na,na,na,tick,tick,tick,tick,na,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,tick,Headache=28;Dry Mouth=19;Sweating=13;Constipation=12;Nausea=12 Infection=10;Insomnia=10;Tremor=10;Dizziness=8;Dyspepsia=6;Nervousness=6;Anxiety=5;Rash=5;Diarrhea=4;Rhinitis=4;Flu Syndrome=3;Myalgia=2,na,300mg,tick,300mg,8 weeks,300mg,300mg,na,na,na,na,na,na,na,na,tick,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,0,na,na,na,na,na,na,na,na,na,na,na,na,na,na,10.70,na,na,na,tick,tick,na,0,na,na,na,na,na,na,na,na,na,na,87998734.0,Continuous,108170.0,113800040.0,1.0,13687717.0,0.0,13671957.0,HAM-A ,1899.0,weeks,8,8 weeks,37312.0,0.0,Bupropion SR 300mg,,Reimherr (1998),Change from baseline;LOCF,113.0,-7.58,5.95,0.0,*bupropion SR,*HAM-A
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37305,Phenelzine 60mg,na,na,na,na,43.1,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,6,na,na,0,na,na,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,60mg,tick,60mg,6 weeks,60mg,60mg,na,na,na,na,na,na,na,na,tick,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,15.12,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107254.0,113393312.0,1.0,13669972.0,0.0,13717211.0,SHID - total anxiety,1896.0,weeks,0,0 weeks,37305.0,0.0,Phenelzine 60mg,,Ravaris (1976),SEConv,14.0,22.1,8.61,0.0,Phenelzine,SHID - anxiety total subscale
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37305,Phenelzine 60mg,na,na,na,na,43.1,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,6,na,na,0,na,na,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,60mg,tick,60mg,6 weeks,60mg,60mg,na,na,na,na,na,na,na,na,tick,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,15.12,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107255.0,113393312.0,3.0,13669972.0,0.0,13717211.0,SHID - total anxiety,1897.0,weeks,6,6 weeks,37305.0,0.0,Phenelzine 60mg,,Ravaris (1976),Mean improvement;SEConv,14.0,12.1,99999.0,0.0,Phenelzine,SHID - anxiety total subscale
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37305,Phenelzine 60mg,na,na,na,na,43.1,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,6,na,na,0,na,na,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,60mg,tick,60mg,6 weeks,60mg,60mg,na,na,na,na,na,na,na,na,tick,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,15.12,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107283.0,113393312.0,1.0,13669972.0,0.0,13717212.0,SHID psychic anxiety,1896.0,weeks,0,0 weeks,37305.0,0.0,Phenelzine 60mg,,Ravaris (1976),SEConv,14.0,13.6,5.24,0.0,Phenelzine,SHID - psychic anxiety item
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37305,Phenelzine 60mg,na,na,na,na,43.1,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,6,na,na,0,na,na,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,60mg,tick,60mg,6 weeks,60mg,60mg,na,na,na,na,na,na,na,na,tick,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,15.12,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107286.0,113393312.0,3.0,13669972.0,0.0,13717212.0,SHID psychic anxiety,1897.0,weeks,6,6 weeks,37305.0,0.0,Phenelzine 60mg,,Ravaris (1976),Mean improvement;SEConv,14.0,8.7,99999.0,0.0,Phenelzine,SHID - psychic anxiety item
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37305,Phenelzine 60mg,na,na,na,na,43.1,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,6,na,na,0,na,na,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,60mg,tick,60mg,6 weeks,60mg,60mg,na,na,na,na,na,na,na,na,tick,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,15.12,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107289.0,113393312.0,1.0,13669972.0,0.0,13717213.0,SHID situational anxiety,1896.0,weeks,0,0 weeks,37305.0,0.0,Phenelzine 60mg,,Ravaris (1976),SEConv,14.0,5.6,99.0,0.0,Phenelzine,SHID - situational anxiety item
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37305,Phenelzine 60mg,na,na,na,na,43.1,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,6,na,na,0,na,na,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,60mg,tick,60mg,6 weeks,60mg,60mg,na,na,na,na,na,na,na,na,tick,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,15.12,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107292.0,113393312.0,1.0,13669972.0,0.0,13717213.0,SHID situational anxiety,1897.0,weeks,6,6 weeks,37305.0,0.0,Phenelzine 60mg,,Ravaris (1976),Mean improvement;SEConv,14.0,2.2,99999.0,0.0,Phenelzine,SHID - situational anxiety item
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37305,Phenelzine 60mg,na,na,na,na,43.1,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,6,na,na,0,na,na,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,60mg,tick,60mg,6 weeks,60mg,60mg,na,na,na,na,na,na,na,na,tick,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,15.12,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107295.0,113393312.0,3.0,13669972.0,0.0,13717214.0,SHID somatic anxiety,1896.0,weeks,0,0 weeks,37305.0,0.0,Phenelzine 60mg,,Ravaris (1976),SEConv,14.0,9.6,3.37,0.0,Phenelzine,SHID - somatic anxiety item
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37305,Phenelzine 60mg,na,na,na,na,43.1,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,6,na,na,0,na,na,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,60mg,tick,60mg,6 weeks,60mg,60mg,na,na,na,na,na,na,na,na,tick,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,15.12,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107298.0,113393312.0,1.0,13669972.0,0.0,13717214.0,SHID somatic anxiety,1897.0,weeks,6,6 weeks,37305.0,0.0,Phenelzine 60mg,,Ravaris (1976),Mean improvement;SEConv,14.0,5.6,99999.0,0.0,Phenelzine,SHID - somatic anxiety item
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37306,Phenelzine 30mg,na,na,na,na,41.2,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,5,na,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,30mg,tick,30mg,5 weeks,30mg,30mg,na,na,na,na,na,na,na,na,tick,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,16.50,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107252.0,113393312.0,1.0,13669972.0,0.0,13717211.0,SHID - total anxiety,1896.0,weeks,0,0 weeks,37306.0,0.0,Phenelzine 30mg,,Ravaris (1976),SEConv,16.0,17.9,6.0,0.0,Phenelzine,SHID - anxiety total subscale
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37306,Phenelzine 30mg,na,na,na,na,41.2,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,5,na,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,30mg,tick,30mg,5 weeks,30mg,30mg,na,na,na,na,na,na,na,na,tick,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,16.50,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107253.0,113393312.0,3.0,13669972.0,0.0,13717211.0,SHID - total anxiety,1897.0,weeks,6,6 weeks,37306.0,0.0,Phenelzine 30mg,,Ravaris (1976),Mean improvement;SEConv,16.0,6.0,99999.0,0.0,Phenelzine,SHID - anxiety total subscale
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37306,Phenelzine 30mg,na,na,na,na,41.2,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,5,na,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,30mg,tick,30mg,5 weeks,30mg,30mg,na,na,na,na,na,na,na,na,tick,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,16.50,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107282.0,113393312.0,1.0,13669972.0,0.0,13717212.0,SHID psychic anxiety,1896.0,weeks,0,0 weeks,37306.0,0.0,Phenelzine 30mg,,Ravaris (1976),SE;Conv,21.0,10.9,4.4,0.0,Phenelzine,SHID - psychic anxiety item
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37306,Phenelzine 30mg,na,na,na,na,41.2,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,5,na,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,30mg,tick,30mg,5 weeks,30mg,30mg,na,na,na,na,na,na,na,na,tick,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,16.50,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107285.0,113393312.0,3.0,13669972.0,0.0,13717212.0,SHID psychic anxiety,1897.0,weeks,6,6 weeks,37306.0,0.0,Phenelzine 30mg,,Ravaris (1976),Mean improvement;SEConv,14.0,4.2,99999.0,0.0,Phenelzine,SHID - psychic anxiety item
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37306,Phenelzine 30mg,na,na,na,na,41.2,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,5,na,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,30mg,tick,30mg,5 weeks,30mg,30mg,na,na,na,na,na,na,na,na,tick,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,16.50,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107288.0,113393312.0,3.0,13669972.0,0.0,13717213.0,SHID situational anxiety,1896.0,weeks,0,0 weeks,37306.0,0.0,Phenelzine 30mg,,Ravaris (1976),SEConv,16.0,3.7,2.4,0.0,Phenelzine,SHID - situational anxiety item
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37306,Phenelzine 30mg,na,na,na,na,41.2,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,5,na,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,30mg,tick,30mg,5 weeks,30mg,30mg,na,na,na,na,na,na,na,na,tick,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,16.50,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107291.0,113393312.0,1.0,13669972.0,0.0,13717213.0,SHID situational anxiety,1897.0,weeks,6,6 weeks,37306.0,0.0,Phenelzine 30mg,,Ravaris (1976),Mean improvement;SEConv,16.0,1.0,99999.0,0.0,Phenelzine,SHID - situational anxiety item
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37306,Phenelzine 30mg,na,na,na,na,41.2,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,5,na,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,30mg,tick,30mg,5 weeks,30mg,30mg,na,na,na,na,na,na,na,na,tick,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,16.50,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107294.0,113393312.0,1.0,13669972.0,0.0,13717214.0,SHID somatic anxiety,1896.0,weeks,0,0 weeks,37306.0,0.0,Phenelzine 30mg,,Ravaris (1976),SEConv,16.0,8.2,3.2,0.0,Phenelzine,SHID - somatic anxiety item
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37306,Phenelzine 30mg,na,na,na,na,41.2,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,5,na,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,30mg,tick,30mg,5 weeks,30mg,30mg,na,na,na,na,na,na,na,na,tick,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,16.50,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107297.0,113393312.0,1.0,13669972.0,0.0,13717214.0,SHID somatic anxiety,1897.0,weeks,6,6 weeks,37306.0,0.0,Phenelzine 30mg,,Ravaris (1976),Mean improvement;SEConv,16.0,2.4,99999.0,0.0,Phenelzine,SHID - somatic anxiety item
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37307,Placebo,na,na,na,na,38.9,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,2,na,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,10.10,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107248.0,113393312.0,1.0,13669974.0,0.0,13717211.0,SHID total anxiety,1896.0,weeks,0,0 weeks,37307.0,0.0,Placebo,,Ravaris (1976),SEConv,19.0,19.6,7.41,0.0,Placebo,SHID - anxiety total subscale
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37307,Placebo,na,na,na,na,38.9,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,2,na,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,10.10,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107251.0,113393312.0,3.0,13669974.0,0.0,13717211.0,SHID total anxiety,1897.0,weeks,6,6 weeks,37307.0,0.0,Placebo,,Ravaris (1976),Mean improvement;SEConv,19.0,6.5,99999.0,0.0,Placebo,SHID - anxiety total subscale
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37307,Placebo,na,na,na,na,38.9,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,2,na,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,10.10,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107281.0,113393312.0,1.0,13669974.0,0.0,13717212.0,SHID psychic anxiety,1896.0,weeks,0,0 weeks,37307.0,0.0,Placebo,,Ravaris (1976),SEConv,19.0,12.2,99999.0,0.0,Placebo,SHID - psychic anxiety item
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37307,Placebo,na,na,na,na,38.9,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,2,na,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,10.10,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107290.0,113393312.0,3.0,13669974.0,0.0,13717212.0,SHID situational anxiety,1897.0,weeks,6,6 weeks,37307.0,0.0,Placebo,,Ravaris (1976),Mean improvement;SEConv,19.0,0.7,99999.0,0.0,Placebo,SHID - psychic anxiety item
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37307,Placebo,na,na,na,na,38.9,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,2,na,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,10.10,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107284.0,113393312.0,3.0,13669974.0,0.0,13717212.0,SHID psychic anxiety,1897.0,weeks,6,6 weeks,37307.0,0.0,Placebo,,Ravaris (1976),Mean improvement;SEConv,21.0,4.8,99999.0,0.0,Placebo,SHID - psychic anxiety item
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37307,Placebo,na,na,na,na,38.9,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,2,na,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,10.10,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107287.0,113393312.0,1.0,13669974.0,0.0,13717213.0,SHID situational anxiety,1896.0,weeks,0,0 weeks,37307.0,0.0,Placebo,,Ravaris (1976),SEConv,19.0,4.4,2.62,0.0,Placebo,SHID - situational anxiety item
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37307,Placebo,na,na,na,na,38.9,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,2,na,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,10.10,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107296.0,113393312.0,3.0,13669974.0,0.0,13717214.0,SHID somatic anxiety,1897.0,weeks,6,6 weeks,37307.0,0.0,Placebo,,Ravaris (1976),Mean improvement;SEConv,19.0,3.0,99999.0,0.0,Placebo,SHID - somatic anxiety item
87999576,"A multiple-dose, controlled study of phenelzine in depression-anxiety states.",Archives of general psychiatry,Ravaris (1976),1976,"Ravaris C L, Nies A, Robinson D S, Ives J O, Lamborn K R, and Korson L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states.. Archives of general psychiatry 33(3), 347-50","[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ravaris[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1976)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""Public Health Service grants\n1 R01 MH15533, 5S01 RR-05429-11, and T02 05935-22, and the Warner\nLambert Research Institut[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the basis of the presence of significant depressive symp""\n""\ntoms as determined in the psychiatric interview.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050664, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Excluded were\npatients with alcoholism, schizophrenia, organic brain syndromes,\nrelatively pure anxiety reactions, serious medical illnesses, and\npotentially lethal suicidal intent.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Ravaris C L et al. - 1976 - A multiple-dose, controlled study of phenelzine in.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37307,Placebo,na,na,na,na,38.9,na,na,21,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,2,na,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,tick,tick,tick,na,na,na,na,na,tick,10.10,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999576.0,Continuous,107293.0,113393312.0,3.0,13669974.0,0.0,13717214.0,SHID somatic anxiety,1896.0,weeks,0,0 weeks,37307.0,0.0,Placebo,,Ravaris (1976),SEConv,19.0,9.4,3.49,0.0,Placebo,SHID - somatic anxiety item
87999631,Adverse reactions to phenelzine: results of a nine-hospital depression study.,The Journal of clinical pharmacology and new drugs,Raskin (1972),1972,"Raskin A (1972) Adverse reactions to phenelzine: results of a nine-hospital depression study.. The Journal of clinical pharmacology and new drugs 12(1), 22-5",Raskin,na,na,1972,na,USA,na,na,NIMH Grants ,na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,7 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37301,Placebo,na,na,na,na,tick,na,tick,111,tick,na,99999,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999631,Adverse reactions to phenelzine: results of a nine-hospital depression study.,The Journal of clinical pharmacology and new drugs,Raskin (1972),1972,"Raskin A (1972) Adverse reactions to phenelzine: results of a nine-hospital depression study.. The Journal of clinical pharmacology and new drugs 12(1), 22-5",Raskin,na,na,1972,na,USA,na,na,NIMH Grants ,na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,7 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37302,Phenelzine,na,na,na,na,37 (median),na,na,110,na,na,72,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,3,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"severe headaches=1;dizziness and faintness=1;Exfoliative dermatitis, gravitational swelling, burning pain, liver enlargement=1",na,22.5mg,tick,45mg,5 weeks,45mg,45mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
90055414,Dopaminergic hypothesis for retarded depression: A symptom profile for predicting therapeutical responses,Acta Psychiatrica Scandinavica,Rampello (1991),1991,"Rampello L, Nicoletti G, and Raffaele R (1991) Dopaminergic hypothesis for retarded depression: A symptom profile for predicting therapeutical responses. Acta Psychiatrica Scandinavica 84(6), 552-554","[{'ItemDocumentId': 1062307, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Nicoletti[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - December 1991 - Rampello.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1062307, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1991[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - December 1991 - Rampello.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1062307, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Italy[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - December 1991 - Rampello.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,na,na,tick,tick,na,na,na,na,na,na,tick,tick,na,na,na,"[{'ItemDocumentId': 1062307, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""psychiatric\ndiagnosis of primary major unipolar depression or\nbipolar affective disorder depressed, according to\nDSM-III-R. According to additional operational""\n""subtype criteria, patients were diagnosed as being\naffected by retarded depression. All patients exhib-\nited at least 8 of the following negative symptoms:\nhypokinesia, anergia, reduction of speech, increased\nsalivation, reduced sexual activity, slowness, hypo-\nmimia, orthostatic hypotension, hypersomnia, Pari-\nnaud’s syndrome, dysphagia and drowsiness.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - December 1991 - Rampello.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1062307, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Pari-\nnaud’s syndrome, dysphagia and drowsiness. Pa-\ntients with alcoholism, organic brain syndromes,\nparkinsonism or with serious cardiac, hepatic, renal\nor thyroid diseases, prostate hypertrophy or glau-\ncoma were not included. A[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - December 1991 - Rampello.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,24,na,na,na,na,na,"[{'ItemDocumentId': 1062307, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""retarded depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - December 1991 - Rampello.pdf', 'ItemArm': ''}]",tick,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,6,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Rampello, 1991",tick,na,20-65,na,na,na,na,na,na,na,na,37298,Minaprine,na,na,na,na,tick,tick,na,10,na,na,tick,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,0,na,na,0,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,100mg,tick,200mg,6 weeks,100,na,na,na,na,na,na,na,na,na,tick,na,na,na,"1x daily (week 1)
2x daily (week 2)",na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,tick,na,na,na,tick,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
90055414,Dopaminergic hypothesis for retarded depression: A symptom profile for predicting therapeutical responses,Acta Psychiatrica Scandinavica,Rampello (1991),1991,"Rampello L, Nicoletti G, and Raffaele R (1991) Dopaminergic hypothesis for retarded depression: A symptom profile for predicting therapeutical responses. Acta Psychiatrica Scandinavica 84(6), 552-554","[{'ItemDocumentId': 1062307, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Nicoletti[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - December 1991 - Rampello.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1062307, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1991[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - December 1991 - Rampello.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1062307, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Italy[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - December 1991 - Rampello.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,na,na,tick,tick,na,na,na,na,na,na,tick,tick,na,na,na,"[{'ItemDocumentId': 1062307, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""psychiatric\ndiagnosis of primary major unipolar depression or\nbipolar affective disorder depressed, according to\nDSM-III-R. According to additional operational""\n""subtype criteria, patients were diagnosed as being\naffected by retarded depression. All patients exhib-\nited at least 8 of the following negative symptoms:\nhypokinesia, anergia, reduction of speech, increased\nsalivation, reduced sexual activity, slowness, hypo-\nmimia, orthostatic hypotension, hypersomnia, Pari-\nnaud’s syndrome, dysphagia and drowsiness.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - December 1991 - Rampello.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1062307, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Pari-\nnaud’s syndrome, dysphagia and drowsiness. Pa-\ntients with alcoholism, organic brain syndromes,\nparkinsonism or with serious cardiac, hepatic, renal\nor thyroid diseases, prostate hypertrophy or glau-\ncoma were not included. A[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - December 1991 - Rampello.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,24,na,na,na,na,na,"[{'ItemDocumentId': 1062307, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""retarded depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Acta Psychiatr Scand - December 1991 - Rampello.pdf', 'ItemArm': ''}]",tick,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,6,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Rampello, 1991",tick,na,20-65,na,na,na,na,na,na,na,na,37299,Placebo,na,na,na,na,tick,na,tick,10,na,na,tick,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,2,na,na,2,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"1x daily (week 1)
2x daily (week 2)",na,na,na,na,na,na,na,na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,na,na,tick,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999485,"Relationship between response to phenelzine and MAO inhibition in a clinical trial of phenelzine, amitriptyline and placebo.",Neuropsychobiology,Raft (1981),1981,"Raft D, Davidson J, Wasik J, and Mattox A (1981) Relationship between response to phenelzine and MAO inhibition in a clinical trial of phenelzine, amitriptyline and placebo.. Neuropsychobiology 7(3), 122-6","[{'ItemDocumentId': 1050769, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Raft[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Raft D et al. - 1981 - Relationship between response to phenelzine and MA.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050769, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1981[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Raft D et al. - 1981 - Relationship between response to phenelzine and MA.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050769, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""NIH Grant DE-02668 t[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Raft D et al. - 1981 - Relationship between response to phenelzine and MA.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,tick,tick,na,na,"[{'ItemDocumentId': 1050769, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""e presence of\ndefinite primary depression,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Raft D et al. - 1981 - Relationship between response to phenelzine and MA.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,29,tick,tick,na,na,na,na,Depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050769, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1974[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Raft D et al. - 1981 - Relationship between response to phenelzine and MA.pdf', 'ItemArm': ''}]",na,na,6,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Raft, 1981",na,na,na,na,na,na,na,na,na,na,na,37291,Phenelzine,na,na,na,na,tick,tick,na,99999,na,tick,99999,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,tick,na,na,na,0,na,na,tick,tick,na,na,na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Dizziness=2;nausea=1;drowsiness=2;excessive weight gain=4,na,30mg,90mg,90mg,5 weeks,90mg,90mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,6,na,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999485,"Relationship between response to phenelzine and MAO inhibition in a clinical trial of phenelzine, amitriptyline and placebo.",Neuropsychobiology,Raft (1981),1981,"Raft D, Davidson J, Wasik J, and Mattox A (1981) Relationship between response to phenelzine and MAO inhibition in a clinical trial of phenelzine, amitriptyline and placebo.. Neuropsychobiology 7(3), 122-6","[{'ItemDocumentId': 1050769, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Raft[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Raft D et al. - 1981 - Relationship between response to phenelzine and MA.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050769, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1981[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Raft D et al. - 1981 - Relationship between response to phenelzine and MA.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050769, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""NIH Grant DE-02668 t[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Raft D et al. - 1981 - Relationship between response to phenelzine and MA.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,tick,tick,na,na,"[{'ItemDocumentId': 1050769, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""e presence of\ndefinite primary depression,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Raft D et al. - 1981 - Relationship between response to phenelzine and MA.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,29,tick,tick,na,na,na,na,Depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050769, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1974[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Raft D et al. - 1981 - Relationship between response to phenelzine and MA.pdf', 'ItemArm': ''}]",na,na,6,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Raft, 1981",na,na,na,na,na,na,na,na,na,na,na,37293,Placebo,na,na,na,na,tick,tick,na,99999,na,tick,99999,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,tick,na,na,na,1,na,na,1,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,dizziness=2;chest pain=1;forgetfulness=2,na,na,na,na,5 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,6x daily (max),na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,5,na,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999150,"Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication.",Archives of general psychiatry,Quitkin (1990),1990,"Quitkin F M, McGrath P J, Stewart J W, Harrison W, Tricamo E, Wager S G, Ocepek-Welikson K, Nunes E, Rabkin J G, and Klein D F (1990) Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication.. Archives of general psychiatry 47(10), 935-41","[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Quitkin[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1990[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",na,USA,tick,na,"[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""grant MH39143 from the National""\n""Institute of Mental Health, Bethesda, Md, and by grant MH30906-11 from the\nNational Health Clinical Research Center, Bethesda, Md,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1. Met Research Diagnostic Criteria for major, minor, or intermit""\n""\ntent depression.15""\n""The following""\n""2. Maintained mood reactivity while they were depressed, defined\npresent ifmood could be lifted at least 50% ofwhen they were not""\n""depressed (scale and anchors available from authors).\n3. Exhibited at least two of the following: increase""\n""weightgain while theywere depressed (defined as present ifappetite""\n""d appetite or""\n""markedly increased or there was at least a""\n""4.5-kg weight gain),\nfatigue that created a""\n""oversleeping (sleeps at least 10 h/d), severe""\n""sensation of leaden paralysis or extreme heaviness of arms o""\n""legs""\n""(defined\nlimbs""\n""as""\n""leaden\npresent""\n""if a""\n""depression with functional impairment, eg, the subject missed work\nor\nschool""\n""was a prominent symptom), and sensitivity to rejection as a""\n""marked decrease""\n""e in e""\n""nergy or heaviness""\n""trait throughout adulthood (defined as\ndepression with functional impairment, eg, the subject missed work""\n""present""\n""ifrejection""\n""Were between 18 and 65 years ofage.\n5. Had no other Axis I diagnoses other than panic disorder.""\n""Had no treatment with 45 mg/d or more ofphenelzine sulfate (or\nepisode""\n""an equivalent MAOI) or more than 150 mg/d ofimipramine hydrochlo""\n""""\n""ride (or an""\n""equivalent TCA) for 2 or more weeks during the current""\n""hose subjects with a lifetime history of at least one\nequivalent TCA) for 2 or more weeks during the current\nspontaneous\nan equivalent MAOI) or more than 150 mg/d ofimipramine hydrochlo""\n""\nride (or an\npanic attack (by Research Diagnostic Criteria) were judged to b""\n""episode.\nTh""\n""panic positive.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,Atypical depression,"[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""panic disorder.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Quitkin, 1990",na,na,na,na,na,na,na,na,na,na,na,37289,Phenelzine,na,na,na,na,38.9,na,na,33,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,3,na,na,1,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,45mg,tick,90mg,6 weeks,90mg,90mg,na,na,na,na,na,na,na,na,tick,na,na,na,3x daily,na,na,na,na,na,tick,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,87999150.0,Continuous,107216.0,113380385.0,1.0,13669972.0,0.0,13709934.0,SCL-90 Anxiety,1886.0,weeks,0,0 weeks,37289.0,0.0,Phenelzine,,Quitkin (1990),AdjMeans,27.0,2.2,99999.0,0.0,Phenelzine,*SCL-90 Anxiety subscale
87999150,"Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication.",Archives of general psychiatry,Quitkin (1990),1990,"Quitkin F M, McGrath P J, Stewart J W, Harrison W, Tricamo E, Wager S G, Ocepek-Welikson K, Nunes E, Rabkin J G, and Klein D F (1990) Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication.. Archives of general psychiatry 47(10), 935-41","[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Quitkin[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1990[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",na,USA,tick,na,"[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""grant MH39143 from the National""\n""Institute of Mental Health, Bethesda, Md, and by grant MH30906-11 from the\nNational Health Clinical Research Center, Bethesda, Md,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1. Met Research Diagnostic Criteria for major, minor, or intermit""\n""\ntent depression.15""\n""The following""\n""2. Maintained mood reactivity while they were depressed, defined\npresent ifmood could be lifted at least 50% ofwhen they were not""\n""depressed (scale and anchors available from authors).\n3. Exhibited at least two of the following: increase""\n""weightgain while theywere depressed (defined as present ifappetite""\n""d appetite or""\n""markedly increased or there was at least a""\n""4.5-kg weight gain),\nfatigue that created a""\n""oversleeping (sleeps at least 10 h/d), severe""\n""sensation of leaden paralysis or extreme heaviness of arms o""\n""legs""\n""(defined\nlimbs""\n""as""\n""leaden\npresent""\n""if a""\n""depression with functional impairment, eg, the subject missed work\nor\nschool""\n""was a prominent symptom), and sensitivity to rejection as a""\n""marked decrease""\n""e in e""\n""nergy or heaviness""\n""trait throughout adulthood (defined as\ndepression with functional impairment, eg, the subject missed work""\n""present""\n""ifrejection""\n""Were between 18 and 65 years ofage.\n5. Had no other Axis I diagnoses other than panic disorder.""\n""Had no treatment with 45 mg/d or more ofphenelzine sulfate (or\nepisode""\n""an equivalent MAOI) or more than 150 mg/d ofimipramine hydrochlo""\n""""\n""ride (or an""\n""equivalent TCA) for 2 or more weeks during the current""\n""hose subjects with a lifetime history of at least one\nequivalent TCA) for 2 or more weeks during the current\nspontaneous\nan equivalent MAOI) or more than 150 mg/d ofimipramine hydrochlo""\n""\nride (or an\npanic attack (by Research Diagnostic Criteria) were judged to b""\n""episode.\nTh""\n""panic positive.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,Atypical depression,"[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""panic disorder.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Quitkin, 1990",na,na,na,na,na,na,na,na,na,na,na,37289,Phenelzine,na,na,na,na,38.9,na,na,33,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,3,na,na,1,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,45mg,tick,90mg,6 weeks,90mg,90mg,na,na,na,na,na,na,na,na,tick,na,na,na,3x daily,na,na,na,na,na,tick,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,87999150.0,Continuous,107217.0,113380385.0,1.0,13669972.0,0.0,13709934.0,SCL-90 Anxiety,1887.0,weeks,6,6 weeks,37289.0,0.0,Phenelzine,,Quitkin (1990),AdjMeans,27.0,1.6,99999.0,0.0,Phenelzine,*SCL-90 Anxiety subscale
87999150,"Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication.",Archives of general psychiatry,Quitkin (1990),1990,"Quitkin F M, McGrath P J, Stewart J W, Harrison W, Tricamo E, Wager S G, Ocepek-Welikson K, Nunes E, Rabkin J G, and Klein D F (1990) Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication.. Archives of general psychiatry 47(10), 935-41","[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Quitkin[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1990[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",na,USA,tick,na,"[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""grant MH39143 from the National""\n""Institute of Mental Health, Bethesda, Md, and by grant MH30906-11 from the\nNational Health Clinical Research Center, Bethesda, Md,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1. Met Research Diagnostic Criteria for major, minor, or intermit""\n""\ntent depression.15""\n""The following""\n""2. Maintained mood reactivity while they were depressed, defined\npresent ifmood could be lifted at least 50% ofwhen they were not""\n""depressed (scale and anchors available from authors).\n3. Exhibited at least two of the following: increase""\n""weightgain while theywere depressed (defined as present ifappetite""\n""d appetite or""\n""markedly increased or there was at least a""\n""4.5-kg weight gain),\nfatigue that created a""\n""oversleeping (sleeps at least 10 h/d), severe""\n""sensation of leaden paralysis or extreme heaviness of arms o""\n""legs""\n""(defined\nlimbs""\n""as""\n""leaden\npresent""\n""if a""\n""depression with functional impairment, eg, the subject missed work\nor\nschool""\n""was a prominent symptom), and sensitivity to rejection as a""\n""marked decrease""\n""e in e""\n""nergy or heaviness""\n""trait throughout adulthood (defined as\ndepression with functional impairment, eg, the subject missed work""\n""present""\n""ifrejection""\n""Were between 18 and 65 years ofage.\n5. Had no other Axis I diagnoses other than panic disorder.""\n""Had no treatment with 45 mg/d or more ofphenelzine sulfate (or\nepisode""\n""an equivalent MAOI) or more than 150 mg/d ofimipramine hydrochlo""\n""""\n""ride (or an""\n""equivalent TCA) for 2 or more weeks during the current""\n""hose subjects with a lifetime history of at least one\nequivalent TCA) for 2 or more weeks during the current\nspontaneous\nan equivalent MAOI) or more than 150 mg/d ofimipramine hydrochlo""\n""\nride (or an\npanic attack (by Research Diagnostic Criteria) were judged to b""\n""episode.\nTh""\n""panic positive.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,Atypical depression,"[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""panic disorder.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Quitkin, 1990",na,na,na,na,na,na,na,na,na,na,na,37290,Placebo,na,na,na,na,30.1,na,na,34,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,8,na,na,2,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,3x daily,na,na,na,na,na,tick,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,87999150.0,Continuous,107214.0,113380385.0,1.0,13669974.0,0.0,13709934.0,SCL-90 Anxiety,1886.0,weeks,0,0 weeks,37290.0,0.0,Placebo,,Quitkin (1990),AdjMeans,23.0,2.2,99999.0,0.0,Placebo,*SCL-90 Anxiety subscale
87999150,"Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication.",Archives of general psychiatry,Quitkin (1990),1990,"Quitkin F M, McGrath P J, Stewart J W, Harrison W, Tricamo E, Wager S G, Ocepek-Welikson K, Nunes E, Rabkin J G, and Klein D F (1990) Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication.. Archives of general psychiatry 47(10), 935-41","[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Quitkin[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1990[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",na,USA,tick,na,"[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""grant MH39143 from the National""\n""Institute of Mental Health, Bethesda, Md, and by grant MH30906-11 from the\nNational Health Clinical Research Center, Bethesda, Md,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1. Met Research Diagnostic Criteria for major, minor, or intermit""\n""\ntent depression.15""\n""The following""\n""2. Maintained mood reactivity while they were depressed, defined\npresent ifmood could be lifted at least 50% ofwhen they were not""\n""depressed (scale and anchors available from authors).\n3. Exhibited at least two of the following: increase""\n""weightgain while theywere depressed (defined as present ifappetite""\n""d appetite or""\n""markedly increased or there was at least a""\n""4.5-kg weight gain),\nfatigue that created a""\n""oversleeping (sleeps at least 10 h/d), severe""\n""sensation of leaden paralysis or extreme heaviness of arms o""\n""legs""\n""(defined\nlimbs""\n""as""\n""leaden\npresent""\n""if a""\n""depression with functional impairment, eg, the subject missed work\nor\nschool""\n""was a prominent symptom), and sensitivity to rejection as a""\n""marked decrease""\n""e in e""\n""nergy or heaviness""\n""trait throughout adulthood (defined as\ndepression with functional impairment, eg, the subject missed work""\n""present""\n""ifrejection""\n""Were between 18 and 65 years ofage.\n5. Had no other Axis I diagnoses other than panic disorder.""\n""Had no treatment with 45 mg/d or more ofphenelzine sulfate (or\nepisode""\n""an equivalent MAOI) or more than 150 mg/d ofimipramine hydrochlo""\n""""\n""ride (or an""\n""equivalent TCA) for 2 or more weeks during the current""\n""hose subjects with a lifetime history of at least one\nequivalent TCA) for 2 or more weeks during the current\nspontaneous\nan equivalent MAOI) or more than 150 mg/d ofimipramine hydrochlo""\n""\nride (or an\npanic attack (by Research Diagnostic Criteria) were judged to b""\n""episode.\nTh""\n""panic positive.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,Atypical depression,"[{'ItemDocumentId': 1050683, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""panic disorder.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Quitkin F M et al. - 1990 - Atypical depression, panic attacks, and response t.pdf', 'ItemArm': ''}]",tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Quitkin, 1990",na,na,na,na,na,na,na,na,na,na,na,37290,Placebo,na,na,na,na,30.1,na,na,34,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,8,na,na,2,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,3x daily,na,na,na,na,na,tick,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,87999150.0,Continuous,107215.0,113380385.0,1.0,13669974.0,0.0,13709934.0,SCL-90 Anxiety,1887.0,weeks,6,6 weeks,37290.0,0.0,Placebo,,Quitkin (1990),AdjMeans,23.0,2.1,99999.0,0.0,Placebo,*SCL-90 Anxiety subscale
90055317,Multicentre controlled randomised double-blind placebo study of minaprine in elderly patients suffering from prolonged depressive reaction,Drug Investigation,Parnetti (1993),1993,"Parnetti L, Sommacal S, Morselli Labate A.M, and Senin U (1993) Multicentre controlled randomised double-blind placebo study of minaprine in elderly patients suffering from prolonged depressive reaction. Drug Investigation 6(4), 181-188","[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Parnetti[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1993[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Italy[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This study was supported by grants from MIDY SpA\n- Gruppo Sanofi, Italy.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""The main inclusion criteria were:\naged between 60 and 85 years, and having received\nschooling for between 3 and 12 years. In order to\nexclude demented patients, the Mini Mental State\nExamination (MMSE) [Folstein et al. 1975] score\nhad to be ;?; 24. A tendency to autosuppression was\nexcluded by means of a score of ~ 3 at the bipolar\nitem n. 25 of the \'Evaluation Clinique de la Per-""\n""sonnalite\' (ECP) Scale (he/she enjoys life - he/she\nattempts suicide) [Israel et al. 1980][¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""The following patients were excluded from the\nstudy: those (a) suffering from severe organic and/\nor systemic diseases, (b) under pharmacological\ntreatment with psychotropic drugs, (c) having other\npsychiatric and neurological illnesses, (d) prone to\ndrug and/or alcohol abuse, and/or (e) having sev-\nere sensorial defects.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,tick,tick,na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""prolonged depressive reaction (ICD 9,309.1[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",tick,tick,na,tick,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,3 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Parnetti, 1993",na,na,na,na,na,na,na,na,na,tick,na,37287,Minipramine,na,na,na,na,71.60,na,na,63,na,na,36,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,4,na,na,tick,na,tick,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"nausea=1;
dry mouth=1;
restlessness=1;",na,200mg,200.00,200mg,90 days,200mg,200mg,na,na,na,na,na,na,na,na,na,na,na,na,2X day,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,6.50,na,na,na,3,na,na,na,na,na,na,na,na,na,na,na,na,na,90055317.0,Continuous,107993.0,113664328.0,1.0,13669967.0,0.0,13769930.0,SRT Anxiety ,1884.0,weeks,0,0 weeks,37287.0,0.0,Minipramine,,Parnetti (1993),,59.0,6.9,4.0,0.0,Minaprine,*SRT Anxiety Subscale
90055317,Multicentre controlled randomised double-blind placebo study of minaprine in elderly patients suffering from prolonged depressive reaction,Drug Investigation,Parnetti (1993),1993,"Parnetti L, Sommacal S, Morselli Labate A.M, and Senin U (1993) Multicentre controlled randomised double-blind placebo study of minaprine in elderly patients suffering from prolonged depressive reaction. Drug Investigation 6(4), 181-188","[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Parnetti[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1993[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Italy[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This study was supported by grants from MIDY SpA\n- Gruppo Sanofi, Italy.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""The main inclusion criteria were:\naged between 60 and 85 years, and having received\nschooling for between 3 and 12 years. In order to\nexclude demented patients, the Mini Mental State\nExamination (MMSE) [Folstein et al. 1975] score\nhad to be ;?; 24. A tendency to autosuppression was\nexcluded by means of a score of ~ 3 at the bipolar\nitem n. 25 of the \'Evaluation Clinique de la Per-""\n""sonnalite\' (ECP) Scale (he/she enjoys life - he/she\nattempts suicide) [Israel et al. 1980][¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""The following patients were excluded from the\nstudy: those (a) suffering from severe organic and/\nor systemic diseases, (b) under pharmacological\ntreatment with psychotropic drugs, (c) having other\npsychiatric and neurological illnesses, (d) prone to\ndrug and/or alcohol abuse, and/or (e) having sev-\nere sensorial defects.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,tick,tick,na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""prolonged depressive reaction (ICD 9,309.1[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",tick,tick,na,tick,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,3 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Parnetti, 1993",na,na,na,na,na,na,na,na,na,tick,na,37287,Minipramine,na,na,na,na,71.60,na,na,63,na,na,36,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,4,na,na,tick,na,tick,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"nausea=1;
dry mouth=1;
restlessness=1;",na,200mg,200.00,200mg,90 days,200mg,200mg,na,na,na,na,na,na,na,na,na,na,na,na,2X day,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,6.50,na,na,na,3,na,na,na,na,na,na,na,na,na,na,na,na,na,90055317.0,Continuous,107995.0,113664328.0,1.0,13669967.0,0.0,13769930.0,SRT Anxiety ,1885.0,weeks,8.57,8.57 weeks,37287.0,0.0,Minipramine,,Parnetti (1993),,59.0,5.2,3.8,0.0,Minaprine,*SRT Anxiety Subscale
90055317,Multicentre controlled randomised double-blind placebo study of minaprine in elderly patients suffering from prolonged depressive reaction,Drug Investigation,Parnetti (1993),1993,"Parnetti L, Sommacal S, Morselli Labate A.M, and Senin U (1993) Multicentre controlled randomised double-blind placebo study of minaprine in elderly patients suffering from prolonged depressive reaction. Drug Investigation 6(4), 181-188","[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Parnetti[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1993[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Italy[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This study was supported by grants from MIDY SpA\n- Gruppo Sanofi, Italy.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""The main inclusion criteria were:\naged between 60 and 85 years, and having received\nschooling for between 3 and 12 years. In order to\nexclude demented patients, the Mini Mental State\nExamination (MMSE) [Folstein et al. 1975] score\nhad to be ;?; 24. A tendency to autosuppression was\nexcluded by means of a score of ~ 3 at the bipolar\nitem n. 25 of the \'Evaluation Clinique de la Per-""\n""sonnalite\' (ECP) Scale (he/she enjoys life - he/she\nattempts suicide) [Israel et al. 1980][¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""The following patients were excluded from the\nstudy: those (a) suffering from severe organic and/\nor systemic diseases, (b) under pharmacological\ntreatment with psychotropic drugs, (c) having other\npsychiatric and neurological illnesses, (d) prone to\ndrug and/or alcohol abuse, and/or (e) having sev-\nere sensorial defects.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,tick,tick,na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""prolonged depressive reaction (ICD 9,309.1[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",tick,tick,na,tick,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,3 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Parnetti, 1993",na,na,na,na,na,na,na,na,na,tick,na,37288,Placebo,na,na,na,na,71.30,na,na,67,na,na,47,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,3,na,na,tick,na,tick,na,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"nausea=1;
mild to moderate rash=1;
diplopia=1;",na,na,na,na,90 days,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2X day,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,6.60,na,na,na,3,na,na,na,na,na,na,na,na,na,na,na,na,na,90055317.0,Continuous,107994.0,113664328.0,1.0,13669974.0,0.0,13769930.0,SRT Anxiety ,1884.0,weeks,0,0 weeks,37288.0,0.0,Placebo,,Parnetti (1993),,64.0,6.7,3.7,0.0,Placebo,*SRT Anxiety Subscale
90055317,Multicentre controlled randomised double-blind placebo study of minaprine in elderly patients suffering from prolonged depressive reaction,Drug Investigation,Parnetti (1993),1993,"Parnetti L, Sommacal S, Morselli Labate A.M, and Senin U (1993) Multicentre controlled randomised double-blind placebo study of minaprine in elderly patients suffering from prolonged depressive reaction. Drug Investigation 6(4), 181-188","[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Parnetti[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1993[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Italy[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This study was supported by grants from MIDY SpA\n- Gruppo Sanofi, Italy.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""The main inclusion criteria were:\naged between 60 and 85 years, and having received\nschooling for between 3 and 12 years. In order to\nexclude demented patients, the Mini Mental State\nExamination (MMSE) [Folstein et al. 1975] score\nhad to be ;?; 24. A tendency to autosuppression was\nexcluded by means of a score of ~ 3 at the bipolar\nitem n. 25 of the \'Evaluation Clinique de la Per-""\n""sonnalite\' (ECP) Scale (he/she enjoys life - he/she\nattempts suicide) [Israel et al. 1980][¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""The following patients were excluded from the\nstudy: those (a) suffering from severe organic and/\nor systemic diseases, (b) under pharmacological\ntreatment with psychotropic drugs, (c) having other\npsychiatric and neurological illnesses, (d) prone to\ndrug and/or alcohol abuse, and/or (e) having sev-\nere sensorial defects.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,tick,tick,na,"[{'ItemDocumentId': 1069968, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""prolonged depressive reaction (ICD 9,309.1[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF03259242.pdf', 'ItemArm': ''}]",tick,tick,na,tick,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,3 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Parnetti, 1993",na,na,na,na,na,na,na,na,na,tick,na,37288,Placebo,na,na,na,na,71.30,na,na,67,na,na,47,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,3,na,na,tick,na,tick,na,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"nausea=1;
mild to moderate rash=1;
diplopia=1;",na,na,na,na,90 days,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2X day,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,6.60,na,na,na,3,na,na,na,na,na,na,na,na,na,na,na,na,na,90055317.0,Continuous,107996.0,113664328.0,1.0,13669974.0,0.0,13769930.0,SRT Anxiety ,1885.0,weeks,8.57,8.57 weeks,37288.0,0.0,Placebo,,Parnetti (1993),,64.0,6.1,4.1,0.0,Placebo,*SRT Anxiety Subscale
87999057,Moclobemide and placebo in mild major depression: a double-blind randomized trial.,Psychopharmacology,Ose (1992),1992,"Ose E, and Holm P (1992) Moclobemide and placebo in mild major depression: a double-blind randomized trial.. Psychopharmacology 106 Suppl, S114-5","[{'ItemDocumentId': 1053006, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ose[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF02246251.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1053006, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1992[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF02246251.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1053006, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Sixty-eight male or female patients, aged between 24 and 79 years,\nmeeting DSM-III criteria for a major depressive episode without\nmelancholia, and presenting with a Hamilton baseline total score\n17 items between 15 and 26[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF02246251.pdf', 'ItemArm': ''}]",na,tick,tick,na,na,na,na,tick,na,na,na,tick,tick,na,"[{'ItemDocumentId': 1053006, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""DSM-III criteria for a major depressive episode without\nmelancholia[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF02246251.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Ose, 1992",na,na,na,na,na,na,na,na,na,na,na,37279,Moclobemide,na,na,na,na,49 (median),na,na,35,na,na,21,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,16,na,na,5,na,na,na,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"agitation=4;
restlessness=3;
weight loss=2;
dizziness=1;
headache=1;
dyspepsia=1;
hypotension=1;
insomnia=1;
fainting=1;",na,300mg,na,500mg,4,300,500.00,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,24-79,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999057,Moclobemide and placebo in mild major depression: a double-blind randomized trial.,Psychopharmacology,Ose (1992),1992,"Ose E, and Holm P (1992) Moclobemide and placebo in mild major depression: a double-blind randomized trial.. Psychopharmacology 106 Suppl, S114-5","[{'ItemDocumentId': 1053006, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Ose[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF02246251.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1053006, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1992[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF02246251.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1053006, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Sixty-eight male or female patients, aged between 24 and 79 years,\nmeeting DSM-III criteria for a major depressive episode without\nmelancholia, and presenting with a Hamilton baseline total score\n17 items between 15 and 26[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF02246251.pdf', 'ItemArm': ''}]",na,tick,tick,na,na,na,na,tick,na,na,na,tick,tick,na,"[{'ItemDocumentId': 1053006, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""DSM-III criteria for a major depressive episode without\nmelancholia[¬e]""', 'IsFromPDF': True, 'DocTitle': 'BF02246251.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Ose, 1992",na,na,na,na,na,na,na,na,na,na,na,37280,Placebo,na,na,na,na,50 (median),na,na,33,na,na,18,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,12,na,na,2,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"agitation=1;
restlessness=1;
weight loss=1;
headache=1;
dyspepsia=1;
insomnia=1;",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,30-72,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87998891,"Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo.",Journal of affective disorders,Nair (1995),1995,"Nair N P, Amin M, Holm P, Katona C, Klitgaard N, Ng Ying Kin, N M, Kragh-Sorensen P, Kuhn H, Leek C A, and Stage K B (1995) Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo.. Journal of affective disorders 33(1), 1-9","[{'ItemDocumentId': 1050744, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Nair a[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Nair N P et al. - 1995 - Moclobemide and nortriptyline in elderly depressed.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050744, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1995[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Nair N P et al. - 1995 - Moclobemide and nortriptyline in elderly depressed.pdf', 'ItemArm': ''}]",na,"Canada, Denmark, UK",na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,tick,tick,na,na,"[{'ItemDocumentId': 1050744, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""60-90 years of age,""\n""meeting the DSM-III-R (APA, 19871 criteria for\nmajor depressive episode, were eligible. At ran-\ndomization (baseline), the total score on the first\n17 items of the Hamilton Rating Scale for De-\npression (HRSD; Hamilton, 1960; Beth, 1981)\nwas at least 18. The duration of the current\nepisode was a minimum of 4 weeks and the\nseverity at least moderate as rated on a Clinician’s\nGlobal Impression of Severity Scale (CGIS)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Nair N P et al. - 1995 - Moclobemide and nortriptyline in elderly depressed.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050744, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria were any other psychiatric or\nneurological\ndiagnosis, known severe systemic\ndiseases, acute infections, clinically significant ab-\nnormal laboratory findings, including ECG, sit-\nting blood pressure of 2 170/I 00 mm Hg and\nheart rate of < 50 or > 100 bpm, orthostatic\nsystolic fall in blood pressure of > 30 mm Hg\nafter lying for 5 min and, finally, any contraindi-\ncations to the trial drugs. Patients who were\nuncooperative,\nthose with a history of drug or\nalcohol abuse or having received cyclic antide-\npressants in the preceding week, MAOIs and\nneuroleptics in the 2 preceding weeks and sleep\ndeprivation or electroconvulsive\ntherapy during\nthe last month were also excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Nair N P et al. - 1995 - Moclobemide and nortriptyline in elderly depressed.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,Only oxazepam or temazepam (max 50mg) or chloral hydrate (max 1000mg) PRN,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,39 months,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,"Nair, 1995; Kin, 1997",na,na,na,na,na,na,na,na,na,na,na,37274,Moclobemide,na,na,na,na,67 (median),na,na,36,na,na,25,na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,21,na,na,2,na,na,na,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"CNS=20
Anticholinergic=13
Orthostatic=8
Cardiovascular=2
Gastrointestinal tract=8
Skin=2
Musculoskeletal system=4
Respiratory system=2
Other=8",na,tick,tick,400mg,7 weeks,400mg,400mg,na,na,na,na,na,na,na,na,tick,na,tick,na,2x daily,na,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,60-90,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87998891,"Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo.",Journal of affective disorders,Nair (1995),1995,"Nair N P, Amin M, Holm P, Katona C, Klitgaard N, Ng Ying Kin, N M, Kragh-Sorensen P, Kuhn H, Leek C A, and Stage K B (1995) Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo.. Journal of affective disorders 33(1), 1-9","[{'ItemDocumentId': 1050744, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Nair a[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Nair N P et al. - 1995 - Moclobemide and nortriptyline in elderly depressed.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050744, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1995[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Nair N P et al. - 1995 - Moclobemide and nortriptyline in elderly depressed.pdf', 'ItemArm': ''}]",na,"Canada, Denmark, UK",na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,tick,tick,na,na,"[{'ItemDocumentId': 1050744, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""60-90 years of age,""\n""meeting the DSM-III-R (APA, 19871 criteria for\nmajor depressive episode, were eligible. At ran-\ndomization (baseline), the total score on the first\n17 items of the Hamilton Rating Scale for De-\npression (HRSD; Hamilton, 1960; Beth, 1981)\nwas at least 18. The duration of the current\nepisode was a minimum of 4 weeks and the\nseverity at least moderate as rated on a Clinician’s\nGlobal Impression of Severity Scale (CGIS)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Nair N P et al. - 1995 - Moclobemide and nortriptyline in elderly depressed.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050744, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria were any other psychiatric or\nneurological\ndiagnosis, known severe systemic\ndiseases, acute infections, clinically significant ab-\nnormal laboratory findings, including ECG, sit-\nting blood pressure of 2 170/I 00 mm Hg and\nheart rate of < 50 or > 100 bpm, orthostatic\nsystolic fall in blood pressure of > 30 mm Hg\nafter lying for 5 min and, finally, any contraindi-\ncations to the trial drugs. Patients who were\nuncooperative,\nthose with a history of drug or\nalcohol abuse or having received cyclic antide-\npressants in the preceding week, MAOIs and\nneuroleptics in the 2 preceding weeks and sleep\ndeprivation or electroconvulsive\ntherapy during\nthe last month were also excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Nair N P et al. - 1995 - Moclobemide and nortriptyline in elderly depressed.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,Only oxazepam or temazepam (max 50mg) or chloral hydrate (max 1000mg) PRN,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,39 months,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,"Nair, 1995; Kin, 1997",na,na,na,na,na,na,na,na,na,na,na,37276,Placebo,na,na,na,na,71 (median),na,na,35,na,na,25,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,15,na,na,1,na,na,na,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,CNS=17;Anticholinergic=17;Orthostatic=9;Cardiovascular=3;Gastrointestinal tract=9;Skin=4;Musculoskeletal system=3;Respiratory system=1;Other=14,na,na,na,na,7 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,62-89,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999225,A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.,Archives of general psychiatry,Mann (1989),1989,"Mann J J, Aarons S F, Wilner P J, Keilp J G, Sweeney J A, Pearlstein T, Frances A J, Kocsis J H, and Brown R P (1989) A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.. Archives of general psychiatry 46(1), 45-50","[{'ItemDocumentId': 1050651, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Mann,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Mann J J et al. - 1989 - A controlled study of the antidepressant efficacy .pdf', 'ItemArm': ''}]",na,na,1989,na,USA,na,na,"[{'ItemDocumentId': 1050651, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 5:\n[¬s]""Dr Mann was supported by a Research Scientist Award from the Irma T.\nHirschl Foundation, New York, and Dr Brown was the recipient of an award\nfrom the Mallinckrodt Foundation, St Louis.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Mann J J et al. - 1989 - A controlled study of the antidepressant efficacy .pdf', 'ItemArm': ''}]",na,na,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"outpatients referred to the Affective Disorders Clinic at the Payne Whitney Psychiatric Clinic, The New York Hospital-Cornell Medical Center. Consecutive patients who were diagnosed by two psychiatrists as having a Major Depressive Episode by DSM-III criteria,and who met the inclusion and exclusion criteria for the protocol and gave written, informed consent as required by the Institutional Review Board, were included in the study. Patients had to meet the following criteria: to have suffered from a depressive episode for at least four weeks; to be drug free for at least two weeks immediately before the study (except for chloral hydrate, oxazepam, or an equivalent drug for distressing insomnia); to be normotensive and free from significant medical illness; to have not received electroconvulsive therapy, an MAO inhibitor, or an experimental drug within the last six months before this study; and to not meet DSM-III criteria for substance abuse.",na,"[{'ItemDocumentId': 1050651, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Delusionally\ndepressed and actively suicidal patients were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Mann J J et al. - 1989 - A controlled study of the antidepressant efficacy .pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive disorder,bipolar disorder=5,na,na,"[{'ItemDocumentId': 1050651, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""chloral hydrate, oxaze-""\n""pam, or an""\n""equivalent drug for distressing insomnia);[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Mann J J et al. - 1989 - A controlled study of the antidepressant efficacy .pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Mann, 1989",na,na,na,na,na,na,na,na,na,na,na,37315,Placebo,na,na,na,na,40.2,na,na,22,na,na,17,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,7,na,na,tick,tick,na,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,Orthostatic symptoms=0;Sexual dysfunction=1;Myoclonic jerks=0;Insomnia=0;Dizziness=6;Dry mouth=5;Constipation=3;Drowsiness=3;Hyperactivity=4;Blurry vision=1;Tremor=3;Headache=11;Nausea=4;Other=8,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.7,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999225,A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.,Archives of general psychiatry,Mann (1989),1989,"Mann J J, Aarons S F, Wilner P J, Keilp J G, Sweeney J A, Pearlstein T, Frances A J, Kocsis J H, and Brown R P (1989) A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.. Archives of general psychiatry 46(1), 45-50","[{'ItemDocumentId': 1050651, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Mann,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Mann J J et al. - 1989 - A controlled study of the antidepressant efficacy .pdf', 'ItemArm': ''}]",na,na,1989,na,USA,na,na,"[{'ItemDocumentId': 1050651, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 5:\n[¬s]""Dr Mann was supported by a Research Scientist Award from the Irma T.\nHirschl Foundation, New York, and Dr Brown was the recipient of an award\nfrom the Mallinckrodt Foundation, St Louis.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Mann J J et al. - 1989 - A controlled study of the antidepressant efficacy .pdf', 'ItemArm': ''}]",na,na,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"outpatients referred to the Affective Disorders Clinic at the Payne Whitney Psychiatric Clinic, The New York Hospital-Cornell Medical Center. Consecutive patients who were diagnosed by two psychiatrists as having a Major Depressive Episode by DSM-III criteria,and who met the inclusion and exclusion criteria for the protocol and gave written, informed consent as required by the Institutional Review Board, were included in the study. Patients had to meet the following criteria: to have suffered from a depressive episode for at least four weeks; to be drug free for at least two weeks immediately before the study (except for chloral hydrate, oxazepam, or an equivalent drug for distressing insomnia); to be normotensive and free from significant medical illness; to have not received electroconvulsive therapy, an MAO inhibitor, or an experimental drug within the last six months before this study; and to not meet DSM-III criteria for substance abuse.",na,"[{'ItemDocumentId': 1050651, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Delusionally\ndepressed and actively suicidal patients were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Mann J J et al. - 1989 - A controlled study of the antidepressant efficacy .pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive disorder,bipolar disorder=5,na,na,"[{'ItemDocumentId': 1050651, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""chloral hydrate, oxaze-""\n""pam, or an""\n""equivalent drug for distressing insomnia);[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Mann J J et al. - 1989 - A controlled study of the antidepressant efficacy .pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Mann, 1989",na,na,na,na,na,na,na,na,na,na,na,37316,Selegiline,na,na,na,na,45.2,na,na,22,na,na,16,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,6,na,na,tick,tick,na,na,tick,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Orthostatic symptoms=1;Sexual dysfunction=2;Myoclonic jerks=1;Insomnia=3;Dizziness=5;Dry mouth=9;Constipation=4;Drowsiness=7;Hyperactivity=1;Blurry vision=4;Tremor=7;Headache=7;Nausea=6;Other=10,na,na,tick,50mg,6 weeks,tick,tick,na,na,tick,na,tick,na,na,na,na,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,12.3,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999380,Phenelzine v imipramine in atypical depression. A preliminary report.,Archives of general psychiatry,Liebowitz (1984),1984,"Liebowitz M R, Quitkin F M, Stewart J W, McGrath P J, Harrison W, Rabkin J, Tricamo E, Markowitz J S, and Klein D F (1984) Phenelzine v imipramine in atypical depression. A preliminary report.. Archives of general psychiatry 41(7), 669-77","[{'ItemDocumentId': 1053857, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Liebowitz[¬e]""', 'IsFromPDF': True, 'DocTitle': 'archpsyc_41_7_005.pdf', 'ItemArm': ''}]",na,na,1984,na,tick,tick,na,"[{'ItemDocumentId': 1053857, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 9:\n[¬s]""This investigation was supported in part by grants MH35297 and""\n""MHCRC30906 from the Public Health Service.""\n""The phenelzine sulfate used""\n""This investigation was supported in part by grants MH35297 and\nsupplied as Nardil by Parke-Davis, Morris Plains, NJ,\nsupplied by Ciba-Geigy, Summit, NJ.""\n""which also provided the matching placebo. The imipramine hydrochloride\n(Tbfranil) and matching placebo were[¬e]""', 'IsFromPDF': True, 'DocTitle': 'archpsyc_41_7_005.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,2 of interest,na,tick,na,na,na,na,tick,na,na,na,na,na,Unclear as mix from referrals from other 'health facilities' and self-referrals,"[{'ItemDocumentId': 1053857, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""The following selection criteria were used: (1) age between 18 and 55 years; (2) presence of the already- mentioned criteria for atypical depression;""\n""absence of serious\nmedical illness; (4) absence of psychotic, sociopathic, obsessive-""\n""compulsive, bipolar, anorectic, or bulimic features (a history of\nm""\n""d hypomania was not, however, reason for exclusion); (5) no\nmaintenance use of medication that could interact with study\n(7) ability to adhere to MAOI food, beverage, and medication\nrestrictions; (8) no treatment with 45 mg/day or more ofphenelzine\nsulfate (or the equivalent amount of another MAOI) or more than""\n""150 mg/day ofimipramine hydrochloride (or the equivalent amount\noutpatient or accept hospitalization\nof another TCA) for two or more weeks during the current episode;""\n""(9) ability to participate as an""\n""on an inpatient research ward; and (10) Hamilton Depression Scale\n(HDS) score equal to or""\n""greater than 10.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'archpsyc_41_7_005.pdf', 'ItemArm': ''}]",na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,3,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,tick,na,"Liebowitz, 1984;
Liebowitz, 1988;
Quitkin, 1989;
McGrath, 1992;
Stewart, 1989;
Stewart, 1989;
Quitkin, 1988;
Stewart, 1992;
Stewart, 1988;
Stewart, 1988;
Quitkin, 1993;
Stewart, 2002;
Stewart, 1989",na,na,na,na,tick,tick,na,tick,tick,na,na,37339,Placebo,na,na,na,na,37.7,na,na,24,na,na,14,na,na,tick,tick,"[{'ItemDocumentId': 1053857, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""atypical depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'archpsyc_41_7_005.pdf', 'ItemArm': 'Placebo'}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,2,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,8.9,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999380.0,Continuous,109607.0,114138832.0,1.0,13669974.0,0.0,13731727.0,HSC Anxiety,1916.0,weeks,0,0 weeks,37339.0,0.0,Placebo,,Liebowitz (1984),90-ltem Hopkins Symptom Checklist Somatization,22.0,1.6,1.0,0.0,Placebo,HSC - anxiety scale
87999380,Phenelzine v imipramine in atypical depression. A preliminary report.,Archives of general psychiatry,Liebowitz (1984),1984,"Liebowitz M R, Quitkin F M, Stewart J W, McGrath P J, Harrison W, Rabkin J, Tricamo E, Markowitz J S, and Klein D F (1984) Phenelzine v imipramine in atypical depression. A preliminary report.. Archives of general psychiatry 41(7), 669-77","[{'ItemDocumentId': 1053857, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Liebowitz[¬e]""', 'IsFromPDF': True, 'DocTitle': 'archpsyc_41_7_005.pdf', 'ItemArm': ''}]",na,na,1984,na,tick,tick,na,"[{'ItemDocumentId': 1053857, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 9:\n[¬s]""This investigation was supported in part by grants MH35297 and""\n""MHCRC30906 from the Public Health Service.""\n""The phenelzine sulfate used""\n""This investigation was supported in part by grants MH35297 and\nsupplied as Nardil by Parke-Davis, Morris Plains, NJ,\nsupplied by Ciba-Geigy, Summit, NJ.""\n""which also provided the matching placebo. The imipramine hydrochloride\n(Tbfranil) and matching placebo were[¬e]""', 'IsFromPDF': True, 'DocTitle': 'archpsyc_41_7_005.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,2 of interest,na,tick,na,na,na,na,tick,na,na,na,na,na,Unclear as mix from referrals from other 'health facilities' and self-referrals,"[{'ItemDocumentId': 1053857, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""The following selection criteria were used: (1) age between 18 and 55 years; (2) presence of the already- mentioned criteria for atypical depression;""\n""absence of serious\nmedical illness; (4) absence of psychotic, sociopathic, obsessive-""\n""compulsive, bipolar, anorectic, or bulimic features (a history of\nm""\n""d hypomania was not, however, reason for exclusion); (5) no\nmaintenance use of medication that could interact with study\n(7) ability to adhere to MAOI food, beverage, and medication\nrestrictions; (8) no treatment with 45 mg/day or more ofphenelzine\nsulfate (or the equivalent amount of another MAOI) or more than""\n""150 mg/day ofimipramine hydrochloride (or the equivalent amount\noutpatient or accept hospitalization\nof another TCA) for two or more weeks during the current episode;""\n""(9) ability to participate as an""\n""on an inpatient research ward; and (10) Hamilton Depression Scale\n(HDS) score equal to or""\n""greater than 10.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'archpsyc_41_7_005.pdf', 'ItemArm': ''}]",na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,3,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,tick,na,"Liebowitz, 1984;
Liebowitz, 1988;
Quitkin, 1989;
McGrath, 1992;
Stewart, 1989;
Stewart, 1989;
Quitkin, 1988;
Stewart, 1992;
Stewart, 1988;
Stewart, 1988;
Quitkin, 1993;
Stewart, 2002;
Stewart, 1989",na,na,na,na,tick,tick,na,tick,tick,na,na,37339,Placebo,na,na,na,na,37.7,na,na,24,na,na,14,na,na,tick,tick,"[{'ItemDocumentId': 1053857, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""atypical depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'archpsyc_41_7_005.pdf', 'ItemArm': 'Placebo'}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,2,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,8.9,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999380.0,Continuous,109608.0,114138832.0,1.0,13669974.0,0.0,13731727.0,HSC Anxiety,1917.0,weeks,6,6 weeks,37339.0,0.0,Placebo,,Liebowitz (1984),90-ltem Hopkins Symptom Checklist Somatization,18.0,1.5,99999.0,0.0,Placebo,HSC - anxiety scale
87999380,Phenelzine v imipramine in atypical depression. A preliminary report.,Archives of general psychiatry,Liebowitz (1984),1984,"Liebowitz M R, Quitkin F M, Stewart J W, McGrath P J, Harrison W, Rabkin J, Tricamo E, Markowitz J S, and Klein D F (1984) Phenelzine v imipramine in atypical depression. A preliminary report.. Archives of general psychiatry 41(7), 669-77","[{'ItemDocumentId': 1053857, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Liebowitz[¬e]""', 'IsFromPDF': True, 'DocTitle': 'archpsyc_41_7_005.pdf', 'ItemArm': ''}]",na,na,1984,na,tick,tick,na,"[{'ItemDocumentId': 1053857, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 9:\n[¬s]""This investigation was supported in part by grants MH35297 and""\n""MHCRC30906 from the Public Health Service.""\n""The phenelzine sulfate used""\n""This investigation was supported in part by grants MH35297 and\nsupplied as Nardil by Parke-Davis, Morris Plains, NJ,\nsupplied by Ciba-Geigy, Summit, NJ.""\n""which also provided the matching placebo. The imipramine hydrochloride\n(Tbfranil) and matching placebo were[¬e]""', 'IsFromPDF': True, 'DocTitle': 'archpsyc_41_7_005.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,2 of interest,na,tick,na,na,na,na,tick,na,na,na,na,na,Unclear as mix from referrals from other 'health facilities' and self-referrals,"[{'ItemDocumentId': 1053857, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""The following selection criteria were used: (1) age between 18 and 55 years; (2) presence of the already- mentioned criteria for atypical depression;""\n""absence of serious\nmedical illness; (4) absence of psychotic, sociopathic, obsessive-""\n""compulsive, bipolar, anorectic, or bulimic features (a history of\nm""\n""d hypomania was not, however, reason for exclusion); (5) no\nmaintenance use of medication that could interact with study\n(7) ability to adhere to MAOI food, beverage, and medication\nrestrictions; (8) no treatment with 45 mg/day or more ofphenelzine\nsulfate (or the equivalent amount of another MAOI) or more than""\n""150 mg/day ofimipramine hydrochloride (or the equivalent amount\noutpatient or accept hospitalization\nof another TCA) for two or more weeks during the current episode;""\n""(9) ability to participate as an""\n""on an inpatient research ward; and (10) Hamilton Depression Scale\n(HDS) score equal to or""\n""greater than 10.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'archpsyc_41_7_005.pdf', 'ItemArm': ''}]",na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,3,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,tick,na,"Liebowitz, 1984;
Liebowitz, 1988;
Quitkin, 1989;
McGrath, 1992;
Stewart, 1989;
Stewart, 1989;
Quitkin, 1988;
Stewart, 1992;
Stewart, 1988;
Stewart, 1988;
Quitkin, 1993;
Stewart, 2002;
Stewart, 1989",na,na,na,na,tick,tick,na,tick,tick,na,na,37341,Phenelzine,na,na,na,na,33.8,na,na,15,na,na,7,na,na,tick,tick,"[{'ItemDocumentId': 1053857, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Atypical Depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'archpsyc_41_7_005.pdf', 'ItemArm': 'Phenelzine'}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,6,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,60mg,74mg,90mg,6 weeks,15mg,90mg,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,9.3,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999380.0,Continuous,109609.0,114138832.0,1.0,13669972.0,0.0,13731727.0,HSC Anxiety,1916.0,weeks,0,0 weeks,37341.0,0.0,Phenelzine,,Liebowitz (1984),90-ltem Hopkins Symptom Checklist Somatization,14.0,1.0,0.6,0.0,Phenelzine,HSC - anxiety scale
87999380,Phenelzine v imipramine in atypical depression. A preliminary report.,Archives of general psychiatry,Liebowitz (1984),1984,"Liebowitz M R, Quitkin F M, Stewart J W, McGrath P J, Harrison W, Rabkin J, Tricamo E, Markowitz J S, and Klein D F (1984) Phenelzine v imipramine in atypical depression. A preliminary report.. Archives of general psychiatry 41(7), 669-77","[{'ItemDocumentId': 1053857, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Liebowitz[¬e]""', 'IsFromPDF': True, 'DocTitle': 'archpsyc_41_7_005.pdf', 'ItemArm': ''}]",na,na,1984,na,tick,tick,na,"[{'ItemDocumentId': 1053857, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 9:\n[¬s]""This investigation was supported in part by grants MH35297 and""\n""MHCRC30906 from the Public Health Service.""\n""The phenelzine sulfate used""\n""This investigation was supported in part by grants MH35297 and\nsupplied as Nardil by Parke-Davis, Morris Plains, NJ,\nsupplied by Ciba-Geigy, Summit, NJ.""\n""which also provided the matching placebo. The imipramine hydrochloride\n(Tbfranil) and matching placebo were[¬e]""', 'IsFromPDF': True, 'DocTitle': 'archpsyc_41_7_005.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,2 of interest,na,tick,na,na,na,na,tick,na,na,na,na,na,Unclear as mix from referrals from other 'health facilities' and self-referrals,"[{'ItemDocumentId': 1053857, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""The following selection criteria were used: (1) age between 18 and 55 years; (2) presence of the already- mentioned criteria for atypical depression;""\n""absence of serious\nmedical illness; (4) absence of psychotic, sociopathic, obsessive-""\n""compulsive, bipolar, anorectic, or bulimic features (a history of\nm""\n""d hypomania was not, however, reason for exclusion); (5) no\nmaintenance use of medication that could interact with study\n(7) ability to adhere to MAOI food, beverage, and medication\nrestrictions; (8) no treatment with 45 mg/day or more ofphenelzine\nsulfate (or the equivalent amount of another MAOI) or more than""\n""150 mg/day ofimipramine hydrochloride (or the equivalent amount\noutpatient or accept hospitalization\nof another TCA) for two or more weeks during the current episode;""\n""(9) ability to participate as an""\n""on an inpatient research ward; and (10) Hamilton Depression Scale\n(HDS) score equal to or""\n""greater than 10.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'archpsyc_41_7_005.pdf', 'ItemArm': ''}]",na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,3,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,tick,na,"Liebowitz, 1984;
Liebowitz, 1988;
Quitkin, 1989;
McGrath, 1992;
Stewart, 1989;
Stewart, 1989;
Quitkin, 1988;
Stewart, 1992;
Stewart, 1988;
Stewart, 1988;
Quitkin, 1993;
Stewart, 2002;
Stewart, 1989",na,na,na,na,tick,tick,na,tick,tick,na,na,37341,Phenelzine,na,na,na,na,33.8,na,na,15,na,na,7,na,na,tick,tick,"[{'ItemDocumentId': 1053857, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Atypical Depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'archpsyc_41_7_005.pdf', 'ItemArm': 'Phenelzine'}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,6,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,60mg,74mg,90mg,6 weeks,15mg,90mg,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,9.3,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999380.0,Continuous,109610.0,114138832.0,1.0,13669972.0,0.0,13731727.0,HSC Anxiety,1917.0,weeks,6,6 weeks,37341.0,0.0,Phenelzine,,Liebowitz (1984),90-ltem Hopkins Symptom Checklist Somatization,12.0,0.9,99999.0,0.0,Phenelzine,HSC - anxiety scale
91551222,"Study 2 from  =  Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials",JOURNAL OF PSYCHOPHARMACOLOGY,Learned (2012b),2012,"Learned S, Graff O, Roychowdhury S, Moate R, Krishnan KR, Archer G, Modell JG, Alexander R, Zamuner S, Lavergne A, Evoniuk G, and Ratti E (2012) Study 2 from  =  Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. JOURNAL OF PSYCHOPHARMACOLOGY 26(5), 653-662 DOI: 10.1177/0269881111424931","[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Learned[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2012[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""37 sites in Bulgaria, Canada, Chile, Costa Rica,\nCroatia, France, Germany, India, Italy, and Poland.[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,na,GSK,na,"GSK372475. [{'ItemDocumentId': 1083972, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""SND103288[¬e]""', 'IsFromPDF': True, 'DocTitle': 'SND 103288-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""male and female patients (18–64 years old) were\nrequired to have a diagnosis of MDE with MDD (single or recur-\nrent episodes according to the Diagnostic and Statistical Manual\nof Mental Disorders, 4th Edition, Text Revision [DSM-IV-TR]),\nwith current episode duration of at least two weeks but less than\ntwo years. Patients were required to have a Clinical Global\nImpression-Severity of Illness (CGI-S) score ≥ 4 at the randomi-\nzation visit and an Inventory of Depressive Symptomatology-Self\nReported (IDS-SR) score ≥ 40 (Study 1) or ≥ 25 (Study 2) at the\nscreening and randomization visits, with a change of no more than\n25% in IDS-SR between these two visits. Additionally, Study 2\nrequired patients to have symptoms of decreased pleasure, inter-\nest, and energy, indicated by a total score of at least 7, and indi-\nvidual scores of at least 1 on four or more of the following five\nitems of the IDS-SR: item 19 – general interest/involvement; item\n20 – energy/fatigability; item 21 – pleasure/enjoyment; item 22 –\nsexual interest; and item 30 – leaden paralysis/physical energy.[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if the symptoms of a presenting illness\nwere better accounted for by another diagnosis or if the patient\nhad a current DSM-IV-TR diagnosis of any of the following:\npanic disorder, antisocial or border line personality disorder, bipo-\nlar disorder, schizophrenia, or other psychotic disorders. Patients\nwere excluded if they had previously failed an adequate therapeu-\ntic course of two or more antidepressants, had started psycho-\ntherapy within three months of screening, or had received\nelectroconvulsive therapy or transcranial magnetic stimulation\nwithin six months of screening. Patients considered by the inves-\ntigator to be at risk for suicide or who had any previous suicide\nattempt or a family history of suicide attempt were excluded.\nPatients with a positive urine drug screen or a positive blood alco-\nhol at screening were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""major\ndepressive disorder[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2008,na,na,19 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Learned, 2012b; SND 103288",na,na,na,na,na,na,na,na,na,na,na,37325,Placebo,na,na,na,na,41.8,na,na,156,na,na,39,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,41,na,na,3,na,na,tick,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Dry mouth=4;Headache=36;Nausea=12;Insomnia=8;Dizziness=7;Constipation=8;Tachycardia=1;Diarrhea=9;Sleep Disorder=3;Hyperhidrosis=5;Palpitations=3,na,na,na,na,10 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,tick,Intentional overdose=1;depression=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.89,na,na,na,tick,na,tick,2,na,na,na,na,na,na,na,na,na,na,91551222.0,Continuous,108057.0,113798537.0,1.0,13669974.0,0.0,13711321.0,MEI Total,1910.0,weeks,0,0 weeks,37325.0,0.0,Placebo,,Learned (2012b),,156.0,99999.0,99999.0,0.0,Placebo,*Motivation and Energy Inventory (MEI)
91551222,"Study 2 from  =  Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials",JOURNAL OF PSYCHOPHARMACOLOGY,Learned (2012b),2012,"Learned S, Graff O, Roychowdhury S, Moate R, Krishnan KR, Archer G, Modell JG, Alexander R, Zamuner S, Lavergne A, Evoniuk G, and Ratti E (2012) Study 2 from  =  Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. JOURNAL OF PSYCHOPHARMACOLOGY 26(5), 653-662 DOI: 10.1177/0269881111424931","[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Learned[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2012[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""37 sites in Bulgaria, Canada, Chile, Costa Rica,\nCroatia, France, Germany, India, Italy, and Poland.[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,na,GSK,na,"GSK372475. [{'ItemDocumentId': 1083972, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""SND103288[¬e]""', 'IsFromPDF': True, 'DocTitle': 'SND 103288-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""male and female patients (18–64 years old) were\nrequired to have a diagnosis of MDE with MDD (single or recur-\nrent episodes according to the Diagnostic and Statistical Manual\nof Mental Disorders, 4th Edition, Text Revision [DSM-IV-TR]),\nwith current episode duration of at least two weeks but less than\ntwo years. Patients were required to have a Clinical Global\nImpression-Severity of Illness (CGI-S) score ≥ 4 at the randomi-\nzation visit and an Inventory of Depressive Symptomatology-Self\nReported (IDS-SR) score ≥ 40 (Study 1) or ≥ 25 (Study 2) at the\nscreening and randomization visits, with a change of no more than\n25% in IDS-SR between these two visits. Additionally, Study 2\nrequired patients to have symptoms of decreased pleasure, inter-\nest, and energy, indicated by a total score of at least 7, and indi-\nvidual scores of at least 1 on four or more of the following five\nitems of the IDS-SR: item 19 – general interest/involvement; item\n20 – energy/fatigability; item 21 – pleasure/enjoyment; item 22 –\nsexual interest; and item 30 – leaden paralysis/physical energy.[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if the symptoms of a presenting illness\nwere better accounted for by another diagnosis or if the patient\nhad a current DSM-IV-TR diagnosis of any of the following:\npanic disorder, antisocial or border line personality disorder, bipo-\nlar disorder, schizophrenia, or other psychotic disorders. Patients\nwere excluded if they had previously failed an adequate therapeu-\ntic course of two or more antidepressants, had started psycho-\ntherapy within three months of screening, or had received\nelectroconvulsive therapy or transcranial magnetic stimulation\nwithin six months of screening. Patients considered by the inves-\ntigator to be at risk for suicide or who had any previous suicide\nattempt or a family history of suicide attempt were excluded.\nPatients with a positive urine drug screen or a positive blood alco-\nhol at screening were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""major\ndepressive disorder[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2008,na,na,19 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Learned, 2012b; SND 103288",na,na,na,na,na,na,na,na,na,na,na,37325,Placebo,na,na,na,na,41.8,na,na,156,na,na,39,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,41,na,na,3,na,na,tick,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Dry mouth=4;Headache=36;Nausea=12;Insomnia=8;Dizziness=7;Constipation=8;Tachycardia=1;Diarrhea=9;Sleep Disorder=3;Hyperhidrosis=5;Palpitations=3,na,na,na,na,10 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,tick,Intentional overdose=1;depression=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.89,na,na,na,tick,na,tick,2,na,na,na,na,na,na,na,na,na,na,91551222.0,Continuous,108058.0,113798537.0,1.0,13669974.0,0.0,13711321.0,MEI Total,1911.0,weeks,10,10 weeks,37325.0,0.0,Placebo,,Learned (2012b),MMRM;Change from baseline;LSMean,156.0,99999.0,99999.0,0.0,Placebo,*Motivation and Energy Inventory (MEI)
91551222,"Study 2 from  =  Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials",JOURNAL OF PSYCHOPHARMACOLOGY,Learned (2012b),2012,"Learned S, Graff O, Roychowdhury S, Moate R, Krishnan KR, Archer G, Modell JG, Alexander R, Zamuner S, Lavergne A, Evoniuk G, and Ratti E (2012) Study 2 from  =  Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. JOURNAL OF PSYCHOPHARMACOLOGY 26(5), 653-662 DOI: 10.1177/0269881111424931","[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Learned[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2012[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""37 sites in Bulgaria, Canada, Chile, Costa Rica,\nCroatia, France, Germany, India, Italy, and Poland.[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,na,GSK,na,"GSK372475. [{'ItemDocumentId': 1083972, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""SND103288[¬e]""', 'IsFromPDF': True, 'DocTitle': 'SND 103288-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""male and female patients (18–64 years old) were\nrequired to have a diagnosis of MDE with MDD (single or recur-\nrent episodes according to the Diagnostic and Statistical Manual\nof Mental Disorders, 4th Edition, Text Revision [DSM-IV-TR]),\nwith current episode duration of at least two weeks but less than\ntwo years. Patients were required to have a Clinical Global\nImpression-Severity of Illness (CGI-S) score ≥ 4 at the randomi-\nzation visit and an Inventory of Depressive Symptomatology-Self\nReported (IDS-SR) score ≥ 40 (Study 1) or ≥ 25 (Study 2) at the\nscreening and randomization visits, with a change of no more than\n25% in IDS-SR between these two visits. Additionally, Study 2\nrequired patients to have symptoms of decreased pleasure, inter-\nest, and energy, indicated by a total score of at least 7, and indi-\nvidual scores of at least 1 on four or more of the following five\nitems of the IDS-SR: item 19 – general interest/involvement; item\n20 – energy/fatigability; item 21 – pleasure/enjoyment; item 22 –\nsexual interest; and item 30 – leaden paralysis/physical energy.[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if the symptoms of a presenting illness\nwere better accounted for by another diagnosis or if the patient\nhad a current DSM-IV-TR diagnosis of any of the following:\npanic disorder, antisocial or border line personality disorder, bipo-\nlar disorder, schizophrenia, or other psychotic disorders. Patients\nwere excluded if they had previously failed an adequate therapeu-\ntic course of two or more antidepressants, had started psycho-\ntherapy within three months of screening, or had received\nelectroconvulsive therapy or transcranial magnetic stimulation\nwithin six months of screening. Patients considered by the inves-\ntigator to be at risk for suicide or who had any previous suicide\nattempt or a family history of suicide attempt were excluded.\nPatients with a positive urine drug screen or a positive blood alco-\nhol at screening were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""major\ndepressive disorder[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2008,na,na,19 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Learned, 2012b; SND 103288",na,na,na,na,na,na,na,na,na,na,na,37326,GSK372475,na,na,na,na,42.4,na,na,171,na,na,54,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,71,na,na,25,na,na,tick,tick,tick,tick,tick,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,Dry mouth=38;Headache=35;Nausea=18;Insomnia=17;Dizziness=17;Constipation=16;Tachycardia=12;Diarrhea=10;Sleep Disorder=10;Hyperhidrosis=9;Palpitations=9,na,1mg,tick,1.5mg,10 weeks,1mg,1.5mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,tick,na,na,na,na,na,na,tick,suicide=1;suicidal ideation=1;adjustment disorder=1;major depression=1,na,na,na,na,na,na,na,na,na,tick,na,na,na,tick,11.64,na,na,na,tick,na,tick,8,na,na,na,na,na,na,na,na,na,na,91551222.0,Continuous,108059.0,113798537.0,1.0,13720235.0,0.0,13711321.0,MEI Total,1910.0,weeks,0,0 weeks,37326.0,0.0,GSK372475,,Learned (2012b),,99999.0,99999.0,99999.0,0.0,*GSK372475,*Motivation and Energy Inventory (MEI)
91551222,"Study 2 from  =  Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials",JOURNAL OF PSYCHOPHARMACOLOGY,Learned (2012b),2012,"Learned S, Graff O, Roychowdhury S, Moate R, Krishnan KR, Archer G, Modell JG, Alexander R, Zamuner S, Lavergne A, Evoniuk G, and Ratti E (2012) Study 2 from  =  Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. JOURNAL OF PSYCHOPHARMACOLOGY 26(5), 653-662 DOI: 10.1177/0269881111424931","[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Learned[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2012[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""37 sites in Bulgaria, Canada, Chile, Costa Rica,\nCroatia, France, Germany, India, Italy, and Poland.[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,na,GSK,na,"GSK372475. [{'ItemDocumentId': 1083972, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""SND103288[¬e]""', 'IsFromPDF': True, 'DocTitle': 'SND 103288-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""male and female patients (18–64 years old) were\nrequired to have a diagnosis of MDE with MDD (single or recur-\nrent episodes according to the Diagnostic and Statistical Manual\nof Mental Disorders, 4th Edition, Text Revision [DSM-IV-TR]),\nwith current episode duration of at least two weeks but less than\ntwo years. Patients were required to have a Clinical Global\nImpression-Severity of Illness (CGI-S) score ≥ 4 at the randomi-\nzation visit and an Inventory of Depressive Symptomatology-Self\nReported (IDS-SR) score ≥ 40 (Study 1) or ≥ 25 (Study 2) at the\nscreening and randomization visits, with a change of no more than\n25% in IDS-SR between these two visits. Additionally, Study 2\nrequired patients to have symptoms of decreased pleasure, inter-\nest, and energy, indicated by a total score of at least 7, and indi-\nvidual scores of at least 1 on four or more of the following five\nitems of the IDS-SR: item 19 – general interest/involvement; item\n20 – energy/fatigability; item 21 – pleasure/enjoyment; item 22 –\nsexual interest; and item 30 – leaden paralysis/physical energy.[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if the symptoms of a presenting illness\nwere better accounted for by another diagnosis or if the patient\nhad a current DSM-IV-TR diagnosis of any of the following:\npanic disorder, antisocial or border line personality disorder, bipo-\nlar disorder, schizophrenia, or other psychotic disorders. Patients\nwere excluded if they had previously failed an adequate therapeu-\ntic course of two or more antidepressants, had started psycho-\ntherapy within three months of screening, or had received\nelectroconvulsive therapy or transcranial magnetic stimulation\nwithin six months of screening. Patients considered by the inves-\ntigator to be at risk for suicide or who had any previous suicide\nattempt or a family history of suicide attempt were excluded.\nPatients with a positive urine drug screen or a positive blood alco-\nhol at screening were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1083953, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""major\ndepressive disorder[¬e]""', 'IsFromPDF': True, 'DocTitle': '4782dc94-3331-41cb-b64b-152f45c08db1.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2008,na,na,19 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Learned, 2012b; SND 103288",na,na,na,na,na,na,na,na,na,na,na,37326,GSK372475,na,na,na,na,42.4,na,na,171,na,na,54,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,71,na,na,25,na,na,tick,tick,tick,tick,tick,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,Dry mouth=38;Headache=35;Nausea=18;Insomnia=17;Dizziness=17;Constipation=16;Tachycardia=12;Diarrhea=10;Sleep Disorder=10;Hyperhidrosis=9;Palpitations=9,na,1mg,tick,1.5mg,10 weeks,1mg,1.5mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,tick,na,na,na,na,na,na,tick,suicide=1;suicidal ideation=1;adjustment disorder=1;major depression=1,na,na,na,na,na,na,na,na,na,tick,na,na,na,tick,11.64,na,na,na,tick,na,tick,8,na,na,na,na,na,na,na,na,na,na,91551222.0,Continuous,108060.0,113798537.0,1.0,13720235.0,0.0,13711321.0,MEI Total,1911.0,weeks,10,10 weeks,37326.0,0.0,GSK372475,,Learned (2012b),MMRM;Change from baseline;LSMean,99999.0,99999.0,99999.0,0.0,*GSK372475,*Motivation and Energy Inventory (MEI)
90047003,"Study 1 from  =  Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials",JOURNAL OF PSYCHOPHARMACOLOGY,Learned (2012a),2012,"Learned S, Graff O, Roychowdhury S, Moate R, Krishnan KR, Archer G, Modell JG, Alexander R, Zamuner S, Lavergne A, Evoniuk G, and Ratti E (2012) Study 1 from  =  Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. JOURNAL OF PSYCHOPHARMACOLOGY 26(5), 653-662 DOI: 10.1177/0269881111424931","[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Learned[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2012[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""36 sites in Australia, Belgium, Bulgaria, Canada, Estonia, Finland,\nFrance, Germany, India, Poland, Slovakia, and South Africa.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,na,GSK,na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""SND103285[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""male and female patients (18–64 years old) were\nrequired to have a diagnosis of MDE with MDD (single or recur-\nrent episodes according to the Diagnostic and Statistical Manual\nof Mental Disorders, 4th Edition, Text Revision [DSM-IV-TR]),\nwith current episode duration of at least two weeks but less than\ntwo years. Patients were required to have a Clinical Global\nImpression-Severity of Illness (CGI-S) score ≥ 4 at the randomi-\nzation visit and an Inventory of Depressive Symptomatology-Self\nReported (IDS-SR) score ≥ 40 (Study 1) or ≥ 25 (Study 2) at the\nscreening and randomization visits, with a change of no more than\n25% in IDS-SR between these two visits. Additionally, Study 2\nrequired patients to have symptoms of decreased pleasure, inter-\nest, and energy, indicated by a total score of at least 7, and indi-\nvidual scores of at least 1 on four or more of the following five\nitems of the IDS-SR: item 19 – general interest/involvement; item\n20 – energy/fatigability; item 21 – pleasure/enjoyment; item 22 –\nsexual interest; and item 30 – leaden paralysis/physical energy.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if the symptoms of a presenting illness\nwere better accounted for by another diagnosis or if the patient\nhad a current DSM-IV-TR diagnosis of any of the following:\npanic disorder, antisocial or border line personality disorder, bipo-\nlar disorder, schizophrenia, or other psychotic disorders. Patients\nwere excluded if they had previously failed an adequate therapeu-\ntic course of two or more antidepressants, had started psycho-\ntherapy within three months of screening, or had received\nelectroconvulsive therapy or transcranial magnetic stimulation\nwithin six months of screening. Patients considered by the inves-\ntigator to be at risk for suicide or who had any previous suicide\nattempt or a family history of suicide attempt were excluded.\nPatients with a positive urine drug screen or a positive blood alco-\nhol at screening were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""major depressive disorder[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2008,na,na,20 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Learned, 2012a; SND 103285",na,na,na,na,na,na,na,na,na,na,na,37322,Placebo,na,na,na,na,41.9,na,na,126,na,na,46,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,42,na,na,7,na,na,tick,tick,tick,tick,tick,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,Dry mouth=5;Headache=24;Nausea=14;Insomnia=11;Dizziness=11;Constipation=9;Tachycardia=4;Anxiety=5;Diarrhea=8;Hyperhidrosis=3;Palpitations=2;Dyspepsia=2;Somnolence=3;Decreased appetite=1;Agitation=4;,na,na,na,na,10 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,ovarian cyst=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.79,na,na,na,tick,tick,na,1,na,na,na,na,na,na,na,na,na,na,90047003.0,Continuous,108105.0,113799026.0,1.0,13669974.0,0.0,13711321.0,MEI Total,1912.0,weeks,1,1 weeks,37322.0,0.0,Placebo,,Learned (2012a),MMRM;change from randomisation to week 1;,126.0,7.0,13.32,0.0,Placebo,*Motivation and Energy Inventory (MEI)
90047003,"Study 1 from  =  Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials",JOURNAL OF PSYCHOPHARMACOLOGY,Learned (2012a),2012,"Learned S, Graff O, Roychowdhury S, Moate R, Krishnan KR, Archer G, Modell JG, Alexander R, Zamuner S, Lavergne A, Evoniuk G, and Ratti E (2012) Study 1 from  =  Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. JOURNAL OF PSYCHOPHARMACOLOGY 26(5), 653-662 DOI: 10.1177/0269881111424931","[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Learned[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2012[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""36 sites in Australia, Belgium, Bulgaria, Canada, Estonia, Finland,\nFrance, Germany, India, Poland, Slovakia, and South Africa.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,na,GSK,na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""SND103285[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""male and female patients (18–64 years old) were\nrequired to have a diagnosis of MDE with MDD (single or recur-\nrent episodes according to the Diagnostic and Statistical Manual\nof Mental Disorders, 4th Edition, Text Revision [DSM-IV-TR]),\nwith current episode duration of at least two weeks but less than\ntwo years. Patients were required to have a Clinical Global\nImpression-Severity of Illness (CGI-S) score ≥ 4 at the randomi-\nzation visit and an Inventory of Depressive Symptomatology-Self\nReported (IDS-SR) score ≥ 40 (Study 1) or ≥ 25 (Study 2) at the\nscreening and randomization visits, with a change of no more than\n25% in IDS-SR between these two visits. Additionally, Study 2\nrequired patients to have symptoms of decreased pleasure, inter-\nest, and energy, indicated by a total score of at least 7, and indi-\nvidual scores of at least 1 on four or more of the following five\nitems of the IDS-SR: item 19 – general interest/involvement; item\n20 – energy/fatigability; item 21 – pleasure/enjoyment; item 22 –\nsexual interest; and item 30 – leaden paralysis/physical energy.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if the symptoms of a presenting illness\nwere better accounted for by another diagnosis or if the patient\nhad a current DSM-IV-TR diagnosis of any of the following:\npanic disorder, antisocial or border line personality disorder, bipo-\nlar disorder, schizophrenia, or other psychotic disorders. Patients\nwere excluded if they had previously failed an adequate therapeu-\ntic course of two or more antidepressants, had started psycho-\ntherapy within three months of screening, or had received\nelectroconvulsive therapy or transcranial magnetic stimulation\nwithin six months of screening. Patients considered by the inves-\ntigator to be at risk for suicide or who had any previous suicide\nattempt or a family history of suicide attempt were excluded.\nPatients with a positive urine drug screen or a positive blood alco-\nhol at screening were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""major depressive disorder[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2008,na,na,20 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Learned, 2012a; SND 103285",na,na,na,na,na,na,na,na,na,na,na,37322,Placebo,na,na,na,na,41.9,na,na,126,na,na,46,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,42,na,na,7,na,na,tick,tick,tick,tick,tick,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,Dry mouth=5;Headache=24;Nausea=14;Insomnia=11;Dizziness=11;Constipation=9;Tachycardia=4;Anxiety=5;Diarrhea=8;Hyperhidrosis=3;Palpitations=2;Dyspepsia=2;Somnolence=3;Decreased appetite=1;Agitation=4;,na,na,na,na,10 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,ovarian cyst=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.79,na,na,na,tick,tick,na,1,na,na,na,na,na,na,na,na,na,na,90047003.0,Continuous,108106.0,113799026.0,1.0,13669974.0,0.0,13711321.0,MEI Total,1909.0,weeks,10,10 weeks,37322.0,0.0,Placebo,,Learned (2012a),MMRM;change from randomisation to week 10;,126.0,26.5,23.12,0.0,Placebo,*Motivation and Energy Inventory (MEI)
90047003,"Study 1 from  =  Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials",JOURNAL OF PSYCHOPHARMACOLOGY,Learned (2012a),2012,"Learned S, Graff O, Roychowdhury S, Moate R, Krishnan KR, Archer G, Modell JG, Alexander R, Zamuner S, Lavergne A, Evoniuk G, and Ratti E (2012) Study 1 from  =  Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. JOURNAL OF PSYCHOPHARMACOLOGY 26(5), 653-662 DOI: 10.1177/0269881111424931","[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Learned[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2012[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""36 sites in Australia, Belgium, Bulgaria, Canada, Estonia, Finland,\nFrance, Germany, India, Poland, Slovakia, and South Africa.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,na,GSK,na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""SND103285[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""male and female patients (18–64 years old) were\nrequired to have a diagnosis of MDE with MDD (single or recur-\nrent episodes according to the Diagnostic and Statistical Manual\nof Mental Disorders, 4th Edition, Text Revision [DSM-IV-TR]),\nwith current episode duration of at least two weeks but less than\ntwo years. Patients were required to have a Clinical Global\nImpression-Severity of Illness (CGI-S) score ≥ 4 at the randomi-\nzation visit and an Inventory of Depressive Symptomatology-Self\nReported (IDS-SR) score ≥ 40 (Study 1) or ≥ 25 (Study 2) at the\nscreening and randomization visits, with a change of no more than\n25% in IDS-SR between these two visits. Additionally, Study 2\nrequired patients to have symptoms of decreased pleasure, inter-\nest, and energy, indicated by a total score of at least 7, and indi-\nvidual scores of at least 1 on four or more of the following five\nitems of the IDS-SR: item 19 – general interest/involvement; item\n20 – energy/fatigability; item 21 – pleasure/enjoyment; item 22 –\nsexual interest; and item 30 – leaden paralysis/physical energy.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if the symptoms of a presenting illness\nwere better accounted for by another diagnosis or if the patient\nhad a current DSM-IV-TR diagnosis of any of the following:\npanic disorder, antisocial or border line personality disorder, bipo-\nlar disorder, schizophrenia, or other psychotic disorders. Patients\nwere excluded if they had previously failed an adequate therapeu-\ntic course of two or more antidepressants, had started psycho-\ntherapy within three months of screening, or had received\nelectroconvulsive therapy or transcranial magnetic stimulation\nwithin six months of screening. Patients considered by the inves-\ntigator to be at risk for suicide or who had any previous suicide\nattempt or a family history of suicide attempt were excluded.\nPatients with a positive urine drug screen or a positive blood alco-\nhol at screening were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""major depressive disorder[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2008,na,na,20 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Learned, 2012a; SND 103285",na,na,na,na,na,na,na,na,na,na,na,37323,GSK372475,na,na,na,na,43.00,na,na,134,na,na,51,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,69,na,na,19,na,na,tick,tick,tick,tick,tick,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,Dry mouth=31;Headache=28;Nausea=18;Insomnia=16;Dizziness=13;Constipation=14;Tachycardia=14;Anxiety=13;Diarrhea=1;Hyperhidrosis=10;Palpitations=8;Dyspepsia=8;Somnolence=7 Decreased appetite=7;Agitation=7,na,1mg,tick,2mg,10 weeks,1.5mg,2mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,tick,na,na,na,na,na,na,na,bronchopneumonia=1;intentional overdose=1;rheumatoid arthritis=1;depression=1,na,na,na,na,na,na,na,na,na,tick,na,na,na,tick,12.07,na,na,na,tick,tick,na,4,na,na,na,na,na,na,na,na,na,na,90047003.0,Continuous,108107.0,113799026.0,1.0,13720235.0,0.0,13711321.0,MEI Total,1912.0,weeks,1,1 weeks,37323.0,0.0,GSK372475,,Learned (2012a),MMRM;change from randomisation to week 1;,99999.0,99999.0,99999.0,0.0,*GSK372475,*Motivation and Energy Inventory (MEI)
90047003,"Study 1 from  =  Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials",JOURNAL OF PSYCHOPHARMACOLOGY,Learned (2012a),2012,"Learned S, Graff O, Roychowdhury S, Moate R, Krishnan KR, Archer G, Modell JG, Alexander R, Zamuner S, Lavergne A, Evoniuk G, and Ratti E (2012) Study 1 from  =  Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. JOURNAL OF PSYCHOPHARMACOLOGY 26(5), 653-662 DOI: 10.1177/0269881111424931","[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Learned[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2012[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""36 sites in Australia, Belgium, Bulgaria, Canada, Estonia, Finland,\nFrance, Germany, India, Poland, Slovakia, and South Africa.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,na,GSK,na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""SND103285[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""male and female patients (18–64 years old) were\nrequired to have a diagnosis of MDE with MDD (single or recur-\nrent episodes according to the Diagnostic and Statistical Manual\nof Mental Disorders, 4th Edition, Text Revision [DSM-IV-TR]),\nwith current episode duration of at least two weeks but less than\ntwo years. Patients were required to have a Clinical Global\nImpression-Severity of Illness (CGI-S) score ≥ 4 at the randomi-\nzation visit and an Inventory of Depressive Symptomatology-Self\nReported (IDS-SR) score ≥ 40 (Study 1) or ≥ 25 (Study 2) at the\nscreening and randomization visits, with a change of no more than\n25% in IDS-SR between these two visits. Additionally, Study 2\nrequired patients to have symptoms of decreased pleasure, inter-\nest, and energy, indicated by a total score of at least 7, and indi-\nvidual scores of at least 1 on four or more of the following five\nitems of the IDS-SR: item 19 – general interest/involvement; item\n20 – energy/fatigability; item 21 – pleasure/enjoyment; item 22 –\nsexual interest; and item 30 – leaden paralysis/physical energy.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if the symptoms of a presenting illness\nwere better accounted for by another diagnosis or if the patient\nhad a current DSM-IV-TR diagnosis of any of the following:\npanic disorder, antisocial or border line personality disorder, bipo-\nlar disorder, schizophrenia, or other psychotic disorders. Patients\nwere excluded if they had previously failed an adequate therapeu-\ntic course of two or more antidepressants, had started psycho-\ntherapy within three months of screening, or had received\nelectroconvulsive therapy or transcranial magnetic stimulation\nwithin six months of screening. Patients considered by the inves-\ntigator to be at risk for suicide or who had any previous suicide\nattempt or a family history of suicide attempt were excluded.\nPatients with a positive urine drug screen or a positive blood alco-\nhol at screening were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1062090, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""major depressive disorder[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Learned 2011.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2008,na,na,20 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Learned, 2012a; SND 103285",na,na,na,na,na,na,na,na,na,na,na,37323,GSK372475,na,na,na,na,43.00,na,na,134,na,na,51,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,69,na,na,19,na,na,tick,tick,tick,tick,tick,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,Dry mouth=31;Headache=28;Nausea=18;Insomnia=16;Dizziness=13;Constipation=14;Tachycardia=14;Anxiety=13;Diarrhea=1;Hyperhidrosis=10;Palpitations=8;Dyspepsia=8;Somnolence=7 Decreased appetite=7;Agitation=7,na,1mg,tick,2mg,10 weeks,1.5mg,2mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,tick,na,na,na,na,na,na,na,bronchopneumonia=1;intentional overdose=1;rheumatoid arthritis=1;depression=1,na,na,na,na,na,na,na,na,na,tick,na,na,na,tick,12.07,na,na,na,tick,tick,na,4,na,na,na,na,na,na,na,na,na,na,90047003.0,Continuous,108108.0,113799026.0,1.0,13720235.0,0.0,13711321.0,MEI Total,1909.0,weeks,10,10 weeks,37323.0,0.0,GSK372475,,Learned (2012a),MMRM;change from randomisation to week 10;,99999.0,99999.0,99999.0,0.0,*GSK372475,*Motivation and Energy Inventory (MEI)
87999196,Moclobemide and clomipramine in reactive depression. A placebo-controlled randomized clinical trial.,Acta psychiatrica Scandinavica,Larsen (1989),1989,"Larsen J K, Holm P, Hoyer E, Mejlhede A, Mikkelsen P L, Olesen A, and Schaumburg E (1989) Moclobemide and clomipramine in reactive depression. A placebo-controlled randomized clinical trial.. Acta psychiatrica Scandinavica 79(6), 530-6","[{'ItemDocumentId': 1050742, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Larsen[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Larsen J K et al. - 1989 - Moclobemide and clomipramine in reactive depressio.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050742, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1989[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Larsen J K et al. - 1989 - Moclobemide and clomipramine in reactive depressio.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050742, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Denmark[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Larsen J K et al. - 1989 - Moclobemide and clomipramine in reactive depressio.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,tick,tick,na,na,"[{'ItemDocumentId': 1050742, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""In- and outpatients of either sex, above 17 years\nof age, suffering from major depressive disorder\n(DSM-111) (2) classified as reactive depression\naccording to the Newcastle I1 scale (3) were eligi-\nble for this double-blind trial. At 2 successive\nexaminations 1 week apart the patients scored at\nleast 15 on the first 17 items of the Hamilton\nRating Scale for Depression (HRSD) (4)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Larsen J K et al. - 1989 - Moclobemide and clomipramine in reactive depressio.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050742, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]"". Exclu-\nsion criteria were: previous manic episodes, ade-\nquate treatment already instituted, need for\nECT, obvious suicide risk, history of drug or\nalcohol abuse, noncooperation or unreliability,\npregnancy, lactation, abnormal hepatic or renal\nfunction and known haematopoietic, metabolic[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Larsen J K et al. - 1989 - Moclobemide and clomipramine in reactive depressio.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1050742, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""or hormonal disorders, diastolic blood pressure\nabove 100 mmHg and any contraindication for\ntricyclic antidepressants.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Larsen J K et al. - 1989 - Moclobemide and clomipramine in reactive depressio.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050742, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""reactive depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Larsen J K et al. - 1989 - Moclobemide and clomipramine in reactive depressio.pdf', 'ItemArm': ''}]",tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Larsen, 1989",na,na,na,na,na,na,na,na,na,na,na,37270,Placebo,na,na,na,na,57,na,na,18,na,na,12,na,na,tick,tick,na,na,na,na,"[{'ItemDocumentId': 1050742, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""6 on placebo received con-\ncomitant psychotropic drugs, mainly ben-\nzodiazepines .[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Larsen J K et al. - 1989 - Moclobemide and clomipramine in reactive depressio.pdf', 'ItemArm': 'Placebo'}]",na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,5,na,na,3,na,na,na,tick,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Dizziness=3;Tremor=0;Anticholinergic symptoms=3,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,6x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,25-76,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999196,Moclobemide and clomipramine in reactive depression. A placebo-controlled randomized clinical trial.,Acta psychiatrica Scandinavica,Larsen (1989),1989,"Larsen J K, Holm P, Hoyer E, Mejlhede A, Mikkelsen P L, Olesen A, and Schaumburg E (1989) Moclobemide and clomipramine in reactive depression. A placebo-controlled randomized clinical trial.. Acta psychiatrica Scandinavica 79(6), 530-6","[{'ItemDocumentId': 1050742, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Larsen[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Larsen J K et al. - 1989 - Moclobemide and clomipramine in reactive depressio.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050742, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1989[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Larsen J K et al. - 1989 - Moclobemide and clomipramine in reactive depressio.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050742, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Denmark[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Larsen J K et al. - 1989 - Moclobemide and clomipramine in reactive depressio.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,tick,tick,na,na,"[{'ItemDocumentId': 1050742, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""In- and outpatients of either sex, above 17 years\nof age, suffering from major depressive disorder\n(DSM-111) (2) classified as reactive depression\naccording to the Newcastle I1 scale (3) were eligi-\nble for this double-blind trial. At 2 successive\nexaminations 1 week apart the patients scored at\nleast 15 on the first 17 items of the Hamilton\nRating Scale for Depression (HRSD) (4)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Larsen J K et al. - 1989 - Moclobemide and clomipramine in reactive depressio.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050742, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]"". Exclu-\nsion criteria were: previous manic episodes, ade-\nquate treatment already instituted, need for\nECT, obvious suicide risk, history of drug or\nalcohol abuse, noncooperation or unreliability,\npregnancy, lactation, abnormal hepatic or renal\nfunction and known haematopoietic, metabolic[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Larsen J K et al. - 1989 - Moclobemide and clomipramine in reactive depressio.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1050742, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""or hormonal disorders, diastolic blood pressure\nabove 100 mmHg and any contraindication for\ntricyclic antidepressants.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Larsen J K et al. - 1989 - Moclobemide and clomipramine in reactive depressio.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050742, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""reactive depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Larsen J K et al. - 1989 - Moclobemide and clomipramine in reactive depressio.pdf', 'ItemArm': ''}]",tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Larsen, 1989",na,na,na,na,na,na,na,na,na,na,na,37271,Moclobemide,na,na,na,na,51,na,na,22,na,na,15,na,na,tick,tick,na,na,na,na,"[{'ItemDocumentId': 1050742, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Seven patients on moclobemid""\n""received con-\ncomitant psychotropic drugs, mainly ben-\nzodiazepines .[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Larsen J K et al. - 1989 - Moclobemide and clomipramine in reactive depressio.pdf', 'ItemArm': 'Moclobemide'}]",na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,6,na,na,2,na,na,na,tick,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Dizziness=2;Tremor=0;Anticholinergic symptoms=3,na,tick,tick,300mg,6 weeks,tick,300mg,na,na,na,na,na,na,na,na,tick,na,tick,na,6x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,28-70,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999015,Thyroid functioning during treatment for depression.,Journal of psychiatry & neuroscience : JPN,Kusalic (1993),1993,"Kusalic M, Engelsmann F, and Bradwejn J (1993) Thyroid functioning during treatment for depression.. Journal of psychiatry & neuroscience : JPN 18(5), 260-3","[{'ItemDocumentId': 1050790, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Kusalic,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Kusalic M et al. - 1993 - Thyroid functioning during treatment for depressio.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050790, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1993[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Kusalic M et al. - 1993 - Thyroid functioning during treatment for depressio.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050790, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""if\nthey suffered from a major depressive episode according to\nthe DSM-III-R criteria and had a score of 18 or more on the\n17-item Hamilton Rating Scale for Depression (HRSD)\n(Hamilton 1967). The subjects were in good physical health,\naccording to a physical examination, a complete blood count,\na chemistry profile including thyroid functions and an\nelectrocardiogram.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Kusalic M et al. - 1993 - Thyroid functioning during treatment for depressio.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050790, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""The patients whose scores on the\nHRSD improved more than 20% or whose scores were lower\nthan 18 after the lead-in period were excluded from the study.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Kusalic M et al. - 1993 - Thyroid functioning during treatment for depressio.pdf', 'ItemArm': ''}]",na,na,41.3,na,na,39,14,na,na,na,na,na,"[{'ItemDocumentId': 1050790, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Kusalic M et al. - 1993 - Thyroid functioning during treatment for depressio.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Kusalic, 1993",tick,10.1,22-61,na,na,na,na,na,na,na,na,37267,Placebo,na,na,na,na,tick,tick,na,9,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,na,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999015,Thyroid functioning during treatment for depression.,Journal of psychiatry & neuroscience : JPN,Kusalic (1993),1993,"Kusalic M, Engelsmann F, and Bradwejn J (1993) Thyroid functioning during treatment for depression.. Journal of psychiatry & neuroscience : JPN 18(5), 260-3","[{'ItemDocumentId': 1050790, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Kusalic,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Kusalic M et al. - 1993 - Thyroid functioning during treatment for depressio.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050790, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1993[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Kusalic M et al. - 1993 - Thyroid functioning during treatment for depressio.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050790, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""if\nthey suffered from a major depressive episode according to\nthe DSM-III-R criteria and had a score of 18 or more on the\n17-item Hamilton Rating Scale for Depression (HRSD)\n(Hamilton 1967). The subjects were in good physical health,\naccording to a physical examination, a complete blood count,\na chemistry profile including thyroid functions and an\nelectrocardiogram.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Kusalic M et al. - 1993 - Thyroid functioning during treatment for depressio.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050790, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""The patients whose scores on the\nHRSD improved more than 20% or whose scores were lower\nthan 18 after the lead-in period were excluded from the study.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Kusalic M et al. - 1993 - Thyroid functioning during treatment for depressio.pdf', 'ItemArm': ''}]",na,na,41.3,na,na,39,14,na,na,na,na,na,"[{'ItemDocumentId': 1050790, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Kusalic M et al. - 1993 - Thyroid functioning during treatment for depressio.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Kusalic, 1993",tick,10.1,22-61,na,na,na,na,na,na,na,na,37268,Moclobemide,na,na,na,na,tick,tick,na,11,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,482.60,tick,6 weeks,na,na,na,na,tick,na,tick,na,tick,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87997374,"The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients.",Neuropsychiatric disease and treatment,Koshino (2013),2013,"Koshino Yoshifumi, Bahk Won-Myong, Sakai Hideaki, and Kobayashi Takayuki (2013) The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients.. Neuropsychiatric disease and treatment 9, 1273-80 DOI: https://dx.doi.org/10.2147/NDT.S48158","[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Koshino[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2013[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,Japan and South Korea,na,na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""NCT01138007[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""at the start of the treatment\nphase (visit 2, week 0): a total score of $20 of the IVR-based\nHAM-D (17 items); IVR-based HAM-D (17 items) total\nscore did not increase or decrease by $25% between visit 1\nand visit 2; a total score of $25 on the IDS-SR; a score of $1\non at least four of five items on the five-item subscale of the\nIDS-SR and a total score of $7 on the five-item subscale of\nthe IDS-SR; and a CGI-SI score of $4 (“Moderately ill” or\nmuch worse).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""past history of seizure or seizure\ndisorder; more than a single febrile seizure in infancy;\ncerebral tumor; head/brain injury (traumatic); a history or\ncurrent diagnosis of anorexia nervosa or bulimia; a primary\nDSM-IV diagnosis of, or received treatment for, panic dis-\norder; obsessive compulsive disorder; post-traumatic stress\ndisorder or acute stress disorder 12 months before the start\nof the run-in phase; a DSM-IV diagnosis of schizophrenia,\nor other psychotic disorder(s), including bipolar disorder;\na history of, or currently has, manic episode(s); poses a\ncurrent serious suicidal risk or has made a suicide attempt\nwithin the past 6 months; pregnant, possibly pregnant,\nlactating women, or females who want to become pregnant\nduring the study.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,na,37.1,na,na,564,304,na,na,tick,tick,na,MDD,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Koshino, 2013",tick,10.84,na,na,na,na,na,na,na,na,na,37256,Bupropion 150mg,na,na,na,na,36.00,na,na,190,na,na,92,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,30,na,na,12,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,tick,na,na,na,na,na,Gastrointestinal disorders=47;Dry mouth=12;Nausea=13;Constipation=8;Infections and infestations=28;Nasopharyngitis=26;Nervous system disorders=29;Headache=16;Tremor=4;Psychiatric disorders=9;Insomnia=0,na,150,tick,150,10 weeks,150,150,na,na,na,na,na,na,na,na,tick,na,na,na,1x daily,na,na,na,na,na,na,na,na,na,Meniscus lesion=1;Headache=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.42,na,na,na,106,na,na,2,na,na,na,na,na,na,na,na,na,tick,87997374.0,Continuous,110850.0,113366897.0,1.0,13687717.0,0.0,14113750.0,MADRS item 8,1855.0,weeks,0,0 weeks,37256.0,0.0,Bupropion 150mg,,Koshino (2013),FAS-LOCF,190.0,3.7,1.16,0.0,*bupropion SR,MADRS anhedonia item
87997374,"The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients.",Neuropsychiatric disease and treatment,Koshino (2013),2013,"Koshino Yoshifumi, Bahk Won-Myong, Sakai Hideaki, and Kobayashi Takayuki (2013) The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients.. Neuropsychiatric disease and treatment 9, 1273-80 DOI: https://dx.doi.org/10.2147/NDT.S48158","[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Koshino[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2013[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,Japan and South Korea,na,na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""NCT01138007[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""at the start of the treatment\nphase (visit 2, week 0): a total score of $20 of the IVR-based\nHAM-D (17 items); IVR-based HAM-D (17 items) total\nscore did not increase or decrease by $25% between visit 1\nand visit 2; a total score of $25 on the IDS-SR; a score of $1\non at least four of five items on the five-item subscale of the\nIDS-SR and a total score of $7 on the five-item subscale of\nthe IDS-SR; and a CGI-SI score of $4 (“Moderately ill” or\nmuch worse).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""past history of seizure or seizure\ndisorder; more than a single febrile seizure in infancy;\ncerebral tumor; head/brain injury (traumatic); a history or\ncurrent diagnosis of anorexia nervosa or bulimia; a primary\nDSM-IV diagnosis of, or received treatment for, panic dis-\norder; obsessive compulsive disorder; post-traumatic stress\ndisorder or acute stress disorder 12 months before the start\nof the run-in phase; a DSM-IV diagnosis of schizophrenia,\nor other psychotic disorder(s), including bipolar disorder;\na history of, or currently has, manic episode(s); poses a\ncurrent serious suicidal risk or has made a suicide attempt\nwithin the past 6 months; pregnant, possibly pregnant,\nlactating women, or females who want to become pregnant\nduring the study.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,na,37.1,na,na,564,304,na,na,tick,tick,na,MDD,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Koshino, 2013",tick,10.84,na,na,na,na,na,na,na,na,na,37256,Bupropion 150mg,na,na,na,na,36.00,na,na,190,na,na,92,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,30,na,na,12,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,tick,na,na,na,na,na,Gastrointestinal disorders=47;Dry mouth=12;Nausea=13;Constipation=8;Infections and infestations=28;Nasopharyngitis=26;Nervous system disorders=29;Headache=16;Tremor=4;Psychiatric disorders=9;Insomnia=0,na,150,tick,150,10 weeks,150,150,na,na,na,na,na,na,na,na,tick,na,na,na,1x daily,na,na,na,na,na,na,na,na,na,Meniscus lesion=1;Headache=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.42,na,na,na,106,na,na,2,na,na,na,na,na,na,na,na,na,tick,87997374.0,Continuous,110851.0,113366897.0,1.0,13687717.0,0.0,14113750.0,MADRS item 8,1856.0,weeks,8,8 weeks,37256.0,0.0,Bupropion 150mg,,Koshino (2013),FAS-LOCF;,190.0,2.0,1.45,0.0,*bupropion SR,MADRS anhedonia item
87997374,"The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients.",Neuropsychiatric disease and treatment,Koshino (2013),2013,"Koshino Yoshifumi, Bahk Won-Myong, Sakai Hideaki, and Kobayashi Takayuki (2013) The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients.. Neuropsychiatric disease and treatment 9, 1273-80 DOI: https://dx.doi.org/10.2147/NDT.S48158","[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Koshino[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2013[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,Japan and South Korea,na,na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""NCT01138007[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""at the start of the treatment\nphase (visit 2, week 0): a total score of $20 of the IVR-based\nHAM-D (17 items); IVR-based HAM-D (17 items) total\nscore did not increase or decrease by $25% between visit 1\nand visit 2; a total score of $25 on the IDS-SR; a score of $1\non at least four of five items on the five-item subscale of the\nIDS-SR and a total score of $7 on the five-item subscale of\nthe IDS-SR; and a CGI-SI score of $4 (“Moderately ill” or\nmuch worse).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""past history of seizure or seizure\ndisorder; more than a single febrile seizure in infancy;\ncerebral tumor; head/brain injury (traumatic); a history or\ncurrent diagnosis of anorexia nervosa or bulimia; a primary\nDSM-IV diagnosis of, or received treatment for, panic dis-\norder; obsessive compulsive disorder; post-traumatic stress\ndisorder or acute stress disorder 12 months before the start\nof the run-in phase; a DSM-IV diagnosis of schizophrenia,\nor other psychotic disorder(s), including bipolar disorder;\na history of, or currently has, manic episode(s); poses a\ncurrent serious suicidal risk or has made a suicide attempt\nwithin the past 6 months; pregnant, possibly pregnant,\nlactating women, or females who want to become pregnant\nduring the study.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,na,37.1,na,na,564,304,na,na,tick,tick,na,MDD,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Koshino, 2013",tick,10.84,na,na,na,na,na,na,na,na,na,37257,Bupropion 300mg,na,na,na,na,37.5,na,na,188,na,na,83,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,9,na,na,12,na,na,na,na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,tick,na,na,na,na,na,Gastrointestinal disorders=63;Dry mouth=28;Nausea=16;Constipation=11;Infections and infestations=35;Nasopharyngitis=29;Nervous system disorders=37;Headache=19;Tremor=9;Psychiatric disorders=18;Insomnia=10,na,300,tick,300,10 weeks,300,300,na,na,na,na,na,na,na,na,tick,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,Pyrexia=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.96,na,na,na,123,na,na,1,na,na,na,na,na,na,na,na,na,tick,87997374.0,Continuous,110852.0,113366897.0,1.0,13687717.0,0.0,14113750.0,MADRS item 8,1855.0,weeks,0,0 weeks,37257.0,0.0,Bupropion 300mg,,Koshino (2013),FAS-LOCF,188.0,3.7,1.09,0.0,*bupropion SR,MADRS anhedonia item
87997374,"The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients.",Neuropsychiatric disease and treatment,Koshino (2013),2013,"Koshino Yoshifumi, Bahk Won-Myong, Sakai Hideaki, and Kobayashi Takayuki (2013) The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients.. Neuropsychiatric disease and treatment 9, 1273-80 DOI: https://dx.doi.org/10.2147/NDT.S48158","[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Koshino[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2013[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,Japan and South Korea,na,na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""NCT01138007[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""at the start of the treatment\nphase (visit 2, week 0): a total score of $20 of the IVR-based\nHAM-D (17 items); IVR-based HAM-D (17 items) total\nscore did not increase or decrease by $25% between visit 1\nand visit 2; a total score of $25 on the IDS-SR; a score of $1\non at least four of five items on the five-item subscale of the\nIDS-SR and a total score of $7 on the five-item subscale of\nthe IDS-SR; and a CGI-SI score of $4 (“Moderately ill” or\nmuch worse).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""past history of seizure or seizure\ndisorder; more than a single febrile seizure in infancy;\ncerebral tumor; head/brain injury (traumatic); a history or\ncurrent diagnosis of anorexia nervosa or bulimia; a primary\nDSM-IV diagnosis of, or received treatment for, panic dis-\norder; obsessive compulsive disorder; post-traumatic stress\ndisorder or acute stress disorder 12 months before the start\nof the run-in phase; a DSM-IV diagnosis of schizophrenia,\nor other psychotic disorder(s), including bipolar disorder;\na history of, or currently has, manic episode(s); poses a\ncurrent serious suicidal risk or has made a suicide attempt\nwithin the past 6 months; pregnant, possibly pregnant,\nlactating women, or females who want to become pregnant\nduring the study.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,na,37.1,na,na,564,304,na,na,tick,tick,na,MDD,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Koshino, 2013",tick,10.84,na,na,na,na,na,na,na,na,na,37257,Bupropion 300mg,na,na,na,na,37.5,na,na,188,na,na,83,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,9,na,na,12,na,na,na,na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,tick,na,na,na,na,na,Gastrointestinal disorders=63;Dry mouth=28;Nausea=16;Constipation=11;Infections and infestations=35;Nasopharyngitis=29;Nervous system disorders=37;Headache=19;Tremor=9;Psychiatric disorders=18;Insomnia=10,na,300,tick,300,10 weeks,300,300,na,na,na,na,na,na,na,na,tick,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,Pyrexia=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.96,na,na,na,123,na,na,1,na,na,na,na,na,na,na,na,na,tick,87997374.0,Continuous,110853.0,113366897.0,1.0,13687717.0,0.0,14113750.0,MADRS item 8,1856.0,weeks,8,8 weeks,37257.0,0.0,Bupropion 300mg,,Koshino (2013),FAS-LOCF,188.0,2.1,1.55,0.0,*bupropion SR,MADRS anhedonia item
87997374,"The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients.",Neuropsychiatric disease and treatment,Koshino (2013),2013,"Koshino Yoshifumi, Bahk Won-Myong, Sakai Hideaki, and Kobayashi Takayuki (2013) The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients.. Neuropsychiatric disease and treatment 9, 1273-80 DOI: https://dx.doi.org/10.2147/NDT.S48158","[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Koshino[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2013[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,Japan and South Korea,na,na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""NCT01138007[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""at the start of the treatment\nphase (visit 2, week 0): a total score of $20 of the IVR-based\nHAM-D (17 items); IVR-based HAM-D (17 items) total\nscore did not increase or decrease by $25% between visit 1\nand visit 2; a total score of $25 on the IDS-SR; a score of $1\non at least four of five items on the five-item subscale of the\nIDS-SR and a total score of $7 on the five-item subscale of\nthe IDS-SR; and a CGI-SI score of $4 (“Moderately ill” or\nmuch worse).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""past history of seizure or seizure\ndisorder; more than a single febrile seizure in infancy;\ncerebral tumor; head/brain injury (traumatic); a history or\ncurrent diagnosis of anorexia nervosa or bulimia; a primary\nDSM-IV diagnosis of, or received treatment for, panic dis-\norder; obsessive compulsive disorder; post-traumatic stress\ndisorder or acute stress disorder 12 months before the start\nof the run-in phase; a DSM-IV diagnosis of schizophrenia,\nor other psychotic disorder(s), including bipolar disorder;\na history of, or currently has, manic episode(s); poses a\ncurrent serious suicidal risk or has made a suicide attempt\nwithin the past 6 months; pregnant, possibly pregnant,\nlactating women, or females who want to become pregnant\nduring the study.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,na,37.1,na,na,564,304,na,na,tick,tick,na,MDD,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Koshino, 2013",tick,10.84,na,na,na,na,na,na,na,na,na,37258,Placebo,na,na,na,na,37.9,na,na,186,na,na,85,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,tick,na,na,na,na,na,22,na,na,4,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Gastrointestinal disorders=39;Dry mouth=8
Nausea=15;Constipation=3;Infections and infestations=42;Nasopharyngitis=35;Nervous system disorders=29;Headache=13;Tremor=0;Psychiatric disorders=14;Insomnia=6",na,na,na,na,10 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1x daily,na,na,na,na,na,na,na,na,na,Osteoarthritis=1;Depression=1,na,na,na,na,na,na,na,na,na,na,na,na,na,11.09,tick,na,na,na,105,na,na,2,na,na,na,na,na,na,na,na,na,tick,87997374.0,Continuous,110848.0,113366897.0,1.0,13669974.0,0.0,14113750.0,MADRS item 8,1855.0,weeks,0,0 weeks,37258.0,0.0,Placebo,,Koshino (2013),FAS-LOCF,186.0,3.7,1.06,0.0,Placebo,MADRS anhedonia item
87997374,"The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients.",Neuropsychiatric disease and treatment,Koshino (2013),2013,"Koshino Yoshifumi, Bahk Won-Myong, Sakai Hideaki, and Kobayashi Takayuki (2013) The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients.. Neuropsychiatric disease and treatment 9, 1273-80 DOI: https://dx.doi.org/10.2147/NDT.S48158","[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Koshino[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2013[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,Japan and South Korea,na,na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""NCT01138007[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""at the start of the treatment\nphase (visit 2, week 0): a total score of $20 of the IVR-based\nHAM-D (17 items); IVR-based HAM-D (17 items) total\nscore did not increase or decrease by $25% between visit 1\nand visit 2; a total score of $25 on the IDS-SR; a score of $1\non at least four of five items on the five-item subscale of the\nIDS-SR and a total score of $7 on the five-item subscale of\nthe IDS-SR; and a CGI-SI score of $4 (“Moderately ill” or\nmuch worse).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050787, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""past history of seizure or seizure\ndisorder; more than a single febrile seizure in infancy;\ncerebral tumor; head/brain injury (traumatic); a history or\ncurrent diagnosis of anorexia nervosa or bulimia; a primary\nDSM-IV diagnosis of, or received treatment for, panic dis-\norder; obsessive compulsive disorder; post-traumatic stress\ndisorder or acute stress disorder 12 months before the start\nof the run-in phase; a DSM-IV diagnosis of schizophrenia,\nor other psychotic disorder(s), including bipolar disorder;\na history of, or currently has, manic episode(s); poses a\ncurrent serious suicidal risk or has made a suicide attempt\nwithin the past 6 months; pregnant, possibly pregnant,\nlactating women, or females who want to become pregnant\nduring the study.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Koshino (2013).pdf', 'ItemArm': ''}]",na,na,37.1,na,na,564,304,na,na,tick,tick,na,MDD,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Koshino, 2013",tick,10.84,na,na,na,na,na,na,na,na,na,37258,Placebo,na,na,na,na,37.9,na,na,186,na,na,85,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,tick,na,na,na,na,na,22,na,na,4,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Gastrointestinal disorders=39;Dry mouth=8
Nausea=15;Constipation=3;Infections and infestations=42;Nasopharyngitis=35;Nervous system disorders=29;Headache=13;Tremor=0;Psychiatric disorders=14;Insomnia=6",na,na,na,na,10 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1x daily,na,na,na,na,na,na,na,na,na,Osteoarthritis=1;Depression=1,na,na,na,na,na,na,na,na,na,na,na,na,na,11.09,tick,na,na,na,105,na,na,2,na,na,na,na,na,na,na,na,na,tick,87997374.0,Continuous,110849.0,113366897.0,1.0,13669974.0,0.0,14113750.0,MADRS item 8,1856.0,weeks,8,8 weeks,37258.0,0.0,Placebo,,Koshino (2013),FAS-LOCF,186.0,2.0,1.45,0.0,Placebo,MADRS anhedonia item
87998173,"Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.",The Journal of clinical psychiatry,Jefferson (2006),2006,"Jefferson James W, Rush A John, Nelson J Craig, VanMeter Susan A, Krishen Alok, Hampton Kenneth D, Wightman Donna S, and Modell Jack G (2006) Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.. The Journal of clinical psychiatry 67(6), 865-73","[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Jefferson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""GlaxoSmithKline[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Eligible patients needed to have demon-\nstrated symptoms of depression for at least 12 weeks but""\n""not more than 2 years before study entry and to have had\na minimum score of 25 on the 30-item Inventory of De-\npressive Symptomatology (IDS-IVR-30)17,18\nwhen mea-\nsured at the screening (day –7) and baseline (day –1) vis-\nits using interactive voice response (IVR) technology.19,20\nEligible patients also had to have demonstrated a total\nscore of ≥ 7 and a minimum score of 1 on at least 4 of\nthe 5-item subset (Items 19, 20, 21, 22, 30) of the IDS-\nIVR-30 that assesses energy, pleasure, and interest at both\nscreening and baseline visits.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included current or past history of\nseizures or brain injury or any condition that predisposes\nto seizures; current or past history of anorexia nervosa or\nbulimia; unstable medical conditions; lifetime diagnosis\nof bipolar I or II disorder or schizophrenia or other psy-\nchotic disorder; primary diagnosis or treatment for panic\ndisorder, obsessive-compulsive disorder, posttraumatic\nstress disorder, or acute stress disorder within the previ-\nous 12 months; history of alcohol or substance abuse or\ndependence within the past 12 months; treatment with\npsychotropic drugs, including psychoactive herbal prepa-\nrations, within 2 weeks prior to the screening visit (4\nweeks for fluoxetine); and total scores on the IDS-IVR-30\nthat increased or decreased by > 25% between the screen-\ning and baseline measurements.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""nonpsy-\nchotic MDD[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",tick,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Use of zolpidem, up to\n10 mg/day, or zaleplon, up to 20 mg/day, was allowed\nsparingly (up to 3–4 times per week) through day 10 of the\ntreatment phase[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,12 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Jefferson, 2006",na,na,na,na,na,na,na,na,na,na,na,37172,Placebo ,na,na,na,na,39.8,na,na,139,na,na,96,na,na,White=108; Black=12; Hispanic=15; Other=4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,29,na,na,3,na,na,tick,tick,tick,tick,na,tick,na,tick,na,na,na,na,na,tick,tick,na,na,na,tick,tick,tick,Dry mouth=8;Dizziness=3;Nausea=7;Insomnia=2;Anxiety=1;Dyspepsia=0;Sinusitis=3;Tremor=0,na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,16-69,na,na,tick,na,tick,0,na,na,na,na,na,na,na,na,na,na,87998173.0,Continuous,109211.0,113972901.0,1.0,13669974.0,0.0,13686049.0,IDS-IVR-30 Pleasure scale,1799.0,weeks,0,0 weeks,37172.0,0.0,Placebo ,,Jefferson (2006),LSMean;SEConv,137.0,99999.0,99999.0,0.0,Placebo,IDS-IVR-30 (energy/pleasure/interest)
87998173,"Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.",The Journal of clinical psychiatry,Jefferson (2006),2006,"Jefferson James W, Rush A John, Nelson J Craig, VanMeter Susan A, Krishen Alok, Hampton Kenneth D, Wightman Donna S, and Modell Jack G (2006) Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.. The Journal of clinical psychiatry 67(6), 865-73","[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Jefferson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""GlaxoSmithKline[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Eligible patients needed to have demon-\nstrated symptoms of depression for at least 12 weeks but""\n""not more than 2 years before study entry and to have had\na minimum score of 25 on the 30-item Inventory of De-\npressive Symptomatology (IDS-IVR-30)17,18\nwhen mea-\nsured at the screening (day –7) and baseline (day –1) vis-\nits using interactive voice response (IVR) technology.19,20\nEligible patients also had to have demonstrated a total\nscore of ≥ 7 and a minimum score of 1 on at least 4 of\nthe 5-item subset (Items 19, 20, 21, 22, 30) of the IDS-\nIVR-30 that assesses energy, pleasure, and interest at both\nscreening and baseline visits.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included current or past history of\nseizures or brain injury or any condition that predisposes\nto seizures; current or past history of anorexia nervosa or\nbulimia; unstable medical conditions; lifetime diagnosis\nof bipolar I or II disorder or schizophrenia or other psy-\nchotic disorder; primary diagnosis or treatment for panic\ndisorder, obsessive-compulsive disorder, posttraumatic\nstress disorder, or acute stress disorder within the previ-\nous 12 months; history of alcohol or substance abuse or\ndependence within the past 12 months; treatment with\npsychotropic drugs, including psychoactive herbal prepa-\nrations, within 2 weeks prior to the screening visit (4\nweeks for fluoxetine); and total scores on the IDS-IVR-30\nthat increased or decreased by > 25% between the screen-\ning and baseline measurements.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""nonpsy-\nchotic MDD[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",tick,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Use of zolpidem, up to\n10 mg/day, or zaleplon, up to 20 mg/day, was allowed\nsparingly (up to 3–4 times per week) through day 10 of the\ntreatment phase[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,12 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Jefferson, 2006",na,na,na,na,na,na,na,na,na,na,na,37172,Placebo ,na,na,na,na,39.8,na,na,139,na,na,96,na,na,White=108; Black=12; Hispanic=15; Other=4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,29,na,na,3,na,na,tick,tick,tick,tick,na,tick,na,tick,na,na,na,na,na,tick,tick,na,na,na,tick,tick,tick,Dry mouth=8;Dizziness=3;Nausea=7;Insomnia=2;Anxiety=1;Dyspepsia=0;Sinusitis=3;Tremor=0,na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,16-69,na,na,tick,na,tick,0,na,na,na,na,na,na,na,na,na,na,87998173.0,Continuous,109218.0,113972901.0,1.0,13669974.0,0.0,13686054.0,IDS-C-30 Pleasure scale,1798.0,weeks,8,8 weeks,37172.0,0.0,Placebo ,,Jefferson (2006),Change from baseline;LSMean:SEConv,137.0,-3.7,4.61,0.0,Placebo,IDS-C-30 (energy/pleasure/interest)
87998173,"Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.",The Journal of clinical psychiatry,Jefferson (2006),2006,"Jefferson James W, Rush A John, Nelson J Craig, VanMeter Susan A, Krishen Alok, Hampton Kenneth D, Wightman Donna S, and Modell Jack G (2006) Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.. The Journal of clinical psychiatry 67(6), 865-73","[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Jefferson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""GlaxoSmithKline[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Eligible patients needed to have demon-\nstrated symptoms of depression for at least 12 weeks but""\n""not more than 2 years before study entry and to have had\na minimum score of 25 on the 30-item Inventory of De-\npressive Symptomatology (IDS-IVR-30)17,18\nwhen mea-\nsured at the screening (day –7) and baseline (day –1) vis-\nits using interactive voice response (IVR) technology.19,20\nEligible patients also had to have demonstrated a total\nscore of ≥ 7 and a minimum score of 1 on at least 4 of\nthe 5-item subset (Items 19, 20, 21, 22, 30) of the IDS-\nIVR-30 that assesses energy, pleasure, and interest at both\nscreening and baseline visits.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included current or past history of\nseizures or brain injury or any condition that predisposes\nto seizures; current or past history of anorexia nervosa or\nbulimia; unstable medical conditions; lifetime diagnosis\nof bipolar I or II disorder or schizophrenia or other psy-\nchotic disorder; primary diagnosis or treatment for panic\ndisorder, obsessive-compulsive disorder, posttraumatic\nstress disorder, or acute stress disorder within the previ-\nous 12 months; history of alcohol or substance abuse or\ndependence within the past 12 months; treatment with\npsychotropic drugs, including psychoactive herbal prepa-\nrations, within 2 weeks prior to the screening visit (4\nweeks for fluoxetine); and total scores on the IDS-IVR-30\nthat increased or decreased by > 25% between the screen-\ning and baseline measurements.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""nonpsy-\nchotic MDD[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",tick,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Use of zolpidem, up to\n10 mg/day, or zaleplon, up to 20 mg/day, was allowed\nsparingly (up to 3–4 times per week) through day 10 of the\ntreatment phase[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,12 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Jefferson, 2006",na,na,na,na,na,na,na,na,na,na,na,37172,Placebo ,na,na,na,na,39.8,na,na,139,na,na,96,na,na,White=108; Black=12; Hispanic=15; Other=4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,29,na,na,3,na,na,tick,tick,tick,tick,na,tick,na,tick,na,na,na,na,na,tick,tick,na,na,na,tick,tick,tick,Dry mouth=8;Dizziness=3;Nausea=7;Insomnia=2;Anxiety=1;Dyspepsia=0;Sinusitis=3;Tremor=0,na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,16-69,na,na,tick,na,tick,0,na,na,na,na,na,na,na,na,na,na,87998173.0,Continuous,109223.0,113972901.0,1.0,13669974.0,0.0,13688667.0,IDS-IVR-30 Anxiety scale,1798.0,weeks,8,8 weeks,37172.0,0.0,Placebo ,,Jefferson (2006),Change from baseline;LSMean;SEConv,137.0,-2.1,3.51,0.0,Placebo,IDS-IVR-30 (anxiety)
87998173,"Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.",The Journal of clinical psychiatry,Jefferson (2006),2006,"Jefferson James W, Rush A John, Nelson J Craig, VanMeter Susan A, Krishen Alok, Hampton Kenneth D, Wightman Donna S, and Modell Jack G (2006) Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.. The Journal of clinical psychiatry 67(6), 865-73","[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Jefferson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""GlaxoSmithKline[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Eligible patients needed to have demon-\nstrated symptoms of depression for at least 12 weeks but""\n""not more than 2 years before study entry and to have had\na minimum score of 25 on the 30-item Inventory of De-\npressive Symptomatology (IDS-IVR-30)17,18\nwhen mea-\nsured at the screening (day –7) and baseline (day –1) vis-\nits using interactive voice response (IVR) technology.19,20\nEligible patients also had to have demonstrated a total\nscore of ≥ 7 and a minimum score of 1 on at least 4 of\nthe 5-item subset (Items 19, 20, 21, 22, 30) of the IDS-\nIVR-30 that assesses energy, pleasure, and interest at both\nscreening and baseline visits.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included current or past history of\nseizures or brain injury or any condition that predisposes\nto seizures; current or past history of anorexia nervosa or\nbulimia; unstable medical conditions; lifetime diagnosis\nof bipolar I or II disorder or schizophrenia or other psy-\nchotic disorder; primary diagnosis or treatment for panic\ndisorder, obsessive-compulsive disorder, posttraumatic\nstress disorder, or acute stress disorder within the previ-\nous 12 months; history of alcohol or substance abuse or\ndependence within the past 12 months; treatment with\npsychotropic drugs, including psychoactive herbal prepa-\nrations, within 2 weeks prior to the screening visit (4\nweeks for fluoxetine); and total scores on the IDS-IVR-30\nthat increased or decreased by > 25% between the screen-\ning and baseline measurements.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""nonpsy-\nchotic MDD[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",tick,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Use of zolpidem, up to\n10 mg/day, or zaleplon, up to 20 mg/day, was allowed\nsparingly (up to 3–4 times per week) through day 10 of the\ntreatment phase[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,12 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Jefferson, 2006",na,na,na,na,na,na,na,na,na,na,na,37172,Placebo ,na,na,na,na,39.8,na,na,139,na,na,96,na,na,White=108; Black=12; Hispanic=15; Other=4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,29,na,na,3,na,na,tick,tick,tick,tick,na,tick,na,tick,na,na,na,na,na,tick,tick,na,na,na,tick,tick,tick,Dry mouth=8;Dizziness=3;Nausea=7;Insomnia=2;Anxiety=1;Dyspepsia=0;Sinusitis=3;Tremor=0,na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,16-69,na,na,tick,na,tick,0,na,na,na,na,na,na,na,na,na,na,87998173.0,Continuous,109227.0,113972901.0,1.0,13669974.0,0.0,13688668.0,IDS-C-30 Anxiety scale,1798.0,weeks,8,8 weeks,37172.0,0.0,Placebo ,,Jefferson (2006),Change from baseline;LSMean;SEConv;LOCF,137.0,-1.6,2.34,0.0,Placebo,IDS-C-30 (anxiety)
87998173,"Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.",The Journal of clinical psychiatry,Jefferson (2006),2006,"Jefferson James W, Rush A John, Nelson J Craig, VanMeter Susan A, Krishen Alok, Hampton Kenneth D, Wightman Donna S, and Modell Jack G (2006) Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.. The Journal of clinical psychiatry 67(6), 865-73","[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Jefferson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""GlaxoSmithKline[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Eligible patients needed to have demon-\nstrated symptoms of depression for at least 12 weeks but""\n""not more than 2 years before study entry and to have had\na minimum score of 25 on the 30-item Inventory of De-\npressive Symptomatology (IDS-IVR-30)17,18\nwhen mea-\nsured at the screening (day –7) and baseline (day –1) vis-\nits using interactive voice response (IVR) technology.19,20\nEligible patients also had to have demonstrated a total\nscore of ≥ 7 and a minimum score of 1 on at least 4 of\nthe 5-item subset (Items 19, 20, 21, 22, 30) of the IDS-\nIVR-30 that assesses energy, pleasure, and interest at both\nscreening and baseline visits.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included current or past history of\nseizures or brain injury or any condition that predisposes\nto seizures; current or past history of anorexia nervosa or\nbulimia; unstable medical conditions; lifetime diagnosis\nof bipolar I or II disorder or schizophrenia or other psy-\nchotic disorder; primary diagnosis or treatment for panic\ndisorder, obsessive-compulsive disorder, posttraumatic\nstress disorder, or acute stress disorder within the previ-\nous 12 months; history of alcohol or substance abuse or\ndependence within the past 12 months; treatment with\npsychotropic drugs, including psychoactive herbal prepa-\nrations, within 2 weeks prior to the screening visit (4\nweeks for fluoxetine); and total scores on the IDS-IVR-30\nthat increased or decreased by > 25% between the screen-\ning and baseline measurements.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""nonpsy-\nchotic MDD[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",tick,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Use of zolpidem, up to\n10 mg/day, or zaleplon, up to 20 mg/day, was allowed\nsparingly (up to 3–4 times per week) through day 10 of the\ntreatment phase[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,12 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Jefferson, 2006",na,na,na,na,na,na,na,na,na,na,na,37172,Placebo ,na,na,na,na,39.8,na,na,139,na,na,96,na,na,White=108; Black=12; Hispanic=15; Other=4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,29,na,na,3,na,na,tick,tick,tick,tick,na,tick,na,tick,na,na,na,na,na,tick,tick,na,na,na,tick,tick,tick,Dry mouth=8;Dizziness=3;Nausea=7;Insomnia=2;Anxiety=1;Dyspepsia=0;Sinusitis=3;Tremor=0,na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,16-69,na,na,tick,na,tick,0,na,na,na,na,na,na,na,na,na,na,87998173.0,Continuous,109428.0,113972901.0,1.0,13669974.0,0.0,13686049.0,IDS-IVR-30 Pleasure scale,1798.0,weeks,8,8 weeks,37172.0,0.0,Placebo ,,Jefferson (2006),Change for baseline;LSMean;SEConv,133.0,-5.3,4.61,0.0,Placebo,IDS-IVR-30 (energy/pleasure/interest)
87998173,"Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.",The Journal of clinical psychiatry,Jefferson (2006),2006,"Jefferson James W, Rush A John, Nelson J Craig, VanMeter Susan A, Krishen Alok, Hampton Kenneth D, Wightman Donna S, and Modell Jack G (2006) Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.. The Journal of clinical psychiatry 67(6), 865-73","[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Jefferson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""GlaxoSmithKline[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Eligible patients needed to have demon-\nstrated symptoms of depression for at least 12 weeks but""\n""not more than 2 years before study entry and to have had\na minimum score of 25 on the 30-item Inventory of De-\npressive Symptomatology (IDS-IVR-30)17,18\nwhen mea-\nsured at the screening (day –7) and baseline (day –1) vis-\nits using interactive voice response (IVR) technology.19,20\nEligible patients also had to have demonstrated a total\nscore of ≥ 7 and a minimum score of 1 on at least 4 of\nthe 5-item subset (Items 19, 20, 21, 22, 30) of the IDS-\nIVR-30 that assesses energy, pleasure, and interest at both\nscreening and baseline visits.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included current or past history of\nseizures or brain injury or any condition that predisposes\nto seizures; current or past history of anorexia nervosa or\nbulimia; unstable medical conditions; lifetime diagnosis\nof bipolar I or II disorder or schizophrenia or other psy-\nchotic disorder; primary diagnosis or treatment for panic\ndisorder, obsessive-compulsive disorder, posttraumatic\nstress disorder, or acute stress disorder within the previ-\nous 12 months; history of alcohol or substance abuse or\ndependence within the past 12 months; treatment with\npsychotropic drugs, including psychoactive herbal prepa-\nrations, within 2 weeks prior to the screening visit (4\nweeks for fluoxetine); and total scores on the IDS-IVR-30\nthat increased or decreased by > 25% between the screen-\ning and baseline measurements.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""nonpsy-\nchotic MDD[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",tick,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Use of zolpidem, up to\n10 mg/day, or zaleplon, up to 20 mg/day, was allowed\nsparingly (up to 3–4 times per week) through day 10 of the\ntreatment phase[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,12 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Jefferson, 2006",na,na,na,na,na,na,na,na,na,na,na,37172,Placebo ,na,na,na,na,39.8,na,na,139,na,na,96,na,na,White=108; Black=12; Hispanic=15; Other=4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,29,na,na,3,na,na,tick,tick,tick,tick,na,tick,na,tick,na,na,na,na,na,tick,tick,na,na,na,tick,tick,tick,Dry mouth=8;Dizziness=3;Nausea=7;Insomnia=2;Anxiety=1;Dyspepsia=0;Sinusitis=3;Tremor=0,na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,16-69,na,na,tick,na,tick,0,na,na,na,na,na,na,na,na,na,na,87998173.0,Continuous,109430.0,113972901.0,1.0,13669974.0,0.0,13686054.0,IDS-C-30 Pleasure scale,1799.0,weeks,0,0 weeks,37172.0,0.0,Placebo ,,Jefferson (2006),LSMean:SEConv,137.0,99999.0,99999.0,0.0,Placebo,IDS-C-30 (energy/pleasure/interest)
87998173,"Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.",The Journal of clinical psychiatry,Jefferson (2006),2006,"Jefferson James W, Rush A John, Nelson J Craig, VanMeter Susan A, Krishen Alok, Hampton Kenneth D, Wightman Donna S, and Modell Jack G (2006) Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.. The Journal of clinical psychiatry 67(6), 865-73","[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Jefferson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""GlaxoSmithKline[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Eligible patients needed to have demon-\nstrated symptoms of depression for at least 12 weeks but""\n""not more than 2 years before study entry and to have had\na minimum score of 25 on the 30-item Inventory of De-\npressive Symptomatology (IDS-IVR-30)17,18\nwhen mea-\nsured at the screening (day –7) and baseline (day –1) vis-\nits using interactive voice response (IVR) technology.19,20\nEligible patients also had to have demonstrated a total\nscore of ≥ 7 and a minimum score of 1 on at least 4 of\nthe 5-item subset (Items 19, 20, 21, 22, 30) of the IDS-\nIVR-30 that assesses energy, pleasure, and interest at both\nscreening and baseline visits.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included current or past history of\nseizures or brain injury or any condition that predisposes\nto seizures; current or past history of anorexia nervosa or\nbulimia; unstable medical conditions; lifetime diagnosis\nof bipolar I or II disorder or schizophrenia or other psy-\nchotic disorder; primary diagnosis or treatment for panic\ndisorder, obsessive-compulsive disorder, posttraumatic\nstress disorder, or acute stress disorder within the previ-\nous 12 months; history of alcohol or substance abuse or\ndependence within the past 12 months; treatment with\npsychotropic drugs, including psychoactive herbal prepa-\nrations, within 2 weeks prior to the screening visit (4\nweeks for fluoxetine); and total scores on the IDS-IVR-30\nthat increased or decreased by > 25% between the screen-\ning and baseline measurements.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""nonpsy-\nchotic MDD[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",tick,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Use of zolpidem, up to\n10 mg/day, or zaleplon, up to 20 mg/day, was allowed\nsparingly (up to 3–4 times per week) through day 10 of the\ntreatment phase[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,12 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Jefferson, 2006",na,na,na,na,na,na,na,na,na,na,na,37172,Placebo ,na,na,na,na,39.8,na,na,139,na,na,96,na,na,White=108; Black=12; Hispanic=15; Other=4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,29,na,na,3,na,na,tick,tick,tick,tick,na,tick,na,tick,na,na,na,na,na,tick,tick,na,na,na,tick,tick,tick,Dry mouth=8;Dizziness=3;Nausea=7;Insomnia=2;Anxiety=1;Dyspepsia=0;Sinusitis=3;Tremor=0,na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,16-69,na,na,tick,na,tick,0,na,na,na,na,na,na,na,na,na,na,87998173.0,Continuous,109434.0,113972901.0,1.0,13669974.0,0.0,13688667.0,IDS-IVR-30 Anxiety scale,1799.0,weeks,0,0 weeks,37172.0,0.0,Placebo ,,Jefferson (2006),LSMean;SEConv,137.0,99999.0,99999.0,0.0,Placebo,IDS-IVR-30 (anxiety)
87998173,"Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.",The Journal of clinical psychiatry,Jefferson (2006),2006,"Jefferson James W, Rush A John, Nelson J Craig, VanMeter Susan A, Krishen Alok, Hampton Kenneth D, Wightman Donna S, and Modell Jack G (2006) Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.. The Journal of clinical psychiatry 67(6), 865-73","[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Jefferson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""GlaxoSmithKline[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Eligible patients needed to have demon-\nstrated symptoms of depression for at least 12 weeks but""\n""not more than 2 years before study entry and to have had\na minimum score of 25 on the 30-item Inventory of De-\npressive Symptomatology (IDS-IVR-30)17,18\nwhen mea-\nsured at the screening (day –7) and baseline (day –1) vis-\nits using interactive voice response (IVR) technology.19,20\nEligible patients also had to have demonstrated a total\nscore of ≥ 7 and a minimum score of 1 on at least 4 of\nthe 5-item subset (Items 19, 20, 21, 22, 30) of the IDS-\nIVR-30 that assesses energy, pleasure, and interest at both\nscreening and baseline visits.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included current or past history of\nseizures or brain injury or any condition that predisposes\nto seizures; current or past history of anorexia nervosa or\nbulimia; unstable medical conditions; lifetime diagnosis\nof bipolar I or II disorder or schizophrenia or other psy-\nchotic disorder; primary diagnosis or treatment for panic\ndisorder, obsessive-compulsive disorder, posttraumatic\nstress disorder, or acute stress disorder within the previ-\nous 12 months; history of alcohol or substance abuse or\ndependence within the past 12 months; treatment with\npsychotropic drugs, including psychoactive herbal prepa-\nrations, within 2 weeks prior to the screening visit (4\nweeks for fluoxetine); and total scores on the IDS-IVR-30\nthat increased or decreased by > 25% between the screen-\ning and baseline measurements.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""nonpsy-\nchotic MDD[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",tick,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Use of zolpidem, up to\n10 mg/day, or zaleplon, up to 20 mg/day, was allowed\nsparingly (up to 3–4 times per week) through day 10 of the\ntreatment phase[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,12 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Jefferson, 2006",na,na,na,na,na,na,na,na,na,na,na,37172,Placebo ,na,na,na,na,39.8,na,na,139,na,na,96,na,na,White=108; Black=12; Hispanic=15; Other=4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,29,na,na,3,na,na,tick,tick,tick,tick,na,tick,na,tick,na,na,na,na,na,tick,tick,na,na,na,tick,tick,tick,Dry mouth=8;Dizziness=3;Nausea=7;Insomnia=2;Anxiety=1;Dyspepsia=0;Sinusitis=3;Tremor=0,na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,16-69,na,na,tick,na,tick,0,na,na,na,na,na,na,na,na,na,na,87998173.0,Continuous,109432.0,113972901.0,1.0,13669974.0,0.0,13688668.0,IDS-C-30 Anxiety scale,1799.0,weeks,0,0 weeks,37172.0,0.0,Placebo ,,Jefferson (2006),LSMean;SEConv,137.0,99999.0,99999.0,0.0,Placebo,IDS-C-30 (anxiety)
87998173,"Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.",The Journal of clinical psychiatry,Jefferson (2006),2006,"Jefferson James W, Rush A John, Nelson J Craig, VanMeter Susan A, Krishen Alok, Hampton Kenneth D, Wightman Donna S, and Modell Jack G (2006) Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.. The Journal of clinical psychiatry 67(6), 865-73","[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Jefferson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""GlaxoSmithKline[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Eligible patients needed to have demon-\nstrated symptoms of depression for at least 12 weeks but""\n""not more than 2 years before study entry and to have had\na minimum score of 25 on the 30-item Inventory of De-\npressive Symptomatology (IDS-IVR-30)17,18\nwhen mea-\nsured at the screening (day –7) and baseline (day –1) vis-\nits using interactive voice response (IVR) technology.19,20\nEligible patients also had to have demonstrated a total\nscore of ≥ 7 and a minimum score of 1 on at least 4 of\nthe 5-item subset (Items 19, 20, 21, 22, 30) of the IDS-\nIVR-30 that assesses energy, pleasure, and interest at both\nscreening and baseline visits.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included current or past history of\nseizures or brain injury or any condition that predisposes\nto seizures; current or past history of anorexia nervosa or\nbulimia; unstable medical conditions; lifetime diagnosis\nof bipolar I or II disorder or schizophrenia or other psy-\nchotic disorder; primary diagnosis or treatment for panic\ndisorder, obsessive-compulsive disorder, posttraumatic\nstress disorder, or acute stress disorder within the previ-\nous 12 months; history of alcohol or substance abuse or\ndependence within the past 12 months; treatment with\npsychotropic drugs, including psychoactive herbal prepa-\nrations, within 2 weeks prior to the screening visit (4\nweeks for fluoxetine); and total scores on the IDS-IVR-30\nthat increased or decreased by > 25% between the screen-\ning and baseline measurements.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""nonpsy-\nchotic MDD[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",tick,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Use of zolpidem, up to\n10 mg/day, or zaleplon, up to 20 mg/day, was allowed\nsparingly (up to 3–4 times per week) through day 10 of the\ntreatment phase[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,12 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Jefferson, 2006",na,na,na,na,na,na,na,na,na,na,na,37173,Bupropion XR,na,na,na,na,40,na,na,135,na,na,89,na,na,White=104; Black=113; Hispanic=13; Other=5,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,32,na,na,12,na,na,tick,tick,tick,tick,na,tick,na,tick,na,na,na,tick,na,tick,tick,na,na,na,tick,tick,tick,Dry mouth=17;Dizziness=14;Nausea=14;Insomnia=10;Anxiety=8;Dyspepsia=7;Sinusitis=7;Tremor=0,na,150mg,tick,450mg,8 weeks,150mg,450mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,20-68,na,na,tick,tick,na,0,na,na,na,na,na,na,na,na,na,na,87998173.0,Continuous,109209.0,113972901.0,1.0,13673273.0,0.0,13686049.0,IDS-IVR-30 Pleasure scale,1798.0,weeks,8,8 weeks,37173.0,0.0,Bupropion XR,,Jefferson (2006),Change from baseline;LSMean;SEConv,133.0,-6.7,4.61,0.0,*Bupropion XR,IDS-IVR-30 (energy/pleasure/interest)
87998173,"Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.",The Journal of clinical psychiatry,Jefferson (2006),2006,"Jefferson James W, Rush A John, Nelson J Craig, VanMeter Susan A, Krishen Alok, Hampton Kenneth D, Wightman Donna S, and Modell Jack G (2006) Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.. The Journal of clinical psychiatry 67(6), 865-73","[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Jefferson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""GlaxoSmithKline[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Eligible patients needed to have demon-\nstrated symptoms of depression for at least 12 weeks but""\n""not more than 2 years before study entry and to have had\na minimum score of 25 on the 30-item Inventory of De-\npressive Symptomatology (IDS-IVR-30)17,18\nwhen mea-\nsured at the screening (day –7) and baseline (day –1) vis-\nits using interactive voice response (IVR) technology.19,20\nEligible patients also had to have demonstrated a total\nscore of ≥ 7 and a minimum score of 1 on at least 4 of\nthe 5-item subset (Items 19, 20, 21, 22, 30) of the IDS-\nIVR-30 that assesses energy, pleasure, and interest at both\nscreening and baseline visits.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included current or past history of\nseizures or brain injury or any condition that predisposes\nto seizures; current or past history of anorexia nervosa or\nbulimia; unstable medical conditions; lifetime diagnosis\nof bipolar I or II disorder or schizophrenia or other psy-\nchotic disorder; primary diagnosis or treatment for panic\ndisorder, obsessive-compulsive disorder, posttraumatic\nstress disorder, or acute stress disorder within the previ-\nous 12 months; history of alcohol or substance abuse or\ndependence within the past 12 months; treatment with\npsychotropic drugs, including psychoactive herbal prepa-\nrations, within 2 weeks prior to the screening visit (4\nweeks for fluoxetine); and total scores on the IDS-IVR-30\nthat increased or decreased by > 25% between the screen-\ning and baseline measurements.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""nonpsy-\nchotic MDD[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",tick,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Use of zolpidem, up to\n10 mg/day, or zaleplon, up to 20 mg/day, was allowed\nsparingly (up to 3–4 times per week) through day 10 of the\ntreatment phase[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,12 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Jefferson, 2006",na,na,na,na,na,na,na,na,na,na,na,37173,Bupropion XR,na,na,na,na,40,na,na,135,na,na,89,na,na,White=104; Black=113; Hispanic=13; Other=5,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,32,na,na,12,na,na,tick,tick,tick,tick,na,tick,na,tick,na,na,na,tick,na,tick,tick,na,na,na,tick,tick,tick,Dry mouth=17;Dizziness=14;Nausea=14;Insomnia=10;Anxiety=8;Dyspepsia=7;Sinusitis=7;Tremor=0,na,150mg,tick,450mg,8 weeks,150mg,450mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,20-68,na,na,tick,tick,na,0,na,na,na,na,na,na,na,na,na,na,87998173.0,Continuous,109215.0,113972901.0,1.0,13673273.0,0.0,13686054.0,IDS-C-30 Pleasure scale,1798.0,weeks,8,8 weeks,37173.0,0.0,Bupropion XR,,Jefferson (2006),Change from baseline;LSMean:SEConv,133.0,-5.5,4.61,0.0,*Bupropion XR,IDS-C-30 (energy/pleasure/interest)
87998173,"Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.",The Journal of clinical psychiatry,Jefferson (2006),2006,"Jefferson James W, Rush A John, Nelson J Craig, VanMeter Susan A, Krishen Alok, Hampton Kenneth D, Wightman Donna S, and Modell Jack G (2006) Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.. The Journal of clinical psychiatry 67(6), 865-73","[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Jefferson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""GlaxoSmithKline[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Eligible patients needed to have demon-\nstrated symptoms of depression for at least 12 weeks but""\n""not more than 2 years before study entry and to have had\na minimum score of 25 on the 30-item Inventory of De-\npressive Symptomatology (IDS-IVR-30)17,18\nwhen mea-\nsured at the screening (day –7) and baseline (day –1) vis-\nits using interactive voice response (IVR) technology.19,20\nEligible patients also had to have demonstrated a total\nscore of ≥ 7 and a minimum score of 1 on at least 4 of\nthe 5-item subset (Items 19, 20, 21, 22, 30) of the IDS-\nIVR-30 that assesses energy, pleasure, and interest at both\nscreening and baseline visits.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included current or past history of\nseizures or brain injury or any condition that predisposes\nto seizures; current or past history of anorexia nervosa or\nbulimia; unstable medical conditions; lifetime diagnosis\nof bipolar I or II disorder or schizophrenia or other psy-\nchotic disorder; primary diagnosis or treatment for panic\ndisorder, obsessive-compulsive disorder, posttraumatic\nstress disorder, or acute stress disorder within the previ-\nous 12 months; history of alcohol or substance abuse or\ndependence within the past 12 months; treatment with\npsychotropic drugs, including psychoactive herbal prepa-\nrations, within 2 weeks prior to the screening visit (4\nweeks for fluoxetine); and total scores on the IDS-IVR-30\nthat increased or decreased by > 25% between the screen-\ning and baseline measurements.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""nonpsy-\nchotic MDD[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",tick,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Use of zolpidem, up to\n10 mg/day, or zaleplon, up to 20 mg/day, was allowed\nsparingly (up to 3–4 times per week) through day 10 of the\ntreatment phase[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,12 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Jefferson, 2006",na,na,na,na,na,na,na,na,na,na,na,37173,Bupropion XR,na,na,na,na,40,na,na,135,na,na,89,na,na,White=104; Black=113; Hispanic=13; Other=5,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,32,na,na,12,na,na,tick,tick,tick,tick,na,tick,na,tick,na,na,na,tick,na,tick,tick,na,na,na,tick,tick,tick,Dry mouth=17;Dizziness=14;Nausea=14;Insomnia=10;Anxiety=8;Dyspepsia=7;Sinusitis=7;Tremor=0,na,150mg,tick,450mg,8 weeks,150mg,450mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,20-68,na,na,tick,tick,na,0,na,na,na,na,na,na,na,na,na,na,87998173.0,Continuous,109221.0,113972901.0,1.0,13673273.0,0.0,13688667.0,IDS-IVR-30 Anxiety scale,1798.0,weeks,8,8 weeks,37173.0,0.0,Bupropion XR,,Jefferson (2006),Change from baseline;LSMean;SEConv,133.0,-2.4,4.0,0.0,*Bupropion XR,IDS-IVR-30 (anxiety)
87998173,"Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.",The Journal of clinical psychiatry,Jefferson (2006),2006,"Jefferson James W, Rush A John, Nelson J Craig, VanMeter Susan A, Krishen Alok, Hampton Kenneth D, Wightman Donna S, and Modell Jack G (2006) Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.. The Journal of clinical psychiatry 67(6), 865-73","[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Jefferson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""GlaxoSmithKline[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Eligible patients needed to have demon-\nstrated symptoms of depression for at least 12 weeks but""\n""not more than 2 years before study entry and to have had\na minimum score of 25 on the 30-item Inventory of De-\npressive Symptomatology (IDS-IVR-30)17,18\nwhen mea-\nsured at the screening (day –7) and baseline (day –1) vis-\nits using interactive voice response (IVR) technology.19,20\nEligible patients also had to have demonstrated a total\nscore of ≥ 7 and a minimum score of 1 on at least 4 of\nthe 5-item subset (Items 19, 20, 21, 22, 30) of the IDS-\nIVR-30 that assesses energy, pleasure, and interest at both\nscreening and baseline visits.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included current or past history of\nseizures or brain injury or any condition that predisposes\nto seizures; current or past history of anorexia nervosa or\nbulimia; unstable medical conditions; lifetime diagnosis\nof bipolar I or II disorder or schizophrenia or other psy-\nchotic disorder; primary diagnosis or treatment for panic\ndisorder, obsessive-compulsive disorder, posttraumatic\nstress disorder, or acute stress disorder within the previ-\nous 12 months; history of alcohol or substance abuse or\ndependence within the past 12 months; treatment with\npsychotropic drugs, including psychoactive herbal prepa-\nrations, within 2 weeks prior to the screening visit (4\nweeks for fluoxetine); and total scores on the IDS-IVR-30\nthat increased or decreased by > 25% between the screen-\ning and baseline measurements.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""nonpsy-\nchotic MDD[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",tick,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Use of zolpidem, up to\n10 mg/day, or zaleplon, up to 20 mg/day, was allowed\nsparingly (up to 3–4 times per week) through day 10 of the\ntreatment phase[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,12 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Jefferson, 2006",na,na,na,na,na,na,na,na,na,na,na,37173,Bupropion XR,na,na,na,na,40,na,na,135,na,na,89,na,na,White=104; Black=113; Hispanic=13; Other=5,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,32,na,na,12,na,na,tick,tick,tick,tick,na,tick,na,tick,na,na,na,tick,na,tick,tick,na,na,na,tick,tick,tick,Dry mouth=17;Dizziness=14;Nausea=14;Insomnia=10;Anxiety=8;Dyspepsia=7;Sinusitis=7;Tremor=0,na,150mg,tick,450mg,8 weeks,150mg,450mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,20-68,na,na,tick,tick,na,0,na,na,na,na,na,na,na,na,na,na,87998173.0,Continuous,109226.0,113972901.0,1.0,13673273.0,0.0,13688668.0,IDS-C-30 Anxiety scale,1798.0,weeks,8,8 weeks,37173.0,0.0,Bupropion XR,,Jefferson (2006),Change from baseline;LSMean;SEConv;LOCF,133.0,-2.0,2.31,0.0,*Bupropion XR,IDS-C-30 (anxiety)
87998173,"Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.",The Journal of clinical psychiatry,Jefferson (2006),2006,"Jefferson James W, Rush A John, Nelson J Craig, VanMeter Susan A, Krishen Alok, Hampton Kenneth D, Wightman Donna S, and Modell Jack G (2006) Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.. The Journal of clinical psychiatry 67(6), 865-73","[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Jefferson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""GlaxoSmithKline[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Eligible patients needed to have demon-\nstrated symptoms of depression for at least 12 weeks but""\n""not more than 2 years before study entry and to have had\na minimum score of 25 on the 30-item Inventory of De-\npressive Symptomatology (IDS-IVR-30)17,18\nwhen mea-\nsured at the screening (day –7) and baseline (day –1) vis-\nits using interactive voice response (IVR) technology.19,20\nEligible patients also had to have demonstrated a total\nscore of ≥ 7 and a minimum score of 1 on at least 4 of\nthe 5-item subset (Items 19, 20, 21, 22, 30) of the IDS-\nIVR-30 that assesses energy, pleasure, and interest at both\nscreening and baseline visits.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included current or past history of\nseizures or brain injury or any condition that predisposes\nto seizures; current or past history of anorexia nervosa or\nbulimia; unstable medical conditions; lifetime diagnosis\nof bipolar I or II disorder or schizophrenia or other psy-\nchotic disorder; primary diagnosis or treatment for panic\ndisorder, obsessive-compulsive disorder, posttraumatic\nstress disorder, or acute stress disorder within the previ-\nous 12 months; history of alcohol or substance abuse or\ndependence within the past 12 months; treatment with\npsychotropic drugs, including psychoactive herbal prepa-\nrations, within 2 weeks prior to the screening visit (4\nweeks for fluoxetine); and total scores on the IDS-IVR-30\nthat increased or decreased by > 25% between the screen-\ning and baseline measurements.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""nonpsy-\nchotic MDD[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",tick,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Use of zolpidem, up to\n10 mg/day, or zaleplon, up to 20 mg/day, was allowed\nsparingly (up to 3–4 times per week) through day 10 of the\ntreatment phase[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,12 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Jefferson, 2006",na,na,na,na,na,na,na,na,na,na,na,37173,Bupropion XR,na,na,na,na,40,na,na,135,na,na,89,na,na,White=104; Black=113; Hispanic=13; Other=5,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,32,na,na,12,na,na,tick,tick,tick,tick,na,tick,na,tick,na,na,na,tick,na,tick,tick,na,na,na,tick,tick,tick,Dry mouth=17;Dizziness=14;Nausea=14;Insomnia=10;Anxiety=8;Dyspepsia=7;Sinusitis=7;Tremor=0,na,150mg,tick,450mg,8 weeks,150mg,450mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,20-68,na,na,tick,tick,na,0,na,na,na,na,na,na,na,na,na,na,87998173.0,Continuous,109427.0,113972901.0,1.0,13673273.0,0.0,13686049.0,IDS-IVR-30 Pleasure scale,1799.0,weeks,0,0 weeks,37173.0,0.0,Bupropion XR,,Jefferson (2006),LSMean;SEConv,133.0,99999.0,99999.0,0.0,*Bupropion XR,IDS-IVR-30 (energy/pleasure/interest)
87998173,"Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.",The Journal of clinical psychiatry,Jefferson (2006),2006,"Jefferson James W, Rush A John, Nelson J Craig, VanMeter Susan A, Krishen Alok, Hampton Kenneth D, Wightman Donna S, and Modell Jack G (2006) Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.. The Journal of clinical psychiatry 67(6), 865-73","[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Jefferson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""GlaxoSmithKline[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Eligible patients needed to have demon-\nstrated symptoms of depression for at least 12 weeks but""\n""not more than 2 years before study entry and to have had\na minimum score of 25 on the 30-item Inventory of De-\npressive Symptomatology (IDS-IVR-30)17,18\nwhen mea-\nsured at the screening (day –7) and baseline (day –1) vis-\nits using interactive voice response (IVR) technology.19,20\nEligible patients also had to have demonstrated a total\nscore of ≥ 7 and a minimum score of 1 on at least 4 of\nthe 5-item subset (Items 19, 20, 21, 22, 30) of the IDS-\nIVR-30 that assesses energy, pleasure, and interest at both\nscreening and baseline visits.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included current or past history of\nseizures or brain injury or any condition that predisposes\nto seizures; current or past history of anorexia nervosa or\nbulimia; unstable medical conditions; lifetime diagnosis\nof bipolar I or II disorder or schizophrenia or other psy-\nchotic disorder; primary diagnosis or treatment for panic\ndisorder, obsessive-compulsive disorder, posttraumatic\nstress disorder, or acute stress disorder within the previ-\nous 12 months; history of alcohol or substance abuse or\ndependence within the past 12 months; treatment with\npsychotropic drugs, including psychoactive herbal prepa-\nrations, within 2 weeks prior to the screening visit (4\nweeks for fluoxetine); and total scores on the IDS-IVR-30\nthat increased or decreased by > 25% between the screen-\ning and baseline measurements.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""nonpsy-\nchotic MDD[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",tick,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Use of zolpidem, up to\n10 mg/day, or zaleplon, up to 20 mg/day, was allowed\nsparingly (up to 3–4 times per week) through day 10 of the\ntreatment phase[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,12 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Jefferson, 2006",na,na,na,na,na,na,na,na,na,na,na,37173,Bupropion XR,na,na,na,na,40,na,na,135,na,na,89,na,na,White=104; Black=113; Hispanic=13; Other=5,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,32,na,na,12,na,na,tick,tick,tick,tick,na,tick,na,tick,na,na,na,tick,na,tick,tick,na,na,na,tick,tick,tick,Dry mouth=17;Dizziness=14;Nausea=14;Insomnia=10;Anxiety=8;Dyspepsia=7;Sinusitis=7;Tremor=0,na,150mg,tick,450mg,8 weeks,150mg,450mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,20-68,na,na,tick,tick,na,0,na,na,na,na,na,na,na,na,na,na,87998173.0,Continuous,109429.0,113972901.0,1.0,13673273.0,0.0,13686054.0,IDS-C-30 Pleasure scale,1799.0,weeks,0,0 weeks,37173.0,0.0,Bupropion XR,,Jefferson (2006),LSMean:SEConv,133.0,99999.0,99999.0,0.0,*Bupropion XR,IDS-C-30 (energy/pleasure/interest)
87998173,"Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.",The Journal of clinical psychiatry,Jefferson (2006),2006,"Jefferson James W, Rush A John, Nelson J Craig, VanMeter Susan A, Krishen Alok, Hampton Kenneth D, Wightman Donna S, and Modell Jack G (2006) Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.. The Journal of clinical psychiatry 67(6), 865-73","[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Jefferson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""GlaxoSmithKline[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Eligible patients needed to have demon-\nstrated symptoms of depression for at least 12 weeks but""\n""not more than 2 years before study entry and to have had\na minimum score of 25 on the 30-item Inventory of De-\npressive Symptomatology (IDS-IVR-30)17,18\nwhen mea-\nsured at the screening (day –7) and baseline (day –1) vis-\nits using interactive voice response (IVR) technology.19,20\nEligible patients also had to have demonstrated a total\nscore of ≥ 7 and a minimum score of 1 on at least 4 of\nthe 5-item subset (Items 19, 20, 21, 22, 30) of the IDS-\nIVR-30 that assesses energy, pleasure, and interest at both\nscreening and baseline visits.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included current or past history of\nseizures or brain injury or any condition that predisposes\nto seizures; current or past history of anorexia nervosa or\nbulimia; unstable medical conditions; lifetime diagnosis\nof bipolar I or II disorder or schizophrenia or other psy-\nchotic disorder; primary diagnosis or treatment for panic\ndisorder, obsessive-compulsive disorder, posttraumatic\nstress disorder, or acute stress disorder within the previ-\nous 12 months; history of alcohol or substance abuse or\ndependence within the past 12 months; treatment with\npsychotropic drugs, including psychoactive herbal prepa-\nrations, within 2 weeks prior to the screening visit (4\nweeks for fluoxetine); and total scores on the IDS-IVR-30\nthat increased or decreased by > 25% between the screen-\ning and baseline measurements.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""nonpsy-\nchotic MDD[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",tick,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Use of zolpidem, up to\n10 mg/day, or zaleplon, up to 20 mg/day, was allowed\nsparingly (up to 3–4 times per week) through day 10 of the\ntreatment phase[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,12 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Jefferson, 2006",na,na,na,na,na,na,na,na,na,na,na,37173,Bupropion XR,na,na,na,na,40,na,na,135,na,na,89,na,na,White=104; Black=113; Hispanic=13; Other=5,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,32,na,na,12,na,na,tick,tick,tick,tick,na,tick,na,tick,na,na,na,tick,na,tick,tick,na,na,na,tick,tick,tick,Dry mouth=17;Dizziness=14;Nausea=14;Insomnia=10;Anxiety=8;Dyspepsia=7;Sinusitis=7;Tremor=0,na,150mg,tick,450mg,8 weeks,150mg,450mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,20-68,na,na,tick,tick,na,0,na,na,na,na,na,na,na,na,na,na,87998173.0,Continuous,109433.0,113972901.0,1.0,13673273.0,0.0,13688667.0,IDS-IVR-30 Anxiety scale,1799.0,weeks,0,0 weeks,37173.0,0.0,Bupropion XR,,Jefferson (2006),LSMean;SEConv,133.0,99999.0,99999.0,0.0,*Bupropion XR,IDS-IVR-30 (anxiety)
87998173,"Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.",The Journal of clinical psychiatry,Jefferson (2006),2006,"Jefferson James W, Rush A John, Nelson J Craig, VanMeter Susan A, Krishen Alok, Hampton Kenneth D, Wightman Donna S, and Modell Jack G (2006) Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.. The Journal of clinical psychiatry 67(6), 865-73","[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Jefferson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""GlaxoSmithKline[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Eligible patients needed to have demon-\nstrated symptoms of depression for at least 12 weeks but""\n""not more than 2 years before study entry and to have had\na minimum score of 25 on the 30-item Inventory of De-\npressive Symptomatology (IDS-IVR-30)17,18\nwhen mea-\nsured at the screening (day –7) and baseline (day –1) vis-\nits using interactive voice response (IVR) technology.19,20\nEligible patients also had to have demonstrated a total\nscore of ≥ 7 and a minimum score of 1 on at least 4 of\nthe 5-item subset (Items 19, 20, 21, 22, 30) of the IDS-\nIVR-30 that assesses energy, pleasure, and interest at both\nscreening and baseline visits.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included current or past history of\nseizures or brain injury or any condition that predisposes\nto seizures; current or past history of anorexia nervosa or\nbulimia; unstable medical conditions; lifetime diagnosis\nof bipolar I or II disorder or schizophrenia or other psy-\nchotic disorder; primary diagnosis or treatment for panic\ndisorder, obsessive-compulsive disorder, posttraumatic\nstress disorder, or acute stress disorder within the previ-\nous 12 months; history of alcohol or substance abuse or\ndependence within the past 12 months; treatment with\npsychotropic drugs, including psychoactive herbal prepa-\nrations, within 2 weeks prior to the screening visit (4\nweeks for fluoxetine); and total scores on the IDS-IVR-30\nthat increased or decreased by > 25% between the screen-\ning and baseline measurements.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""nonpsy-\nchotic MDD[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",tick,na,tick,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Use of zolpidem, up to\n10 mg/day, or zaleplon, up to 20 mg/day, was allowed\nsparingly (up to 3–4 times per week) through day 10 of the\ntreatment phase[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050729, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2004[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jefferson James W et al. - 2006 - Extended-release bupropion for patients with major.pdf', 'ItemArm': ''}]",na,na,12 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Jefferson, 2006",na,na,na,na,na,na,na,na,na,na,na,37173,Bupropion XR,na,na,na,na,40,na,na,135,na,na,89,na,na,White=104; Black=113; Hispanic=13; Other=5,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,32,na,na,12,na,na,tick,tick,tick,tick,na,tick,na,tick,na,na,na,tick,na,tick,tick,na,na,na,tick,tick,tick,Dry mouth=17;Dizziness=14;Nausea=14;Insomnia=10;Anxiety=8;Dyspepsia=7;Sinusitis=7;Tremor=0,na,150mg,tick,450mg,8 weeks,150mg,450mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,20-68,na,na,tick,tick,na,0,na,na,na,na,na,na,na,na,na,na,87998173.0,Continuous,109431.0,113972901.0,1.0,13673273.0,0.0,13688668.0,IDS-C-30 Anxiety scale,1799.0,weeks,0,0 weeks,37173.0,0.0,Bupropion XR,,Jefferson (2006),LSMean;SEConv,133.0,99999.0,99999.0,0.0,*Bupropion XR,IDS-C-30 (anxiety)
87998702,"Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial.",Comment in: Arch Gen Psychiatry. 2000 Nov;57(11):1084; author reply 1084-5 PMID: 11074875 [https://www.ncbi.nlm.nih.gov/pubmed/11074875],Jarrett (1999),1999,"Jarrett R B, Schaffer M, McIntire D, Witt-Browder A, Kraft D, and Risser R C (1999) Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial.. Comment in: Arch Gen Psychiatry. 2000 Nov,57(11):1084, and author reply 1084-5 PMID: 11074875 [https://www.ncbi.nlm.nih.gov/pubmed/11074875] 56(5), 431-7","[{'ItemDocumentId': 1050793, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Jarrett,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jarrett R B et al. - 1999 - Treatment of atypical depression with cognitive th.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050793, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1999[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jarrett R B et al. - 1999 - Treatment of atypical depression with cognitive th.pdf', 'ItemArm': ''}]",na,na,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,tick,tick,na,na,tick,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050793, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""” Criteria\n(according to the Atypical Depression Diagnostic Scale)\nfor depression with atypical features included (1) main-\ntains reactive mood and (2) shows 2 or more of the fol-\nlowing: (a) increased appetite or weight gain; (b) over-\nsleeping; (c) sensation of leaden paralysis or extreme\nheaviness of arms or legs, while depressed; and (d) life-\ntime sensitivity to interpersonal rejection.1,2\nDiagnoses were confirmed by a faculty-level diagnos-\ntician at a follow-up interview. Entry criteria were (1) DSM-\nIII-R MDD, (2) definite atypical depression, and (3) score\nof14 or more on the 21-item Hamilton Rating Scale for De-\npression (HRSD-21)24\nat the initial or follow-up inter-\nview. All patients provided a medical history and a physi-\ncian reviewed laboratory screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jarrett R B et al. - 1999 - Treatment of atypical depression with cognitive th.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050793, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if they (1) had a concurrent\nmedical disorder or treatment that might cause depressive\nsymptoms or required medication incompatible with\nMAOIs; (2) refused to be randomized or to maintain a ty-\nramine-free diet; (3) had other current primary comorbid\npsychiatric disorders (eg, organic mental disorders, psy-\nchotic disorders, schizophrenia, schizoaffective disorders,\nalcoholism, or drug abuse or dependency in the last 6\nmonths); (4) scored less than 14 on the HRSD-21 at diag-\nnostic evaluation and follow-up, or before randomization\n(see description of nonspecific treatment below); (5) could\nnot complete questionnaires; (6) represented an immi-\nnent suicide risk; or (7) had previously had an adequate\ntrial of MAOIs or cognitive therapy that failed[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jarrett R B et al. - 1999 - Treatment of atypical depression with cognitive th.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050793, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""MDDand atypi-\ncal features[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jarrett R B et al. - 1999 - Treatment of atypical depression with cognitive th.pdf', 'ItemArm': ''}]","[{'ItemDocumentId': 1050793, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""atypi-\ncal features[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jarrett R B et al. - 1999 - Treatment of atypical depression with cognitive th.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,tick,na,na,na,tick,tick,na,10,na,na,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,37253,Phenelzine,na,na,na,na,38.70,na,na,36,na,na,25,na,na,white=34,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,9,na,na,5,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,64mg sd(2.4),na,8.8 weeks,0.85mg/kg,1mg/kg,na,na,na,na,na,na,na,na,na,na,na,na,once or twice daily,na,na,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,9.78,na,na,na,tick,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87998702,"Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial.",Comment in: Arch Gen Psychiatry. 2000 Nov;57(11):1084; author reply 1084-5 PMID: 11074875 [https://www.ncbi.nlm.nih.gov/pubmed/11074875],Jarrett (1999),1999,"Jarrett R B, Schaffer M, McIntire D, Witt-Browder A, Kraft D, and Risser R C (1999) Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial.. Comment in: Arch Gen Psychiatry. 2000 Nov,57(11):1084, and author reply 1084-5 PMID: 11074875 [https://www.ncbi.nlm.nih.gov/pubmed/11074875] 56(5), 431-7","[{'ItemDocumentId': 1050793, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Jarrett,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jarrett R B et al. - 1999 - Treatment of atypical depression with cognitive th.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050793, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1999[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jarrett R B et al. - 1999 - Treatment of atypical depression with cognitive th.pdf', 'ItemArm': ''}]",na,na,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,tick,tick,na,na,tick,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050793, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""” Criteria\n(according to the Atypical Depression Diagnostic Scale)\nfor depression with atypical features included (1) main-\ntains reactive mood and (2) shows 2 or more of the fol-\nlowing: (a) increased appetite or weight gain; (b) over-\nsleeping; (c) sensation of leaden paralysis or extreme\nheaviness of arms or legs, while depressed; and (d) life-\ntime sensitivity to interpersonal rejection.1,2\nDiagnoses were confirmed by a faculty-level diagnos-\ntician at a follow-up interview. Entry criteria were (1) DSM-\nIII-R MDD, (2) definite atypical depression, and (3) score\nof14 or more on the 21-item Hamilton Rating Scale for De-\npression (HRSD-21)24\nat the initial or follow-up inter-\nview. All patients provided a medical history and a physi-\ncian reviewed laboratory screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jarrett R B et al. - 1999 - Treatment of atypical depression with cognitive th.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050793, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if they (1) had a concurrent\nmedical disorder or treatment that might cause depressive\nsymptoms or required medication incompatible with\nMAOIs; (2) refused to be randomized or to maintain a ty-\nramine-free diet; (3) had other current primary comorbid\npsychiatric disorders (eg, organic mental disorders, psy-\nchotic disorders, schizophrenia, schizoaffective disorders,\nalcoholism, or drug abuse or dependency in the last 6\nmonths); (4) scored less than 14 on the HRSD-21 at diag-\nnostic evaluation and follow-up, or before randomization\n(see description of nonspecific treatment below); (5) could\nnot complete questionnaires; (6) represented an immi-\nnent suicide risk; or (7) had previously had an adequate\ntrial of MAOIs or cognitive therapy that failed[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jarrett R B et al. - 1999 - Treatment of atypical depression with cognitive th.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050793, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""MDDand atypi-\ncal features[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jarrett R B et al. - 1999 - Treatment of atypical depression with cognitive th.pdf', 'ItemArm': ''}]","[{'ItemDocumentId': 1050793, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""atypi-\ncal features[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Jarrett R B et al. - 1999 - Treatment of atypical depression with cognitive th.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,tick,na,na,na,tick,tick,na,10,na,na,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,37254,Placebo,na,na,na,na,40.30,na,na,36,na,na,22,na,na,white=34,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,23,na,na,15,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,10 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,once or twice daily,na,na,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,10.08,na,na,na,tick,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87996305,Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI).,The Journal of clinical psychiatry,Iosifescu (2022),2022,"Iosifescu Dan V, Jones Amanda, O'Gorman Cedric, Streicher Caroline, Feliz Samantha, Fava Maurizio, and Tabuteau Herriot (2022) Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI).. The Journal of clinical psychiatry 83(4),  DOI: https://dx.doi.org/10.4088/JCP.21m14345","[{'ItemDocumentId': 1050722, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Iosifescu,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Iosifescu (2022).pdf', 'ItemArm': ''}]",na,na,tick,na,"[{'ItemDocumentId': 1050722, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""e United States[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Iosifescu (2022).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050722, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 8:\n[¬s]""Funding/support: This study was funded by\nAxsome Therapeutics[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Iosifescu (2022).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050722, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""NCT04019704[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Iosifescu (2022).pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050722, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were men or women 18–65 years of age with a\nprimary diagnosis of MDD, experiencing a major depressive\nepisode of at least 4 weeks in duration, and having a\nMontgomery-Asberg Depression Rating Scale (MADRS)18\ntotal score of 25 or higher, corresponding to moderate or\ngreater severity, with higher scores indicating more severe\ndepression. Patients were also required to have a score on\nthe Clinician Global Impression-Severity (CGI-S)19 scale\nof 4 or higher (range, 1 to 7, with higher scores indicating\ngreater severity of illness). The diagnosis of depression was\nestablished using the Diagnostic and Statistical Manual of\nMental Disorders, Fifth Edition (DSM-5), criteria for MDD\nwithout psychotic features, based on the Structured Clinical\nInterview,20 which has been shown to diagnose MDD more""\n""As part of\nthe screening process, an independent assessor confirmed\nthe eligibility and symptom severity of each patient. The\nassessment consisted of a clinical review of all available\ndocumentation including complete medical history, and\nclinician- and patient-reported outcome measures.""\n""conservatively t[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Iosifescu (2022).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050722, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Key exclusion criteria included bipolar disorder,\npsychotic disorder, panic disorder, obsessive-compulsive\ndisorder, treatment-resistant depression (defined as ≥ 2\nadequate failed antidepressant treatments in the current\nmajor depressive episode), alcohol/substance use disorder\nwithin the past year, clinically significant risk of suicide, and\nhistory of seizure disorder.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Iosifescu (2022).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050722, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""primary diagnosis of MDD[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Iosifescu (2022).pdf', 'ItemArm': ''}]",tick,na,tick,tick,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,6,45.0,105.00,"[{'ItemDocumentId': 1050722, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2019[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Iosifescu (2022).pdf', 'ItemArm': ''}]",na,na,7 months,na,na,na,na,na,once daily for three days and then 2X day,na,tick,na,na,na,na,na,na,na,na,"Iosifescu, 2022; Jones, 2021a; Jones, 2021b; Jones, 2023; O'gorman, 2020; O'Gorman, 2021",na,na,na,na,na,na,na,na,na,na,na,37251,Dextromethorphan- Bupropion,na,na,na,na,42.10,na,na,156,na,na,95,na,na,"White=84;
Black or African-American=58;
Asian=9;
Multiple=3;
Other=2;",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,40,na,na,10,na,na,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Dizziness=26;
Nausea=21;
Headache=13;
Diarrhea=11;
Somnolence=11;
Dry mouth=9;
Hyperhidrosis=8;
Anxiety=7;
Constipation=3;
Decreased appetite=6;
Insomnia=6;
Upper respiratory tract infection=5;",na,tick,tick,tick,6 weeks,45mg,105mg,na,na,na,na,na,na,tick,na,tick,na,tick,na,1Xday for 3 days then 2X day,na,na,na,na,na,na,na,tick,na,Pancreatitis=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,12.80,18.00-64.00,na,na,100,na,na,1,na,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87996305,Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI).,The Journal of clinical psychiatry,Iosifescu (2022),2022,"Iosifescu Dan V, Jones Amanda, O'Gorman Cedric, Streicher Caroline, Feliz Samantha, Fava Maurizio, and Tabuteau Herriot (2022) Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI).. The Journal of clinical psychiatry 83(4),  DOI: https://dx.doi.org/10.4088/JCP.21m14345","[{'ItemDocumentId': 1050722, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Iosifescu,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Iosifescu (2022).pdf', 'ItemArm': ''}]",na,na,tick,na,"[{'ItemDocumentId': 1050722, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""e United States[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Iosifescu (2022).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050722, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 8:\n[¬s]""Funding/support: This study was funded by\nAxsome Therapeutics[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Iosifescu (2022).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050722, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""NCT04019704[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Iosifescu (2022).pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050722, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were men or women 18–65 years of age with a\nprimary diagnosis of MDD, experiencing a major depressive\nepisode of at least 4 weeks in duration, and having a\nMontgomery-Asberg Depression Rating Scale (MADRS)18\ntotal score of 25 or higher, corresponding to moderate or\ngreater severity, with higher scores indicating more severe\ndepression. Patients were also required to have a score on\nthe Clinician Global Impression-Severity (CGI-S)19 scale\nof 4 or higher (range, 1 to 7, with higher scores indicating\ngreater severity of illness). The diagnosis of depression was\nestablished using the Diagnostic and Statistical Manual of\nMental Disorders, Fifth Edition (DSM-5), criteria for MDD\nwithout psychotic features, based on the Structured Clinical\nInterview,20 which has been shown to diagnose MDD more""\n""As part of\nthe screening process, an independent assessor confirmed\nthe eligibility and symptom severity of each patient. The\nassessment consisted of a clinical review of all available\ndocumentation including complete medical history, and\nclinician- and patient-reported outcome measures.""\n""conservatively t[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Iosifescu (2022).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050722, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Key exclusion criteria included bipolar disorder,\npsychotic disorder, panic disorder, obsessive-compulsive\ndisorder, treatment-resistant depression (defined as ≥ 2\nadequate failed antidepressant treatments in the current\nmajor depressive episode), alcohol/substance use disorder\nwithin the past year, clinically significant risk of suicide, and\nhistory of seizure disorder.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Iosifescu (2022).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050722, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""primary diagnosis of MDD[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Iosifescu (2022).pdf', 'ItemArm': ''}]",tick,na,tick,tick,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,6,45.0,105.00,"[{'ItemDocumentId': 1050722, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2019[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Iosifescu (2022).pdf', 'ItemArm': ''}]",na,na,7 months,na,na,na,na,na,once daily for three days and then 2X day,na,tick,na,na,na,na,na,na,na,na,"Iosifescu, 2022; Jones, 2021a; Jones, 2021b; Jones, 2023; O'gorman, 2020; O'Gorman, 2021",na,na,na,na,na,na,na,na,na,na,na,37252,Placebo,na,na,na,na,41.20,na,na,162,na,na,117,na,na,"White = 92;
Black or African-American = 54;
Asian = 8;
Multiple = 2;
Other = 6;",na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,17,na,na,1,na,na,na,tick,tick,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Dizziness=10;
Nausea=14;
Headache=6;
Diarrhea=5;
Somnolence=5;
Dry mouth=4;
Hyperhidrosis=0;
Anxiety=2;
Constipation=3;
Decreased appetite=1;
Insomnia=3;
Upper respiratory tract infection=5;",na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,13.77,18.00-65.00,na,na,74,na,na,0,na,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87997769,"Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.","Journal of psychopharmacology (Oxford, England)",Hewett (2010b),2010,"Hewett K, Chrzanowski W, Jokinen R, Felgentreff R, Shrivastava R K, Gee M D, Wightman D S, O'Leary M C, Millen L S, Leon M C, Briggs M A, Krishen A, and Modell J G (2010) Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.. Journal of psychopharmacology (Oxford, and England) 24(4), 521-9 DOI: https://dx.doi.org/10.1177/0269881108100254","[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Australia (6), Belgium (2), Canada (4), Croatia (2), Finland (5), France (9),\nGermany (16), India (3), Latvia (3), Netherlands (4), Norway (2), Poland (2), Republic of South Africa (5), Russia (3)\nand United States (19).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,GSK,na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""AK130940[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,tick,na,tick,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients aged 65 years or older, with a diagnosis\nof MDD according to Diagnostic and Statistical Manual of\nMental Disorders-IV criteria for at least 8 weeks, were consid-\nered eligible for the study. Patients were required to have a\nHamilton Rating Scale for Depression (HAM-D) 17-item\ntotal score (assessed via interactive voice response system) of\n≥18 at screening and baseline visits (with a change of ≤25%\nbetween visits), and a score of ≥4 on the Clinical Global\nImpressions-Severity of Illness (CGI-S) scale at screening and\nbaseline visits. Patients with comorbidities such as diabetes,\nhigh blood pressure, hypothyroidism or chronic respiratory or\nother medical conditions were enrolled only if their condition\nhad been stable with standard therapy for at least 3 months.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were not eligible if they had been diagnosed with\ndementia, had a score of ≤24 on the Mini-Mental State Exami-\nnation or had been homicidal at any time or suicidal within the\npast 6 months. Patients with a diagnosis of anorexia nervosa or\nbulimia within the past 12 months, a psychotic disorder, a\nmyocardial infarction within the past year, a seizure disorder\nor blood pressure ≥150/95 mmHg were also excluded. Indivi-\nduals who had taken bupropion within the past 6 months, or\nwho had experienced a significant AE when receiving bupro-\npion previously, were ineligible to participate. Further,\nexcluded were the patients who failed to respond to adequate\ntreatment from two previous antidepressants of different clas-\nses and those who had begun psychotherapy within the last\n3 months. Patients who had taken psychotropic drugs or\nother medications, which would lower seizure threshold or\nhave potential pharmacokinetic interactions with bupropion\nXR, within 2 weeks prior to the study were not permitted to\nparticipate.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive disorder,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients with comorbidities such as diabetes,\nhigh blood pressure, hypothyroidism or chronic respiratory or\nother medical conditions were enrolled only if their condition\nhad been stable with standard therapy for at least 3 months.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients who had taken psychotropic drugs or\nother medications, which would lower seizure threshold or\nhave potential pharmacokinetic interactions with bupropion\nXR, within 2 weeks prior to the study were not permitted to\nparticipate. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2005[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,15 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010b; EUCTR2004-004409-24-DE, 2005; Glaxosmithkline - AK130940",na,na,na,na,na,na,na,na,na,na,na,37265,Placebo,na,na,na,na,71.3,na,na,207,na,na,144,na,na,White=178;Black=1;Asian=6;American Hispanic=21;Other=1,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,46,na,na,22,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,Headache=22;Dry mouth=10;Nausea=17;Constipation=7;Insomnia=8;Dizziness=13;Hyperhidrosis=10;Nasopharyngitis=4;Fatigue=6;Diarrhea=6;Agitation=2;Anorexia=1;Back pain=1;Tinnitus=1;Restlessness=0;Tension=0;Chest pain=7;Depression=6,na,na,na,na,10 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,tick,Depression=2;Major depression=1;Suicidal ideation=1;Arrhythmia supraventricular=1;Gastrooesophageal reflux disease=0;Bronchitis=1;Vaginal inflammation=0;Chronic obstructive pulmonary disease=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,5.9,na,na,na,122,na,na,7,na,na,na,na,na,na,na,na,na,na,87997769.0,Continuous,107837.0,113663084.0,1.0,13669974.0,0.0,13671957.0,HAM-A Total Score,1861.0,weeks,0,0 weeks,37265.0,0.0,Placebo,,Hewett (2010b),,204.0,20.3,5.68,0.0,Placebo,*HAM-A
87997769,"Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.","Journal of psychopharmacology (Oxford, England)",Hewett (2010b),2010,"Hewett K, Chrzanowski W, Jokinen R, Felgentreff R, Shrivastava R K, Gee M D, Wightman D S, O'Leary M C, Millen L S, Leon M C, Briggs M A, Krishen A, and Modell J G (2010) Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.. Journal of psychopharmacology (Oxford, and England) 24(4), 521-9 DOI: https://dx.doi.org/10.1177/0269881108100254","[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Australia (6), Belgium (2), Canada (4), Croatia (2), Finland (5), France (9),\nGermany (16), India (3), Latvia (3), Netherlands (4), Norway (2), Poland (2), Republic of South Africa (5), Russia (3)\nand United States (19).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,GSK,na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""AK130940[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,tick,na,tick,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients aged 65 years or older, with a diagnosis\nof MDD according to Diagnostic and Statistical Manual of\nMental Disorders-IV criteria for at least 8 weeks, were consid-\nered eligible for the study. Patients were required to have a\nHamilton Rating Scale for Depression (HAM-D) 17-item\ntotal score (assessed via interactive voice response system) of\n≥18 at screening and baseline visits (with a change of ≤25%\nbetween visits), and a score of ≥4 on the Clinical Global\nImpressions-Severity of Illness (CGI-S) scale at screening and\nbaseline visits. Patients with comorbidities such as diabetes,\nhigh blood pressure, hypothyroidism or chronic respiratory or\nother medical conditions were enrolled only if their condition\nhad been stable with standard therapy for at least 3 months.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were not eligible if they had been diagnosed with\ndementia, had a score of ≤24 on the Mini-Mental State Exami-\nnation or had been homicidal at any time or suicidal within the\npast 6 months. Patients with a diagnosis of anorexia nervosa or\nbulimia within the past 12 months, a psychotic disorder, a\nmyocardial infarction within the past year, a seizure disorder\nor blood pressure ≥150/95 mmHg were also excluded. Indivi-\nduals who had taken bupropion within the past 6 months, or\nwho had experienced a significant AE when receiving bupro-\npion previously, were ineligible to participate. Further,\nexcluded were the patients who failed to respond to adequate\ntreatment from two previous antidepressants of different clas-\nses and those who had begun psychotherapy within the last\n3 months. Patients who had taken psychotropic drugs or\nother medications, which would lower seizure threshold or\nhave potential pharmacokinetic interactions with bupropion\nXR, within 2 weeks prior to the study were not permitted to\nparticipate.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive disorder,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients with comorbidities such as diabetes,\nhigh blood pressure, hypothyroidism or chronic respiratory or\nother medical conditions were enrolled only if their condition\nhad been stable with standard therapy for at least 3 months.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients who had taken psychotropic drugs or\nother medications, which would lower seizure threshold or\nhave potential pharmacokinetic interactions with bupropion\nXR, within 2 weeks prior to the study were not permitted to\nparticipate. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2005[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,15 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010b; EUCTR2004-004409-24-DE, 2005; Glaxosmithkline - AK130940",na,na,na,na,na,na,na,na,na,na,na,37265,Placebo,na,na,na,na,71.3,na,na,207,na,na,144,na,na,White=178;Black=1;Asian=6;American Hispanic=21;Other=1,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,46,na,na,22,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,Headache=22;Dry mouth=10;Nausea=17;Constipation=7;Insomnia=8;Dizziness=13;Hyperhidrosis=10;Nasopharyngitis=4;Fatigue=6;Diarrhea=6;Agitation=2;Anorexia=1;Back pain=1;Tinnitus=1;Restlessness=0;Tension=0;Chest pain=7;Depression=6,na,na,na,na,10 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,tick,Depression=2;Major depression=1;Suicidal ideation=1;Arrhythmia supraventricular=1;Gastrooesophageal reflux disease=0;Bronchitis=1;Vaginal inflammation=0;Chronic obstructive pulmonary disease=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,5.9,na,na,na,122,na,na,7,na,na,na,na,na,na,na,na,na,na,87997769.0,Continuous,107839.0,113663084.0,1.0,13669974.0,0.0,13671957.0,HAM-A Total Score,1893.0,weeks,10,10 weeks,37265.0,0.0,Placebo,,Hewett (2010b),Change from baseline;convSE;LOCF;LSMeans,204.0,-7.3,6.71,0.0,Placebo,*HAM-A
87997769,"Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.","Journal of psychopharmacology (Oxford, England)",Hewett (2010b),2010,"Hewett K, Chrzanowski W, Jokinen R, Felgentreff R, Shrivastava R K, Gee M D, Wightman D S, O'Leary M C, Millen L S, Leon M C, Briggs M A, Krishen A, and Modell J G (2010) Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.. Journal of psychopharmacology (Oxford, and England) 24(4), 521-9 DOI: https://dx.doi.org/10.1177/0269881108100254","[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Australia (6), Belgium (2), Canada (4), Croatia (2), Finland (5), France (9),\nGermany (16), India (3), Latvia (3), Netherlands (4), Norway (2), Poland (2), Republic of South Africa (5), Russia (3)\nand United States (19).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,GSK,na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""AK130940[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,tick,na,tick,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients aged 65 years or older, with a diagnosis\nof MDD according to Diagnostic and Statistical Manual of\nMental Disorders-IV criteria for at least 8 weeks, were consid-\nered eligible for the study. Patients were required to have a\nHamilton Rating Scale for Depression (HAM-D) 17-item\ntotal score (assessed via interactive voice response system) of\n≥18 at screening and baseline visits (with a change of ≤25%\nbetween visits), and a score of ≥4 on the Clinical Global\nImpressions-Severity of Illness (CGI-S) scale at screening and\nbaseline visits. Patients with comorbidities such as diabetes,\nhigh blood pressure, hypothyroidism or chronic respiratory or\nother medical conditions were enrolled only if their condition\nhad been stable with standard therapy for at least 3 months.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were not eligible if they had been diagnosed with\ndementia, had a score of ≤24 on the Mini-Mental State Exami-\nnation or had been homicidal at any time or suicidal within the\npast 6 months. Patients with a diagnosis of anorexia nervosa or\nbulimia within the past 12 months, a psychotic disorder, a\nmyocardial infarction within the past year, a seizure disorder\nor blood pressure ≥150/95 mmHg were also excluded. Indivi-\nduals who had taken bupropion within the past 6 months, or\nwho had experienced a significant AE when receiving bupro-\npion previously, were ineligible to participate. Further,\nexcluded were the patients who failed to respond to adequate\ntreatment from two previous antidepressants of different clas-\nses and those who had begun psychotherapy within the last\n3 months. Patients who had taken psychotropic drugs or\nother medications, which would lower seizure threshold or\nhave potential pharmacokinetic interactions with bupropion\nXR, within 2 weeks prior to the study were not permitted to\nparticipate.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive disorder,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients with comorbidities such as diabetes,\nhigh blood pressure, hypothyroidism or chronic respiratory or\nother medical conditions were enrolled only if their condition\nhad been stable with standard therapy for at least 3 months.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients who had taken psychotropic drugs or\nother medications, which would lower seizure threshold or\nhave potential pharmacokinetic interactions with bupropion\nXR, within 2 weeks prior to the study were not permitted to\nparticipate. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2005[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,15 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010b; EUCTR2004-004409-24-DE, 2005; Glaxosmithkline - AK130940",na,na,na,na,na,na,na,na,na,na,na,37265,Placebo,na,na,na,na,71.3,na,na,207,na,na,144,na,na,White=178;Black=1;Asian=6;American Hispanic=21;Other=1,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,46,na,na,22,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,Headache=22;Dry mouth=10;Nausea=17;Constipation=7;Insomnia=8;Dizziness=13;Hyperhidrosis=10;Nasopharyngitis=4;Fatigue=6;Diarrhea=6;Agitation=2;Anorexia=1;Back pain=1;Tinnitus=1;Restlessness=0;Tension=0;Chest pain=7;Depression=6,na,na,na,na,10 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,tick,Depression=2;Major depression=1;Suicidal ideation=1;Arrhythmia supraventricular=1;Gastrooesophageal reflux disease=0;Bronchitis=1;Vaginal inflammation=0;Chronic obstructive pulmonary disease=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,5.9,na,na,na,122,na,na,7,na,na,na,na,na,na,na,na,na,na,87997769.0,Continuous,107871.0,113663084.0,1.0,13669974.0,0.0,13711321.0,MEI Total,1893.0,weeks,10,10 weeks,37265.0,0.0,Placebo,,Hewett (2010b),Change from baseline;LSMean;ConvSE;LOCF,204.0,16.9,23.42,0.0,Placebo,*Motivation and Energy Inventory (MEI)
87997769,"Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.","Journal of psychopharmacology (Oxford, England)",Hewett (2010b),2010,"Hewett K, Chrzanowski W, Jokinen R, Felgentreff R, Shrivastava R K, Gee M D, Wightman D S, O'Leary M C, Millen L S, Leon M C, Briggs M A, Krishen A, and Modell J G (2010) Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.. Journal of psychopharmacology (Oxford, and England) 24(4), 521-9 DOI: https://dx.doi.org/10.1177/0269881108100254","[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Australia (6), Belgium (2), Canada (4), Croatia (2), Finland (5), France (9),\nGermany (16), India (3), Latvia (3), Netherlands (4), Norway (2), Poland (2), Republic of South Africa (5), Russia (3)\nand United States (19).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,GSK,na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""AK130940[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,tick,na,tick,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients aged 65 years or older, with a diagnosis\nof MDD according to Diagnostic and Statistical Manual of\nMental Disorders-IV criteria for at least 8 weeks, were consid-\nered eligible for the study. Patients were required to have a\nHamilton Rating Scale for Depression (HAM-D) 17-item\ntotal score (assessed via interactive voice response system) of\n≥18 at screening and baseline visits (with a change of ≤25%\nbetween visits), and a score of ≥4 on the Clinical Global\nImpressions-Severity of Illness (CGI-S) scale at screening and\nbaseline visits. Patients with comorbidities such as diabetes,\nhigh blood pressure, hypothyroidism or chronic respiratory or\nother medical conditions were enrolled only if their condition\nhad been stable with standard therapy for at least 3 months.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were not eligible if they had been diagnosed with\ndementia, had a score of ≤24 on the Mini-Mental State Exami-\nnation or had been homicidal at any time or suicidal within the\npast 6 months. Patients with a diagnosis of anorexia nervosa or\nbulimia within the past 12 months, a psychotic disorder, a\nmyocardial infarction within the past year, a seizure disorder\nor blood pressure ≥150/95 mmHg were also excluded. Indivi-\nduals who had taken bupropion within the past 6 months, or\nwho had experienced a significant AE when receiving bupro-\npion previously, were ineligible to participate. Further,\nexcluded were the patients who failed to respond to adequate\ntreatment from two previous antidepressants of different clas-\nses and those who had begun psychotherapy within the last\n3 months. Patients who had taken psychotropic drugs or\nother medications, which would lower seizure threshold or\nhave potential pharmacokinetic interactions with bupropion\nXR, within 2 weeks prior to the study were not permitted to\nparticipate.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive disorder,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients with comorbidities such as diabetes,\nhigh blood pressure, hypothyroidism or chronic respiratory or\nother medical conditions were enrolled only if their condition\nhad been stable with standard therapy for at least 3 months.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients who had taken psychotropic drugs or\nother medications, which would lower seizure threshold or\nhave potential pharmacokinetic interactions with bupropion\nXR, within 2 weeks prior to the study were not permitted to\nparticipate. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2005[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,15 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010b; EUCTR2004-004409-24-DE, 2005; Glaxosmithkline - AK130940",na,na,na,na,na,na,na,na,na,na,na,37265,Placebo,na,na,na,na,71.3,na,na,207,na,na,144,na,na,White=178;Black=1;Asian=6;American Hispanic=21;Other=1,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,46,na,na,22,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,Headache=22;Dry mouth=10;Nausea=17;Constipation=7;Insomnia=8;Dizziness=13;Hyperhidrosis=10;Nasopharyngitis=4;Fatigue=6;Diarrhea=6;Agitation=2;Anorexia=1;Back pain=1;Tinnitus=1;Restlessness=0;Tension=0;Chest pain=7;Depression=6,na,na,na,na,10 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,tick,Depression=2;Major depression=1;Suicidal ideation=1;Arrhythmia supraventricular=1;Gastrooesophageal reflux disease=0;Bronchitis=1;Vaginal inflammation=0;Chronic obstructive pulmonary disease=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,5.9,na,na,na,122,na,na,7,na,na,na,na,na,na,na,na,na,na,87997769.0,Continuous,107873.0,113663084.0,1.0,13669974.0,0.0,13711321.0,MEI Total,1861.0,weeks,0,0 weeks,37265.0,0.0,Placebo,,Hewett (2010b),,204.0,29.5,15.16,0.0,Placebo,*Motivation and Energy Inventory (MEI)
87997769,"Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.","Journal of psychopharmacology (Oxford, England)",Hewett (2010b),2010,"Hewett K, Chrzanowski W, Jokinen R, Felgentreff R, Shrivastava R K, Gee M D, Wightman D S, O'Leary M C, Millen L S, Leon M C, Briggs M A, Krishen A, and Modell J G (2010) Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.. Journal of psychopharmacology (Oxford, and England) 24(4), 521-9 DOI: https://dx.doi.org/10.1177/0269881108100254","[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Australia (6), Belgium (2), Canada (4), Croatia (2), Finland (5), France (9),\nGermany (16), India (3), Latvia (3), Netherlands (4), Norway (2), Poland (2), Republic of South Africa (5), Russia (3)\nand United States (19).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,GSK,na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""AK130940[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,tick,na,tick,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients aged 65 years or older, with a diagnosis\nof MDD according to Diagnostic and Statistical Manual of\nMental Disorders-IV criteria for at least 8 weeks, were consid-\nered eligible for the study. Patients were required to have a\nHamilton Rating Scale for Depression (HAM-D) 17-item\ntotal score (assessed via interactive voice response system) of\n≥18 at screening and baseline visits (with a change of ≤25%\nbetween visits), and a score of ≥4 on the Clinical Global\nImpressions-Severity of Illness (CGI-S) scale at screening and\nbaseline visits. Patients with comorbidities such as diabetes,\nhigh blood pressure, hypothyroidism or chronic respiratory or\nother medical conditions were enrolled only if their condition\nhad been stable with standard therapy for at least 3 months.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were not eligible if they had been diagnosed with\ndementia, had a score of ≤24 on the Mini-Mental State Exami-\nnation or had been homicidal at any time or suicidal within the\npast 6 months. Patients with a diagnosis of anorexia nervosa or\nbulimia within the past 12 months, a psychotic disorder, a\nmyocardial infarction within the past year, a seizure disorder\nor blood pressure ≥150/95 mmHg were also excluded. Indivi-\nduals who had taken bupropion within the past 6 months, or\nwho had experienced a significant AE when receiving bupro-\npion previously, were ineligible to participate. Further,\nexcluded were the patients who failed to respond to adequate\ntreatment from two previous antidepressants of different clas-\nses and those who had begun psychotherapy within the last\n3 months. Patients who had taken psychotropic drugs or\nother medications, which would lower seizure threshold or\nhave potential pharmacokinetic interactions with bupropion\nXR, within 2 weeks prior to the study were not permitted to\nparticipate.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive disorder,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients with comorbidities such as diabetes,\nhigh blood pressure, hypothyroidism or chronic respiratory or\nother medical conditions were enrolled only if their condition\nhad been stable with standard therapy for at least 3 months.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients who had taken psychotropic drugs or\nother medications, which would lower seizure threshold or\nhave potential pharmacokinetic interactions with bupropion\nXR, within 2 weeks prior to the study were not permitted to\nparticipate. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2005[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,15 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010b; EUCTR2004-004409-24-DE, 2005; Glaxosmithkline - AK130940",na,na,na,na,na,na,na,na,na,na,na,37266,Bupropion XR,na,na,na,na,70.9,na,na,211,na,na,157,na,na,White=177;Black=4;Asian=8;American Hispanic=20;Other=2,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,48,na,na,17,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,tick,Headache=20;Dry mouth=18;Nausea=14;Constipation=13;Insomnia=13;Dizziness=12;Hyperhidrosis=7;Nasopharyngitis=6;Fatigue=5;Diarrhea=4;Agitation=4;Anorexia=4;Back pain=4;Tinnitus=4;Restlessness=4;Tension=4;Chest pain=2;Depression=2,na,150mg,tick,300mg,10 weeks,150mg,300mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,tick,na,na,na,na,na,na,tick,Depression=0;Major depression=0;Suicidal ideation=0;Arrhythmia supraventricular=0;Gastrooesophageal reflux disease=1;Bronchitis=0;Vaginal inflammation=1;Chronic obstructive pulmonary disease=-0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,5.6,na,na,na,121,na,na,2,na,na,na,na,na,na,na,na,na,na,87997769.0,Continuous,107845.0,113663084.0,1.0,13673273.0,0.0,13671957.0,HAM-A Total Score,1861.0,weeks,0,0 weeks,37266.0,0.0,Bupropion XR,,Hewett (2010b),,210.0,20.4,5.47,0.0,*Bupropion XR,*HAM-A
87997769,"Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.","Journal of psychopharmacology (Oxford, England)",Hewett (2010b),2010,"Hewett K, Chrzanowski W, Jokinen R, Felgentreff R, Shrivastava R K, Gee M D, Wightman D S, O'Leary M C, Millen L S, Leon M C, Briggs M A, Krishen A, and Modell J G (2010) Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.. Journal of psychopharmacology (Oxford, and England) 24(4), 521-9 DOI: https://dx.doi.org/10.1177/0269881108100254","[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Australia (6), Belgium (2), Canada (4), Croatia (2), Finland (5), France (9),\nGermany (16), India (3), Latvia (3), Netherlands (4), Norway (2), Poland (2), Republic of South Africa (5), Russia (3)\nand United States (19).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,GSK,na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""AK130940[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,tick,na,tick,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients aged 65 years or older, with a diagnosis\nof MDD according to Diagnostic and Statistical Manual of\nMental Disorders-IV criteria for at least 8 weeks, were consid-\nered eligible for the study. Patients were required to have a\nHamilton Rating Scale for Depression (HAM-D) 17-item\ntotal score (assessed via interactive voice response system) of\n≥18 at screening and baseline visits (with a change of ≤25%\nbetween visits), and a score of ≥4 on the Clinical Global\nImpressions-Severity of Illness (CGI-S) scale at screening and\nbaseline visits. Patients with comorbidities such as diabetes,\nhigh blood pressure, hypothyroidism or chronic respiratory or\nother medical conditions were enrolled only if their condition\nhad been stable with standard therapy for at least 3 months.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were not eligible if they had been diagnosed with\ndementia, had a score of ≤24 on the Mini-Mental State Exami-\nnation or had been homicidal at any time or suicidal within the\npast 6 months. Patients with a diagnosis of anorexia nervosa or\nbulimia within the past 12 months, a psychotic disorder, a\nmyocardial infarction within the past year, a seizure disorder\nor blood pressure ≥150/95 mmHg were also excluded. Indivi-\nduals who had taken bupropion within the past 6 months, or\nwho had experienced a significant AE when receiving bupro-\npion previously, were ineligible to participate. Further,\nexcluded were the patients who failed to respond to adequate\ntreatment from two previous antidepressants of different clas-\nses and those who had begun psychotherapy within the last\n3 months. Patients who had taken psychotropic drugs or\nother medications, which would lower seizure threshold or\nhave potential pharmacokinetic interactions with bupropion\nXR, within 2 weeks prior to the study were not permitted to\nparticipate.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive disorder,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients with comorbidities such as diabetes,\nhigh blood pressure, hypothyroidism or chronic respiratory or\nother medical conditions were enrolled only if their condition\nhad been stable with standard therapy for at least 3 months.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients who had taken psychotropic drugs or\nother medications, which would lower seizure threshold or\nhave potential pharmacokinetic interactions with bupropion\nXR, within 2 weeks prior to the study were not permitted to\nparticipate. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2005[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,15 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010b; EUCTR2004-004409-24-DE, 2005; Glaxosmithkline - AK130940",na,na,na,na,na,na,na,na,na,na,na,37266,Bupropion XR,na,na,na,na,70.9,na,na,211,na,na,157,na,na,White=177;Black=4;Asian=8;American Hispanic=20;Other=2,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,48,na,na,17,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,tick,Headache=20;Dry mouth=18;Nausea=14;Constipation=13;Insomnia=13;Dizziness=12;Hyperhidrosis=7;Nasopharyngitis=6;Fatigue=5;Diarrhea=4;Agitation=4;Anorexia=4;Back pain=4;Tinnitus=4;Restlessness=4;Tension=4;Chest pain=2;Depression=2,na,150mg,tick,300mg,10 weeks,150mg,300mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,tick,na,na,na,na,na,na,tick,Depression=0;Major depression=0;Suicidal ideation=0;Arrhythmia supraventricular=0;Gastrooesophageal reflux disease=1;Bronchitis=0;Vaginal inflammation=1;Chronic obstructive pulmonary disease=-0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,5.6,na,na,na,121,na,na,2,na,na,na,na,na,na,na,na,na,na,87997769.0,Continuous,107851.0,113663084.0,1.0,13673273.0,0.0,13671957.0,HAM-A Total Score,1893.0,weeks,10,10 weeks,37266.0,0.0,Bupropion XR,,Hewett (2010b),Change from baseline;LSMean;LOCF;convSE,210.0,-8.1,6.67,0.0,*Bupropion XR,*HAM-A
87997769,"Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.","Journal of psychopharmacology (Oxford, England)",Hewett (2010b),2010,"Hewett K, Chrzanowski W, Jokinen R, Felgentreff R, Shrivastava R K, Gee M D, Wightman D S, O'Leary M C, Millen L S, Leon M C, Briggs M A, Krishen A, and Modell J G (2010) Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.. Journal of psychopharmacology (Oxford, and England) 24(4), 521-9 DOI: https://dx.doi.org/10.1177/0269881108100254","[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Australia (6), Belgium (2), Canada (4), Croatia (2), Finland (5), France (9),\nGermany (16), India (3), Latvia (3), Netherlands (4), Norway (2), Poland (2), Republic of South Africa (5), Russia (3)\nand United States (19).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,GSK,na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""AK130940[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,tick,na,tick,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients aged 65 years or older, with a diagnosis\nof MDD according to Diagnostic and Statistical Manual of\nMental Disorders-IV criteria for at least 8 weeks, were consid-\nered eligible for the study. Patients were required to have a\nHamilton Rating Scale for Depression (HAM-D) 17-item\ntotal score (assessed via interactive voice response system) of\n≥18 at screening and baseline visits (with a change of ≤25%\nbetween visits), and a score of ≥4 on the Clinical Global\nImpressions-Severity of Illness (CGI-S) scale at screening and\nbaseline visits. Patients with comorbidities such as diabetes,\nhigh blood pressure, hypothyroidism or chronic respiratory or\nother medical conditions were enrolled only if their condition\nhad been stable with standard therapy for at least 3 months.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were not eligible if they had been diagnosed with\ndementia, had a score of ≤24 on the Mini-Mental State Exami-\nnation or had been homicidal at any time or suicidal within the\npast 6 months. Patients with a diagnosis of anorexia nervosa or\nbulimia within the past 12 months, a psychotic disorder, a\nmyocardial infarction within the past year, a seizure disorder\nor blood pressure ≥150/95 mmHg were also excluded. Indivi-\nduals who had taken bupropion within the past 6 months, or\nwho had experienced a significant AE when receiving bupro-\npion previously, were ineligible to participate. Further,\nexcluded were the patients who failed to respond to adequate\ntreatment from two previous antidepressants of different clas-\nses and those who had begun psychotherapy within the last\n3 months. Patients who had taken psychotropic drugs or\nother medications, which would lower seizure threshold or\nhave potential pharmacokinetic interactions with bupropion\nXR, within 2 weeks prior to the study were not permitted to\nparticipate.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive disorder,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients with comorbidities such as diabetes,\nhigh blood pressure, hypothyroidism or chronic respiratory or\nother medical conditions were enrolled only if their condition\nhad been stable with standard therapy for at least 3 months.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients who had taken psychotropic drugs or\nother medications, which would lower seizure threshold or\nhave potential pharmacokinetic interactions with bupropion\nXR, within 2 weeks prior to the study were not permitted to\nparticipate. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2005[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,15 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010b; EUCTR2004-004409-24-DE, 2005; Glaxosmithkline - AK130940",na,na,na,na,na,na,na,na,na,na,na,37266,Bupropion XR,na,na,na,na,70.9,na,na,211,na,na,157,na,na,White=177;Black=4;Asian=8;American Hispanic=20;Other=2,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,48,na,na,17,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,tick,Headache=20;Dry mouth=18;Nausea=14;Constipation=13;Insomnia=13;Dizziness=12;Hyperhidrosis=7;Nasopharyngitis=6;Fatigue=5;Diarrhea=4;Agitation=4;Anorexia=4;Back pain=4;Tinnitus=4;Restlessness=4;Tension=4;Chest pain=2;Depression=2,na,150mg,tick,300mg,10 weeks,150mg,300mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,tick,na,na,na,na,na,na,tick,Depression=0;Major depression=0;Suicidal ideation=0;Arrhythmia supraventricular=0;Gastrooesophageal reflux disease=1;Bronchitis=0;Vaginal inflammation=1;Chronic obstructive pulmonary disease=-0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,5.6,na,na,na,121,na,na,2,na,na,na,na,na,na,na,na,na,na,87997769.0,Continuous,107879.0,113663084.0,1.0,13673273.0,0.0,13711321.0,MEI Total,1861.0,weeks,0,0 weeks,37266.0,0.0,Bupropion XR,,Hewett (2010b),,210.0,29.0,13.85,0.0,*Bupropion XR,*Motivation and Energy Inventory (MEI)
87997769,"Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.","Journal of psychopharmacology (Oxford, England)",Hewett (2010b),2010,"Hewett K, Chrzanowski W, Jokinen R, Felgentreff R, Shrivastava R K, Gee M D, Wightman D S, O'Leary M C, Millen L S, Leon M C, Briggs M A, Krishen A, and Modell J G (2010) Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.. Journal of psychopharmacology (Oxford, and England) 24(4), 521-9 DOI: https://dx.doi.org/10.1177/0269881108100254","[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Australia (6), Belgium (2), Canada (4), Croatia (2), Finland (5), France (9),\nGermany (16), India (3), Latvia (3), Netherlands (4), Norway (2), Poland (2), Republic of South Africa (5), Russia (3)\nand United States (19).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,GSK,na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""AK130940[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,tick,na,tick,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients aged 65 years or older, with a diagnosis\nof MDD according to Diagnostic and Statistical Manual of\nMental Disorders-IV criteria for at least 8 weeks, were consid-\nered eligible for the study. Patients were required to have a\nHamilton Rating Scale for Depression (HAM-D) 17-item\ntotal score (assessed via interactive voice response system) of\n≥18 at screening and baseline visits (with a change of ≤25%\nbetween visits), and a score of ≥4 on the Clinical Global\nImpressions-Severity of Illness (CGI-S) scale at screening and\nbaseline visits. Patients with comorbidities such as diabetes,\nhigh blood pressure, hypothyroidism or chronic respiratory or\nother medical conditions were enrolled only if their condition\nhad been stable with standard therapy for at least 3 months.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were not eligible if they had been diagnosed with\ndementia, had a score of ≤24 on the Mini-Mental State Exami-\nnation or had been homicidal at any time or suicidal within the\npast 6 months. Patients with a diagnosis of anorexia nervosa or\nbulimia within the past 12 months, a psychotic disorder, a\nmyocardial infarction within the past year, a seizure disorder\nor blood pressure ≥150/95 mmHg were also excluded. Indivi-\nduals who had taken bupropion within the past 6 months, or\nwho had experienced a significant AE when receiving bupro-\npion previously, were ineligible to participate. Further,\nexcluded were the patients who failed to respond to adequate\ntreatment from two previous antidepressants of different clas-\nses and those who had begun psychotherapy within the last\n3 months. Patients who had taken psychotropic drugs or\nother medications, which would lower seizure threshold or\nhave potential pharmacokinetic interactions with bupropion\nXR, within 2 weeks prior to the study were not permitted to\nparticipate.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive disorder,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients with comorbidities such as diabetes,\nhigh blood pressure, hypothyroidism or chronic respiratory or\nother medical conditions were enrolled only if their condition\nhad been stable with standard therapy for at least 3 months.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050706, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients who had taken psychotropic drugs or\nother medications, which would lower seizure threshold or\nhave potential pharmacokinetic interactions with bupropion\nXR, within 2 weeks prior to the study were not permitted to\nparticipate. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett (2010).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1064817, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2005[¬e]""', 'IsFromPDF': True, 'DocTitle': 'AK130940-Clinical-Study-Result-Summary.pdf', 'ItemArm': ''}]",na,na,15 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010b; EUCTR2004-004409-24-DE, 2005; Glaxosmithkline - AK130940",na,na,na,na,na,na,na,na,na,na,na,37266,Bupropion XR,na,na,na,na,70.9,na,na,211,na,na,157,na,na,White=177;Black=4;Asian=8;American Hispanic=20;Other=2,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,48,na,na,17,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,tick,Headache=20;Dry mouth=18;Nausea=14;Constipation=13;Insomnia=13;Dizziness=12;Hyperhidrosis=7;Nasopharyngitis=6;Fatigue=5;Diarrhea=4;Agitation=4;Anorexia=4;Back pain=4;Tinnitus=4;Restlessness=4;Tension=4;Chest pain=2;Depression=2,na,150mg,tick,300mg,10 weeks,150mg,300mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,tick,na,na,na,na,na,na,tick,Depression=0;Major depression=0;Suicidal ideation=0;Arrhythmia supraventricular=0;Gastrooesophageal reflux disease=1;Bronchitis=0;Vaginal inflammation=1;Chronic obstructive pulmonary disease=-0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,5.6,na,na,na,121,na,na,2,na,na,na,na,na,na,na,na,na,na,87997769.0,Continuous,107886.0,113663084.0,1.0,13673273.0,0.0,13711321.0,MEI Total,1893.0,weeks,10,10 weeks,37266.0,0.0,Bupropion XR,,Hewett (2010b),Change from baseline;LSMean;ConvSE;LOCF,210.0,23.6,22.89,0.0,*Bupropion XR,*Motivation and Energy Inventory (MEI)
87997755,"Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2010a),2010,"Hewett Karen, Gee Michelle D, Krishen Alok, Wunderlich Hans-Peter, Le Clus Alfred, Evoniuk Gary, and Modell Jack G (2010) Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 24(8), 1209-16 DOI: https://dx.doi.org/10.1177/0269881109106953","[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett1,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083365, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""62 centres in Australia (7 centres), France (15 centres), Germany (18 centres), the Netherlands (6 centres),\nNorway (5 centres), South Africa (6 centres) and Sweden (5 centres).[¬e]""', 'IsFromPDF': True, 'DocTitle': '23134-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This study (AK130939) was sponsored by GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""(AK130939)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients aged 18–64 years with a DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks duration were eligible for inclu-\nsion. Eligible patients required an Interactive Voice Response\nSystem (IVRS) Hamilton Depression Rating Scale (HAMD)\n17-Item total score of\t18 at both screening and baseline visits\n(Kobak et al., 1999), which must not have decreased or\nincreased by more than 25% between visits. A score of \t4\non the Clinical Global Impressions–Severity of Illness\n(CGI-S) scale at both screening and baseline was also required.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if they had a history of manic epi-\nsodes, past or current psychotic disorder or a current Axis II\ndiagnosis that suggested non-responsiveness or non-compli-\nance with therapy. Also excluded were patients that had been\nhomicidal at any time in their lives or suicidal within the past\n6 months, those with anorexia nervosa or bulimia within the\npast year, myocardial infarction within the past year, any\nhistory of seizure disorder or brain injury, blood pressure\n\t150/95mmHg, or unstable medical disorder. Patients were\nnot eligible to participate if they had taken bupropion or\nvenlafaxine within the past six months, or had experienced\na signiﬁcant adverse response to either antidepressant in the\npast. Patients who had failed to respond to adequate treat-\nment from two previous antidepressants of diﬀerent classes\nwere also excluded. To be eligible, patients could not have[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""had any psychotherapy or taken any psychotropic drugs,\nother medications with potential pharmacokinetic interac-\ntions, or any medication that might lower the seizure thresh-\nold in the two weeks prior to screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,588.00,387.00,na,na,tick,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,tick,131.00,na,na,37,na,na,na,tick,tick,tick,na,tick,tick,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,2005,tick,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010a; AK130939",na,na,na,na,na,na,na,na,na,na,na,37132,Placebo ,na,na,na,na,44.50,na,na,189.00,na,na,125.00,na,na,"White = 179
Black = 4
American Hispanic = 1
Other = 3",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,41,na,na,11,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,"Any adverse event=112;
Dry mouth=13;
Headache=31;
Nausea=16;
Insomnia=8;
Dizziness=11;
Hyperhidrosis=7;
Diarrhoea=9;
Fatigue=13;
Nasopharyngitis=9;
Upper abdominal pain=8;
Constipation=3;
Tremor=2;
Influenza=9;
Somnolence=9;
Anorexia=2;",na,na,na,na,8 weeks,tick,tick,na,na,na,na,tick,na,na,na,na,na,na,na,daily,na,na,na,na,na,na,na,na,na,suicidal depression=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.79,na,na,na,121,na,na,1,na,na,na,na,na,na,na,na,na,na,87997755.0,Continuous,106813.0,113200557.0,3.0,13669974.0,0.0,13669990.0,MADRAS,1767.0,weeks,0,0 weeks,37132.0,0.0,Placebo ,,Hewett (2010a),,186.0,30.6,0.38,0.0,Placebo,MADRS
87997755,"Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2010a),2010,"Hewett Karen, Gee Michelle D, Krishen Alok, Wunderlich Hans-Peter, Le Clus Alfred, Evoniuk Gary, and Modell Jack G (2010) Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 24(8), 1209-16 DOI: https://dx.doi.org/10.1177/0269881109106953","[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett1,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083365, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""62 centres in Australia (7 centres), France (15 centres), Germany (18 centres), the Netherlands (6 centres),\nNorway (5 centres), South Africa (6 centres) and Sweden (5 centres).[¬e]""', 'IsFromPDF': True, 'DocTitle': '23134-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This study (AK130939) was sponsored by GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""(AK130939)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients aged 18–64 years with a DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks duration were eligible for inclu-\nsion. Eligible patients required an Interactive Voice Response\nSystem (IVRS) Hamilton Depression Rating Scale (HAMD)\n17-Item total score of\t18 at both screening and baseline visits\n(Kobak et al., 1999), which must not have decreased or\nincreased by more than 25% between visits. A score of \t4\non the Clinical Global Impressions–Severity of Illness\n(CGI-S) scale at both screening and baseline was also required.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if they had a history of manic epi-\nsodes, past or current psychotic disorder or a current Axis II\ndiagnosis that suggested non-responsiveness or non-compli-\nance with therapy. Also excluded were patients that had been\nhomicidal at any time in their lives or suicidal within the past\n6 months, those with anorexia nervosa or bulimia within the\npast year, myocardial infarction within the past year, any\nhistory of seizure disorder or brain injury, blood pressure\n\t150/95mmHg, or unstable medical disorder. Patients were\nnot eligible to participate if they had taken bupropion or\nvenlafaxine within the past six months, or had experienced\na signiﬁcant adverse response to either antidepressant in the\npast. Patients who had failed to respond to adequate treat-\nment from two previous antidepressants of diﬀerent classes\nwere also excluded. To be eligible, patients could not have[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""had any psychotherapy or taken any psychotropic drugs,\nother medications with potential pharmacokinetic interac-\ntions, or any medication that might lower the seizure thresh-\nold in the two weeks prior to screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,588.00,387.00,na,na,tick,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,tick,131.00,na,na,37,na,na,na,tick,tick,tick,na,tick,tick,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,2005,tick,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010a; AK130939",na,na,na,na,na,na,na,na,na,na,na,37132,Placebo ,na,na,na,na,44.50,na,na,189.00,na,na,125.00,na,na,"White = 179
Black = 4
American Hispanic = 1
Other = 3",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,41,na,na,11,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,"Any adverse event=112;
Dry mouth=13;
Headache=31;
Nausea=16;
Insomnia=8;
Dizziness=11;
Hyperhidrosis=7;
Diarrhoea=9;
Fatigue=13;
Nasopharyngitis=9;
Upper abdominal pain=8;
Constipation=3;
Tremor=2;
Influenza=9;
Somnolence=9;
Anorexia=2;",na,na,na,na,8 weeks,tick,tick,na,na,na,na,tick,na,na,na,na,na,na,na,daily,na,na,na,na,na,na,na,na,na,suicidal depression=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.79,na,na,na,121,na,na,1,na,na,na,na,na,na,na,na,na,na,87997755.0,Continuous,106817.0,113200557.0,3.0,13669974.0,0.0,13669990.0,MADRS ,1770.0,weeks,8,8 weeks,37132.0,0.0,Placebo ,,Hewett (2010a),LSMean and SE converted to SD,186.0,-13.2,-24.54,0.0,Placebo,MADRS
87997755,"Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2010a),2010,"Hewett Karen, Gee Michelle D, Krishen Alok, Wunderlich Hans-Peter, Le Clus Alfred, Evoniuk Gary, and Modell Jack G (2010) Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 24(8), 1209-16 DOI: https://dx.doi.org/10.1177/0269881109106953","[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett1,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083365, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""62 centres in Australia (7 centres), France (15 centres), Germany (18 centres), the Netherlands (6 centres),\nNorway (5 centres), South Africa (6 centres) and Sweden (5 centres).[¬e]""', 'IsFromPDF': True, 'DocTitle': '23134-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This study (AK130939) was sponsored by GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""(AK130939)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients aged 18–64 years with a DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks duration were eligible for inclu-\nsion. Eligible patients required an Interactive Voice Response\nSystem (IVRS) Hamilton Depression Rating Scale (HAMD)\n17-Item total score of\t18 at both screening and baseline visits\n(Kobak et al., 1999), which must not have decreased or\nincreased by more than 25% between visits. A score of \t4\non the Clinical Global Impressions–Severity of Illness\n(CGI-S) scale at both screening and baseline was also required.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if they had a history of manic epi-\nsodes, past or current psychotic disorder or a current Axis II\ndiagnosis that suggested non-responsiveness or non-compli-\nance with therapy. Also excluded were patients that had been\nhomicidal at any time in their lives or suicidal within the past\n6 months, those with anorexia nervosa or bulimia within the\npast year, myocardial infarction within the past year, any\nhistory of seizure disorder or brain injury, blood pressure\n\t150/95mmHg, or unstable medical disorder. Patients were\nnot eligible to participate if they had taken bupropion or\nvenlafaxine within the past six months, or had experienced\na signiﬁcant adverse response to either antidepressant in the\npast. Patients who had failed to respond to adequate treat-\nment from two previous antidepressants of diﬀerent classes\nwere also excluded. To be eligible, patients could not have[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""had any psychotherapy or taken any psychotropic drugs,\nother medications with potential pharmacokinetic interac-\ntions, or any medication that might lower the seizure thresh-\nold in the two weeks prior to screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,588.00,387.00,na,na,tick,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,tick,131.00,na,na,37,na,na,na,tick,tick,tick,na,tick,tick,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,2005,tick,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010a; AK130939",na,na,na,na,na,na,na,na,na,na,na,37132,Placebo ,na,na,na,na,44.50,na,na,189.00,na,na,125.00,na,na,"White = 179
Black = 4
American Hispanic = 1
Other = 3",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,41,na,na,11,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,"Any adverse event=112;
Dry mouth=13;
Headache=31;
Nausea=16;
Insomnia=8;
Dizziness=11;
Hyperhidrosis=7;
Diarrhoea=9;
Fatigue=13;
Nasopharyngitis=9;
Upper abdominal pain=8;
Constipation=3;
Tremor=2;
Influenza=9;
Somnolence=9;
Anorexia=2;",na,na,na,na,8 weeks,tick,tick,na,na,na,na,tick,na,na,na,na,na,na,na,daily,na,na,na,na,na,na,na,na,na,suicidal depression=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.79,na,na,na,121,na,na,1,na,na,na,na,na,na,na,na,na,na,87997755.0,Continuous,106821.0,113200557.0,1.0,13669974.0,0.0,13671957.0,HAM-A,1767.0,weeks,0,0 weeks,37132.0,0.0,Placebo ,,Hewett (2010a),SEConv,186.0,23.6,6.81,0.0,Placebo,*HAM-A
87997755,"Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2010a),2010,"Hewett Karen, Gee Michelle D, Krishen Alok, Wunderlich Hans-Peter, Le Clus Alfred, Evoniuk Gary, and Modell Jack G (2010) Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 24(8), 1209-16 DOI: https://dx.doi.org/10.1177/0269881109106953","[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett1,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083365, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""62 centres in Australia (7 centres), France (15 centres), Germany (18 centres), the Netherlands (6 centres),\nNorway (5 centres), South Africa (6 centres) and Sweden (5 centres).[¬e]""', 'IsFromPDF': True, 'DocTitle': '23134-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This study (AK130939) was sponsored by GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""(AK130939)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients aged 18–64 years with a DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks duration were eligible for inclu-\nsion. Eligible patients required an Interactive Voice Response\nSystem (IVRS) Hamilton Depression Rating Scale (HAMD)\n17-Item total score of\t18 at both screening and baseline visits\n(Kobak et al., 1999), which must not have decreased or\nincreased by more than 25% between visits. A score of \t4\non the Clinical Global Impressions–Severity of Illness\n(CGI-S) scale at both screening and baseline was also required.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if they had a history of manic epi-\nsodes, past or current psychotic disorder or a current Axis II\ndiagnosis that suggested non-responsiveness or non-compli-\nance with therapy. Also excluded were patients that had been\nhomicidal at any time in their lives or suicidal within the past\n6 months, those with anorexia nervosa or bulimia within the\npast year, myocardial infarction within the past year, any\nhistory of seizure disorder or brain injury, blood pressure\n\t150/95mmHg, or unstable medical disorder. Patients were\nnot eligible to participate if they had taken bupropion or\nvenlafaxine within the past six months, or had experienced\na signiﬁcant adverse response to either antidepressant in the\npast. Patients who had failed to respond to adequate treat-\nment from two previous antidepressants of diﬀerent classes\nwere also excluded. To be eligible, patients could not have[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""had any psychotherapy or taken any psychotropic drugs,\nother medications with potential pharmacokinetic interac-\ntions, or any medication that might lower the seizure thresh-\nold in the two weeks prior to screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,588.00,387.00,na,na,tick,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,tick,131.00,na,na,37,na,na,na,tick,tick,tick,na,tick,tick,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,2005,tick,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010a; AK130939",na,na,na,na,na,na,na,na,na,na,na,37132,Placebo ,na,na,na,na,44.50,na,na,189.00,na,na,125.00,na,na,"White = 179
Black = 4
American Hispanic = 1
Other = 3",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,41,na,na,11,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,"Any adverse event=112;
Dry mouth=13;
Headache=31;
Nausea=16;
Insomnia=8;
Dizziness=11;
Hyperhidrosis=7;
Diarrhoea=9;
Fatigue=13;
Nasopharyngitis=9;
Upper abdominal pain=8;
Constipation=3;
Tremor=2;
Influenza=9;
Somnolence=9;
Anorexia=2;",na,na,na,na,8 weeks,tick,tick,na,na,na,na,tick,na,na,na,na,na,na,na,daily,na,na,na,na,na,na,na,na,na,suicidal depression=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.79,na,na,na,121,na,na,1,na,na,na,na,na,na,na,na,na,na,87997755.0,Continuous,106823.0,113200557.0,1.0,13669974.0,0.0,13671957.0,HAM-A ,1770.0,weeks,8,8 weeks,37132.0,0.0,Placebo ,,Hewett (2010a),LSMean;SEConv;Change from baseline,186.0,-8.8,9.0,0.0,Placebo,*HAM-A
87997755,"Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2010a),2010,"Hewett Karen, Gee Michelle D, Krishen Alok, Wunderlich Hans-Peter, Le Clus Alfred, Evoniuk Gary, and Modell Jack G (2010) Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 24(8), 1209-16 DOI: https://dx.doi.org/10.1177/0269881109106953","[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett1,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083365, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""62 centres in Australia (7 centres), France (15 centres), Germany (18 centres), the Netherlands (6 centres),\nNorway (5 centres), South Africa (6 centres) and Sweden (5 centres).[¬e]""', 'IsFromPDF': True, 'DocTitle': '23134-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This study (AK130939) was sponsored by GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""(AK130939)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients aged 18–64 years with a DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks duration were eligible for inclu-\nsion. Eligible patients required an Interactive Voice Response\nSystem (IVRS) Hamilton Depression Rating Scale (HAMD)\n17-Item total score of\t18 at both screening and baseline visits\n(Kobak et al., 1999), which must not have decreased or\nincreased by more than 25% between visits. A score of \t4\non the Clinical Global Impressions–Severity of Illness\n(CGI-S) scale at both screening and baseline was also required.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if they had a history of manic epi-\nsodes, past or current psychotic disorder or a current Axis II\ndiagnosis that suggested non-responsiveness or non-compli-\nance with therapy. Also excluded were patients that had been\nhomicidal at any time in their lives or suicidal within the past\n6 months, those with anorexia nervosa or bulimia within the\npast year, myocardial infarction within the past year, any\nhistory of seizure disorder or brain injury, blood pressure\n\t150/95mmHg, or unstable medical disorder. Patients were\nnot eligible to participate if they had taken bupropion or\nvenlafaxine within the past six months, or had experienced\na signiﬁcant adverse response to either antidepressant in the\npast. Patients who had failed to respond to adequate treat-\nment from two previous antidepressants of diﬀerent classes\nwere also excluded. To be eligible, patients could not have[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""had any psychotherapy or taken any psychotropic drugs,\nother medications with potential pharmacokinetic interac-\ntions, or any medication that might lower the seizure thresh-\nold in the two weeks prior to screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,588.00,387.00,na,na,tick,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,tick,131.00,na,na,37,na,na,na,tick,tick,tick,na,tick,tick,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,2005,tick,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010a; AK130939",na,na,na,na,na,na,na,na,na,na,na,37132,Placebo ,na,na,na,na,44.50,na,na,189.00,na,na,125.00,na,na,"White = 179
Black = 4
American Hispanic = 1
Other = 3",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,41,na,na,11,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,"Any adverse event=112;
Dry mouth=13;
Headache=31;
Nausea=16;
Insomnia=8;
Dizziness=11;
Hyperhidrosis=7;
Diarrhoea=9;
Fatigue=13;
Nasopharyngitis=9;
Upper abdominal pain=8;
Constipation=3;
Tremor=2;
Influenza=9;
Somnolence=9;
Anorexia=2;",na,na,na,na,8 weeks,tick,tick,na,na,na,na,tick,na,na,na,na,na,na,na,daily,na,na,na,na,na,na,na,na,na,suicidal depression=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.79,na,na,na,121,na,na,1,na,na,na,na,na,na,na,na,na,na,87997755.0,Continuous,109222.0,113200557.0,1.0,13669974.0,0.0,13671961.0,Motivation and Energy Inventory,1767.0,weeks,0,0 weeks,37132.0,0.0,Placebo ,,Hewett (2010a),SEConv,186.0,25.3,12.81,0.0,Placebo,*Motivation and Energy Inventory
87997755,"Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2010a),2010,"Hewett Karen, Gee Michelle D, Krishen Alok, Wunderlich Hans-Peter, Le Clus Alfred, Evoniuk Gary, and Modell Jack G (2010) Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 24(8), 1209-16 DOI: https://dx.doi.org/10.1177/0269881109106953","[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett1,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083365, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""62 centres in Australia (7 centres), France (15 centres), Germany (18 centres), the Netherlands (6 centres),\nNorway (5 centres), South Africa (6 centres) and Sweden (5 centres).[¬e]""', 'IsFromPDF': True, 'DocTitle': '23134-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This study (AK130939) was sponsored by GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""(AK130939)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients aged 18–64 years with a DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks duration were eligible for inclu-\nsion. Eligible patients required an Interactive Voice Response\nSystem (IVRS) Hamilton Depression Rating Scale (HAMD)\n17-Item total score of\t18 at both screening and baseline visits\n(Kobak et al., 1999), which must not have decreased or\nincreased by more than 25% between visits. A score of \t4\non the Clinical Global Impressions–Severity of Illness\n(CGI-S) scale at both screening and baseline was also required.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if they had a history of manic epi-\nsodes, past or current psychotic disorder or a current Axis II\ndiagnosis that suggested non-responsiveness or non-compli-\nance with therapy. Also excluded were patients that had been\nhomicidal at any time in their lives or suicidal within the past\n6 months, those with anorexia nervosa or bulimia within the\npast year, myocardial infarction within the past year, any\nhistory of seizure disorder or brain injury, blood pressure\n\t150/95mmHg, or unstable medical disorder. Patients were\nnot eligible to participate if they had taken bupropion or\nvenlafaxine within the past six months, or had experienced\na signiﬁcant adverse response to either antidepressant in the\npast. Patients who had failed to respond to adequate treat-\nment from two previous antidepressants of diﬀerent classes\nwere also excluded. To be eligible, patients could not have[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""had any psychotherapy or taken any psychotropic drugs,\nother medications with potential pharmacokinetic interac-\ntions, or any medication that might lower the seizure thresh-\nold in the two weeks prior to screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,588.00,387.00,na,na,tick,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,tick,131.00,na,na,37,na,na,na,tick,tick,tick,na,tick,tick,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,2005,tick,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010a; AK130939",na,na,na,na,na,na,na,na,na,na,na,37132,Placebo ,na,na,na,na,44.50,na,na,189.00,na,na,125.00,na,na,"White = 179
Black = 4
American Hispanic = 1
Other = 3",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,41,na,na,11,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,"Any adverse event=112;
Dry mouth=13;
Headache=31;
Nausea=16;
Insomnia=8;
Dizziness=11;
Hyperhidrosis=7;
Diarrhoea=9;
Fatigue=13;
Nasopharyngitis=9;
Upper abdominal pain=8;
Constipation=3;
Tremor=2;
Influenza=9;
Somnolence=9;
Anorexia=2;",na,na,na,na,8 weeks,tick,tick,na,na,na,na,tick,na,na,na,na,na,na,na,daily,na,na,na,na,na,na,na,na,na,suicidal depression=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.79,na,na,na,121,na,na,1,na,na,na,na,na,na,na,na,na,na,87997755.0,Continuous,109225.0,113200557.0,1.0,13669974.0,0.0,13671961.0,Motivation and Energy Inventory ,1770.0,weeks,8,8 weeks,37132.0,0.0,Placebo ,,Hewett (2010a),Change from baseline;LS means;SEConv,186.0,18.3,21.95,0.0,Placebo,*Motivation and Energy Inventory
87997755,"Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2010a),2010,"Hewett Karen, Gee Michelle D, Krishen Alok, Wunderlich Hans-Peter, Le Clus Alfred, Evoniuk Gary, and Modell Jack G (2010) Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 24(8), 1209-16 DOI: https://dx.doi.org/10.1177/0269881109106953","[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett1,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083365, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""62 centres in Australia (7 centres), France (15 centres), Germany (18 centres), the Netherlands (6 centres),\nNorway (5 centres), South Africa (6 centres) and Sweden (5 centres).[¬e]""', 'IsFromPDF': True, 'DocTitle': '23134-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This study (AK130939) was sponsored by GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""(AK130939)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients aged 18–64 years with a DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks duration were eligible for inclu-\nsion. Eligible patients required an Interactive Voice Response\nSystem (IVRS) Hamilton Depression Rating Scale (HAMD)\n17-Item total score of\t18 at both screening and baseline visits\n(Kobak et al., 1999), which must not have decreased or\nincreased by more than 25% between visits. A score of \t4\non the Clinical Global Impressions–Severity of Illness\n(CGI-S) scale at both screening and baseline was also required.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if they had a history of manic epi-\nsodes, past or current psychotic disorder or a current Axis II\ndiagnosis that suggested non-responsiveness or non-compli-\nance with therapy. Also excluded were patients that had been\nhomicidal at any time in their lives or suicidal within the past\n6 months, those with anorexia nervosa or bulimia within the\npast year, myocardial infarction within the past year, any\nhistory of seizure disorder or brain injury, blood pressure\n\t150/95mmHg, or unstable medical disorder. Patients were\nnot eligible to participate if they had taken bupropion or\nvenlafaxine within the past six months, or had experienced\na signiﬁcant adverse response to either antidepressant in the\npast. Patients who had failed to respond to adequate treat-\nment from two previous antidepressants of diﬀerent classes\nwere also excluded. To be eligible, patients could not have[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""had any psychotherapy or taken any psychotropic drugs,\nother medications with potential pharmacokinetic interac-\ntions, or any medication that might lower the seizure thresh-\nold in the two weeks prior to screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,588.00,387.00,na,na,tick,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,tick,131.00,na,na,37,na,na,na,tick,tick,tick,na,tick,tick,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,2005,tick,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010a; AK130939",na,na,na,na,na,na,na,na,na,na,na,37133,venlafaxine,na,na,na,na,44.10,na,na,203.00,na,na,127.00,na,na,"White = 186
Black = 3
American Hispanic = 2
Other = 7",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87997755,"Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2010a),2010,"Hewett Karen, Gee Michelle D, Krishen Alok, Wunderlich Hans-Peter, Le Clus Alfred, Evoniuk Gary, and Modell Jack G (2010) Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 24(8), 1209-16 DOI: https://dx.doi.org/10.1177/0269881109106953","[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett1,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083365, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""62 centres in Australia (7 centres), France (15 centres), Germany (18 centres), the Netherlands (6 centres),\nNorway (5 centres), South Africa (6 centres) and Sweden (5 centres).[¬e]""', 'IsFromPDF': True, 'DocTitle': '23134-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This study (AK130939) was sponsored by GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""(AK130939)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients aged 18–64 years with a DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks duration were eligible for inclu-\nsion. Eligible patients required an Interactive Voice Response\nSystem (IVRS) Hamilton Depression Rating Scale (HAMD)\n17-Item total score of\t18 at both screening and baseline visits\n(Kobak et al., 1999), which must not have decreased or\nincreased by more than 25% between visits. A score of \t4\non the Clinical Global Impressions–Severity of Illness\n(CGI-S) scale at both screening and baseline was also required.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if they had a history of manic epi-\nsodes, past or current psychotic disorder or a current Axis II\ndiagnosis that suggested non-responsiveness or non-compli-\nance with therapy. Also excluded were patients that had been\nhomicidal at any time in their lives or suicidal within the past\n6 months, those with anorexia nervosa or bulimia within the\npast year, myocardial infarction within the past year, any\nhistory of seizure disorder or brain injury, blood pressure\n\t150/95mmHg, or unstable medical disorder. Patients were\nnot eligible to participate if they had taken bupropion or\nvenlafaxine within the past six months, or had experienced\na signiﬁcant adverse response to either antidepressant in the\npast. Patients who had failed to respond to adequate treat-\nment from two previous antidepressants of diﬀerent classes\nwere also excluded. To be eligible, patients could not have[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""had any psychotherapy or taken any psychotropic drugs,\nother medications with potential pharmacokinetic interac-\ntions, or any medication that might lower the seizure thresh-\nold in the two weeks prior to screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,588.00,387.00,na,na,tick,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,tick,131.00,na,na,37,na,na,na,tick,tick,tick,na,tick,tick,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,2005,tick,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010a; AK130939",na,na,na,na,na,na,na,na,na,na,na,37134,bupropion XR,na,na,na,na,45.60,na,na,204.00,na,na,127.00,na,na,"White = 196
Black = 3
American Hispanic = 1
Other = 3",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,44,na,na,11,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,"Any adverse event=108;
Dry mouth=32;
Headache=30;
Nausea=27;
Insomnia=15;
Dizziness=14;
Hyperhidrosis=14;
Diarrhoea=8;
Fatigue=7;
Nasopharyngitis=7;
Upper abdominal pain=7;
Constipation=7;
Tremor=5;
Influenza=3;
Somnolence=3;
Anorexia=2",na,150mg,180mg,300mg,8 weeks,150mg,300mg,na,na,na,na,na,na,na,na,na,na,na,na,daily,na,na,na,na,na,na,na,na,na,"worsening depression=1;
pyelonephritis=1;
QTc prolongation=1;
gastritis=1;",na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.76,na,na,na,113,na,na,1,na,na,na,na,na,na,na,na,na,na,87997755.0,Continuous,106814.0,113200557.0,3.0,13673273.0,0.0,13669990.0,MADRAS,1767.0,weeks,0,0 weeks,37134.0,0.0,bupropion XR,,Hewett (2010a),,193.0,30.6,0.34,0.0,*Bupropion XR,MADRS
87997755,"Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2010a),2010,"Hewett Karen, Gee Michelle D, Krishen Alok, Wunderlich Hans-Peter, Le Clus Alfred, Evoniuk Gary, and Modell Jack G (2010) Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 24(8), 1209-16 DOI: https://dx.doi.org/10.1177/0269881109106953","[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett1,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083365, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""62 centres in Australia (7 centres), France (15 centres), Germany (18 centres), the Netherlands (6 centres),\nNorway (5 centres), South Africa (6 centres) and Sweden (5 centres).[¬e]""', 'IsFromPDF': True, 'DocTitle': '23134-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This study (AK130939) was sponsored by GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""(AK130939)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients aged 18–64 years with a DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks duration were eligible for inclu-\nsion. Eligible patients required an Interactive Voice Response\nSystem (IVRS) Hamilton Depression Rating Scale (HAMD)\n17-Item total score of\t18 at both screening and baseline visits\n(Kobak et al., 1999), which must not have decreased or\nincreased by more than 25% between visits. A score of \t4\non the Clinical Global Impressions–Severity of Illness\n(CGI-S) scale at both screening and baseline was also required.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if they had a history of manic epi-\nsodes, past or current psychotic disorder or a current Axis II\ndiagnosis that suggested non-responsiveness or non-compli-\nance with therapy. Also excluded were patients that had been\nhomicidal at any time in their lives or suicidal within the past\n6 months, those with anorexia nervosa or bulimia within the\npast year, myocardial infarction within the past year, any\nhistory of seizure disorder or brain injury, blood pressure\n\t150/95mmHg, or unstable medical disorder. Patients were\nnot eligible to participate if they had taken bupropion or\nvenlafaxine within the past six months, or had experienced\na signiﬁcant adverse response to either antidepressant in the\npast. Patients who had failed to respond to adequate treat-\nment from two previous antidepressants of diﬀerent classes\nwere also excluded. To be eligible, patients could not have[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""had any psychotherapy or taken any psychotropic drugs,\nother medications with potential pharmacokinetic interac-\ntions, or any medication that might lower the seizure thresh-\nold in the two weeks prior to screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,588.00,387.00,na,na,tick,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,tick,131.00,na,na,37,na,na,na,tick,tick,tick,na,tick,tick,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,2005,tick,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010a; AK130939",na,na,na,na,na,na,na,na,na,na,na,37134,bupropion XR,na,na,na,na,45.60,na,na,204.00,na,na,127.00,na,na,"White = 196
Black = 3
American Hispanic = 1
Other = 3",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,44,na,na,11,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,"Any adverse event=108;
Dry mouth=32;
Headache=30;
Nausea=27;
Insomnia=15;
Dizziness=14;
Hyperhidrosis=14;
Diarrhoea=8;
Fatigue=7;
Nasopharyngitis=7;
Upper abdominal pain=7;
Constipation=7;
Tremor=5;
Influenza=3;
Somnolence=3;
Anorexia=2",na,150mg,180mg,300mg,8 weeks,150mg,300mg,na,na,na,na,na,na,na,na,na,na,na,na,daily,na,na,na,na,na,na,na,na,na,"worsening depression=1;
pyelonephritis=1;
QTc prolongation=1;
gastritis=1;",na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.76,na,na,na,113,na,na,1,na,na,na,na,na,na,na,na,na,na,87997755.0,Continuous,106818.0,113200557.0,1.0,13673273.0,0.0,13669990.0,MADRS ,1770.0,weeks,8,8 weeks,37134.0,0.0,bupropion XR,,Hewett (2010a),LS Mean and SE converted to SD,202.0,-14.7,10.51,0.0,*Bupropion XR,MADRS
87997755,"Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2010a),2010,"Hewett Karen, Gee Michelle D, Krishen Alok, Wunderlich Hans-Peter, Le Clus Alfred, Evoniuk Gary, and Modell Jack G (2010) Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 24(8), 1209-16 DOI: https://dx.doi.org/10.1177/0269881109106953","[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett1,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083365, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""62 centres in Australia (7 centres), France (15 centres), Germany (18 centres), the Netherlands (6 centres),\nNorway (5 centres), South Africa (6 centres) and Sweden (5 centres).[¬e]""', 'IsFromPDF': True, 'DocTitle': '23134-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This study (AK130939) was sponsored by GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""(AK130939)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients aged 18–64 years with a DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks duration were eligible for inclu-\nsion. Eligible patients required an Interactive Voice Response\nSystem (IVRS) Hamilton Depression Rating Scale (HAMD)\n17-Item total score of\t18 at both screening and baseline visits\n(Kobak et al., 1999), which must not have decreased or\nincreased by more than 25% between visits. A score of \t4\non the Clinical Global Impressions–Severity of Illness\n(CGI-S) scale at both screening and baseline was also required.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if they had a history of manic epi-\nsodes, past or current psychotic disorder or a current Axis II\ndiagnosis that suggested non-responsiveness or non-compli-\nance with therapy. Also excluded were patients that had been\nhomicidal at any time in their lives or suicidal within the past\n6 months, those with anorexia nervosa or bulimia within the\npast year, myocardial infarction within the past year, any\nhistory of seizure disorder or brain injury, blood pressure\n\t150/95mmHg, or unstable medical disorder. Patients were\nnot eligible to participate if they had taken bupropion or\nvenlafaxine within the past six months, or had experienced\na signiﬁcant adverse response to either antidepressant in the\npast. Patients who had failed to respond to adequate treat-\nment from two previous antidepressants of diﬀerent classes\nwere also excluded. To be eligible, patients could not have[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""had any psychotherapy or taken any psychotropic drugs,\nother medications with potential pharmacokinetic interac-\ntions, or any medication that might lower the seizure thresh-\nold in the two weeks prior to screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,588.00,387.00,na,na,tick,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,tick,131.00,na,na,37,na,na,na,tick,tick,tick,na,tick,tick,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,2005,tick,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010a; AK130939",na,na,na,na,na,na,na,na,na,na,na,37134,bupropion XR,na,na,na,na,45.60,na,na,204.00,na,na,127.00,na,na,"White = 196
Black = 3
American Hispanic = 1
Other = 3",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,44,na,na,11,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,"Any adverse event=108;
Dry mouth=32;
Headache=30;
Nausea=27;
Insomnia=15;
Dizziness=14;
Hyperhidrosis=14;
Diarrhoea=8;
Fatigue=7;
Nasopharyngitis=7;
Upper abdominal pain=7;
Constipation=7;
Tremor=5;
Influenza=3;
Somnolence=3;
Anorexia=2",na,150mg,180mg,300mg,8 weeks,150mg,300mg,na,na,na,na,na,na,na,na,na,na,na,na,daily,na,na,na,na,na,na,na,na,na,"worsening depression=1;
pyelonephritis=1;
QTc prolongation=1;
gastritis=1;",na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.76,na,na,na,113,na,na,1,na,na,na,na,na,na,na,na,na,na,87997755.0,Continuous,106822.0,113200557.0,1.0,13673273.0,0.0,13671957.0,HAM-A,1767.0,weeks,0,0 weeks,37134.0,0.0,bupropion XR,,Hewett (2010a),SEConv,202.0,23.0,6.53,0.0,*Bupropion XR,*HAM-A
87997755,"Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2010a),2010,"Hewett Karen, Gee Michelle D, Krishen Alok, Wunderlich Hans-Peter, Le Clus Alfred, Evoniuk Gary, and Modell Jack G (2010) Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 24(8), 1209-16 DOI: https://dx.doi.org/10.1177/0269881109106953","[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett1,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083365, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""62 centres in Australia (7 centres), France (15 centres), Germany (18 centres), the Netherlands (6 centres),\nNorway (5 centres), South Africa (6 centres) and Sweden (5 centres).[¬e]""', 'IsFromPDF': True, 'DocTitle': '23134-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This study (AK130939) was sponsored by GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""(AK130939)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients aged 18–64 years with a DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks duration were eligible for inclu-\nsion. Eligible patients required an Interactive Voice Response\nSystem (IVRS) Hamilton Depression Rating Scale (HAMD)\n17-Item total score of\t18 at both screening and baseline visits\n(Kobak et al., 1999), which must not have decreased or\nincreased by more than 25% between visits. A score of \t4\non the Clinical Global Impressions–Severity of Illness\n(CGI-S) scale at both screening and baseline was also required.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if they had a history of manic epi-\nsodes, past or current psychotic disorder or a current Axis II\ndiagnosis that suggested non-responsiveness or non-compli-\nance with therapy. Also excluded were patients that had been\nhomicidal at any time in their lives or suicidal within the past\n6 months, those with anorexia nervosa or bulimia within the\npast year, myocardial infarction within the past year, any\nhistory of seizure disorder or brain injury, blood pressure\n\t150/95mmHg, or unstable medical disorder. Patients were\nnot eligible to participate if they had taken bupropion or\nvenlafaxine within the past six months, or had experienced\na signiﬁcant adverse response to either antidepressant in the\npast. Patients who had failed to respond to adequate treat-\nment from two previous antidepressants of diﬀerent classes\nwere also excluded. To be eligible, patients could not have[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""had any psychotherapy or taken any psychotropic drugs,\nother medications with potential pharmacokinetic interac-\ntions, or any medication that might lower the seizure thresh-\nold in the two weeks prior to screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,588.00,387.00,na,na,tick,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,tick,131.00,na,na,37,na,na,na,tick,tick,tick,na,tick,tick,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,2005,tick,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010a; AK130939",na,na,na,na,na,na,na,na,na,na,na,37134,bupropion XR,na,na,na,na,45.60,na,na,204.00,na,na,127.00,na,na,"White = 196
Black = 3
American Hispanic = 1
Other = 3",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,44,na,na,11,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,"Any adverse event=108;
Dry mouth=32;
Headache=30;
Nausea=27;
Insomnia=15;
Dizziness=14;
Hyperhidrosis=14;
Diarrhoea=8;
Fatigue=7;
Nasopharyngitis=7;
Upper abdominal pain=7;
Constipation=7;
Tremor=5;
Influenza=3;
Somnolence=3;
Anorexia=2",na,150mg,180mg,300mg,8 weeks,150mg,300mg,na,na,na,na,na,na,na,na,na,na,na,na,daily,na,na,na,na,na,na,na,na,na,"worsening depression=1;
pyelonephritis=1;
QTc prolongation=1;
gastritis=1;",na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.76,na,na,na,113,na,na,1,na,na,na,na,na,na,na,na,na,na,87997755.0,Continuous,106824.0,113200557.0,1.0,13673273.0,0.0,13671957.0,HAM-A ,1770.0,weeks,8,8 weeks,37134.0,0.0,bupropion XR,,Hewett (2010a),LSMean;SEConv;Change from baseline,202.0,-10.1,7.0,0.0,*Bupropion XR,*HAM-A
87997755,"Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2010a),2010,"Hewett Karen, Gee Michelle D, Krishen Alok, Wunderlich Hans-Peter, Le Clus Alfred, Evoniuk Gary, and Modell Jack G (2010) Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 24(8), 1209-16 DOI: https://dx.doi.org/10.1177/0269881109106953","[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett1,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083365, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""62 centres in Australia (7 centres), France (15 centres), Germany (18 centres), the Netherlands (6 centres),\nNorway (5 centres), South Africa (6 centres) and Sweden (5 centres).[¬e]""', 'IsFromPDF': True, 'DocTitle': '23134-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This study (AK130939) was sponsored by GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""(AK130939)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients aged 18–64 years with a DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks duration were eligible for inclu-\nsion. Eligible patients required an Interactive Voice Response\nSystem (IVRS) Hamilton Depression Rating Scale (HAMD)\n17-Item total score of\t18 at both screening and baseline visits\n(Kobak et al., 1999), which must not have decreased or\nincreased by more than 25% between visits. A score of \t4\non the Clinical Global Impressions–Severity of Illness\n(CGI-S) scale at both screening and baseline was also required.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if they had a history of manic epi-\nsodes, past or current psychotic disorder or a current Axis II\ndiagnosis that suggested non-responsiveness or non-compli-\nance with therapy. Also excluded were patients that had been\nhomicidal at any time in their lives or suicidal within the past\n6 months, those with anorexia nervosa or bulimia within the\npast year, myocardial infarction within the past year, any\nhistory of seizure disorder or brain injury, blood pressure\n\t150/95mmHg, or unstable medical disorder. Patients were\nnot eligible to participate if they had taken bupropion or\nvenlafaxine within the past six months, or had experienced\na signiﬁcant adverse response to either antidepressant in the\npast. Patients who had failed to respond to adequate treat-\nment from two previous antidepressants of diﬀerent classes\nwere also excluded. To be eligible, patients could not have[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""had any psychotherapy or taken any psychotropic drugs,\nother medications with potential pharmacokinetic interac-\ntions, or any medication that might lower the seizure thresh-\nold in the two weeks prior to screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,588.00,387.00,na,na,tick,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,tick,131.00,na,na,37,na,na,na,tick,tick,tick,na,tick,tick,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,2005,tick,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010a; AK130939",na,na,na,na,na,na,na,na,na,na,na,37134,bupropion XR,na,na,na,na,45.60,na,na,204.00,na,na,127.00,na,na,"White = 196
Black = 3
American Hispanic = 1
Other = 3",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,44,na,na,11,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,"Any adverse event=108;
Dry mouth=32;
Headache=30;
Nausea=27;
Insomnia=15;
Dizziness=14;
Hyperhidrosis=14;
Diarrhoea=8;
Fatigue=7;
Nasopharyngitis=7;
Upper abdominal pain=7;
Constipation=7;
Tremor=5;
Influenza=3;
Somnolence=3;
Anorexia=2",na,150mg,180mg,300mg,8 weeks,150mg,300mg,na,na,na,na,na,na,na,na,na,na,na,na,daily,na,na,na,na,na,na,na,na,na,"worsening depression=1;
pyelonephritis=1;
QTc prolongation=1;
gastritis=1;",na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.76,na,na,na,113,na,na,1,na,na,na,na,na,na,na,na,na,na,87997755.0,Continuous,109228.0,113200557.0,1.0,13673273.0,0.0,13671961.0,Motivation and Energy Inventory,1770.0,weeks,8,8 weeks,37134.0,0.0,bupropion XR,,Hewett (2010a),Change from baseline;LSMean;SEConv,202.0,20.8,21.74,0.0,*Bupropion XR,*Motivation and Energy Inventory
87997755,"Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2010a),2010,"Hewett Karen, Gee Michelle D, Krishen Alok, Wunderlich Hans-Peter, Le Clus Alfred, Evoniuk Gary, and Modell Jack G (2010) Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 24(8), 1209-16 DOI: https://dx.doi.org/10.1177/0269881109106953","[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett1,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2010[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1083365, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""62 centres in Australia (7 centres), France (15 centres), Germany (18 centres), the Netherlands (6 centres),\nNorway (5 centres), South Africa (6 centres) and Sweden (5 centres).[¬e]""', 'IsFromPDF': True, 'DocTitle': '23134-v1.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This study (AK130939) was sponsored by GlaxoSmithKline.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""(AK130939)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients aged 18–64 years with a DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks duration were eligible for inclu-\nsion. Eligible patients required an Interactive Voice Response\nSystem (IVRS) Hamilton Depression Rating Scale (HAMD)\n17-Item total score of\t18 at both screening and baseline visits\n(Kobak et al., 1999), which must not have decreased or\nincreased by more than 25% between visits. A score of \t4\non the Clinical Global Impressions–Severity of Illness\n(CGI-S) scale at both screening and baseline was also required.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if they had a history of manic epi-\nsodes, past or current psychotic disorder or a current Axis II\ndiagnosis that suggested non-responsiveness or non-compli-\nance with therapy. Also excluded were patients that had been\nhomicidal at any time in their lives or suicidal within the past\n6 months, those with anorexia nervosa or bulimia within the\npast year, myocardial infarction within the past year, any\nhistory of seizure disorder or brain injury, blood pressure\n\t150/95mmHg, or unstable medical disorder. Patients were\nnot eligible to participate if they had taken bupropion or\nvenlafaxine within the past six months, or had experienced\na signiﬁcant adverse response to either antidepressant in the\npast. Patients who had failed to respond to adequate treat-\nment from two previous antidepressants of diﬀerent classes\nwere also excluded. To be eligible, patients could not have[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""had any psychotherapy or taken any psychotropic drugs,\nother medications with potential pharmacokinetic interac-\ntions, or any medication that might lower the seizure thresh-\nold in the two weeks prior to screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,588.00,387.00,na,na,tick,tick,na,"[{'ItemDocumentId': 1052160, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""DSM-IV diagnosis ofMDD\nfor a minimum of eight weeks[¬e]""', 'IsFromPDF': True, 'DocTitle': 'hewett-et-al-2009-double-blind-placebo-controlled-comparison-of-the-antidepressant-efficacy-and-tolerability-of.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,tick,131.00,na,na,37,na,na,na,tick,tick,tick,na,tick,tick,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,2005,tick,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2010a; AK130939",na,na,na,na,na,na,na,na,na,na,na,37134,bupropion XR,na,na,na,na,45.60,na,na,204.00,na,na,127.00,na,na,"White = 196
Black = 3
American Hispanic = 1
Other = 3",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,44,na,na,11,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,"Any adverse event=108;
Dry mouth=32;
Headache=30;
Nausea=27;
Insomnia=15;
Dizziness=14;
Hyperhidrosis=14;
Diarrhoea=8;
Fatigue=7;
Nasopharyngitis=7;
Upper abdominal pain=7;
Constipation=7;
Tremor=5;
Influenza=3;
Somnolence=3;
Anorexia=2",na,150mg,180mg,300mg,8 weeks,150mg,300mg,na,na,na,na,na,na,na,na,na,na,na,na,daily,na,na,na,na,na,na,na,na,na,"worsening depression=1;
pyelonephritis=1;
QTc prolongation=1;
gastritis=1;",na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.76,na,na,na,113,na,na,1,na,na,na,na,na,na,na,na,na,na,87997755.0,Continuous,109224.0,113200557.0,1.0,13673273.0,0.0,13671961.0,Motivation and Energy Inventory,1767.0,weeks,0,0 weeks,37134.0,0.0,bupropion XR,,Hewett (2010a),SEConv,202.0,27.2,13.5,0.0,*Bupropion XR,*Motivation and Energy Inventory
87997883,"Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2009),2009,"Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary M O, and Modell J (2009) Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 23(5), 531-8 DOI: https://dx.doi.org/10.1177/0269881108089602","[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2009[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063713, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""49 centres in Austria (3), Belgium (3), Bulgaria (5), Croatia (2), Estonia (3), Finland (4), Greece (3), Ireland\n(2), Latvia (3), Netherlands (2), Poland (2), Portugal (3), Russia (3), Slovakia (4), Spain (3), Sweden (4) and\nMexico (1)[¬e]""', 'IsFromPDF': True, 'DocTitle': '101497-Clinical-Study-Result-Summary (1).pdf', 'ItemArm': ''}]",na,na,GSK,na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1063713, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Male or female outpatients aged between 18 and 64 years (inclusive) who had: a diagnosis of\nMDD, as defined by DSM-IV (296.2/296.3); an interactive voice response system 17-Item Hamilton Depression Rating\nScale (IVRS HAMD-17) total score of ≥18, at both the Screening Visit and the Baseline Visit, and no increase or\ndecrease in the IVRS HAMD-17 total score of more than 25% between Screening and Baseline, irrespective of the\nactual IVRS HAMD-17 score; and a Clinical Global Impression Severity of Illness (CGI-S) score of ≥4 at both the\nScreening Visit and the Baseline Visit.[¬e]""', 'IsFromPDF': True, 'DocTitle': '101497-Clinical-Study-Result-Summary (1).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were excluded if they had been homicidal at any time\nor suicidal within the past 6 months. Those with anorexia nervosa\nor bulimia (within the past 12 months), psychotic disorders, myo-\ncardial infarction within the past year, a seizure disorder or blood\npressure ≥150/95 mmHg were also excluded. Patients were not\neligible to participate if they had taken bupropion or venlafaxine\nwithin the past 6 months, or had experienced a significant adverse\nresponse to either antidepressant in the past. Patients who had\nfailed to respond to adequate treatment from two previous anti-\ndepressants of different classes were also excluded[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive disorder,tick,na,tick,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""during the 2 weeks prior to the study, patients should not have\nused the following: any psychotherapy or psychotropic drugs;\nother medications with potential pharmacokinetic interactions\nor any medication that might lower the seizure threshold.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2005[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,13 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2009; EUCTR2004-003803-19-SE, 2004; Glaxosmithkline (WXL101497)",na,na,na,na,na,na,na,na,na,na,na,37248,Placebo,na,na,na,na,41.8,na,na,199,na,na,142,na,na,white=189;black=0;American hispanic=4;other=4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,30,na,na,10,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,tick,"Headache=19;Dry mouth=11;Nausaea=21;Insomnia=4;Hyperhidrosis=2;Dizziness=14;Constipation=1;Nasopharyngitis=5;Abdominal pain, upper=6;Fatigue=4;Anxiety=9;Diarrhea=5;Somnolence=4;Anorexia=0;Influenza=5",na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1x daily,na,na,na,na,na,na,na,na,na,Convulsion=4;Major depression=2;Syncope=1;Overdose=0;Suicide attempt=0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.56,na,na,na,95,na,na,4,na,na,na,na,na,na,na,na,na,na,87997883.0,Continuous,107785.0,113632724.0,1.0,13669974.0,0.0,13671957.0,HAM-A,1849.0,weeks,0,0 weeks,37248.0,0.0,Placebo,,Hewett (2009),,197.0,21.8,6.7,0.0,Placebo,*HAM-A
87997883,"Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2009),2009,"Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary M O, and Modell J (2009) Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 23(5), 531-8 DOI: https://dx.doi.org/10.1177/0269881108089602","[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2009[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063713, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""49 centres in Austria (3), Belgium (3), Bulgaria (5), Croatia (2), Estonia (3), Finland (4), Greece (3), Ireland\n(2), Latvia (3), Netherlands (2), Poland (2), Portugal (3), Russia (3), Slovakia (4), Spain (3), Sweden (4) and\nMexico (1)[¬e]""', 'IsFromPDF': True, 'DocTitle': '101497-Clinical-Study-Result-Summary (1).pdf', 'ItemArm': ''}]",na,na,GSK,na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1063713, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Male or female outpatients aged between 18 and 64 years (inclusive) who had: a diagnosis of\nMDD, as defined by DSM-IV (296.2/296.3); an interactive voice response system 17-Item Hamilton Depression Rating\nScale (IVRS HAMD-17) total score of ≥18, at both the Screening Visit and the Baseline Visit, and no increase or\ndecrease in the IVRS HAMD-17 total score of more than 25% between Screening and Baseline, irrespective of the\nactual IVRS HAMD-17 score; and a Clinical Global Impression Severity of Illness (CGI-S) score of ≥4 at both the\nScreening Visit and the Baseline Visit.[¬e]""', 'IsFromPDF': True, 'DocTitle': '101497-Clinical-Study-Result-Summary (1).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were excluded if they had been homicidal at any time\nor suicidal within the past 6 months. Those with anorexia nervosa\nor bulimia (within the past 12 months), psychotic disorders, myo-\ncardial infarction within the past year, a seizure disorder or blood\npressure ≥150/95 mmHg were also excluded. Patients were not\neligible to participate if they had taken bupropion or venlafaxine\nwithin the past 6 months, or had experienced a significant adverse\nresponse to either antidepressant in the past. Patients who had\nfailed to respond to adequate treatment from two previous anti-\ndepressants of different classes were also excluded[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive disorder,tick,na,tick,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""during the 2 weeks prior to the study, patients should not have\nused the following: any psychotherapy or psychotropic drugs;\nother medications with potential pharmacokinetic interactions\nor any medication that might lower the seizure threshold.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2005[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,13 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2009; EUCTR2004-003803-19-SE, 2004; Glaxosmithkline (WXL101497)",na,na,na,na,na,na,na,na,na,na,na,37248,Placebo,na,na,na,na,41.8,na,na,199,na,na,142,na,na,white=189;black=0;American hispanic=4;other=4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,30,na,na,10,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,tick,"Headache=19;Dry mouth=11;Nausaea=21;Insomnia=4;Hyperhidrosis=2;Dizziness=14;Constipation=1;Nasopharyngitis=5;Abdominal pain, upper=6;Fatigue=4;Anxiety=9;Diarrhea=5;Somnolence=4;Anorexia=0;Influenza=5",na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1x daily,na,na,na,na,na,na,na,na,na,Convulsion=4;Major depression=2;Syncope=1;Overdose=0;Suicide attempt=0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.56,na,na,na,95,na,na,4,na,na,na,na,na,na,na,na,na,na,87997883.0,Continuous,107789.0,113632724.0,1.0,13669974.0,0.0,13671957.0,HAM-A,1850.0,weeks,8,8 weeks,37248.0,0.0,Placebo,,Hewett (2009),LOCF;Change from baseline;convSE,197.0,-9.8,7.58,0.0,Placebo,*HAM-A
87997883,"Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2009),2009,"Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary M O, and Modell J (2009) Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 23(5), 531-8 DOI: https://dx.doi.org/10.1177/0269881108089602","[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2009[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063713, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""49 centres in Austria (3), Belgium (3), Bulgaria (5), Croatia (2), Estonia (3), Finland (4), Greece (3), Ireland\n(2), Latvia (3), Netherlands (2), Poland (2), Portugal (3), Russia (3), Slovakia (4), Spain (3), Sweden (4) and\nMexico (1)[¬e]""', 'IsFromPDF': True, 'DocTitle': '101497-Clinical-Study-Result-Summary (1).pdf', 'ItemArm': ''}]",na,na,GSK,na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1063713, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Male or female outpatients aged between 18 and 64 years (inclusive) who had: a diagnosis of\nMDD, as defined by DSM-IV (296.2/296.3); an interactive voice response system 17-Item Hamilton Depression Rating\nScale (IVRS HAMD-17) total score of ≥18, at both the Screening Visit and the Baseline Visit, and no increase or\ndecrease in the IVRS HAMD-17 total score of more than 25% between Screening and Baseline, irrespective of the\nactual IVRS HAMD-17 score; and a Clinical Global Impression Severity of Illness (CGI-S) score of ≥4 at both the\nScreening Visit and the Baseline Visit.[¬e]""', 'IsFromPDF': True, 'DocTitle': '101497-Clinical-Study-Result-Summary (1).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were excluded if they had been homicidal at any time\nor suicidal within the past 6 months. Those with anorexia nervosa\nor bulimia (within the past 12 months), psychotic disorders, myo-\ncardial infarction within the past year, a seizure disorder or blood\npressure ≥150/95 mmHg were also excluded. Patients were not\neligible to participate if they had taken bupropion or venlafaxine\nwithin the past 6 months, or had experienced a significant adverse\nresponse to either antidepressant in the past. Patients who had\nfailed to respond to adequate treatment from two previous anti-\ndepressants of different classes were also excluded[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive disorder,tick,na,tick,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""during the 2 weeks prior to the study, patients should not have\nused the following: any psychotherapy or psychotropic drugs;\nother medications with potential pharmacokinetic interactions\nor any medication that might lower the seizure threshold.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2005[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,13 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2009; EUCTR2004-003803-19-SE, 2004; Glaxosmithkline (WXL101497)",na,na,na,na,na,na,na,na,na,na,na,37248,Placebo,na,na,na,na,41.8,na,na,199,na,na,142,na,na,white=189;black=0;American hispanic=4;other=4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,30,na,na,10,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,tick,"Headache=19;Dry mouth=11;Nausaea=21;Insomnia=4;Hyperhidrosis=2;Dizziness=14;Constipation=1;Nasopharyngitis=5;Abdominal pain, upper=6;Fatigue=4;Anxiety=9;Diarrhea=5;Somnolence=4;Anorexia=0;Influenza=5",na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1x daily,na,na,na,na,na,na,na,na,na,Convulsion=4;Major depression=2;Syncope=1;Overdose=0;Suicide attempt=0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.56,na,na,na,95,na,na,4,na,na,na,na,na,na,na,na,na,na,87997883.0,Continuous,107905.0,113632724.0,1.0,13669974.0,0.0,13711321.0,MEI Total,1849.0,weeks,0,0 weeks,37248.0,0.0,Placebo,,Hewett (2009),,197.0,26.4,12.79,0.0,Placebo,*Motivation and Energy Inventory (MEI)
87997883,"Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2009),2009,"Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary M O, and Modell J (2009) Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 23(5), 531-8 DOI: https://dx.doi.org/10.1177/0269881108089602","[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2009[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063713, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""49 centres in Austria (3), Belgium (3), Bulgaria (5), Croatia (2), Estonia (3), Finland (4), Greece (3), Ireland\n(2), Latvia (3), Netherlands (2), Poland (2), Portugal (3), Russia (3), Slovakia (4), Spain (3), Sweden (4) and\nMexico (1)[¬e]""', 'IsFromPDF': True, 'DocTitle': '101497-Clinical-Study-Result-Summary (1).pdf', 'ItemArm': ''}]",na,na,GSK,na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1063713, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Male or female outpatients aged between 18 and 64 years (inclusive) who had: a diagnosis of\nMDD, as defined by DSM-IV (296.2/296.3); an interactive voice response system 17-Item Hamilton Depression Rating\nScale (IVRS HAMD-17) total score of ≥18, at both the Screening Visit and the Baseline Visit, and no increase or\ndecrease in the IVRS HAMD-17 total score of more than 25% between Screening and Baseline, irrespective of the\nactual IVRS HAMD-17 score; and a Clinical Global Impression Severity of Illness (CGI-S) score of ≥4 at both the\nScreening Visit and the Baseline Visit.[¬e]""', 'IsFromPDF': True, 'DocTitle': '101497-Clinical-Study-Result-Summary (1).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were excluded if they had been homicidal at any time\nor suicidal within the past 6 months. Those with anorexia nervosa\nor bulimia (within the past 12 months), psychotic disorders, myo-\ncardial infarction within the past year, a seizure disorder or blood\npressure ≥150/95 mmHg were also excluded. Patients were not\neligible to participate if they had taken bupropion or venlafaxine\nwithin the past 6 months, or had experienced a significant adverse\nresponse to either antidepressant in the past. Patients who had\nfailed to respond to adequate treatment from two previous anti-\ndepressants of different classes were also excluded[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive disorder,tick,na,tick,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""during the 2 weeks prior to the study, patients should not have\nused the following: any psychotherapy or psychotropic drugs;\nother medications with potential pharmacokinetic interactions\nor any medication that might lower the seizure threshold.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2005[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,13 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2009; EUCTR2004-003803-19-SE, 2004; Glaxosmithkline (WXL101497)",na,na,na,na,na,na,na,na,na,na,na,37248,Placebo,na,na,na,na,41.8,na,na,199,na,na,142,na,na,white=189;black=0;American hispanic=4;other=4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,30,na,na,10,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,tick,"Headache=19;Dry mouth=11;Nausaea=21;Insomnia=4;Hyperhidrosis=2;Dizziness=14;Constipation=1;Nasopharyngitis=5;Abdominal pain, upper=6;Fatigue=4;Anxiety=9;Diarrhea=5;Somnolence=4;Anorexia=0;Influenza=5",na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1x daily,na,na,na,na,na,na,na,na,na,Convulsion=4;Major depression=2;Syncope=1;Overdose=0;Suicide attempt=0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.56,na,na,na,95,na,na,4,na,na,na,na,na,na,na,na,na,na,87997883.0,Continuous,107906.0,113632724.0,1.0,13669974.0,0.0,13711321.0,MEI Total,1850.0,weeks,8,8 weeks,37248.0,0.0,Placebo,,Hewett (2009),Change from baseline;LSMean;convSE;LOCF,197.0,17.4,19.37,0.0,Placebo,*Motivation and Energy Inventory (MEI)
87997883,"Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2009),2009,"Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary M O, and Modell J (2009) Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 23(5), 531-8 DOI: https://dx.doi.org/10.1177/0269881108089602","[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2009[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063713, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""49 centres in Austria (3), Belgium (3), Bulgaria (5), Croatia (2), Estonia (3), Finland (4), Greece (3), Ireland\n(2), Latvia (3), Netherlands (2), Poland (2), Portugal (3), Russia (3), Slovakia (4), Spain (3), Sweden (4) and\nMexico (1)[¬e]""', 'IsFromPDF': True, 'DocTitle': '101497-Clinical-Study-Result-Summary (1).pdf', 'ItemArm': ''}]",na,na,GSK,na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1063713, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Male or female outpatients aged between 18 and 64 years (inclusive) who had: a diagnosis of\nMDD, as defined by DSM-IV (296.2/296.3); an interactive voice response system 17-Item Hamilton Depression Rating\nScale (IVRS HAMD-17) total score of ≥18, at both the Screening Visit and the Baseline Visit, and no increase or\ndecrease in the IVRS HAMD-17 total score of more than 25% between Screening and Baseline, irrespective of the\nactual IVRS HAMD-17 score; and a Clinical Global Impression Severity of Illness (CGI-S) score of ≥4 at both the\nScreening Visit and the Baseline Visit.[¬e]""', 'IsFromPDF': True, 'DocTitle': '101497-Clinical-Study-Result-Summary (1).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were excluded if they had been homicidal at any time\nor suicidal within the past 6 months. Those with anorexia nervosa\nor bulimia (within the past 12 months), psychotic disorders, myo-\ncardial infarction within the past year, a seizure disorder or blood\npressure ≥150/95 mmHg were also excluded. Patients were not\neligible to participate if they had taken bupropion or venlafaxine\nwithin the past 6 months, or had experienced a significant adverse\nresponse to either antidepressant in the past. Patients who had\nfailed to respond to adequate treatment from two previous anti-\ndepressants of different classes were also excluded[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive disorder,tick,na,tick,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""during the 2 weeks prior to the study, patients should not have\nused the following: any psychotherapy or psychotropic drugs;\nother medications with potential pharmacokinetic interactions\nor any medication that might lower the seizure threshold.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2005[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,13 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2009; EUCTR2004-003803-19-SE, 2004; Glaxosmithkline (WXL101497)",na,na,na,na,na,na,na,na,na,na,na,37249,Bupropion XR,na,na,na,na,41.8,na,na,188,na,na,138,na,na,white=180;black=1;American hispanic=4;other=2,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,33,na,na,7,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,tick,tick,na,na,na,na,na,na,na,na,tick,"Headache=23;Dry mouth=16;Nausaea=11;Insomnia=10;Hyperhidrosis=7;Dizziness=7;Constipation=7;Nasopharyngitis=7;Abdominal pain, upper=6;Fatigue=5;Anxiety=5;Diarrhea=3;Somnolence=2;Anorexia=2;Influenza=0",na,na,170.1mg,na,8 weeks,150mg,300mg,na,na,na,na,na,na,tick,na,na,na,tick,na,1x daily,na,na,na,na,na,na,na,na,na,Convulsion=0;Major depression=0;Syncope=0;Overdose=1;Suicide attempt=0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.68,na,na,na,88,na,na,1,na,na,na,na,na,na,na,na,na,na,87997883.0,Continuous,107790.0,113632724.0,1.0,13673273.0,0.0,13671957.0,HAM-A,1849.0,weeks,0,0 weeks,37249.0,0.0,Bupropion XR,,Hewett (2009),,187.0,22.0,6.49,0.0,*Bupropion XR,*HAM-A
87997883,"Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2009),2009,"Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary M O, and Modell J (2009) Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 23(5), 531-8 DOI: https://dx.doi.org/10.1177/0269881108089602","[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2009[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063713, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""49 centres in Austria (3), Belgium (3), Bulgaria (5), Croatia (2), Estonia (3), Finland (4), Greece (3), Ireland\n(2), Latvia (3), Netherlands (2), Poland (2), Portugal (3), Russia (3), Slovakia (4), Spain (3), Sweden (4) and\nMexico (1)[¬e]""', 'IsFromPDF': True, 'DocTitle': '101497-Clinical-Study-Result-Summary (1).pdf', 'ItemArm': ''}]",na,na,GSK,na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1063713, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Male or female outpatients aged between 18 and 64 years (inclusive) who had: a diagnosis of\nMDD, as defined by DSM-IV (296.2/296.3); an interactive voice response system 17-Item Hamilton Depression Rating\nScale (IVRS HAMD-17) total score of ≥18, at both the Screening Visit and the Baseline Visit, and no increase or\ndecrease in the IVRS HAMD-17 total score of more than 25% between Screening and Baseline, irrespective of the\nactual IVRS HAMD-17 score; and a Clinical Global Impression Severity of Illness (CGI-S) score of ≥4 at both the\nScreening Visit and the Baseline Visit.[¬e]""', 'IsFromPDF': True, 'DocTitle': '101497-Clinical-Study-Result-Summary (1).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were excluded if they had been homicidal at any time\nor suicidal within the past 6 months. Those with anorexia nervosa\nor bulimia (within the past 12 months), psychotic disorders, myo-\ncardial infarction within the past year, a seizure disorder or blood\npressure ≥150/95 mmHg were also excluded. Patients were not\neligible to participate if they had taken bupropion or venlafaxine\nwithin the past 6 months, or had experienced a significant adverse\nresponse to either antidepressant in the past. Patients who had\nfailed to respond to adequate treatment from two previous anti-\ndepressants of different classes were also excluded[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive disorder,tick,na,tick,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""during the 2 weeks prior to the study, patients should not have\nused the following: any psychotherapy or psychotropic drugs;\nother medications with potential pharmacokinetic interactions\nor any medication that might lower the seizure threshold.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2005[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,13 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2009; EUCTR2004-003803-19-SE, 2004; Glaxosmithkline (WXL101497)",na,na,na,na,na,na,na,na,na,na,na,37249,Bupropion XR,na,na,na,na,41.8,na,na,188,na,na,138,na,na,white=180;black=1;American hispanic=4;other=2,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,33,na,na,7,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,tick,tick,na,na,na,na,na,na,na,na,tick,"Headache=23;Dry mouth=16;Nausaea=11;Insomnia=10;Hyperhidrosis=7;Dizziness=7;Constipation=7;Nasopharyngitis=7;Abdominal pain, upper=6;Fatigue=5;Anxiety=5;Diarrhea=3;Somnolence=2;Anorexia=2;Influenza=0",na,na,170.1mg,na,8 weeks,150mg,300mg,na,na,na,na,na,na,tick,na,na,na,tick,na,1x daily,na,na,na,na,na,na,na,na,na,Convulsion=0;Major depression=0;Syncope=0;Overdose=1;Suicide attempt=0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.68,na,na,na,88,na,na,1,na,na,na,na,na,na,na,na,na,na,87997883.0,Continuous,107791.0,113632724.0,1.0,13673273.0,0.0,13671957.0,HAM-A,1850.0,weeks,8,8 weeks,37249.0,0.0,Bupropion XR,,Hewett (2009),LOCF;convSE;change from baseline,187.0,-11.5,7.38,0.0,*Bupropion XR,*HAM-A
87997883,"Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2009),2009,"Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary M O, and Modell J (2009) Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 23(5), 531-8 DOI: https://dx.doi.org/10.1177/0269881108089602","[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2009[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063713, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""49 centres in Austria (3), Belgium (3), Bulgaria (5), Croatia (2), Estonia (3), Finland (4), Greece (3), Ireland\n(2), Latvia (3), Netherlands (2), Poland (2), Portugal (3), Russia (3), Slovakia (4), Spain (3), Sweden (4) and\nMexico (1)[¬e]""', 'IsFromPDF': True, 'DocTitle': '101497-Clinical-Study-Result-Summary (1).pdf', 'ItemArm': ''}]",na,na,GSK,na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1063713, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Male or female outpatients aged between 18 and 64 years (inclusive) who had: a diagnosis of\nMDD, as defined by DSM-IV (296.2/296.3); an interactive voice response system 17-Item Hamilton Depression Rating\nScale (IVRS HAMD-17) total score of ≥18, at both the Screening Visit and the Baseline Visit, and no increase or\ndecrease in the IVRS HAMD-17 total score of more than 25% between Screening and Baseline, irrespective of the\nactual IVRS HAMD-17 score; and a Clinical Global Impression Severity of Illness (CGI-S) score of ≥4 at both the\nScreening Visit and the Baseline Visit.[¬e]""', 'IsFromPDF': True, 'DocTitle': '101497-Clinical-Study-Result-Summary (1).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were excluded if they had been homicidal at any time\nor suicidal within the past 6 months. Those with anorexia nervosa\nor bulimia (within the past 12 months), psychotic disorders, myo-\ncardial infarction within the past year, a seizure disorder or blood\npressure ≥150/95 mmHg were also excluded. Patients were not\neligible to participate if they had taken bupropion or venlafaxine\nwithin the past 6 months, or had experienced a significant adverse\nresponse to either antidepressant in the past. Patients who had\nfailed to respond to adequate treatment from two previous anti-\ndepressants of different classes were also excluded[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive disorder,tick,na,tick,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""during the 2 weeks prior to the study, patients should not have\nused the following: any psychotherapy or psychotropic drugs;\nother medications with potential pharmacokinetic interactions\nor any medication that might lower the seizure threshold.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2005[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,13 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2009; EUCTR2004-003803-19-SE, 2004; Glaxosmithkline (WXL101497)",na,na,na,na,na,na,na,na,na,na,na,37249,Bupropion XR,na,na,na,na,41.8,na,na,188,na,na,138,na,na,white=180;black=1;American hispanic=4;other=2,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,33,na,na,7,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,tick,tick,na,na,na,na,na,na,na,na,tick,"Headache=23;Dry mouth=16;Nausaea=11;Insomnia=10;Hyperhidrosis=7;Dizziness=7;Constipation=7;Nasopharyngitis=7;Abdominal pain, upper=6;Fatigue=5;Anxiety=5;Diarrhea=3;Somnolence=2;Anorexia=2;Influenza=0",na,na,170.1mg,na,8 weeks,150mg,300mg,na,na,na,na,na,na,tick,na,na,na,tick,na,1x daily,na,na,na,na,na,na,na,na,na,Convulsion=0;Major depression=0;Syncope=0;Overdose=1;Suicide attempt=0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.68,na,na,na,88,na,na,1,na,na,na,na,na,na,na,na,na,na,87997883.0,Continuous,107907.0,113632724.0,1.0,13673273.0,0.0,13711321.0,MEI Total,1849.0,weeks,0,0 weeks,37249.0,0.0,Bupropion XR,,Hewett (2009),,187.0,26.8,12.95,0.0,*Bupropion XR,*Motivation and Energy Inventory (MEI)
87997883,"Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.","Journal of psychopharmacology (Oxford, England)",Hewett (2009),2009,"Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary M O, and Modell J (2009) Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.. Journal of psychopharmacology (Oxford, and England) 23(5), 531-8 DOI: https://dx.doi.org/10.1177/0269881108089602","[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Hewett[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2009[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063713, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""49 centres in Austria (3), Belgium (3), Bulgaria (5), Croatia (2), Estonia (3), Finland (4), Greece (3), Ireland\n(2), Latvia (3), Netherlands (2), Poland (2), Portugal (3), Russia (3), Slovakia (4), Spain (3), Sweden (4) and\nMexico (1)[¬e]""', 'IsFromPDF': True, 'DocTitle': '101497-Clinical-Study-Result-Summary (1).pdf', 'ItemArm': ''}]",na,na,GSK,na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1063713, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Male or female outpatients aged between 18 and 64 years (inclusive) who had: a diagnosis of\nMDD, as defined by DSM-IV (296.2/296.3); an interactive voice response system 17-Item Hamilton Depression Rating\nScale (IVRS HAMD-17) total score of ≥18, at both the Screening Visit and the Baseline Visit, and no increase or\ndecrease in the IVRS HAMD-17 total score of more than 25% between Screening and Baseline, irrespective of the\nactual IVRS HAMD-17 score; and a Clinical Global Impression Severity of Illness (CGI-S) score of ≥4 at both the\nScreening Visit and the Baseline Visit.[¬e]""', 'IsFromPDF': True, 'DocTitle': '101497-Clinical-Study-Result-Summary (1).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were excluded if they had been homicidal at any time\nor suicidal within the past 6 months. Those with anorexia nervosa\nor bulimia (within the past 12 months), psychotic disorders, myo-\ncardial infarction within the past year, a seizure disorder or blood\npressure ≥150/95 mmHg were also excluded. Patients were not\neligible to participate if they had taken bupropion or venlafaxine\nwithin the past 6 months, or had experienced a significant adverse\nresponse to either antidepressant in the past. Patients who had\nfailed to respond to adequate treatment from two previous anti-\ndepressants of different classes were also excluded[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive disorder,tick,na,tick,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""during the 2 weeks prior to the study, patients should not have\nused the following: any psychotherapy or psychotropic drugs;\nother medications with potential pharmacokinetic interactions\nor any medication that might lower the seizure threshold.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050727, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""2005[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Hewett K et al. - 2009 - Eight-week, placebo-controlled, double-blind compa.pdf', 'ItemArm': ''}]",na,na,13 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Hewett, 2009; EUCTR2004-003803-19-SE, 2004; Glaxosmithkline (WXL101497)",na,na,na,na,na,na,na,na,na,na,na,37249,Bupropion XR,na,na,na,na,41.8,na,na,188,na,na,138,na,na,white=180;black=1;American hispanic=4;other=2,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,33,na,na,7,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,tick,tick,na,na,na,na,na,na,na,na,tick,"Headache=23;Dry mouth=16;Nausaea=11;Insomnia=10;Hyperhidrosis=7;Dizziness=7;Constipation=7;Nasopharyngitis=7;Abdominal pain, upper=6;Fatigue=5;Anxiety=5;Diarrhea=3;Somnolence=2;Anorexia=2;Influenza=0",na,na,170.1mg,na,8 weeks,150mg,300mg,na,na,na,na,na,na,tick,na,na,na,tick,na,1x daily,na,na,na,na,na,na,na,na,na,Convulsion=0;Major depression=0;Syncope=0;Overdose=1;Suicide attempt=0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.68,na,na,na,88,na,na,1,na,na,na,na,na,na,na,na,na,na,87997883.0,Continuous,107910.0,113632724.0,1.0,13673273.0,0.0,13711321.0,MEI Total,1850.0,weeks,8,8 weeks,37249.0,0.0,Bupropion XR,,Hewett (2009),Change from baseline;LSMeans;convSE;LOCF,187.0,24.6,19.69,0.0,*Bupropion XR,*Motivation and Energy Inventory (MEI)
87997489,Bupropion in the treatment of problematic online game play in patients with major depressive disorder.,"Journal of psychopharmacology (Oxford, England)",Han (2012),2012,"Han Doug Hyun, and Renshaw Perry F (2012) Bupropion in the treatment of problematic online game play in patients with major depressive disorder.. Journal of psychopharmacology (Oxford, and England) 26(5), 689-96 DOI: https://dx.doi.org/10.1177/0269881111400647","[{'ItemDocumentId': 1050686, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Han1[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Han (2012).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050686, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2012[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Han (2012).pdf', 'ItemArm': ''}]",na,Korea,na,na,"[{'ItemDocumentId': 1050686, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This work was supported by a Korea Research Foundation Grant\nfunded by the Korean Government (grant number KRF-2008-331-\nE00177) and by NIDA (grant number 8K24DA015116).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Han (2012).pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1050686, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""problematic online\ngame play and MDD""\n""diagnosed by a psychiatrist as having\nMDD. The deﬁnition for problematic online game play in\nthis study was extensive game play time (more than 4 hours\nper day/30 hours per week)""\n""; a score of more\nthan 50 on the YIAS""\n""and\nimpaired behaviors or distress due to a maladaptive pattern\nof online game play.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Han (2012).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050686, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included (1) history of prior MDD\nor current episode of other axis I psychiatric diseases, (2)\nsubstance abuse history (except for alcohol and tobacco\nabuse), and (3) patients with neurological or medical disor-\nders.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Han (2012).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,MDD and problematic online game play,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,12 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37246,Placebo,na,na,na,na,18.1,na,na,28,na,na,0,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,tick,na,na,na,na,3,na,na,0,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1,na,na,na,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,6.2,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87997489,Bupropion in the treatment of problematic online game play in patients with major depressive disorder.,"Journal of psychopharmacology (Oxford, England)",Han (2012),2012,"Han Doug Hyun, and Renshaw Perry F (2012) Bupropion in the treatment of problematic online game play in patients with major depressive disorder.. Journal of psychopharmacology (Oxford, and England) 26(5), 689-96 DOI: https://dx.doi.org/10.1177/0269881111400647","[{'ItemDocumentId': 1050686, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Han1[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Han (2012).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050686, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2012[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Han (2012).pdf', 'ItemArm': ''}]",na,Korea,na,na,"[{'ItemDocumentId': 1050686, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""This work was supported by a Korea Research Foundation Grant\nfunded by the Korean Government (grant number KRF-2008-331-\nE00177) and by NIDA (grant number 8K24DA015116).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Han (2012).pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1050686, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""problematic online\ngame play and MDD""\n""diagnosed by a psychiatrist as having\nMDD. The deﬁnition for problematic online game play in\nthis study was extensive game play time (more than 4 hours\nper day/30 hours per week)""\n""; a score of more\nthan 50 on the YIAS""\n""and\nimpaired behaviors or distress due to a maladaptive pattern\nof online game play.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Han (2012).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050686, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included (1) history of prior MDD\nor current episode of other axis I psychiatric diseases, (2)\nsubstance abuse history (except for alcohol and tobacco\nabuse), and (3) patients with neurological or medical disor-\nders.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Han (2012).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,MDD and problematic online game play,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,12 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37247,Bupropion,na,na,na,na,21.2,na,na,29,na,na,0,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,4,na,na,4,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,8 weeks,150mg,300mg,na,na,na,na,na,na,tick,na,tick,na,na,na,1,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,8.0,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
89913899,A multicenter evaluation of the safety and efficacy of two flexible doses of WELLBUTRIN sustained-release versus placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1994),1994,"GlaxoSmithKline  (1994) A multicenter evaluation of the safety and efficacy of two flexible doses of WELLBUTRIN sustained-release versus placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",Glaxo,tick,na,1999,na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,GSK,tick,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 212[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Male or female subjects, aged 18 years or older, who had a diagnosis of Major Depressive\nDisorder, who had been in a Major Depressive Episode of at least 4 weeks but not greater than 24 months, who scored\na minimum of 20 on the HAMD-21 on Day –6 and Day 0, who also scored a minimum of 2 on the Depressed Mood item\n(Item 1) of the HAMD-31 on Days –6 and Day 0 were eligible for this study.[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were not eligible for inclusion in\nthis study if any of the following criteria applied: predisposition to seizures; significant DSM-III-R Axis II diagnosis that\nwould suggest non-responsiveness to pharmacotherapy for depression; history or current diagnosis of anorexia\nnervosa or bulimia; unstable medical disorder or disorder that would interfere with the adsorption, metabolism or\nexcretion of bupropion, or interfere with the accurate assessment of depression; females who were pregnant or\nlactating, or did not agree to employ contraceptive methods acceptable to the investigator to avoid pregnancy; history of\nalcohol or substance abuse; received any psychoactive drugs within 1 week of the Treatment Phase; previous history of\ntreatment with WELLBUTRIN or WELLBUTRIN SR; incapable of spontaneous conversation or activity; actively suicidal;\nor refused to give informed consent[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Major Depressive\nDisorder,[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",tick,na,tick,tick,na,tick,tick,na,na,na,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,8.00 weeks,na,na,"1994. [{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1994[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,GSK-WELL-212,na,na,na,na,2,na,na,na,na,na,na,37373,Bupropion 50-150,na,na,na,na,39.10,na,na,152,na,na,90,na,na,white=134,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,33,na,na,5,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Headache=34;
Dry mouth=21;
Nausea=18;
Rhinitis=15;
Flu syndrome=13;
Dizziness=11;
Consipation=10;
Insomnia=9;
Nervousness=8;
Tinnitus=7;
Dyspepsia=7;
Diarrhea=6;
Infection=4",na,50.00mg,na,150.00mg,na,50mg,150mg,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,12.2,na,na,na,na,tick,na,Basal cell carcinoma excised=1;intradermal nevus excised=1;,na,na,na,na,na,na,na,na,na,na,89913899.0,Continuous,107527.0,113521249.0,1.0,13687717.0,0.0,13671957.0,HAMA ,1934.0,weeks,0,0 weeks,37373.0,0.0,Bupropion 50-150,,GlaxoSmithKline (1994),,146.0,16.33,4.88,0.0,*bupropion SR,*HAM-A
89913899,A multicenter evaluation of the safety and efficacy of two flexible doses of WELLBUTRIN sustained-release versus placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1994),1994,"GlaxoSmithKline  (1994) A multicenter evaluation of the safety and efficacy of two flexible doses of WELLBUTRIN sustained-release versus placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",Glaxo,tick,na,1999,na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,GSK,tick,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 212[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Male or female subjects, aged 18 years or older, who had a diagnosis of Major Depressive\nDisorder, who had been in a Major Depressive Episode of at least 4 weeks but not greater than 24 months, who scored\na minimum of 20 on the HAMD-21 on Day –6 and Day 0, who also scored a minimum of 2 on the Depressed Mood item\n(Item 1) of the HAMD-31 on Days –6 and Day 0 were eligible for this study.[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were not eligible for inclusion in\nthis study if any of the following criteria applied: predisposition to seizures; significant DSM-III-R Axis II diagnosis that\nwould suggest non-responsiveness to pharmacotherapy for depression; history or current diagnosis of anorexia\nnervosa or bulimia; unstable medical disorder or disorder that would interfere with the adsorption, metabolism or\nexcretion of bupropion, or interfere with the accurate assessment of depression; females who were pregnant or\nlactating, or did not agree to employ contraceptive methods acceptable to the investigator to avoid pregnancy; history of\nalcohol or substance abuse; received any psychoactive drugs within 1 week of the Treatment Phase; previous history of\ntreatment with WELLBUTRIN or WELLBUTRIN SR; incapable of spontaneous conversation or activity; actively suicidal;\nor refused to give informed consent[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Major Depressive\nDisorder,[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",tick,na,tick,tick,na,tick,tick,na,na,na,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,8.00 weeks,na,na,"1994. [{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1994[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,GSK-WELL-212,na,na,na,na,2,na,na,na,na,na,na,37373,Bupropion 50-150,na,na,na,na,39.10,na,na,152,na,na,90,na,na,white=134,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,33,na,na,5,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Headache=34;
Dry mouth=21;
Nausea=18;
Rhinitis=15;
Flu syndrome=13;
Dizziness=11;
Consipation=10;
Insomnia=9;
Nervousness=8;
Tinnitus=7;
Dyspepsia=7;
Diarrhea=6;
Infection=4",na,50.00mg,na,150.00mg,na,50mg,150mg,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,12.2,na,na,na,na,tick,na,Basal cell carcinoma excised=1;intradermal nevus excised=1;,na,na,na,na,na,na,na,na,na,na,89913899.0,Continuous,107528.0,113521249.0,1.0,13687717.0,0.0,13671957.0,HAMA ,1935.0,weeks,8,8 weeks,37373.0,0.0,Bupropion 50-150,,GlaxoSmithKline (1994),mean change from baseline,146.0,-7.74,6.55,0.0,*bupropion SR,*HAM-A
89913899,A multicenter evaluation of the safety and efficacy of two flexible doses of WELLBUTRIN sustained-release versus placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1994),1994,"GlaxoSmithKline  (1994) A multicenter evaluation of the safety and efficacy of two flexible doses of WELLBUTRIN sustained-release versus placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",Glaxo,tick,na,1999,na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,GSK,tick,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 212[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Male or female subjects, aged 18 years or older, who had a diagnosis of Major Depressive\nDisorder, who had been in a Major Depressive Episode of at least 4 weeks but not greater than 24 months, who scored\na minimum of 20 on the HAMD-21 on Day –6 and Day 0, who also scored a minimum of 2 on the Depressed Mood item\n(Item 1) of the HAMD-31 on Days –6 and Day 0 were eligible for this study.[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were not eligible for inclusion in\nthis study if any of the following criteria applied: predisposition to seizures; significant DSM-III-R Axis II diagnosis that\nwould suggest non-responsiveness to pharmacotherapy for depression; history or current diagnosis of anorexia\nnervosa or bulimia; unstable medical disorder or disorder that would interfere with the adsorption, metabolism or\nexcretion of bupropion, or interfere with the accurate assessment of depression; females who were pregnant or\nlactating, or did not agree to employ contraceptive methods acceptable to the investigator to avoid pregnancy; history of\nalcohol or substance abuse; received any psychoactive drugs within 1 week of the Treatment Phase; previous history of\ntreatment with WELLBUTRIN or WELLBUTRIN SR; incapable of spontaneous conversation or activity; actively suicidal;\nor refused to give informed consent[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Major Depressive\nDisorder,[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",tick,na,tick,tick,na,tick,tick,na,na,na,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,8.00 weeks,na,na,"1994. [{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1994[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,GSK-WELL-212,na,na,na,na,2,na,na,na,na,na,na,37374,Placebo ,na,na,na,na,38.20,na,na,154,na,na,99,na,na,white=135,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,48,na,na,3,na,na,na,tick,tick,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,"Headache=27;
Dry mouth=14;
Nausea=12;
Rhinitis=17;
Flu syndrome=6;
Dizziness=9;
Consipation=9;
Insomnia=8;
Nervousness=5;
Tinnitus=3;
Dyspepsia=8;
Diarrhea=8;
Infection=10",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,11.4,na,na,na,na,tick,na,0,na,na,na,na,na,na,na,na,na,na,89913899.0,Continuous,107531.0,113521249.0,1.0,13687717.0,0.0,13671957.0,HAMA ,1934.0,weeks,0,0 weeks,37374.0,0.0,Placebo ,,GlaxoSmithKline (1994),,148.0,16.58,5.45,0.0,*bupropion SR,*HAM-A
89913899,A multicenter evaluation of the safety and efficacy of two flexible doses of WELLBUTRIN sustained-release versus placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1994),1994,"GlaxoSmithKline  (1994) A multicenter evaluation of the safety and efficacy of two flexible doses of WELLBUTRIN sustained-release versus placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",Glaxo,tick,na,1999,na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,GSK,tick,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 212[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Male or female subjects, aged 18 years or older, who had a diagnosis of Major Depressive\nDisorder, who had been in a Major Depressive Episode of at least 4 weeks but not greater than 24 months, who scored\na minimum of 20 on the HAMD-21 on Day –6 and Day 0, who also scored a minimum of 2 on the Depressed Mood item\n(Item 1) of the HAMD-31 on Days –6 and Day 0 were eligible for this study.[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were not eligible for inclusion in\nthis study if any of the following criteria applied: predisposition to seizures; significant DSM-III-R Axis II diagnosis that\nwould suggest non-responsiveness to pharmacotherapy for depression; history or current diagnosis of anorexia\nnervosa or bulimia; unstable medical disorder or disorder that would interfere with the adsorption, metabolism or\nexcretion of bupropion, or interfere with the accurate assessment of depression; females who were pregnant or\nlactating, or did not agree to employ contraceptive methods acceptable to the investigator to avoid pregnancy; history of\nalcohol or substance abuse; received any psychoactive drugs within 1 week of the Treatment Phase; previous history of\ntreatment with WELLBUTRIN or WELLBUTRIN SR; incapable of spontaneous conversation or activity; actively suicidal;\nor refused to give informed consent[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Major Depressive\nDisorder,[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",tick,na,tick,tick,na,tick,tick,na,na,na,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,8.00 weeks,na,na,"1994. [{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1994[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,GSK-WELL-212,na,na,na,na,2,na,na,na,na,na,na,37375,Bupropion 100-300,na,na,na,na,37.2,na,na,150,na,na,98,na,na,white=135,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,47,na,na,7,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Headache=38;
Dry mouth=25;
Nausea=22;
Rhinitis=6;
Flu syndrome=2;
Dizziness=11;
Consipation=14;
Insomnia=13;
Nervousness=9;
Tinnitus=10;
Dyspepsia=4;
Diarrhea=8;
Infection=12",na,100.00mg,na,300.00mg,na,100mg,300mg,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,"Basal cell carcinoma excised=1;
metaplasoa, dysplasia, and focal areas of cervical carcinoma=1;",na,na,na,na,na,na,na,na,na,na,na,na,na,na,11.3,na,na,na,na,tick,na,2,na,na,na,na,na,na,na,na,na,na,89913899.0,Continuous,107529.0,113521249.0,1.0,13687717.0,0.0,13671957.0,HAMA,1934.0,weeks,0,0 weeks,37375.0,0.0,Bupropion 100-300,,GlaxoSmithKline (1994),,144.0,16.34,4.72,0.0,*bupropion SR,*HAM-A
89913899,A multicenter evaluation of the safety and efficacy of two flexible doses of WELLBUTRIN sustained-release versus placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1994),1994,"GlaxoSmithKline  (1994) A multicenter evaluation of the safety and efficacy of two flexible doses of WELLBUTRIN sustained-release versus placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",Glaxo,tick,na,1999,na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,GSK,tick,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 212[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Male or female subjects, aged 18 years or older, who had a diagnosis of Major Depressive\nDisorder, who had been in a Major Depressive Episode of at least 4 weeks but not greater than 24 months, who scored\na minimum of 20 on the HAMD-21 on Day –6 and Day 0, who also scored a minimum of 2 on the Depressed Mood item\n(Item 1) of the HAMD-31 on Days –6 and Day 0 were eligible for this study.[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were not eligible for inclusion in\nthis study if any of the following criteria applied: predisposition to seizures; significant DSM-III-R Axis II diagnosis that\nwould suggest non-responsiveness to pharmacotherapy for depression; history or current diagnosis of anorexia\nnervosa or bulimia; unstable medical disorder or disorder that would interfere with the adsorption, metabolism or\nexcretion of bupropion, or interfere with the accurate assessment of depression; females who were pregnant or\nlactating, or did not agree to employ contraceptive methods acceptable to the investigator to avoid pregnancy; history of\nalcohol or substance abuse; received any psychoactive drugs within 1 week of the Treatment Phase; previous history of\ntreatment with WELLBUTRIN or WELLBUTRIN SR; incapable of spontaneous conversation or activity; actively suicidal;\nor refused to give informed consent[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Major Depressive\nDisorder,[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",tick,na,tick,tick,na,tick,tick,na,na,na,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,8.00 weeks,na,na,"1994. [{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1994[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,GSK-WELL-212,na,na,na,na,2,na,na,na,na,na,na,37375,Bupropion 100-300,na,na,na,na,37.2,na,na,150,na,na,98,na,na,white=135,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,47,na,na,7,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Headache=38;
Dry mouth=25;
Nausea=22;
Rhinitis=6;
Flu syndrome=2;
Dizziness=11;
Consipation=14;
Insomnia=13;
Nervousness=9;
Tinnitus=10;
Dyspepsia=4;
Diarrhea=8;
Infection=12",na,100.00mg,na,300.00mg,na,100mg,300mg,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,"Basal cell carcinoma excised=1;
metaplasoa, dysplasia, and focal areas of cervical carcinoma=1;",na,na,na,na,na,na,na,na,na,na,na,na,na,na,11.3,na,na,na,na,tick,na,2,na,na,na,na,na,na,na,na,na,na,89913899.0,Continuous,107530.0,113521249.0,1.0,13687717.0,0.0,13671957.0,HAMA ,1935.0,weeks,8,8 weeks,37375.0,0.0,Bupropion 100-300,,GlaxoSmithKline (1994),mean change from baseline,146.0,-6.9,6.51,0.0,*bupropion SR,*HAM-A
89913899,A multicenter evaluation of the safety and efficacy of two flexible doses of WELLBUTRIN sustained-release versus placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1994),1994,"GlaxoSmithKline  (1994) A multicenter evaluation of the safety and efficacy of two flexible doses of WELLBUTRIN sustained-release versus placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",Glaxo,tick,na,1999,na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,GSK,tick,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 212[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Male or female subjects, aged 18 years or older, who had a diagnosis of Major Depressive\nDisorder, who had been in a Major Depressive Episode of at least 4 weeks but not greater than 24 months, who scored\na minimum of 20 on the HAMD-21 on Day –6 and Day 0, who also scored a minimum of 2 on the Depressed Mood item\n(Item 1) of the HAMD-31 on Days –6 and Day 0 were eligible for this study.[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were not eligible for inclusion in\nthis study if any of the following criteria applied: predisposition to seizures; significant DSM-III-R Axis II diagnosis that\nwould suggest non-responsiveness to pharmacotherapy for depression; history or current diagnosis of anorexia\nnervosa or bulimia; unstable medical disorder or disorder that would interfere with the adsorption, metabolism or\nexcretion of bupropion, or interfere with the accurate assessment of depression; females who were pregnant or\nlactating, or did not agree to employ contraceptive methods acceptable to the investigator to avoid pregnancy; history of\nalcohol or substance abuse; received any psychoactive drugs within 1 week of the Treatment Phase; previous history of\ntreatment with WELLBUTRIN or WELLBUTRIN SR; incapable of spontaneous conversation or activity; actively suicidal;\nor refused to give informed consent[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Major Depressive\nDisorder,[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",tick,na,tick,tick,na,tick,tick,na,na,na,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,8.00 weeks,na,na,"1994. [{'ItemDocumentId': 1062904, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1994[¬e]""', 'IsFromPDF': True, 'DocTitle': '850-v1.pdf', 'ItemArm': ''}]",na,na,14 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,GSK-WELL-212,na,na,na,na,2,na,na,na,na,na,na,37375,Bupropion 100-300,na,na,na,na,37.2,na,na,150,na,na,98,na,na,white=135,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,47,na,na,7,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Headache=38;
Dry mouth=25;
Nausea=22;
Rhinitis=6;
Flu syndrome=2;
Dizziness=11;
Consipation=14;
Insomnia=13;
Nervousness=9;
Tinnitus=10;
Dyspepsia=4;
Diarrhea=8;
Infection=12",na,100.00mg,na,300.00mg,na,100mg,300mg,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,"Basal cell carcinoma excised=1;
metaplasoa, dysplasia, and focal areas of cervical carcinoma=1;",na,na,na,na,na,na,na,na,na,na,na,na,na,na,11.3,na,na,na,na,tick,na,2,na,na,na,na,na,na,na,na,na,na,89913899.0,Continuous,107532.0,113521249.0,1.0,13687717.0,0.0,13671957.0,HAMA ,1935.0,weeks,8,8 weeks,37375.0,0.0,Bupropion 100-300,,GlaxoSmithKline (1994),mean change from baseline,148.0,-6.39,6.55,0.0,*bupropion SR,*HAM-A
89913900,A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1993),1993,"GlaxoSmithKline  (1993) A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,tick,na,tick,tick,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"GSK. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,Unclear of where outpatient,tick,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"12 months. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""26 February 1992 – 25 February 1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,"Glaxosmithkline (Well205), 1993",na,na,na,na,na,na,na,na,na,na,na,37364,Placebo,na,na,na,na,40.7,na,na,124,na,na,80,na,na,White=106,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,39,na,na,7,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Headache=42
Rhinitis=14
Dry Mouth=6
Insomnia=11
Nausea=10
Dizziness=10
Constipation=9
Pharyngitis=1",na,na,na,na,8 weeks,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,twice daily,na,na,na,na,na,na,na,na,na,0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.6,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,89913900.0,Continuous,109354.0,113476959.0,1.0,13669974.0,0.0,13671957.0,HAM-A Anxiety,1926.0,weeks,0,0 weeks,37364.0,0.0,Placebo,,GlaxoSmithKline (1993),,116.0,18.0,6.1,0.0,Placebo,*HAM-A
89913900,A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1993),1993,"GlaxoSmithKline  (1993) A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,tick,na,tick,tick,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"GSK. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,Unclear of where outpatient,tick,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"12 months. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""26 February 1992 – 25 February 1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,"Glaxosmithkline (Well205), 1993",na,na,na,na,na,na,na,na,na,na,na,37364,Placebo,na,na,na,na,40.7,na,na,124,na,na,80,na,na,White=106,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,39,na,na,7,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Headache=42
Rhinitis=14
Dry Mouth=6
Insomnia=11
Nausea=10
Dizziness=10
Constipation=9
Pharyngitis=1",na,na,na,na,8 weeks,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,twice daily,na,na,na,na,na,na,na,na,na,0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.6,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,89913900.0,Continuous,109356.0,113476959.0,1.0,13669974.0,0.0,13671957.0,HAM-A Anxiety,1927.0,weeks,8,8 weeks,37364.0,0.0,Placebo,,GlaxoSmithKline (1993),"Change from Baseline, LOCF",116.0,-5.8,6.6,0.0,Placebo,*HAM-A
89913900,A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1993),1993,"GlaxoSmithKline  (1993) A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,tick,na,tick,tick,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"GSK. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,Unclear of where outpatient,tick,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"12 months. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""26 February 1992 – 25 February 1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,"Glaxosmithkline (Well205), 1993",na,na,na,na,na,na,na,na,na,na,na,37365,Bupropion SR 100mg,na,na,na,na,39.6,na,na,119,na,na,77,na,na,White=106,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,38,na,na,2,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Headache=45
Rhinitis=14
Dry Mouth=13
Insomnia=12
Nausea=12
Dizziness=9
Constipation=9
Pharyngitis=3",na,tick,tick,tick,8 weeks,100mg,100mg,na,tick,na,na,na,na,tick,na,tick,na,tick,na,twice daily,na,na,na,na,na,na,na,na,na,2,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.9,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,89913900.0,Continuous,109358.0,113476959.0,1.0,13687717.0,0.0,13671957.0,HAM-A Anxiety,1926.0,weeks,0,0 weeks,37365.0,0.0,Bupropion SR 100mg,,GlaxoSmithKline (1993),,112.0,17.3,6.2,0.0,*bupropion SR,*HAM-A
89913900,A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1993),1993,"GlaxoSmithKline  (1993) A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,tick,na,tick,tick,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"GSK. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,Unclear of where outpatient,tick,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"12 months. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""26 February 1992 – 25 February 1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,"Glaxosmithkline (Well205), 1993",na,na,na,na,na,na,na,na,na,na,na,37365,Bupropion SR 100mg,na,na,na,na,39.6,na,na,119,na,na,77,na,na,White=106,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,38,na,na,2,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Headache=45
Rhinitis=14
Dry Mouth=13
Insomnia=12
Nausea=12
Dizziness=9
Constipation=9
Pharyngitis=3",na,tick,tick,tick,8 weeks,100mg,100mg,na,tick,na,na,na,na,tick,na,tick,na,tick,na,twice daily,na,na,na,na,na,na,na,na,na,2,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.9,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,89913900.0,Continuous,109360.0,113476959.0,1.0,13687717.0,0.0,13671957.0,HAM-A Anxiety,1927.0,weeks,8,8 weeks,37365.0,0.0,Bupropion SR 100mg,,GlaxoSmithKline (1993),"Change from Baseline, LOCF",112.0,-7.2,6.6,0.0,*bupropion SR,*HAM-A
89913900,A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1993),1993,"GlaxoSmithKline  (1993) A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,tick,na,tick,tick,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"GSK. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,Unclear of where outpatient,tick,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"12 months. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""26 February 1992 – 25 February 1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,"Glaxosmithkline (Well205), 1993",na,na,na,na,na,na,na,na,na,na,na,37365,Bupropion SR 100mg,na,na,na,na,39.6,na,na,119,na,na,77,na,na,White=106,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,38,na,na,2,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Headache=45
Rhinitis=14
Dry Mouth=13
Insomnia=12
Nausea=12
Dizziness=9
Constipation=9
Pharyngitis=3",na,tick,tick,tick,8 weeks,100mg,100mg,na,tick,na,na,na,na,tick,na,tick,na,tick,na,twice daily,na,na,na,na,na,na,na,na,na,2,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.9,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,89913900.0,Continuous,109364.0,113476959.0,1.0,13687717.0,0.0,13671957.0,HAM-A Anxiety,1927.0,weeks,8,8 weeks,37365.0,0.0,Bupropion SR 100mg,,GlaxoSmithKline (1993),"Change from Baseline, LOCF",114.0,-6.6,6.0,0.0,*bupropion SR,*HAM-A
89913900,A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1993),1993,"GlaxoSmithKline  (1993) A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,tick,na,tick,tick,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"GSK. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,Unclear of where outpatient,tick,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"12 months. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""26 February 1992 – 25 February 1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,"Glaxosmithkline (Well205), 1993",na,na,na,na,na,na,na,na,na,na,na,37366,Bupropion SR 200mg,na,na,na,na,39.6,na,na,120,na,na,65,na,na,White=98,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,42,na,na,9,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Headache=35
Rhinitis=14
Dry Mouth=16
Insomnia=13
Nausea=13
Dizziness=17
Constipation=14
Pharyngitis=3",na,tick,tick,tick,8 weeks,200mg,200mg,na,tick,na,na,na,na,tick,na,tick,na,tick,na,twice daily,na,na,na,na,na,na,na,na,na,0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,89913900.0,Continuous,109361.0,113476959.0,1.0,13687717.0,0.0,13671957.0,HAM-A Anxiety,1926.0,weeks,0,0 weeks,37366.0,0.0,Bupropion SR 200mg,,GlaxoSmithKline (1993),,114.0,17.4,5.9,0.0,*bupropion SR,*HAM-A
89913900,A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1993),1993,"GlaxoSmithKline  (1993) A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,tick,na,tick,tick,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"GSK. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,Unclear of where outpatient,tick,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"12 months. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""26 February 1992 – 25 February 1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,"Glaxosmithkline (Well205), 1993",na,na,na,na,na,na,na,na,na,na,na,37367,Bupropion SR 300mg,na,na,na,na,39.9,na,na,120,na,na,70,na,na,White=95,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,51,na,na,13,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Headache=31
Rhinitis=8
Dry Mouth=21
Insomnia=20
Nausea=15
Dizziness=6
Constipation=13
Pharyngitis=4",na,tick,tick,tick,8 weeks,300mg,300mg,na,tick,na,na,na,na,tick,na,tick,na,tick,na,twice daily,na,na,na,na,na,na,na,na,na,1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,89913900.0,Continuous,109367.0,113476959.0,1.0,13687717.0,0.0,13671957.0,HAM-A Anxiety,1926.0,weeks,0,0 weeks,37367.0,0.0,Bupropion SR 300mg,,GlaxoSmithKline (1993),,111.0,18.0,6.4,0.0,*bupropion SR,*HAM-A
89913900,A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1993),1993,"GlaxoSmithKline  (1993) A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,tick,na,tick,tick,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"GSK. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,Unclear of where outpatient,tick,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"12 months. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""26 February 1992 – 25 February 1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,"Glaxosmithkline (Well205), 1993",na,na,na,na,na,na,na,na,na,na,na,37367,Bupropion SR 300mg,na,na,na,na,39.9,na,na,120,na,na,70,na,na,White=95,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,51,na,na,13,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Headache=31
Rhinitis=8
Dry Mouth=21
Insomnia=20
Nausea=15
Dizziness=6
Constipation=13
Pharyngitis=4",na,tick,tick,tick,8 weeks,300mg,300mg,na,tick,na,na,na,na,tick,na,tick,na,tick,na,twice daily,na,na,na,na,na,na,na,na,na,1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,89913900.0,Continuous,109368.0,113476959.0,1.0,13687717.0,0.0,13671957.0,HAM-A Anxiety,1927.0,weeks,8,8 weeks,37367.0,0.0,Bupropion SR 300mg,,GlaxoSmithKline (1993),"Change from Baseline, LOCF",111.0,-6.2,7.7,0.0,*bupropion SR,*HAM-A
89913900,A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1993),1993,"GlaxoSmithKline  (1993) A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,tick,na,tick,tick,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"GSK. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,Unclear of where outpatient,tick,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"12 months. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""26 February 1992 – 25 February 1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,"Glaxosmithkline (Well205), 1993",na,na,na,na,na,na,na,na,na,na,na,37368,Bupropion SR 400mg,na,na,na,na,38.8,na,na,119,na,na,66,na,na,White=100,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,43,na,na,12,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Headache=29
Rhinitis=7
Dry Mouth=27
Insomnia=18
Nausea=20
Dizziness=13
Constipation=6
Pharyngitis=11",na,tick,tick,tick,8 weeks,400mg,400mg,na,tick,na,na,na,na,tick,na,tick,na,tick,na,twice daily,na,na,na,na,na,na,na,na,na,1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.7,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,89913900.0,Continuous,109369.0,113476959.0,1.0,13687717.0,0.0,13671957.0,HAM-A Anxiety,1926.0,weeks,0,0 weeks,37368.0,0.0,Bupropion SR 400mg,,GlaxoSmithKline (1993),,111.0,17.3,5.8,0.0,*bupropion SR,*HAM-A
89913900,A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1993),1993,"GlaxoSmithKline  (1993) A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,tick,na,tick,tick,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"GSK. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""WELL 205[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,Unclear of where outpatient,tick,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,"12 months. [{'ItemDocumentId': 1063758, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""26 February 1992 – 25 February 1993[¬e]""', 'IsFromPDF': True, 'DocTitle': '853-v1.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,"Glaxosmithkline (Well205), 1993",na,na,na,na,na,na,na,na,na,na,na,37368,Bupropion SR 400mg,na,na,na,na,38.8,na,na,119,na,na,66,na,na,White=100,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,43,na,na,12,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Headache=29
Rhinitis=7
Dry Mouth=27
Insomnia=18
Nausea=20
Dizziness=13
Constipation=6
Pharyngitis=11",na,tick,tick,tick,8 weeks,400mg,400mg,na,tick,na,na,na,na,tick,na,tick,na,tick,na,twice daily,na,na,na,na,na,na,na,na,na,1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.7,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,89913900.0,Continuous,109370.0,113476959.0,1.0,13687717.0,0.0,13671957.0,HAM-A Anxiety,1927.0,weeks,8,8 weeks,37368.0,0.0,Bupropion SR 400mg,,GlaxoSmithKline (1993),"Change from Baseline, LOCF",111.0,-5.6,7.2,0.0,*bupropion SR,*HAM-A
89913880,Multicenter Evaluation of the Efficacy and Safety of Bupropion vs. Placebo in Depressed Inpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1985),1985,"GlaxoSmithKline  (1985) Multicenter Evaluation of the Efficacy and Safety of Bupropion vs. Placebo in Depressed Inpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,tick,na,Not published but report dated 1985,na,USA;Canada,na,na,GSK,na,"[{'ItemDocumentId': 1061476, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Wellbutrin 25[¬e]""', 'IsFromPDF': True, 'DocTitle': 'GSK 1985.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,"[{'ItemDocumentId': 1061476, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects =18 years old with non-psychotic depressive disorder for >4 weeks but <2 years with a\nminimum HAMD-21 score of 18 and a moderately ill rating (4) on the CGI Severity of Illness Scale, not receiving\npsychoactive drugs for a period of 1 week prior to start of study medication (2 weeks in the case of monoamine oxidase\ninhibitors and phenothiazines; one month in the case of prolixin decanoate, prolixin enanthate or long-acting\nneuroleptics),[¬e]""', 'IsFromPDF': True, 'DocTitle': 'GSK 1985.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1061476, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""not demented, incapable of conversation, actively suicidal or schizophrenic. Additionally, subjects with a\nhistory of a seizure disorder or head trauma were excluded from the study.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'GSK 1985.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline Wellbutrin-25, 1985",na,na,na,na,na,na,na,na,na,na,na,37360,Placebo,na,na,na,na,51.9,na,na,43,na,na,20,na,na,Caucasian=36,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,24,na,na,0,na,na,na,na,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Constipation=11;Tremor=4;Dry mouth=10;Insomnia=11;Excessive sweating=3;Sedation=8;Disturbed concentration=7;Blurred vision=4;Headache/migraine=9;Palpitations=4;Rash=3;Nausea/Vomiting=5;Urinary Frequency=3;Impaired Sleep Quality=2;Sensory Disturbance=5;Agitation=6;Confusion=7;Fatigue=6,na,na,na,na,4 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,3x daily,na,na,na,na,na,na,na,na,na,0,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,25-78,na,na,tick,tick,na,0,na,na,na,na,na,na,na,na,na,na,89913880.0,Continuous,107748.0,113628595.0,1.0,13669974.0,0.0,13734021.0,HAMD-21 Anxiety/Somatisation,1924.0,weeks,0,0 weeks,37360.0,0.0,Placebo,,GlaxoSmithKline (1985),LOCF,39.0,1.64,0.43,0.0,Placebo,*HAMD-21 Anxiety/Somatization Item
89913880,Multicenter Evaluation of the Efficacy and Safety of Bupropion vs. Placebo in Depressed Inpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1985),1985,"GlaxoSmithKline  (1985) Multicenter Evaluation of the Efficacy and Safety of Bupropion vs. Placebo in Depressed Inpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,tick,na,Not published but report dated 1985,na,USA;Canada,na,na,GSK,na,"[{'ItemDocumentId': 1061476, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Wellbutrin 25[¬e]""', 'IsFromPDF': True, 'DocTitle': 'GSK 1985.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,"[{'ItemDocumentId': 1061476, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects =18 years old with non-psychotic depressive disorder for >4 weeks but <2 years with a\nminimum HAMD-21 score of 18 and a moderately ill rating (4) on the CGI Severity of Illness Scale, not receiving\npsychoactive drugs for a period of 1 week prior to start of study medication (2 weeks in the case of monoamine oxidase\ninhibitors and phenothiazines; one month in the case of prolixin decanoate, prolixin enanthate or long-acting\nneuroleptics),[¬e]""', 'IsFromPDF': True, 'DocTitle': 'GSK 1985.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1061476, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""not demented, incapable of conversation, actively suicidal or schizophrenic. Additionally, subjects with a\nhistory of a seizure disorder or head trauma were excluded from the study.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'GSK 1985.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline Wellbutrin-25, 1985",na,na,na,na,na,na,na,na,na,na,na,37360,Placebo,na,na,na,na,51.9,na,na,43,na,na,20,na,na,Caucasian=36,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,24,na,na,0,na,na,na,na,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Constipation=11;Tremor=4;Dry mouth=10;Insomnia=11;Excessive sweating=3;Sedation=8;Disturbed concentration=7;Blurred vision=4;Headache/migraine=9;Palpitations=4;Rash=3;Nausea/Vomiting=5;Urinary Frequency=3;Impaired Sleep Quality=2;Sensory Disturbance=5;Agitation=6;Confusion=7;Fatigue=6,na,na,na,na,4 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,3x daily,na,na,na,na,na,na,na,na,na,0,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,25-78,na,na,tick,tick,na,0,na,na,na,na,na,na,na,na,na,na,89913880.0,Continuous,107749.0,113628595.0,1.0,13669974.0,0.0,13734021.0,HAMD-21 Anxiety/Somatisation,1925.0,weeks,4,4 weeks,37360.0,0.0,Placebo,,GlaxoSmithKline (1985),LOCF,39.0,1.16,0.65,0.0,Placebo,*HAMD-21 Anxiety/Somatization Item
89913880,Multicenter Evaluation of the Efficacy and Safety of Bupropion vs. Placebo in Depressed Inpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1985),1985,"GlaxoSmithKline  (1985) Multicenter Evaluation of the Efficacy and Safety of Bupropion vs. Placebo in Depressed Inpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,tick,na,Not published but report dated 1985,na,USA;Canada,na,na,GSK,na,"[{'ItemDocumentId': 1061476, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Wellbutrin 25[¬e]""', 'IsFromPDF': True, 'DocTitle': 'GSK 1985.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,"[{'ItemDocumentId': 1061476, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects =18 years old with non-psychotic depressive disorder for >4 weeks but <2 years with a\nminimum HAMD-21 score of 18 and a moderately ill rating (4) on the CGI Severity of Illness Scale, not receiving\npsychoactive drugs for a period of 1 week prior to start of study medication (2 weeks in the case of monoamine oxidase\ninhibitors and phenothiazines; one month in the case of prolixin decanoate, prolixin enanthate or long-acting\nneuroleptics),[¬e]""', 'IsFromPDF': True, 'DocTitle': 'GSK 1985.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1061476, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""not demented, incapable of conversation, actively suicidal or schizophrenic. Additionally, subjects with a\nhistory of a seizure disorder or head trauma were excluded from the study.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'GSK 1985.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline Wellbutrin-25, 1985",na,na,na,na,na,na,na,na,na,na,na,37361,Bupropion 300mg,na,na,na,na,52.4,na,na,45,na,na,18,na,na,Caucasian=33,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,22,na,na,4,na,na,na,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Constipation=11;Tremor=7;Dry mouth=12;Insomnia=12;Excessive sweating=9;Sedation=8;Disturbed concentration=8;Blurred vision=8;Headache/migraine=5;Palpitations=6;Rash=6;Nausea/Vomiting=5;Urinary Frequency=6;Impaired Sleep Quality=6;Sensory Disturbance=3;Agitation=7;Confusion=4;Fatigue=6,na,300,tick,300mg,4 weeks,300mg,300mg,na,na,na,na,na,na,na,na,tick,na,na,na,3x daily,na,na,na,na,na,na,na,na,na,0,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,26-80,na,na,tick,tick,na,0,na,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
89913880,Multicenter Evaluation of the Efficacy and Safety of Bupropion vs. Placebo in Depressed Inpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1985),1985,"GlaxoSmithKline  (1985) Multicenter Evaluation of the Efficacy and Safety of Bupropion vs. Placebo in Depressed Inpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,tick,na,Not published but report dated 1985,na,USA;Canada,na,na,GSK,na,"[{'ItemDocumentId': 1061476, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Wellbutrin 25[¬e]""', 'IsFromPDF': True, 'DocTitle': 'GSK 1985.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,"[{'ItemDocumentId': 1061476, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects =18 years old with non-psychotic depressive disorder for >4 weeks but <2 years with a\nminimum HAMD-21 score of 18 and a moderately ill rating (4) on the CGI Severity of Illness Scale, not receiving\npsychoactive drugs for a period of 1 week prior to start of study medication (2 weeks in the case of monoamine oxidase\ninhibitors and phenothiazines; one month in the case of prolixin decanoate, prolixin enanthate or long-acting\nneuroleptics),[¬e]""', 'IsFromPDF': True, 'DocTitle': 'GSK 1985.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1061476, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""not demented, incapable of conversation, actively suicidal or schizophrenic. Additionally, subjects with a\nhistory of a seizure disorder or head trauma were excluded from the study.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'GSK 1985.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline Wellbutrin-25, 1985",na,na,na,na,na,na,na,na,na,na,na,37362,Bupropion 450mg,na,na,na,na,47.5,na,na,40,na,na,18,na,na,Caucasian=34,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,24,na,na,7,na,na,na,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Constipation=13;Tremor=13;Dry mouth=6;Insomnia=10;Excessive sweating=8;Sedation=9 Disturbed concentration=2;Blurred vision=5;Headache/migraine=6;Palpitations=6;Rash=4;Nausea/Vomiting=3;Urinary Frequency=1;Impaired Sleep;Quality=6;Sensory;Disturbance=5;Agitation=7;Confusion=7;Fatigue=1,na,450mg,tick,450mg,4 weeks,450mg,450mg,na,na,na,na,na,na,na,na,tick,na,na,na,3x daily,na,na,na,na,na,na,na,na,na,0,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,20-73,na,na,tick,tick,na,0,na,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
89913880,Multicenter Evaluation of the Efficacy and Safety of Bupropion vs. Placebo in Depressed Inpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1985),1985,"GlaxoSmithKline  (1985) Multicenter Evaluation of the Efficacy and Safety of Bupropion vs. Placebo in Depressed Inpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,tick,na,Not published but report dated 1985,na,USA;Canada,na,na,GSK,na,"[{'ItemDocumentId': 1061476, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Wellbutrin 25[¬e]""', 'IsFromPDF': True, 'DocTitle': 'GSK 1985.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,"[{'ItemDocumentId': 1061476, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects =18 years old with non-psychotic depressive disorder for >4 weeks but <2 years with a\nminimum HAMD-21 score of 18 and a moderately ill rating (4) on the CGI Severity of Illness Scale, not receiving\npsychoactive drugs for a period of 1 week prior to start of study medication (2 weeks in the case of monoamine oxidase\ninhibitors and phenothiazines; one month in the case of prolixin decanoate, prolixin enanthate or long-acting\nneuroleptics),[¬e]""', 'IsFromPDF': True, 'DocTitle': 'GSK 1985.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1061476, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""not demented, incapable of conversation, actively suicidal or schizophrenic. Additionally, subjects with a\nhistory of a seizure disorder or head trauma were excluded from the study.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'GSK 1985.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline Wellbutrin-25, 1985",na,na,na,na,na,na,na,na,na,na,na,37363,Bupropion arms combined,na,na,na,na,na,na,na,85,na,na,36,na,na,caucasian=67,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,46,na,na,11,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,49.65,20-80,na,na,72,na,na,0,na,na,na,na,na,na,na,na,na,na,89913880.0,Continuous,107746.0,113628595.0,1.0,13669949.0,0.0,13734021.0,HAMD-21 Anxiety/Somatisation,1924.0,weeks,0,0 weeks,37363.0,0.0,Bupropion arms combined,,GlaxoSmithKline (1985),LOCF,70.0,1.56,0.43,0.0,Bupropion,*HAMD-21 Anxiety/Somatization Item
89913880,Multicenter Evaluation of the Efficacy and Safety of Bupropion vs. Placebo in Depressed Inpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1985),1985,"GlaxoSmithKline  (1985) Multicenter Evaluation of the Efficacy and Safety of Bupropion vs. Placebo in Depressed Inpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,tick,na,Not published but report dated 1985,na,USA;Canada,na,na,GSK,na,"[{'ItemDocumentId': 1061476, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Wellbutrin 25[¬e]""', 'IsFromPDF': True, 'DocTitle': 'GSK 1985.pdf', 'ItemArm': ''}]",na,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,"[{'ItemDocumentId': 1061476, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects =18 years old with non-psychotic depressive disorder for >4 weeks but <2 years with a\nminimum HAMD-21 score of 18 and a moderately ill rating (4) on the CGI Severity of Illness Scale, not receiving\npsychoactive drugs for a period of 1 week prior to start of study medication (2 weeks in the case of monoamine oxidase\ninhibitors and phenothiazines; one month in the case of prolixin decanoate, prolixin enanthate or long-acting\nneuroleptics),[¬e]""', 'IsFromPDF': True, 'DocTitle': 'GSK 1985.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1061476, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""not demented, incapable of conversation, actively suicidal or schizophrenic. Additionally, subjects with a\nhistory of a seizure disorder or head trauma were excluded from the study.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'GSK 1985.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline Wellbutrin-25, 1985",na,na,na,na,na,na,na,na,na,na,na,37363,Bupropion arms combined,na,na,na,na,na,na,na,85,na,na,36,na,na,caucasian=67,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,46,na,na,11,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,49.65,20-80,na,na,72,na,na,0,na,na,na,na,na,na,na,na,na,na,89913880.0,Continuous,107747.0,113628595.0,1.0,13669949.0,0.0,13734021.0,HAMD-21 Anxiety/Somatisation,1925.0,weeks,4,4 weeks,37363.0,0.0,Bupropion arms combined,,GlaxoSmithKline (1985),LOCF,70.0,0.84,0.54,0.0,Bupropion,*HAMD-21 Anxiety/Somatization Item
89913897,Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1980),1980,"GlaxoSmithKline  (1980) Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,na,tick,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,USA,na,na,GSK,tick,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Non-psychotic subjects ≥21 years of age with major depressive disorder and score of ≥20 on the HAMD-21\nscale, who were free of psychotropic medication for at least one week prior to entering the study (2 weeks for monoamine oxidase\ninhibitors and phenothiazines, one month for prolixin decanoate, prolixin enanthate or other long acting neuroleptics)[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were\nexcluded if they were actively suicidal, had severe dementia, or had a hypersensitivity to antidepressants, central nervous system\nstimulants or other psychoactive agents. At the end of the PBO run-in period (baseline) subjects showing a large PBO response\nwere removed (i.e. improvement of ≥10 points on the HAMD-21 scale and/or HAMD-21 total score of <15 at Day 7).[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,na,36.40,na,na,110,79,na,na,168 Caucasian,na,na,Depression,tick,tick,na,None permitted,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1980,na,na,28 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline 09, 1980",na,na,na,na,na,na,na,na,na,na,na,37129,Bupropion 150-450mg,tick,na,na,na,36.40,na,na,52,na,na,35,na,na,Caucasian=43,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,16,tick,na,6,na,na,na,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,Depressive Affect=51;Insomnia=52;Weight Loss=42;Headache=41;Sweating=27;Syncope/ Dizziness=18;Anorexia/ Decreased Appetite=29;Nausea/ Vomiting=29;Decreased Motor Activity=22;Excitement/ Agitation=26;Drowsiness=30;Dry Mouth=21;Constipation=23;Weight Gain=2,na,tick,tick,tick,6 weeks,150mg,450mg,na,na,na,na,na,na,na,tick,na,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,21-67,na,na,52,na,na,0,na,na,na,na,na,na,na,na,na,na,89913897.0,Continuous,109383.0,113197383.0,1.0,13669949.0,0.0,13671957.0,HAM-A,1765.0,weeks,0,0 weeks,37129.0,0.0,Bupropion 150-450mg,,GlaxoSmithKline (1980),SEConv,42.0,20.7,6.48,0.0,Bupropion,*HAM-A
89913897,Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1980),1980,"GlaxoSmithKline  (1980) Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,na,tick,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,USA,na,na,GSK,tick,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Non-psychotic subjects ≥21 years of age with major depressive disorder and score of ≥20 on the HAMD-21\nscale, who were free of psychotropic medication for at least one week prior to entering the study (2 weeks for monoamine oxidase\ninhibitors and phenothiazines, one month for prolixin decanoate, prolixin enanthate or other long acting neuroleptics)[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were\nexcluded if they were actively suicidal, had severe dementia, or had a hypersensitivity to antidepressants, central nervous system\nstimulants or other psychoactive agents. At the end of the PBO run-in period (baseline) subjects showing a large PBO response\nwere removed (i.e. improvement of ≥10 points on the HAMD-21 scale and/or HAMD-21 total score of <15 at Day 7).[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,na,36.40,na,na,110,79,na,na,168 Caucasian,na,na,Depression,tick,tick,na,None permitted,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1980,na,na,28 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline 09, 1980",na,na,na,na,na,na,na,na,na,na,na,37129,Bupropion 150-450mg,tick,na,na,na,36.40,na,na,52,na,na,35,na,na,Caucasian=43,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,16,tick,na,6,na,na,na,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,Depressive Affect=51;Insomnia=52;Weight Loss=42;Headache=41;Sweating=27;Syncope/ Dizziness=18;Anorexia/ Decreased Appetite=29;Nausea/ Vomiting=29;Decreased Motor Activity=22;Excitement/ Agitation=26;Drowsiness=30;Dry Mouth=21;Constipation=23;Weight Gain=2,na,tick,tick,tick,6 weeks,150mg,450mg,na,na,na,na,na,na,na,tick,na,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,21-67,na,na,52,na,na,0,na,na,na,na,na,na,na,na,na,na,89913897.0,Continuous,109384.0,113197383.0,1.0,13669949.0,0.0,13671957.0,HAM-A,1766.0,weeks,6,6 weeks,37129.0,0.0,Bupropion 150-450mg,,GlaxoSmithKline (1980),LOCF;SEConv,42.0,15.1,9.0,0.0,Bupropion,*HAM-A
89913897,Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1980),1980,"GlaxoSmithKline  (1980) Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,na,tick,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,USA,na,na,GSK,tick,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Non-psychotic subjects ≥21 years of age with major depressive disorder and score of ≥20 on the HAMD-21\nscale, who were free of psychotropic medication for at least one week prior to entering the study (2 weeks for monoamine oxidase\ninhibitors and phenothiazines, one month for prolixin decanoate, prolixin enanthate or other long acting neuroleptics)[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were\nexcluded if they were actively suicidal, had severe dementia, or had a hypersensitivity to antidepressants, central nervous system\nstimulants or other psychoactive agents. At the end of the PBO run-in period (baseline) subjects showing a large PBO response\nwere removed (i.e. improvement of ≥10 points on the HAMD-21 scale and/or HAMD-21 total score of <15 at Day 7).[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,na,36.40,na,na,110,79,na,na,168 Caucasian,na,na,Depression,tick,tick,na,None permitted,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1980,na,na,28 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline 09, 1980",na,na,na,na,na,na,na,na,na,na,na,37129,Bupropion 150-450mg,tick,na,na,na,36.40,na,na,52,na,na,35,na,na,Caucasian=43,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,16,tick,na,6,na,na,na,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,Depressive Affect=51;Insomnia=52;Weight Loss=42;Headache=41;Sweating=27;Syncope/ Dizziness=18;Anorexia/ Decreased Appetite=29;Nausea/ Vomiting=29;Decreased Motor Activity=22;Excitement/ Agitation=26;Drowsiness=30;Dry Mouth=21;Constipation=23;Weight Gain=2,na,tick,tick,tick,6 weeks,150mg,450mg,na,na,na,na,na,na,na,tick,na,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,21-67,na,na,52,na,na,0,na,na,na,na,na,na,na,na,na,na,89913897.0,Continuous,109390.0,113197383.0,1.0,13669949.0,0.0,13732988.0,Zung SAS,1765.0,weeks,0,0 weeks,37129.0,0.0,Bupropion 150-450mg,,GlaxoSmithKline (1980),SEConv,42.0,53.9,10.34,0.0,Bupropion,Zung SAS 
89913897,Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1980),1980,"GlaxoSmithKline  (1980) Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,na,tick,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,USA,na,na,GSK,tick,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Non-psychotic subjects ≥21 years of age with major depressive disorder and score of ≥20 on the HAMD-21\nscale, who were free of psychotropic medication for at least one week prior to entering the study (2 weeks for monoamine oxidase\ninhibitors and phenothiazines, one month for prolixin decanoate, prolixin enanthate or other long acting neuroleptics)[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were\nexcluded if they were actively suicidal, had severe dementia, or had a hypersensitivity to antidepressants, central nervous system\nstimulants or other psychoactive agents. At the end of the PBO run-in period (baseline) subjects showing a large PBO response\nwere removed (i.e. improvement of ≥10 points on the HAMD-21 scale and/or HAMD-21 total score of <15 at Day 7).[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,na,36.40,na,na,110,79,na,na,168 Caucasian,na,na,Depression,tick,tick,na,None permitted,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1980,na,na,28 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline 09, 1980",na,na,na,na,na,na,na,na,na,na,na,37129,Bupropion 150-450mg,tick,na,na,na,36.40,na,na,52,na,na,35,na,na,Caucasian=43,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,16,tick,na,6,na,na,na,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,Depressive Affect=51;Insomnia=52;Weight Loss=42;Headache=41;Sweating=27;Syncope/ Dizziness=18;Anorexia/ Decreased Appetite=29;Nausea/ Vomiting=29;Decreased Motor Activity=22;Excitement/ Agitation=26;Drowsiness=30;Dry Mouth=21;Constipation=23;Weight Gain=2,na,tick,tick,tick,6 weeks,150mg,450mg,na,na,na,na,na,na,na,tick,na,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,21-67,na,na,52,na,na,0,na,na,na,na,na,na,na,na,na,na,89913897.0,Continuous,109392.0,113197383.0,1.0,13669949.0,0.0,13732988.0,Zung SAS,1766.0,weeks,6,6 weeks,37129.0,0.0,Bupropion 150-450mg,,GlaxoSmithKline (1980),LOCF;SEConv,42.0,46.6,12.31,0.0,Bupropion,Zung SAS 
89913897,Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1980),1980,"GlaxoSmithKline  (1980) Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,na,tick,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,USA,na,na,GSK,tick,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Non-psychotic subjects ≥21 years of age with major depressive disorder and score of ≥20 on the HAMD-21\nscale, who were free of psychotropic medication for at least one week prior to entering the study (2 weeks for monoamine oxidase\ninhibitors and phenothiazines, one month for prolixin decanoate, prolixin enanthate or other long acting neuroleptics)[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were\nexcluded if they were actively suicidal, had severe dementia, or had a hypersensitivity to antidepressants, central nervous system\nstimulants or other psychoactive agents. At the end of the PBO run-in period (baseline) subjects showing a large PBO response\nwere removed (i.e. improvement of ≥10 points on the HAMD-21 scale and/or HAMD-21 total score of <15 at Day 7).[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,na,36.40,na,na,110,79,na,na,168 Caucasian,na,na,Depression,tick,tick,na,None permitted,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1980,na,na,28 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline 09, 1980",na,na,na,na,na,na,na,na,na,na,na,37129,Bupropion 150-450mg,tick,na,na,na,36.40,na,na,52,na,na,35,na,na,Caucasian=43,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,16,tick,na,6,na,na,na,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,Depressive Affect=51;Insomnia=52;Weight Loss=42;Headache=41;Sweating=27;Syncope/ Dizziness=18;Anorexia/ Decreased Appetite=29;Nausea/ Vomiting=29;Decreased Motor Activity=22;Excitement/ Agitation=26;Drowsiness=30;Dry Mouth=21;Constipation=23;Weight Gain=2,na,tick,tick,tick,6 weeks,150mg,450mg,na,na,na,na,na,na,na,tick,na,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,21-67,na,na,52,na,na,0,na,na,na,na,na,na,na,na,na,na,89913897.0,Continuous,109403.0,113197383.0,1.0,13669949.0,0.0,13734021.0,HAM-D Anxiety/somatisation,1765.0,weeks,0,0 weeks,37129.0,0.0,Bupropion 150-450mg,,GlaxoSmithKline (1980),SEConv,42.0,1.24,0.32,0.0,Bupropion,*HAMD-21 Anxiety/Somatization Item
89913897,Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1980),1980,"GlaxoSmithKline  (1980) Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,na,tick,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,USA,na,na,GSK,tick,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Non-psychotic subjects ≥21 years of age with major depressive disorder and score of ≥20 on the HAMD-21\nscale, who were free of psychotropic medication for at least one week prior to entering the study (2 weeks for monoamine oxidase\ninhibitors and phenothiazines, one month for prolixin decanoate, prolixin enanthate or other long acting neuroleptics)[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were\nexcluded if they were actively suicidal, had severe dementia, or had a hypersensitivity to antidepressants, central nervous system\nstimulants or other psychoactive agents. At the end of the PBO run-in period (baseline) subjects showing a large PBO response\nwere removed (i.e. improvement of ≥10 points on the HAMD-21 scale and/or HAMD-21 total score of <15 at Day 7).[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,na,36.40,na,na,110,79,na,na,168 Caucasian,na,na,Depression,tick,tick,na,None permitted,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1980,na,na,28 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline 09, 1980",na,na,na,na,na,na,na,na,na,na,na,37129,Bupropion 150-450mg,tick,na,na,na,36.40,na,na,52,na,na,35,na,na,Caucasian=43,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,16,tick,na,6,na,na,na,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,Depressive Affect=51;Insomnia=52;Weight Loss=42;Headache=41;Sweating=27;Syncope/ Dizziness=18;Anorexia/ Decreased Appetite=29;Nausea/ Vomiting=29;Decreased Motor Activity=22;Excitement/ Agitation=26;Drowsiness=30;Dry Mouth=21;Constipation=23;Weight Gain=2,na,tick,tick,tick,6 weeks,150mg,450mg,na,na,na,na,na,na,na,tick,na,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,21-67,na,na,52,na,na,0,na,na,na,na,na,na,na,na,na,na,89913897.0,Continuous,109404.0,113197383.0,1.0,13669949.0,0.0,13734021.0,HAM-D Anxiety/somatisation,1766.0,weeks,6,6 weeks,37129.0,0.0,Bupropion 150-450mg,,GlaxoSmithKline (1980),SEConv,42.0,0.79,0.52,0.0,Bupropion,*HAMD-21 Anxiety/Somatization Item
89913897,Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1980),1980,"GlaxoSmithKline  (1980) Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,na,tick,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,USA,na,na,GSK,tick,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Non-psychotic subjects ≥21 years of age with major depressive disorder and score of ≥20 on the HAMD-21\nscale, who were free of psychotropic medication for at least one week prior to entering the study (2 weeks for monoamine oxidase\ninhibitors and phenothiazines, one month for prolixin decanoate, prolixin enanthate or other long acting neuroleptics)[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were\nexcluded if they were actively suicidal, had severe dementia, or had a hypersensitivity to antidepressants, central nervous system\nstimulants or other psychoactive agents. At the end of the PBO run-in period (baseline) subjects showing a large PBO response\nwere removed (i.e. improvement of ≥10 points on the HAMD-21 scale and/or HAMD-21 total score of <15 at Day 7).[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,na,36.40,na,na,110,79,na,na,168 Caucasian,na,na,Depression,tick,tick,na,None permitted,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1980,na,na,28 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline 09, 1980",na,na,na,na,na,na,na,na,na,na,na,37130,Bupropion 300-900mg,tick,na,na,na,37.8,na,na,23,na,na,13,na,na,Caucasian=18,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,10,na,na,4,na,na,na,tick,tick,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,Depressive Affect=21;Insomnia=20;Weight Loss=15;Headache=17;Sweating=16;Syncope/ Dizziness=15;Anorexia/ Decreased Appetite=13;Nausea/ Vomiting=12;Decreased Motor Activity=14;Excitement/ Agitation=14;Drowsiness=11;Dry Mouth=12;Constipation=10;Weight Gain=11,na,tick,tick,tick,6 weeks,300mg,900mg,na,na,na,na,na,na,na,tick,na,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,21-62,na,na,21,na,na,0,na,na,na,na,na,na,na,na,na,na,89913897.0,Continuous,106835.0,113197383.0,1.0,13669949.0,0.0,13671957.0,HAM-A,1765.0,weeks,0,0 weeks,37130.0,0.0,Bupropion 300-900mg,,GlaxoSmithKline (1980),SEConv,14.0,21.3,8.23,0.0,Bupropion,*HAM-A
89913897,Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1980),1980,"GlaxoSmithKline  (1980) Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,na,tick,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,USA,na,na,GSK,tick,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Non-psychotic subjects ≥21 years of age with major depressive disorder and score of ≥20 on the HAMD-21\nscale, who were free of psychotropic medication for at least one week prior to entering the study (2 weeks for monoamine oxidase\ninhibitors and phenothiazines, one month for prolixin decanoate, prolixin enanthate or other long acting neuroleptics)[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were\nexcluded if they were actively suicidal, had severe dementia, or had a hypersensitivity to antidepressants, central nervous system\nstimulants or other psychoactive agents. At the end of the PBO run-in period (baseline) subjects showing a large PBO response\nwere removed (i.e. improvement of ≥10 points on the HAMD-21 scale and/or HAMD-21 total score of <15 at Day 7).[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,na,36.40,na,na,110,79,na,na,168 Caucasian,na,na,Depression,tick,tick,na,None permitted,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1980,na,na,28 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline 09, 1980",na,na,na,na,na,na,na,na,na,na,na,37130,Bupropion 300-900mg,tick,na,na,na,37.8,na,na,23,na,na,13,na,na,Caucasian=18,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,10,na,na,4,na,na,na,tick,tick,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,Depressive Affect=21;Insomnia=20;Weight Loss=15;Headache=17;Sweating=16;Syncope/ Dizziness=15;Anorexia/ Decreased Appetite=13;Nausea/ Vomiting=12;Decreased Motor Activity=14;Excitement/ Agitation=14;Drowsiness=11;Dry Mouth=12;Constipation=10;Weight Gain=11,na,tick,tick,tick,6 weeks,300mg,900mg,na,na,na,na,na,na,na,tick,na,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,21-62,na,na,21,na,na,0,na,na,na,na,na,na,na,na,na,na,89913897.0,Continuous,106836.0,113197383.0,1.0,13669949.0,0.0,13671957.0,HAM-A,1766.0,weeks,6,6 weeks,37130.0,0.0,Bupropion 300-900mg,,GlaxoSmithKline (1980),LOCF;SEConv,14.0,17.6,7.48,0.0,Bupropion,*HAM-A
89913897,Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1980),1980,"GlaxoSmithKline  (1980) Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,na,tick,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,USA,na,na,GSK,tick,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Non-psychotic subjects ≥21 years of age with major depressive disorder and score of ≥20 on the HAMD-21\nscale, who were free of psychotropic medication for at least one week prior to entering the study (2 weeks for monoamine oxidase\ninhibitors and phenothiazines, one month for prolixin decanoate, prolixin enanthate or other long acting neuroleptics)[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were\nexcluded if they were actively suicidal, had severe dementia, or had a hypersensitivity to antidepressants, central nervous system\nstimulants or other psychoactive agents. At the end of the PBO run-in period (baseline) subjects showing a large PBO response\nwere removed (i.e. improvement of ≥10 points on the HAMD-21 scale and/or HAMD-21 total score of <15 at Day 7).[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,na,36.40,na,na,110,79,na,na,168 Caucasian,na,na,Depression,tick,tick,na,None permitted,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1980,na,na,28 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline 09, 1980",na,na,na,na,na,na,na,na,na,na,na,37130,Bupropion 300-900mg,tick,na,na,na,37.8,na,na,23,na,na,13,na,na,Caucasian=18,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,10,na,na,4,na,na,na,tick,tick,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,Depressive Affect=21;Insomnia=20;Weight Loss=15;Headache=17;Sweating=16;Syncope/ Dizziness=15;Anorexia/ Decreased Appetite=13;Nausea/ Vomiting=12;Decreased Motor Activity=14;Excitement/ Agitation=14;Drowsiness=11;Dry Mouth=12;Constipation=10;Weight Gain=11,na,tick,tick,tick,6 weeks,300mg,900mg,na,na,na,na,na,na,na,tick,na,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,21-62,na,na,21,na,na,0,na,na,na,na,na,na,na,na,na,na,89913897.0,Continuous,109394.0,113197383.0,1.0,13669949.0,0.0,13732988.0,Zung SAS,1765.0,weeks,0,0 weeks,37130.0,0.0,Bupropion 300-900mg,,GlaxoSmithKline (1980),SEConv,14.0,50.8,10.48,0.0,Bupropion,Zung SAS 
89913897,Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1980),1980,"GlaxoSmithKline  (1980) Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,na,tick,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,USA,na,na,GSK,tick,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Non-psychotic subjects ≥21 years of age with major depressive disorder and score of ≥20 on the HAMD-21\nscale, who were free of psychotropic medication for at least one week prior to entering the study (2 weeks for monoamine oxidase\ninhibitors and phenothiazines, one month for prolixin decanoate, prolixin enanthate or other long acting neuroleptics)[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were\nexcluded if they were actively suicidal, had severe dementia, or had a hypersensitivity to antidepressants, central nervous system\nstimulants or other psychoactive agents. At the end of the PBO run-in period (baseline) subjects showing a large PBO response\nwere removed (i.e. improvement of ≥10 points on the HAMD-21 scale and/or HAMD-21 total score of <15 at Day 7).[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,na,36.40,na,na,110,79,na,na,168 Caucasian,na,na,Depression,tick,tick,na,None permitted,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1980,na,na,28 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline 09, 1980",na,na,na,na,na,na,na,na,na,na,na,37130,Bupropion 300-900mg,tick,na,na,na,37.8,na,na,23,na,na,13,na,na,Caucasian=18,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,10,na,na,4,na,na,na,tick,tick,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,Depressive Affect=21;Insomnia=20;Weight Loss=15;Headache=17;Sweating=16;Syncope/ Dizziness=15;Anorexia/ Decreased Appetite=13;Nausea/ Vomiting=12;Decreased Motor Activity=14;Excitement/ Agitation=14;Drowsiness=11;Dry Mouth=12;Constipation=10;Weight Gain=11,na,tick,tick,tick,6 weeks,300mg,900mg,na,na,na,na,na,na,na,tick,na,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,21-62,na,na,21,na,na,0,na,na,na,na,na,na,na,na,na,na,89913897.0,Continuous,109396.0,113197383.0,1.0,13669949.0,0.0,13732988.0,Zung SAS,1766.0,weeks,6,6 weeks,37130.0,0.0,Bupropion 300-900mg,,GlaxoSmithKline (1980),LOCF;SEConv,14.0,47.5,8.23,0.0,Bupropion,Zung SAS 
89913897,Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1980),1980,"GlaxoSmithKline  (1980) Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,na,tick,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,USA,na,na,GSK,tick,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Non-psychotic subjects ≥21 years of age with major depressive disorder and score of ≥20 on the HAMD-21\nscale, who were free of psychotropic medication for at least one week prior to entering the study (2 weeks for monoamine oxidase\ninhibitors and phenothiazines, one month for prolixin decanoate, prolixin enanthate or other long acting neuroleptics)[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were\nexcluded if they were actively suicidal, had severe dementia, or had a hypersensitivity to antidepressants, central nervous system\nstimulants or other psychoactive agents. At the end of the PBO run-in period (baseline) subjects showing a large PBO response\nwere removed (i.e. improvement of ≥10 points on the HAMD-21 scale and/or HAMD-21 total score of <15 at Day 7).[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,na,36.40,na,na,110,79,na,na,168 Caucasian,na,na,Depression,tick,tick,na,None permitted,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1980,na,na,28 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline 09, 1980",na,na,na,na,na,na,na,na,na,na,na,37130,Bupropion 300-900mg,tick,na,na,na,37.8,na,na,23,na,na,13,na,na,Caucasian=18,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,10,na,na,4,na,na,na,tick,tick,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,Depressive Affect=21;Insomnia=20;Weight Loss=15;Headache=17;Sweating=16;Syncope/ Dizziness=15;Anorexia/ Decreased Appetite=13;Nausea/ Vomiting=12;Decreased Motor Activity=14;Excitement/ Agitation=14;Drowsiness=11;Dry Mouth=12;Constipation=10;Weight Gain=11,na,tick,tick,tick,6 weeks,300mg,900mg,na,na,na,na,na,na,na,tick,na,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,21-62,na,na,21,na,na,0,na,na,na,na,na,na,na,na,na,na,89913897.0,Continuous,109409.0,113197383.0,1.0,13669949.0,0.0,13734021.0,HAM-D Anxiety/somatisation,1766.0,weeks,6,6 weeks,37130.0,0.0,Bupropion 300-900mg,,GlaxoSmithKline (1980),SEConv,14.0,0.86,0.41,0.0,Bupropion,*HAMD-21 Anxiety/Somatization Item
89913897,Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1980),1980,"GlaxoSmithKline  (1980) Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,na,tick,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,USA,na,na,GSK,tick,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Non-psychotic subjects ≥21 years of age with major depressive disorder and score of ≥20 on the HAMD-21\nscale, who were free of psychotropic medication for at least one week prior to entering the study (2 weeks for monoamine oxidase\ninhibitors and phenothiazines, one month for prolixin decanoate, prolixin enanthate or other long acting neuroleptics)[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were\nexcluded if they were actively suicidal, had severe dementia, or had a hypersensitivity to antidepressants, central nervous system\nstimulants or other psychoactive agents. At the end of the PBO run-in period (baseline) subjects showing a large PBO response\nwere removed (i.e. improvement of ≥10 points on the HAMD-21 scale and/or HAMD-21 total score of <15 at Day 7).[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,na,36.40,na,na,110,79,na,na,168 Caucasian,na,na,Depression,tick,tick,na,None permitted,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1980,na,na,28 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline 09, 1980",na,na,na,na,na,na,na,na,na,na,na,37130,Bupropion 300-900mg,tick,na,na,na,37.8,na,na,23,na,na,13,na,na,Caucasian=18,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,10,na,na,4,na,na,na,tick,tick,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,Depressive Affect=21;Insomnia=20;Weight Loss=15;Headache=17;Sweating=16;Syncope/ Dizziness=15;Anorexia/ Decreased Appetite=13;Nausea/ Vomiting=12;Decreased Motor Activity=14;Excitement/ Agitation=14;Drowsiness=11;Dry Mouth=12;Constipation=10;Weight Gain=11,na,tick,tick,tick,6 weeks,300mg,900mg,na,na,na,na,na,na,na,tick,na,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,21-62,na,na,21,na,na,0,na,na,na,na,na,na,na,na,na,na,89913897.0,Continuous,109426.0,113197383.0,1.0,13669949.0,0.0,13734021.0,HAM-D Anxiety/somatisation,1765.0,weeks,0,0 weeks,37130.0,0.0,Bupropion 300-900mg,,GlaxoSmithKline (1980),SEConv,14.0,1.18,0.41,0.0,Bupropion,*HAMD-21 Anxiety/Somatization Item
89913897,Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1980),1980,"GlaxoSmithKline  (1980) Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,na,tick,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,USA,na,na,GSK,tick,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Non-psychotic subjects ≥21 years of age with major depressive disorder and score of ≥20 on the HAMD-21\nscale, who were free of psychotropic medication for at least one week prior to entering the study (2 weeks for monoamine oxidase\ninhibitors and phenothiazines, one month for prolixin decanoate, prolixin enanthate or other long acting neuroleptics)[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were\nexcluded if they were actively suicidal, had severe dementia, or had a hypersensitivity to antidepressants, central nervous system\nstimulants or other psychoactive agents. At the end of the PBO run-in period (baseline) subjects showing a large PBO response\nwere removed (i.e. improvement of ≥10 points on the HAMD-21 scale and/or HAMD-21 total score of <15 at Day 7).[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,na,36.40,na,na,110,79,na,na,168 Caucasian,na,na,Depression,tick,tick,na,None permitted,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1980,na,na,28 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline 09, 1980",na,na,na,na,na,na,na,na,na,na,na,37131,Placebo,tick,na,na,na,37.40,na,na,47,na,na,31,na,na,Caucasian=36,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,na,10,na,na,1,na,na,na,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,Depressive Affect=45;Insomnia=43;Weight Loss=28;Headache=34;Sweating=23;Syncope/ Dizziness=12;Anorexia/ Decreased Appetite=24;Nausea/ Vomiting=17;Decreased Motor Activity=27;Excitement/ Agitation=21;Drowsiness=22;Dry Mouth=16;Constipation=14;Weight Gain=30,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,21-60,na,na,47,na,na,0,na,na,na,na,na,na,na,na,na,na,89913897.0,Continuous,109386.0,113197383.0,1.0,13669974.0,0.0,13671957.0,HAM-A,1765.0,weeks,0,0 weeks,37131.0,0.0,Placebo,,GlaxoSmithKline (1980),SEConv,40.0,22.7,5.69,0.0,Placebo,*HAM-A
89913897,Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1980),1980,"GlaxoSmithKline  (1980) Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,na,tick,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,USA,na,na,GSK,tick,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Non-psychotic subjects ≥21 years of age with major depressive disorder and score of ≥20 on the HAMD-21\nscale, who were free of psychotropic medication for at least one week prior to entering the study (2 weeks for monoamine oxidase\ninhibitors and phenothiazines, one month for prolixin decanoate, prolixin enanthate or other long acting neuroleptics)[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were\nexcluded if they were actively suicidal, had severe dementia, or had a hypersensitivity to antidepressants, central nervous system\nstimulants or other psychoactive agents. At the end of the PBO run-in period (baseline) subjects showing a large PBO response\nwere removed (i.e. improvement of ≥10 points on the HAMD-21 scale and/or HAMD-21 total score of <15 at Day 7).[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,na,36.40,na,na,110,79,na,na,168 Caucasian,na,na,Depression,tick,tick,na,None permitted,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1980,na,na,28 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline 09, 1980",na,na,na,na,na,na,na,na,na,na,na,37131,Placebo,tick,na,na,na,37.40,na,na,47,na,na,31,na,na,Caucasian=36,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,na,10,na,na,1,na,na,na,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,Depressive Affect=45;Insomnia=43;Weight Loss=28;Headache=34;Sweating=23;Syncope/ Dizziness=12;Anorexia/ Decreased Appetite=24;Nausea/ Vomiting=17;Decreased Motor Activity=27;Excitement/ Agitation=21;Drowsiness=22;Dry Mouth=16;Constipation=14;Weight Gain=30,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,21-60,na,na,47,na,na,0,na,na,na,na,na,na,na,na,na,na,89913897.0,Continuous,109388.0,113197383.0,1.0,13669974.0,0.0,13671957.0,HAM-A,1766.0,weeks,6,6 weeks,37131.0,0.0,Placebo,,GlaxoSmithKline (1980),LOCF;SEConv,40.0,15.6,9.49,0.0,Placebo,*HAM-A
89913897,Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1980),1980,"GlaxoSmithKline  (1980) Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,na,tick,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,USA,na,na,GSK,tick,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Non-psychotic subjects ≥21 years of age with major depressive disorder and score of ≥20 on the HAMD-21\nscale, who were free of psychotropic medication for at least one week prior to entering the study (2 weeks for monoamine oxidase\ninhibitors and phenothiazines, one month for prolixin decanoate, prolixin enanthate or other long acting neuroleptics)[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were\nexcluded if they were actively suicidal, had severe dementia, or had a hypersensitivity to antidepressants, central nervous system\nstimulants or other psychoactive agents. At the end of the PBO run-in period (baseline) subjects showing a large PBO response\nwere removed (i.e. improvement of ≥10 points on the HAMD-21 scale and/or HAMD-21 total score of <15 at Day 7).[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,na,36.40,na,na,110,79,na,na,168 Caucasian,na,na,Depression,tick,tick,na,None permitted,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1980,na,na,28 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline 09, 1980",na,na,na,na,na,na,na,na,na,na,na,37131,Placebo,tick,na,na,na,37.40,na,na,47,na,na,31,na,na,Caucasian=36,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,na,10,na,na,1,na,na,na,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,Depressive Affect=45;Insomnia=43;Weight Loss=28;Headache=34;Sweating=23;Syncope/ Dizziness=12;Anorexia/ Decreased Appetite=24;Nausea/ Vomiting=17;Decreased Motor Activity=27;Excitement/ Agitation=21;Drowsiness=22;Dry Mouth=16;Constipation=14;Weight Gain=30,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,21-60,na,na,47,na,na,0,na,na,na,na,na,na,na,na,na,na,89913897.0,Continuous,109399.0,113197383.0,1.0,13669974.0,0.0,13732988.0,Zung SAS,1765.0,weeks,0,0 weeks,37131.0,0.0,Placebo,,GlaxoSmithKline (1980),SEConv,40.0,54.0,12.02,0.0,Placebo,Zung SAS 
89913897,Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1980),1980,"GlaxoSmithKline  (1980) Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,na,tick,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,USA,na,na,GSK,tick,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Non-psychotic subjects ≥21 years of age with major depressive disorder and score of ≥20 on the HAMD-21\nscale, who were free of psychotropic medication for at least one week prior to entering the study (2 weeks for monoamine oxidase\ninhibitors and phenothiazines, one month for prolixin decanoate, prolixin enanthate or other long acting neuroleptics)[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were\nexcluded if they were actively suicidal, had severe dementia, or had a hypersensitivity to antidepressants, central nervous system\nstimulants or other psychoactive agents. At the end of the PBO run-in period (baseline) subjects showing a large PBO response\nwere removed (i.e. improvement of ≥10 points on the HAMD-21 scale and/or HAMD-21 total score of <15 at Day 7).[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,na,36.40,na,na,110,79,na,na,168 Caucasian,na,na,Depression,tick,tick,na,None permitted,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1980,na,na,28 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline 09, 1980",na,na,na,na,na,na,na,na,na,na,na,37131,Placebo,tick,na,na,na,37.40,na,na,47,na,na,31,na,na,Caucasian=36,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,na,10,na,na,1,na,na,na,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,Depressive Affect=45;Insomnia=43;Weight Loss=28;Headache=34;Sweating=23;Syncope/ Dizziness=12;Anorexia/ Decreased Appetite=24;Nausea/ Vomiting=17;Decreased Motor Activity=27;Excitement/ Agitation=21;Drowsiness=22;Dry Mouth=16;Constipation=14;Weight Gain=30,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,21-60,na,na,47,na,na,0,na,na,na,na,na,na,na,na,na,na,89913897.0,Continuous,109401.0,113197383.0,1.0,13669974.0,0.0,13732988.0,Zung SAS,1766.0,weeks,6,6 weeks,37131.0,0.0,Placebo,,GlaxoSmithKline (1980),LOCF;SEConv,40.0,47.4,12.02,0.0,Placebo,Zung SAS 
89913897,Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1980),1980,"GlaxoSmithKline  (1980) Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,na,tick,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,USA,na,na,GSK,tick,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Non-psychotic subjects ≥21 years of age with major depressive disorder and score of ≥20 on the HAMD-21\nscale, who were free of psychotropic medication for at least one week prior to entering the study (2 weeks for monoamine oxidase\ninhibitors and phenothiazines, one month for prolixin decanoate, prolixin enanthate or other long acting neuroleptics)[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were\nexcluded if they were actively suicidal, had severe dementia, or had a hypersensitivity to antidepressants, central nervous system\nstimulants or other psychoactive agents. At the end of the PBO run-in period (baseline) subjects showing a large PBO response\nwere removed (i.e. improvement of ≥10 points on the HAMD-21 scale and/or HAMD-21 total score of <15 at Day 7).[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,na,36.40,na,na,110,79,na,na,168 Caucasian,na,na,Depression,tick,tick,na,None permitted,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1980,na,na,28 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline 09, 1980",na,na,na,na,na,na,na,na,na,na,na,37131,Placebo,tick,na,na,na,37.40,na,na,47,na,na,31,na,na,Caucasian=36,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,na,10,na,na,1,na,na,na,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,Depressive Affect=45;Insomnia=43;Weight Loss=28;Headache=34;Sweating=23;Syncope/ Dizziness=12;Anorexia/ Decreased Appetite=24;Nausea/ Vomiting=17;Decreased Motor Activity=27;Excitement/ Agitation=21;Drowsiness=22;Dry Mouth=16;Constipation=14;Weight Gain=30,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,21-60,na,na,47,na,na,0,na,na,na,na,na,na,na,na,na,na,89913897.0,Continuous,109411.0,113197383.0,1.0,13669974.0,0.0,13734021.0,HAM-D Anxiety/somatisation,1766.0,weeks,6,6 weeks,37131.0,0.0,Placebo,,GlaxoSmithKline (1980),SEConv,40.0,0.95,0.51,0.0,Placebo,*HAMD-21 Anxiety/Somatization Item
89913897,Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients,GSK - clinical study register [www.gsk-clinicalstudyregister.com],GlaxoSmithKline (1980),1980,"GlaxoSmithKline  (1980) Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients. GSK - clinical study register [www.gsk-clinicalstudyregister.com] ,",tick,na,tick,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1980[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,USA,na,na,GSK,tick,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Non-psychotic subjects ≥21 years of age with major depressive disorder and score of ≥20 on the HAMD-21\nscale, who were free of psychotropic medication for at least one week prior to entering the study (2 weeks for monoamine oxidase\ninhibitors and phenothiazines, one month for prolixin decanoate, prolixin enanthate or other long acting neuroleptics)[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063638, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Subjects were\nexcluded if they were actively suicidal, had severe dementia, or had a hypersensitivity to antidepressants, central nervous system\nstimulants or other psychoactive agents. At the end of the PBO run-in period (baseline) subjects showing a large PBO response\nwere removed (i.e. improvement of ≥10 points on the HAMD-21 scale and/or HAMD-21 total score of <15 at Day 7).[¬e]""', 'IsFromPDF': True, 'DocTitle': '845-v1.pdf', 'ItemArm': ''}]",na,na,36.40,na,na,110,79,na,na,168 Caucasian,na,na,Depression,tick,tick,na,None permitted,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1980,na,na,28 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Glaxosmithkline 09, 1980",na,na,na,na,na,na,na,na,na,na,na,37131,Placebo,tick,na,na,na,37.40,na,na,47,na,na,31,na,na,Caucasian=36,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,na,10,na,na,1,na,na,na,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,Depressive Affect=45;Insomnia=43;Weight Loss=28;Headache=34;Sweating=23;Syncope/ Dizziness=12;Anorexia/ Decreased Appetite=24;Nausea/ Vomiting=17;Decreased Motor Activity=27;Excitement/ Agitation=21;Drowsiness=22;Dry Mouth=16;Constipation=14;Weight Gain=30,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,21-60,na,na,47,na,na,0,na,na,na,na,na,na,na,na,na,na,89913897.0,Continuous,109407.0,113197383.0,1.0,13669974.0,0.0,13734021.0,HAM-D Anxiety/somatisation,1765.0,weeks,0,0 weeks,37131.0,0.0,Placebo,,GlaxoSmithKline (1980),SEConv,40.0,1.26,0.32,0.0,Placebo,*HAMD-21 Anxiety/Somatization Item
87999463,Monoamine oxidase inhibitor-responsive depression.,Psychiatry research,Giller (1982),1982,"Giller E, Bialos D, Riddle M, Sholomskas A, and Harkness L (1982) Monoamine oxidase inhibitor-responsive depression.. Psychiatry research 6(1), 41-8","[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Giller,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1982)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""VA research funds,""\n""NIMH Grant MH-30939, a""\n""nd Hoffman-LaRoche.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,na,na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Inclusion criteria included dysphoricmood\n(depressed,\nof\nsad, blue, hopeless,""\n""low, down in the dumps, irritable), anxiety, somatic symptoms of anxiety, a Hamilton Depres-\nsion Scale (24 items) sum equal to or greater than 20, and a Covi anxiety score equal to or greater\nthan 8. The Covi anxiety scale consists of three items: verbal report, observed behavior, and\nsomatic symptoms. These were rated 1 (not at all) to 5 (very much). The duration of the current\nepisode was at least 1 month. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Excluded were patients with schizophrenia, mania, alcoholism, drug d""\n""ependency,""\n""organic brain syndrome, or obsessive compulsive neuro-""\n""sis, as well as those with marked suicidal ideation,""\n""convulsive disorder, moderate to severe""\n""cardiovascular\ndisease, electroconvulsive""\n""therapy within the previous month,""\n""tricyclic treat-""\n""ment within the previous 14 days, or""\n""benzodiazepine""\n""within the previous 7 days.\ntreatment[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,50.3,na,na,30,0,na,na,Predominantly white,na,na,Depression,Anxiety,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Giller, 1982",tick,10.8,28-64,na,na,na,na,na,na,na,na,37281,Placebo,na,na,na,na,tick,tick,na,tick,na,tick,0,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,na,tick,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,73mg,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,tick,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,na,tick,tick,na,tick,na,na,tick,tick,na,na,na,na,87999463.0,Continuous,107734.0,113628121.0,1.0,13669974.0,0.0,13709935.0,Covi Anxiety Scale Total,1871.0,weeks,0,0 weeks,37281.0,0.0,Placebo,,Giller (1982),,11.0,9.5,1.6,0.0,Placebo,*Covi Anxiety Scale Total
87999463,Monoamine oxidase inhibitor-responsive depression.,Psychiatry research,Giller (1982),1982,"Giller E, Bialos D, Riddle M, Sholomskas A, and Harkness L (1982) Monoamine oxidase inhibitor-responsive depression.. Psychiatry research 6(1), 41-8","[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Giller,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1982)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""VA research funds,""\n""NIMH Grant MH-30939, a""\n""nd Hoffman-LaRoche.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,na,na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Inclusion criteria included dysphoricmood\n(depressed,\nof\nsad, blue, hopeless,""\n""low, down in the dumps, irritable), anxiety, somatic symptoms of anxiety, a Hamilton Depres-\nsion Scale (24 items) sum equal to or greater than 20, and a Covi anxiety score equal to or greater\nthan 8. The Covi anxiety scale consists of three items: verbal report, observed behavior, and\nsomatic symptoms. These were rated 1 (not at all) to 5 (very much). The duration of the current\nepisode was at least 1 month. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Excluded were patients with schizophrenia, mania, alcoholism, drug d""\n""ependency,""\n""organic brain syndrome, or obsessive compulsive neuro-""\n""sis, as well as those with marked suicidal ideation,""\n""convulsive disorder, moderate to severe""\n""cardiovascular\ndisease, electroconvulsive""\n""therapy within the previous month,""\n""tricyclic treat-""\n""ment within the previous 14 days, or""\n""benzodiazepine""\n""within the previous 7 days.\ntreatment[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,50.3,na,na,30,0,na,na,Predominantly white,na,na,Depression,Anxiety,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Giller, 1982",tick,10.8,28-64,na,na,na,na,na,na,na,na,37281,Placebo,na,na,na,na,tick,tick,na,tick,na,tick,0,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,na,tick,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,73mg,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,tick,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,na,tick,tick,na,tick,na,na,tick,tick,na,na,na,na,87999463.0,Continuous,107735.0,113628121.0,1.0,13669974.0,0.0,13709935.0,Covi Anxiety Scale Total,1872.0,weeks,6,6 weeks,37281.0,0.0,Placebo,,Giller (1982),,11.0,8.7,1.8,0.0,Placebo,*Covi Anxiety Scale Total
87999463,Monoamine oxidase inhibitor-responsive depression.,Psychiatry research,Giller (1982),1982,"Giller E, Bialos D, Riddle M, Sholomskas A, and Harkness L (1982) Monoamine oxidase inhibitor-responsive depression.. Psychiatry research 6(1), 41-8","[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Giller,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1982)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""VA research funds,""\n""NIMH Grant MH-30939, a""\n""nd Hoffman-LaRoche.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,na,na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Inclusion criteria included dysphoricmood\n(depressed,\nof\nsad, blue, hopeless,""\n""low, down in the dumps, irritable), anxiety, somatic symptoms of anxiety, a Hamilton Depres-\nsion Scale (24 items) sum equal to or greater than 20, and a Covi anxiety score equal to or greater\nthan 8. The Covi anxiety scale consists of three items: verbal report, observed behavior, and\nsomatic symptoms. These were rated 1 (not at all) to 5 (very much). The duration of the current\nepisode was at least 1 month. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Excluded were patients with schizophrenia, mania, alcoholism, drug d""\n""ependency,""\n""organic brain syndrome, or obsessive compulsive neuro-""\n""sis, as well as those with marked suicidal ideation,""\n""convulsive disorder, moderate to severe""\n""cardiovascular\ndisease, electroconvulsive""\n""therapy within the previous month,""\n""tricyclic treat-""\n""ment within the previous 14 days, or""\n""benzodiazepine""\n""within the previous 7 days.\ntreatment[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,50.3,na,na,30,0,na,na,Predominantly white,na,na,Depression,Anxiety,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Giller, 1982",tick,10.8,28-64,na,na,na,na,na,na,na,na,37281,Placebo,na,na,na,na,tick,tick,na,tick,na,tick,0,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,na,tick,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,73mg,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,tick,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,na,tick,tick,na,tick,na,na,tick,tick,na,na,na,na,87999463.0,Continuous,107738.0,113628121.0,1.0,13669974.0,0.0,13756694.0,Covi Anxiety Scale Verbal,1871.0,weeks,0,0 weeks,37281.0,0.0,Placebo,,Giller (1982),,11.0,3.5,0.7,0.0,Placebo,*Covi Anxiety Scale Verbal
87999463,Monoamine oxidase inhibitor-responsive depression.,Psychiatry research,Giller (1982),1982,"Giller E, Bialos D, Riddle M, Sholomskas A, and Harkness L (1982) Monoamine oxidase inhibitor-responsive depression.. Psychiatry research 6(1), 41-8","[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Giller,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1982)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""VA research funds,""\n""NIMH Grant MH-30939, a""\n""nd Hoffman-LaRoche.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,na,na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Inclusion criteria included dysphoricmood\n(depressed,\nof\nsad, blue, hopeless,""\n""low, down in the dumps, irritable), anxiety, somatic symptoms of anxiety, a Hamilton Depres-\nsion Scale (24 items) sum equal to or greater than 20, and a Covi anxiety score equal to or greater\nthan 8. The Covi anxiety scale consists of three items: verbal report, observed behavior, and\nsomatic symptoms. These were rated 1 (not at all) to 5 (very much). The duration of the current\nepisode was at least 1 month. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Excluded were patients with schizophrenia, mania, alcoholism, drug d""\n""ependency,""\n""organic brain syndrome, or obsessive compulsive neuro-""\n""sis, as well as those with marked suicidal ideation,""\n""convulsive disorder, moderate to severe""\n""cardiovascular\ndisease, electroconvulsive""\n""therapy within the previous month,""\n""tricyclic treat-""\n""ment within the previous 14 days, or""\n""benzodiazepine""\n""within the previous 7 days.\ntreatment[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,50.3,na,na,30,0,na,na,Predominantly white,na,na,Depression,Anxiety,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Giller, 1982",tick,10.8,28-64,na,na,na,na,na,na,na,na,37281,Placebo,na,na,na,na,tick,tick,na,tick,na,tick,0,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,na,tick,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,73mg,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,tick,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,na,tick,tick,na,tick,na,na,tick,tick,na,na,na,na,87999463.0,Continuous,107739.0,113628121.0,1.0,13669974.0,0.0,13756694.0,Covi Anxiety Scale Verbal,1872.0,weeks,6,6 weeks,37281.0,0.0,Placebo,,Giller (1982),,11.0,3.2,0.8,0.0,Placebo,*Covi Anxiety Scale Verbal
87999463,Monoamine oxidase inhibitor-responsive depression.,Psychiatry research,Giller (1982),1982,"Giller E, Bialos D, Riddle M, Sholomskas A, and Harkness L (1982) Monoamine oxidase inhibitor-responsive depression.. Psychiatry research 6(1), 41-8","[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Giller,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1982)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""VA research funds,""\n""NIMH Grant MH-30939, a""\n""nd Hoffman-LaRoche.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,na,na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Inclusion criteria included dysphoricmood\n(depressed,\nof\nsad, blue, hopeless,""\n""low, down in the dumps, irritable), anxiety, somatic symptoms of anxiety, a Hamilton Depres-\nsion Scale (24 items) sum equal to or greater than 20, and a Covi anxiety score equal to or greater\nthan 8. The Covi anxiety scale consists of three items: verbal report, observed behavior, and\nsomatic symptoms. These were rated 1 (not at all) to 5 (very much). The duration of the current\nepisode was at least 1 month. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Excluded were patients with schizophrenia, mania, alcoholism, drug d""\n""ependency,""\n""organic brain syndrome, or obsessive compulsive neuro-""\n""sis, as well as those with marked suicidal ideation,""\n""convulsive disorder, moderate to severe""\n""cardiovascular\ndisease, electroconvulsive""\n""therapy within the previous month,""\n""tricyclic treat-""\n""ment within the previous 14 days, or""\n""benzodiazepine""\n""within the previous 7 days.\ntreatment[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,50.3,na,na,30,0,na,na,Predominantly white,na,na,Depression,Anxiety,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Giller, 1982",tick,10.8,28-64,na,na,na,na,na,na,na,na,37281,Placebo,na,na,na,na,tick,tick,na,tick,na,tick,0,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,na,tick,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,73mg,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,tick,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,na,tick,tick,na,tick,na,na,tick,tick,na,na,na,na,87999463.0,Continuous,107744.0,113628121.0,1.0,13669974.0,0.0,13756695.0,Covi Anxiety Scale Somatic,1871.0,weeks,0,0 weeks,37281.0,0.0,Placebo,,Giller (1982),,11.0,3.6,0.7,0.0,Placebo,*Covi Anxiety Scale Somatic
87999463,Monoamine oxidase inhibitor-responsive depression.,Psychiatry research,Giller (1982),1982,"Giller E, Bialos D, Riddle M, Sholomskas A, and Harkness L (1982) Monoamine oxidase inhibitor-responsive depression.. Psychiatry research 6(1), 41-8","[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Giller,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1982)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""VA research funds,""\n""NIMH Grant MH-30939, a""\n""nd Hoffman-LaRoche.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,na,na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Inclusion criteria included dysphoricmood\n(depressed,\nof\nsad, blue, hopeless,""\n""low, down in the dumps, irritable), anxiety, somatic symptoms of anxiety, a Hamilton Depres-\nsion Scale (24 items) sum equal to or greater than 20, and a Covi anxiety score equal to or greater\nthan 8. The Covi anxiety scale consists of three items: verbal report, observed behavior, and\nsomatic symptoms. These were rated 1 (not at all) to 5 (very much). The duration of the current\nepisode was at least 1 month. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Excluded were patients with schizophrenia, mania, alcoholism, drug d""\n""ependency,""\n""organic brain syndrome, or obsessive compulsive neuro-""\n""sis, as well as those with marked suicidal ideation,""\n""convulsive disorder, moderate to severe""\n""cardiovascular\ndisease, electroconvulsive""\n""therapy within the previous month,""\n""tricyclic treat-""\n""ment within the previous 14 days, or""\n""benzodiazepine""\n""within the previous 7 days.\ntreatment[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,50.3,na,na,30,0,na,na,Predominantly white,na,na,Depression,Anxiety,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Giller, 1982",tick,10.8,28-64,na,na,na,na,na,na,na,na,37281,Placebo,na,na,na,na,tick,tick,na,tick,na,tick,0,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,na,tick,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,73mg,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,tick,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,na,tick,tick,na,tick,na,na,tick,tick,na,na,na,na,87999463.0,Continuous,107745.0,113628121.0,1.0,13669974.0,0.0,13756695.0,Covi Anxiety Scale Somatic,1872.0,weeks,6,6 weeks,37281.0,0.0,Placebo,,Giller (1982),,11.0,3.4,0.8,0.0,Placebo,*Covi Anxiety Scale Somatic
87999463,Monoamine oxidase inhibitor-responsive depression.,Psychiatry research,Giller (1982),1982,"Giller E, Bialos D, Riddle M, Sholomskas A, and Harkness L (1982) Monoamine oxidase inhibitor-responsive depression.. Psychiatry research 6(1), 41-8","[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Giller,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1982)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""VA research funds,""\n""NIMH Grant MH-30939, a""\n""nd Hoffman-LaRoche.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,na,na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Inclusion criteria included dysphoricmood\n(depressed,\nof\nsad, blue, hopeless,""\n""low, down in the dumps, irritable), anxiety, somatic symptoms of anxiety, a Hamilton Depres-\nsion Scale (24 items) sum equal to or greater than 20, and a Covi anxiety score equal to or greater\nthan 8. The Covi anxiety scale consists of three items: verbal report, observed behavior, and\nsomatic symptoms. These were rated 1 (not at all) to 5 (very much). The duration of the current\nepisode was at least 1 month. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Excluded were patients with schizophrenia, mania, alcoholism, drug d""\n""ependency,""\n""organic brain syndrome, or obsessive compulsive neuro-""\n""sis, as well as those with marked suicidal ideation,""\n""convulsive disorder, moderate to severe""\n""cardiovascular\ndisease, electroconvulsive""\n""therapy within the previous month,""\n""tricyclic treat-""\n""ment within the previous 14 days, or""\n""benzodiazepine""\n""within the previous 7 days.\ntreatment[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,50.3,na,na,30,0,na,na,Predominantly white,na,na,Depression,Anxiety,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Giller, 1982",tick,10.8,28-64,na,na,na,na,na,na,na,na,37282,Isocarboxazid,na,na,na,na,tick,tick,na,tick,tick,na,0,na,na,tick,tick,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,tick,na,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,48mg,tick,6 weeks,tick,tick,na,na,tick,na,tick,na,tick,na,na,na,tick,na,tick,na,na,tick,na,na,na,tick,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,tick,tick,na,na,na,na,87999463.0,Continuous,107736.0,113628121.0,1.0,13669960.0,0.0,13709935.0,Covi Anxiety Scale Total,1871.0,weeks,0,0 weeks,37282.0,0.0,Isocarboxazid,,Giller (1982),,13.0,10.2,1.4,0.0,Isocarboxazid,*Covi Anxiety Scale Total
87999463,Monoamine oxidase inhibitor-responsive depression.,Psychiatry research,Giller (1982),1982,"Giller E, Bialos D, Riddle M, Sholomskas A, and Harkness L (1982) Monoamine oxidase inhibitor-responsive depression.. Psychiatry research 6(1), 41-8","[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Giller,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1982)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""VA research funds,""\n""NIMH Grant MH-30939, a""\n""nd Hoffman-LaRoche.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,na,na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Inclusion criteria included dysphoricmood\n(depressed,\nof\nsad, blue, hopeless,""\n""low, down in the dumps, irritable), anxiety, somatic symptoms of anxiety, a Hamilton Depres-\nsion Scale (24 items) sum equal to or greater than 20, and a Covi anxiety score equal to or greater\nthan 8. The Covi anxiety scale consists of three items: verbal report, observed behavior, and\nsomatic symptoms. These were rated 1 (not at all) to 5 (very much). The duration of the current\nepisode was at least 1 month. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Excluded were patients with schizophrenia, mania, alcoholism, drug d""\n""ependency,""\n""organic brain syndrome, or obsessive compulsive neuro-""\n""sis, as well as those with marked suicidal ideation,""\n""convulsive disorder, moderate to severe""\n""cardiovascular\ndisease, electroconvulsive""\n""therapy within the previous month,""\n""tricyclic treat-""\n""ment within the previous 14 days, or""\n""benzodiazepine""\n""within the previous 7 days.\ntreatment[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,50.3,na,na,30,0,na,na,Predominantly white,na,na,Depression,Anxiety,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Giller, 1982",tick,10.8,28-64,na,na,na,na,na,na,na,na,37282,Isocarboxazid,na,na,na,na,tick,tick,na,tick,tick,na,0,na,na,tick,tick,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,tick,na,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,48mg,tick,6 weeks,tick,tick,na,na,tick,na,tick,na,tick,na,na,na,tick,na,tick,na,na,tick,na,na,na,tick,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,tick,tick,na,na,na,na,87999463.0,Continuous,107737.0,113628121.0,1.0,13669960.0,0.0,13709935.0,Covi Anxiety Scale Total,1872.0,weeks,6,6 weeks,37282.0,0.0,Isocarboxazid,,Giller (1982),,13.0,6.1,3.1,0.0,Isocarboxazid,*Covi Anxiety Scale Total
87999463,Monoamine oxidase inhibitor-responsive depression.,Psychiatry research,Giller (1982),1982,"Giller E, Bialos D, Riddle M, Sholomskas A, and Harkness L (1982) Monoamine oxidase inhibitor-responsive depression.. Psychiatry research 6(1), 41-8","[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Giller,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1982)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""VA research funds,""\n""NIMH Grant MH-30939, a""\n""nd Hoffman-LaRoche.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,na,na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Inclusion criteria included dysphoricmood\n(depressed,\nof\nsad, blue, hopeless,""\n""low, down in the dumps, irritable), anxiety, somatic symptoms of anxiety, a Hamilton Depres-\nsion Scale (24 items) sum equal to or greater than 20, and a Covi anxiety score equal to or greater\nthan 8. The Covi anxiety scale consists of three items: verbal report, observed behavior, and\nsomatic symptoms. These were rated 1 (not at all) to 5 (very much). The duration of the current\nepisode was at least 1 month. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Excluded were patients with schizophrenia, mania, alcoholism, drug d""\n""ependency,""\n""organic brain syndrome, or obsessive compulsive neuro-""\n""sis, as well as those with marked suicidal ideation,""\n""convulsive disorder, moderate to severe""\n""cardiovascular\ndisease, electroconvulsive""\n""therapy within the previous month,""\n""tricyclic treat-""\n""ment within the previous 14 days, or""\n""benzodiazepine""\n""within the previous 7 days.\ntreatment[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,50.3,na,na,30,0,na,na,Predominantly white,na,na,Depression,Anxiety,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Giller, 1982",tick,10.8,28-64,na,na,na,na,na,na,na,na,37282,Isocarboxazid,na,na,na,na,tick,tick,na,tick,tick,na,0,na,na,tick,tick,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,tick,na,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,48mg,tick,6 weeks,tick,tick,na,na,tick,na,tick,na,tick,na,na,na,tick,na,tick,na,na,tick,na,na,na,tick,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,tick,tick,na,na,na,na,87999463.0,Continuous,107740.0,113628121.0,1.0,13669960.0,0.0,13756694.0,Covi Anxiety Scale Verbal,1871.0,weeks,0,0 weeks,37282.0,0.0,Isocarboxazid,,Giller (1982),,13.0,3.8,0.6,0.0,Isocarboxazid,*Covi Anxiety Scale Verbal
87999463,Monoamine oxidase inhibitor-responsive depression.,Psychiatry research,Giller (1982),1982,"Giller E, Bialos D, Riddle M, Sholomskas A, and Harkness L (1982) Monoamine oxidase inhibitor-responsive depression.. Psychiatry research 6(1), 41-8","[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Giller,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1982)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""VA research funds,""\n""NIMH Grant MH-30939, a""\n""nd Hoffman-LaRoche.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,na,na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Inclusion criteria included dysphoricmood\n(depressed,\nof\nsad, blue, hopeless,""\n""low, down in the dumps, irritable), anxiety, somatic symptoms of anxiety, a Hamilton Depres-\nsion Scale (24 items) sum equal to or greater than 20, and a Covi anxiety score equal to or greater\nthan 8. The Covi anxiety scale consists of three items: verbal report, observed behavior, and\nsomatic symptoms. These were rated 1 (not at all) to 5 (very much). The duration of the current\nepisode was at least 1 month. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Excluded were patients with schizophrenia, mania, alcoholism, drug d""\n""ependency,""\n""organic brain syndrome, or obsessive compulsive neuro-""\n""sis, as well as those with marked suicidal ideation,""\n""convulsive disorder, moderate to severe""\n""cardiovascular\ndisease, electroconvulsive""\n""therapy within the previous month,""\n""tricyclic treat-""\n""ment within the previous 14 days, or""\n""benzodiazepine""\n""within the previous 7 days.\ntreatment[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,50.3,na,na,30,0,na,na,Predominantly white,na,na,Depression,Anxiety,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Giller, 1982",tick,10.8,28-64,na,na,na,na,na,na,na,na,37282,Isocarboxazid,na,na,na,na,tick,tick,na,tick,tick,na,0,na,na,tick,tick,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,tick,na,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,48mg,tick,6 weeks,tick,tick,na,na,tick,na,tick,na,tick,na,na,na,tick,na,tick,na,na,tick,na,na,na,tick,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,tick,tick,na,na,na,na,87999463.0,Continuous,107741.0,113628121.0,1.0,13669960.0,0.0,13756694.0,Covi Anxiety Scale Verbal,1872.0,weeks,6,6 weeks,37282.0,0.0,Isocarboxazid,,Giller (1982),,13.0,2.2,1.4,0.0,Isocarboxazid,*Covi Anxiety Scale Verbal
87999463,Monoamine oxidase inhibitor-responsive depression.,Psychiatry research,Giller (1982),1982,"Giller E, Bialos D, Riddle M, Sholomskas A, and Harkness L (1982) Monoamine oxidase inhibitor-responsive depression.. Psychiatry research 6(1), 41-8","[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Giller,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1982)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""VA research funds,""\n""NIMH Grant MH-30939, a""\n""nd Hoffman-LaRoche.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,na,na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Inclusion criteria included dysphoricmood\n(depressed,\nof\nsad, blue, hopeless,""\n""low, down in the dumps, irritable), anxiety, somatic symptoms of anxiety, a Hamilton Depres-\nsion Scale (24 items) sum equal to or greater than 20, and a Covi anxiety score equal to or greater\nthan 8. The Covi anxiety scale consists of three items: verbal report, observed behavior, and\nsomatic symptoms. These were rated 1 (not at all) to 5 (very much). The duration of the current\nepisode was at least 1 month. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Excluded were patients with schizophrenia, mania, alcoholism, drug d""\n""ependency,""\n""organic brain syndrome, or obsessive compulsive neuro-""\n""sis, as well as those with marked suicidal ideation,""\n""convulsive disorder, moderate to severe""\n""cardiovascular\ndisease, electroconvulsive""\n""therapy within the previous month,""\n""tricyclic treat-""\n""ment within the previous 14 days, or""\n""benzodiazepine""\n""within the previous 7 days.\ntreatment[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,50.3,na,na,30,0,na,na,Predominantly white,na,na,Depression,Anxiety,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Giller, 1982",tick,10.8,28-64,na,na,na,na,na,na,na,na,37282,Isocarboxazid,na,na,na,na,tick,tick,na,tick,tick,na,0,na,na,tick,tick,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,tick,na,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,48mg,tick,6 weeks,tick,tick,na,na,tick,na,tick,na,tick,na,na,na,tick,na,tick,na,na,tick,na,na,na,tick,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,tick,tick,na,na,na,na,87999463.0,Continuous,107742.0,113628121.0,1.0,13669960.0,0.0,13756695.0,Covi Anxiety Scale Somatic,1871.0,weeks,0,0 weeks,37282.0,0.0,Isocarboxazid,,Giller (1982),,13.0,3.4,0.5,0.0,Isocarboxazid,*Covi Anxiety Scale Somatic
87999463,Monoamine oxidase inhibitor-responsive depression.,Psychiatry research,Giller (1982),1982,"Giller E, Bialos D, Riddle M, Sholomskas A, and Harkness L (1982) Monoamine oxidase inhibitor-responsive depression.. Psychiatry research 6(1), 41-8","[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Giller,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1982)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""USA.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""VA research funds,""\n""NIMH Grant MH-30939, a""\n""nd Hoffman-LaRoche.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,na,na,na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Inclusion criteria included dysphoricmood\n(depressed,\nof\nsad, blue, hopeless,""\n""low, down in the dumps, irritable), anxiety, somatic symptoms of anxiety, a Hamilton Depres-\nsion Scale (24 items) sum equal to or greater than 20, and a Covi anxiety score equal to or greater\nthan 8. The Covi anxiety scale consists of three items: verbal report, observed behavior, and\nsomatic symptoms. These were rated 1 (not at all) to 5 (very much). The duration of the current\nepisode was at least 1 month. E[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050750, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Excluded were patients with schizophrenia, mania, alcoholism, drug d""\n""ependency,""\n""organic brain syndrome, or obsessive compulsive neuro-""\n""sis, as well as those with marked suicidal ideation,""\n""convulsive disorder, moderate to severe""\n""cardiovascular\ndisease, electroconvulsive""\n""therapy within the previous month,""\n""tricyclic treat-""\n""ment within the previous 14 days, or""\n""benzodiazepine""\n""within the previous 7 days.\ntreatment[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Giller E et al. - 1982 - Monoamine oxidase inhibitor-responsive depression..pdf', 'ItemArm': ''}]",na,na,50.3,na,na,30,0,na,na,Predominantly white,na,na,Depression,Anxiety,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Giller, 1982",tick,10.8,28-64,na,na,na,na,na,na,na,na,37282,Isocarboxazid,na,na,na,na,tick,tick,na,tick,tick,na,0,na,na,tick,tick,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,tick,na,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,48mg,tick,6 weeks,tick,tick,na,na,tick,na,tick,na,tick,na,na,na,tick,na,tick,na,na,tick,na,na,na,tick,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,tick,tick,na,na,na,na,87999463.0,Continuous,107743.0,113628121.0,1.0,13669960.0,0.0,13756695.0,Covi Anxiety Scale Somatic,1872.0,weeks,6,6 weeks,37282.0,0.0,Isocarboxazid,,Giller (1982),,13.0,1.9,1.1,0.0,Isocarboxazid,*Covi Anxiety Scale Somatic
87999298,Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly.,Biological psychiatry,Georgotas (1986),1986,"Georgotas A, McCue R E, Hapworth W, Friedman E, Kim O M, Welkowitz J, Chang I, and Cooper T B (1986) Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly.. Biological psychiatry 21(12), 1155-66","[{'ItemDocumentId': 1050699, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Georgotas,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Georgotas A et al. - 1986 - Comparative efficacy and safety of MAOIs versus TC.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050699, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1986[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Georgotas A et al. - 1986 - Comparative efficacy and safety of MAOIs versus TC.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050699, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Supported in pat by NIMH Grant MH351% (A.G.).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Georgotas A et al. - 1986 - Comparative efficacy and safety of MAOIs versus TC.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1050699, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Men and women, 55 years of age and older,""\n""diagnosed by two psychiatrists as suffering from a major depressive disorder as defined by the Research Diagnostic Criteria (Spitzer et al. 1978). A score of 16 or greater on the Hamilton Rating Scale for Depression was also required for inclusion.""\n""Patients\ninctuded in the study were independently d""\n"". The depressive subtype (endogenous/nonendogenous) according\nto RDC was also ascertained.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Georgotas A et al. - 1986 - Comparative efficacy and safety of MAOIs versus TC.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050699, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if they showed evidence of moderate to severe dementia, drug\nor alcohol dependence as defined by DSM-III, mental re~rdat~on, serious n~urologicai\ndisorders, other preexisting major psychiatric disorders, serious medicaf illness, urinary\nretention, narrow-angle glaucoma, or supersensitivity to TCAs or MAOIs. The severity[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Georgotas A et al. - 1986 - Comparative efficacy and safety of MAOIs versus TC.pdf', 'ItemArm': ''}]",na,na,na,na,na,90,na,na,na,na,na,na,Major depressive disorder as defined by the Research Diagnostic Criteria (Spitzer et al.1978),Patients with chronic illnesses that were under control were included provided that they met the other criteria and had obtained clearance from their personal physician.,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Georgotas, 1986",na,na,na,na,na,na,na,na,na,na,na,37294,Placebo,tick,na,na,na,64.70,na,na,28,na,na,15,na,na,white=27;black=1,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,12,na,na,0,na,na,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Drowsiness=3;Tremor=0;Dry mouth=10;Constipation=3;Micturition=1;Diarrhea=4;Syncope/dizziness=10;Orthostatic effects=6;Dermatological=2,na,na,na,na,7 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,7.60,55-75,na,na,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999298,Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly.,Biological psychiatry,Georgotas (1986),1986,"Georgotas A, McCue R E, Hapworth W, Friedman E, Kim O M, Welkowitz J, Chang I, and Cooper T B (1986) Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly.. Biological psychiatry 21(12), 1155-66","[{'ItemDocumentId': 1050699, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Georgotas,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Georgotas A et al. - 1986 - Comparative efficacy and safety of MAOIs versus TC.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050699, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1986[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Georgotas A et al. - 1986 - Comparative efficacy and safety of MAOIs versus TC.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050699, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Supported in pat by NIMH Grant MH351% (A.G.).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Georgotas A et al. - 1986 - Comparative efficacy and safety of MAOIs versus TC.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1050699, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Men and women, 55 years of age and older,""\n""diagnosed by two psychiatrists as suffering from a major depressive disorder as defined by the Research Diagnostic Criteria (Spitzer et al. 1978). A score of 16 or greater on the Hamilton Rating Scale for Depression was also required for inclusion.""\n""Patients\ninctuded in the study were independently d""\n"". The depressive subtype (endogenous/nonendogenous) according\nto RDC was also ascertained.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Georgotas A et al. - 1986 - Comparative efficacy and safety of MAOIs versus TC.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050699, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded if they showed evidence of moderate to severe dementia, drug\nor alcohol dependence as defined by DSM-III, mental re~rdat~on, serious n~urologicai\ndisorders, other preexisting major psychiatric disorders, serious medicaf illness, urinary\nretention, narrow-angle glaucoma, or supersensitivity to TCAs or MAOIs. The severity[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Georgotas A et al. - 1986 - Comparative efficacy and safety of MAOIs versus TC.pdf', 'ItemArm': ''}]",na,na,na,na,na,90,na,na,na,na,na,na,Major depressive disorder as defined by the Research Diagnostic Criteria (Spitzer et al.1978),Patients with chronic illnesses that were under control were included provided that they met the other criteria and had obtained clearance from their personal physician.,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Georgotas, 1986",na,na,na,na,na,na,na,na,na,na,na,37295,Phenelzine,tick,na,na,na,65.50,na,na,22,na,na,13,na,na,white=21;black=1,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,4,na,na,2,na,na,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Drowsiness=10;Tremor=3;Dry mouth=13;Constipation=6;Micturition=7;Diarrhea=6;Syncope/dizziness=11;Orthostatic effects=10;Dermatological=4,na,tick,53.90mg,tick,7 weeks,tick,tick,na,na,na,tick,na,tick,tick,na,na,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,4.4,56-72,na,na,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999367,A double-blind study of bupropion and placebo in depression.,The American journal of psychiatry,Feighner (1984),1984,"Feighner J P, Meredith C H, Stern W C, Hendrickson G, and Miller L L (1984) A double-blind study of bupropion and placebo in depression.. The American journal of psychiatry 141(4), 525-9",Feighner,na,na,1984,na,tick,tick,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,"Hospitalized patients with depression had to meet a standard set of inclusion criteria. Those with marked to severe major depressive disorder had to meet the diagnostic criteria of Feighner and associates (7) for primary depression. Although their diagnostic profiles were not quantitated, virtually all patients met the Research Diagnostic Criteria (RDC) for endogenous depression.",na,"Antecedent psychiatric illness, active suicidal behaviour, organic disease of the CNS, dementia, muteness, history of seizures, pregnancy, lactation, refusal to employ contraceptives, hypersensitivity to antidepressants, significantly abnormal ECG and clinical laboratory test results, age under 18 years, and refusal to sign an informed consent form.",na,na,na,na,na,tick,na,na,na,na,na,na,MDD,tick,tick,na,Not permitted aside from chloral hydrate,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Feigner, 1984",na,na,na,na,na,na,na,na,na,na,na,37277,Placebo,na,na,na,na,49.00,na,na,22,na,na,19,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,7,na,na,3,na,na,na,tick,tick,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,4 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,3x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,22-78,na,na,tick,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999367,A double-blind study of bupropion and placebo in depression.,The American journal of psychiatry,Feighner (1984),1984,"Feighner J P, Meredith C H, Stern W C, Hendrickson G, and Miller L L (1984) A double-blind study of bupropion and placebo in depression.. The American journal of psychiatry 141(4), 525-9",Feighner,na,na,1984,na,tick,tick,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,"Hospitalized patients with depression had to meet a standard set of inclusion criteria. Those with marked to severe major depressive disorder had to meet the diagnostic criteria of Feighner and associates (7) for primary depression. Although their diagnostic profiles were not quantitated, virtually all patients met the Research Diagnostic Criteria (RDC) for endogenous depression.",na,"Antecedent psychiatric illness, active suicidal behaviour, organic disease of the CNS, dementia, muteness, history of seizures, pregnancy, lactation, refusal to employ contraceptives, hypersensitivity to antidepressants, significantly abnormal ECG and clinical laboratory test results, age under 18 years, and refusal to sign an informed consent form.",na,na,na,na,na,tick,na,na,na,na,na,na,MDD,tick,tick,na,Not permitted aside from chloral hydrate,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Feigner, 1984",na,na,na,na,na,na,na,na,na,na,na,37278,Bupropion,na,na,na,na,43.90,na,na,44,na,na,30,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,10,na,na,8,na,na,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,300mg,392mg,600mg,4 weeks,tick,600mg,na,na,na,tick,na,na,na,na,na,na,na,na,3x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,20-70,na,na,tick,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87998150,"Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.",The Journal of clinical psychiatry,Feiger (2006),2006,"Feiger Alan D, Rickels Karl, Rynn Moira A, Zimbroff Dan L, and Robinson Donald S (2006) Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.. The Journal of clinical psychiatry 67(9), 1354-61","[{'ItemDocumentId': 1050777, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Feiger[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Feiger Alan D et al. - 2006 - Selegiline transdermal system for the treatment of.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050777, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Feiger Alan D et al. - 2006 - Selegiline transdermal system for the treatment of.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050777, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""This research was supported by a grant from Somerset\nPharmaceuticals, Inc., Tampa, Fla. Funding for assistance\nwith manuscript editing was provided by Bristol-Myers Squibb.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Feiger Alan D et al. - 2006 - Selegiline transdermal system for the treatment of.pdf', 'ItemArm': ''}]",na,"""The study protocol was reviewed and approved by the institutional review board at each of the 3 study sites""",tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1050777, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Men and women, 18 years and older, meeting DSM-IV\ncriteria for MDD, single episode or recurrent, moderate to\nsevere, were eligible for enrollment in this study, which\nran from September 2001 through August 2002. A diagno-\nsis of MDD was made after psychiatric interview by an\nexperienced clinician and use of the semi-structured Mini-\nInternational Neuropsychiatric Interview. Scores of ≥ 20""\n""on the 17-item Hamilton Rating Scale for Depression""\n""(HAM-D17\n)""\n""and ≥ 4 (moderately ill) on the 7-point Clini-""\n""cal Global Impressions-Severity (CGI-S)""\n""scale were re-""\n""quired during screening and at the baseline visit. Duration\nof the index depressive episode must have been at least\n2 months but not exceeding 2 years.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Feiger Alan D et al. - 2006 - Selegiline transdermal system for the treatment of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050777, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded from the trial for presence of a""\n""DSM-IV Axis I disorder other than MDD (except for dys-\nthymia) or an Axis II disorder that made it unlikely that\nthe patient would be compliant or treatment-responsive.\nPregnant and lactating women were excluded, and all\nwomen of childbearing age agreed to use a medically ac-\nceptable method of birth control during study treatment.\nOther exclusion criteria included unstable psychosocial\nsituations or recent Axis IV stressors; investigational drug\nuse within 60 days; nonresponse to a previous trial of an\nMAOI; known or suspected hypersensitivity to selegiline;\nand a clinically significant medical condition that might\naffect protocol implementation, including skin abnormali-\nties, serious central nervous system disorders""\n""(e.g., Alz-\nheimer’s disease, Parkinson’s disease, or epilepsy), and\nsignificant cardiovascular disease (i.e., unstable angina,\ncongestive heart failure, poorly regulated hypertension\n[diastolic blood pressure > 100 mm Hg]).\nConcomitant use of medications that could interact\nwith selegiline or alter mood and depressive symptoms\n(e.g., meperidine, dextromethorphan, other opioids, sym-\npathomimetic agents, antidepressants, antipsychotics,\nmood stabilizers) was prohibited. Patients were required\nto be free of psychoactive medications for at least 5 half-\nlives, usually 1 week (longer for fluoxetine), before start-\ning study medication. Zolpidem and chloral hydrate were\nallowed for sleep, as were chlorpheniramine""\n""diphenhy-\ndramine, loratadine, and fexofenadine.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Feiger Alan D et al. - 2006 - Selegiline transdermal system for the treatment of.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,tick,na,na,tick,Major depressive disorder according to DSM-IV criteria,Dysthymia,na,na,"Zolpidem and chloral hydrate were allowed for sleep, as were chlorpheniramine, diphenhydramine, loratadine, and fexofenadine.",na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2002,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Feiger, 2006",na,na,na,na,na,na,na,na,na,na,na,37127,Selegiline Transdermal System,tick,na,na,na,42.00,na,na,132,na,na,81,na,na,white=106,na,na,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,32,na,na,9,na,na,na,tick,tick,tick,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,Application-site reaction=53;Insomnia=40;Infection=18;Dizziness=17;Dry mouth=16;Nervousness=13;Diarrhea=13,na,6.00mg,tick,12.00mg,8 weeks,6.00mg,12.00mg,na,na,na,na,na,na,na,na,na,na,na,na,1 per day,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,105,na,na,tick,na,tick,na,na,na,na,na,na,na,na,87998150.0,Continuous,106807.0,113197242.0,1.0,13669983.0,0.0,13670000.0,HAM-D,1758.0,weeks,0,0 weeks,37127.0,0.0,Selegiline Transdermal System,,Feiger (2006),,129.0,28.3,3.7,0.0,Selegiline,HAM-D
87998150,"Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.",The Journal of clinical psychiatry,Feiger (2006),2006,"Feiger Alan D, Rickels Karl, Rynn Moira A, Zimbroff Dan L, and Robinson Donald S (2006) Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.. The Journal of clinical psychiatry 67(9), 1354-61","[{'ItemDocumentId': 1050777, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Feiger[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Feiger Alan D et al. - 2006 - Selegiline transdermal system for the treatment of.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050777, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Feiger Alan D et al. - 2006 - Selegiline transdermal system for the treatment of.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050777, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""This research was supported by a grant from Somerset\nPharmaceuticals, Inc., Tampa, Fla. Funding for assistance\nwith manuscript editing was provided by Bristol-Myers Squibb.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Feiger Alan D et al. - 2006 - Selegiline transdermal system for the treatment of.pdf', 'ItemArm': ''}]",na,"""The study protocol was reviewed and approved by the institutional review board at each of the 3 study sites""",tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1050777, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Men and women, 18 years and older, meeting DSM-IV\ncriteria for MDD, single episode or recurrent, moderate to\nsevere, were eligible for enrollment in this study, which\nran from September 2001 through August 2002. A diagno-\nsis of MDD was made after psychiatric interview by an\nexperienced clinician and use of the semi-structured Mini-\nInternational Neuropsychiatric Interview. Scores of ≥ 20""\n""on the 17-item Hamilton Rating Scale for Depression""\n""(HAM-D17\n)""\n""and ≥ 4 (moderately ill) on the 7-point Clini-""\n""cal Global Impressions-Severity (CGI-S)""\n""scale were re-""\n""quired during screening and at the baseline visit. Duration\nof the index depressive episode must have been at least\n2 months but not exceeding 2 years.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Feiger Alan D et al. - 2006 - Selegiline transdermal system for the treatment of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050777, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded from the trial for presence of a""\n""DSM-IV Axis I disorder other than MDD (except for dys-\nthymia) or an Axis II disorder that made it unlikely that\nthe patient would be compliant or treatment-responsive.\nPregnant and lactating women were excluded, and all\nwomen of childbearing age agreed to use a medically ac-\nceptable method of birth control during study treatment.\nOther exclusion criteria included unstable psychosocial\nsituations or recent Axis IV stressors; investigational drug\nuse within 60 days; nonresponse to a previous trial of an\nMAOI; known or suspected hypersensitivity to selegiline;\nand a clinically significant medical condition that might\naffect protocol implementation, including skin abnormali-\nties, serious central nervous system disorders""\n""(e.g., Alz-\nheimer’s disease, Parkinson’s disease, or epilepsy), and\nsignificant cardiovascular disease (i.e., unstable angina,\ncongestive heart failure, poorly regulated hypertension\n[diastolic blood pressure > 100 mm Hg]).\nConcomitant use of medications that could interact\nwith selegiline or alter mood and depressive symptoms\n(e.g., meperidine, dextromethorphan, other opioids, sym-\npathomimetic agents, antidepressants, antipsychotics,\nmood stabilizers) was prohibited. Patients were required\nto be free of psychoactive medications for at least 5 half-\nlives, usually 1 week (longer for fluoxetine), before start-\ning study medication. Zolpidem and chloral hydrate were\nallowed for sleep, as were chlorpheniramine""\n""diphenhy-\ndramine, loratadine, and fexofenadine.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Feiger Alan D et al. - 2006 - Selegiline transdermal system for the treatment of.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,tick,na,na,tick,Major depressive disorder according to DSM-IV criteria,Dysthymia,na,na,"Zolpidem and chloral hydrate were allowed for sleep, as were chlorpheniramine, diphenhydramine, loratadine, and fexofenadine.",na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2002,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Feiger, 2006",na,na,na,na,na,na,na,na,na,na,na,37127,Selegiline Transdermal System,tick,na,na,na,42.00,na,na,132,na,na,81,na,na,white=106,na,na,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,32,na,na,9,na,na,na,tick,tick,tick,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,Application-site reaction=53;Insomnia=40;Infection=18;Dizziness=17;Dry mouth=16;Nervousness=13;Diarrhea=13,na,6.00mg,tick,12.00mg,8 weeks,6.00mg,12.00mg,na,na,na,na,na,na,na,na,na,na,na,na,1 per day,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,105,na,na,tick,na,tick,na,na,na,na,na,na,na,na,87998150.0,Continuous,106808.0,113197242.0,1.0,13669983.0,0.0,13670000.0,HAM-D,0.0,,,,37127.0,0.0,Selegiline Transdermal System,,Feiger (2006),,129.0,19.1,7.0,0.0,Selegiline,HAM-D
87998150,"Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.",The Journal of clinical psychiatry,Feiger (2006),2006,"Feiger Alan D, Rickels Karl, Rynn Moira A, Zimbroff Dan L, and Robinson Donald S (2006) Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.. The Journal of clinical psychiatry 67(9), 1354-61","[{'ItemDocumentId': 1050777, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Feiger[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Feiger Alan D et al. - 2006 - Selegiline transdermal system for the treatment of.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050777, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2006[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Feiger Alan D et al. - 2006 - Selegiline transdermal system for the treatment of.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050777, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""This research was supported by a grant from Somerset\nPharmaceuticals, Inc., Tampa, Fla. Funding for assistance\nwith manuscript editing was provided by Bristol-Myers Squibb.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Feiger Alan D et al. - 2006 - Selegiline transdermal system for the treatment of.pdf', 'ItemArm': ''}]",na,"""The study protocol was reviewed and approved by the institutional review board at each of the 3 study sites""",tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1050777, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Men and women, 18 years and older, meeting DSM-IV\ncriteria for MDD, single episode or recurrent, moderate to\nsevere, were eligible for enrollment in this study, which\nran from September 2001 through August 2002. A diagno-\nsis of MDD was made after psychiatric interview by an\nexperienced clinician and use of the semi-structured Mini-\nInternational Neuropsychiatric Interview. Scores of ≥ 20""\n""on the 17-item Hamilton Rating Scale for Depression""\n""(HAM-D17\n)""\n""and ≥ 4 (moderately ill) on the 7-point Clini-""\n""cal Global Impressions-Severity (CGI-S)""\n""scale were re-""\n""quired during screening and at the baseline visit. Duration\nof the index depressive episode must have been at least\n2 months but not exceeding 2 years.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Feiger Alan D et al. - 2006 - Selegiline transdermal system for the treatment of.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050777, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded from the trial for presence of a""\n""DSM-IV Axis I disorder other than MDD (except for dys-\nthymia) or an Axis II disorder that made it unlikely that\nthe patient would be compliant or treatment-responsive.\nPregnant and lactating women were excluded, and all\nwomen of childbearing age agreed to use a medically ac-\nceptable method of birth control during study treatment.\nOther exclusion criteria included unstable psychosocial\nsituations or recent Axis IV stressors; investigational drug\nuse within 60 days; nonresponse to a previous trial of an\nMAOI; known or suspected hypersensitivity to selegiline;\nand a clinically significant medical condition that might\naffect protocol implementation, including skin abnormali-\nties, serious central nervous system disorders""\n""(e.g., Alz-\nheimer’s disease, Parkinson’s disease, or epilepsy), and\nsignificant cardiovascular disease (i.e., unstable angina,\ncongestive heart failure, poorly regulated hypertension\n[diastolic blood pressure > 100 mm Hg]).\nConcomitant use of medications that could interact\nwith selegiline or alter mood and depressive symptoms\n(e.g., meperidine, dextromethorphan, other opioids, sym-\npathomimetic agents, antidepressants, antipsychotics,\nmood stabilizers) was prohibited. Patients were required\nto be free of psychoactive medications for at least 5 half-\nlives, usually 1 week (longer for fluoxetine), before start-\ning study medication. Zolpidem and chloral hydrate were\nallowed for sleep, as were chlorpheniramine""\n""diphenhy-\ndramine, loratadine, and fexofenadine.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Feiger Alan D et al. - 2006 - Selegiline transdermal system for the treatment of.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,tick,na,na,tick,Major depressive disorder according to DSM-IV criteria,Dysthymia,na,na,"Zolpidem and chloral hydrate were allowed for sleep, as were chlorpheniramine, diphenhydramine, loratadine, and fexofenadine.",na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2002,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Feiger, 2006",na,na,na,na,na,na,na,na,na,na,na,37128,Placebo,tick,na,na,na,42.00,na,na,133,na,na,71,na,na,white=108,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,27,na,na,3,na,na,na,tick,tick,tick,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,Application-site reaction=27;Insomnia=19;Infection=17;Dizziness=9;Dry mouth=10;Nervousness=8;Diarrhea=5,na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1 per day,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,98,na,na,tick,na,tick,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87997132,"A double-blind, placebo-controlled study of selegiline transdermal system in depressed adolescents.",Journal of child and adolescent psychopharmacology,DelBello (2014),2014,"DelBello Melissa P, Hochadel Thomas J, Portland Kimberly Blanchard, Azzaro Albert J, Katic Alain, Khan Arif, and Emslie Graham (2014) A double-blind, placebo-controlled study of selegiline transdermal system in depressed adolescents.. Journal of child and adolescent psychopharmacology 24(6), 311-7 DOI: https://dx.doi.org/10.1089/cap.2013.0138","[{'ItemDocumentId': 1050660, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""DelBello,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'DelBello (2014).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050660, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2014[¬e]""', 'IsFromPDF': True, 'DocTitle': 'DelBello (2014).pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050660, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Funding: This study was sponsored by Somerset Pharmaceutical, Inc., Tampa, FL (acquired by Mylan Specialty L.P., Baskin Ridge, NJ).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'DelBello (2014).pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,Conducted at 26 clinical investigational sites,na,tick,na,na,"[{'ItemDocumentId': 1050660, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Outpatients, 12–17 years of age, who met the criteria for mod-\nerate to severe MDD, based upon the Kiddie Schedule for Affective\nDisorders and Schizophrenia for School Aged Children (K-SADS)\nsemistructured psychiatric interview, and a Children’s Depression""\n""Rating Scale-Revised (CDRS-R) score of ‡ 45, were eligible for\nenrollment. Subjects were included who had a current episode of\nMDD of at least 2 months’ duration, but not more than 2 years’\nduration.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'DelBello (2014).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050660, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Subjects were included who had a current episode of\nMDD of at least 2 months’ duration, but not more than 2 years’\nduration. Patients were excluded if they had psychotic features,\nanother primary American Psychiatric Association, Diagnostic and\nStatistical Manual of Mental Disorders, 4th ed., Text Revision\n(DSM-IV-TR) Axis-I or Axis-II diagnosis, a diagnosis of conduct\ndisorder, or a history of a substance use disorder, as deﬁned by\nDSM-IV-TR criteria (American Psychiatric Association 2000). In\naddition, patients were excluded if they had a medical illness that\ncould compromise their safety or the interpretation of the results.\nGirls who were pregnant or breast-feeding were excluded, and all\nother girls were required to use a reliable method of contraception\nto remain in the trial[¬e]""', 'IsFromPDF': True, 'DocTitle': 'DelBello (2014).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"Moderate or severe Major Depressive Disorder. [{'ItemDocumentId': 1050660, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""moderate or severe MDD.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'DelBello (2014).pdf', 'ItemArm': ''}]",None,na,na,None,na,na,na,na,na,na,na,na,na,na,na,na,na,93.00,na,na,15.00,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,12 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,"DelBello, 2014;Nakonezny, 2015",na,na,na,na,na,na,na,na,na,na,na,37240,Placebo,tick,na,na,tick,14.70,na,na,156,na,na,104,na,na,Caucasian=77;Black=34;Hispanic=37;Asian=2;Native American=1;Mixed race=5,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,42,na,na,5,na,na,na,tick,tick,tick,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,"Gastrointestinal disorders=31;Abdominal pain=4;Abdominal pain upper=7;Diarrhea=7;Nausea=12;Vomiting=4;General disorders & administration site conditions=42;Application site reaction=34;Fatigue=4;Infections and infestations=18;Nasopharyngitis=7;Metabolism and nutrition disorders=4;Decreased appetite =2;Musculoskeletal & connective tissue disorders=9;Back pain=4;Nervous system disorders=11;Dizziness=7;Headache=26;Somnolence=4;Psychiatric disorders17;Agitation=3;Anxiety=2;Insomnia=4;Irritability=4;Suicidal ideation=4;Respiratory, thoracic & mediastinal disorders=12;Pharyngolaryngeal pain=3;Upper respiratory tract infection=4",na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1 per day,na,na,na,na,na,na,na,na,na,"medication-induced agitation;agitation;uncontrollable screaming;vomiting;loss of consciousness;hospitalization for
mood swings;suicidal ideation;gastritis;anxiety;syn-
cope;orthostatic hypotension;psychotic break",na,na,na,na,na,na,na,na,na,na,na,na,na,1.6,1.60,na,na,na,90,na,na,tick,na,tick,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87997132,"A double-blind, placebo-controlled study of selegiline transdermal system in depressed adolescents.",Journal of child and adolescent psychopharmacology,DelBello (2014),2014,"DelBello Melissa P, Hochadel Thomas J, Portland Kimberly Blanchard, Azzaro Albert J, Katic Alain, Khan Arif, and Emslie Graham (2014) A double-blind, placebo-controlled study of selegiline transdermal system in depressed adolescents.. Journal of child and adolescent psychopharmacology 24(6), 311-7 DOI: https://dx.doi.org/10.1089/cap.2013.0138","[{'ItemDocumentId': 1050660, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""DelBello,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'DelBello (2014).pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050660, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2014[¬e]""', 'IsFromPDF': True, 'DocTitle': 'DelBello (2014).pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050660, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Funding: This study was sponsored by Somerset Pharmaceutical, Inc., Tampa, FL (acquired by Mylan Specialty L.P., Baskin Ridge, NJ).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'DelBello (2014).pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,Conducted at 26 clinical investigational sites,na,tick,na,na,"[{'ItemDocumentId': 1050660, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Outpatients, 12–17 years of age, who met the criteria for mod-\nerate to severe MDD, based upon the Kiddie Schedule for Affective\nDisorders and Schizophrenia for School Aged Children (K-SADS)\nsemistructured psychiatric interview, and a Children’s Depression""\n""Rating Scale-Revised (CDRS-R) score of ‡ 45, were eligible for\nenrollment. Subjects were included who had a current episode of\nMDD of at least 2 months’ duration, but not more than 2 years’\nduration.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'DelBello (2014).pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050660, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Subjects were included who had a current episode of\nMDD of at least 2 months’ duration, but not more than 2 years’\nduration. Patients were excluded if they had psychotic features,\nanother primary American Psychiatric Association, Diagnostic and\nStatistical Manual of Mental Disorders, 4th ed., Text Revision\n(DSM-IV-TR) Axis-I or Axis-II diagnosis, a diagnosis of conduct\ndisorder, or a history of a substance use disorder, as deﬁned by\nDSM-IV-TR criteria (American Psychiatric Association 2000). In\naddition, patients were excluded if they had a medical illness that\ncould compromise their safety or the interpretation of the results.\nGirls who were pregnant or breast-feeding were excluded, and all\nother girls were required to use a reliable method of contraception\nto remain in the trial[¬e]""', 'IsFromPDF': True, 'DocTitle': 'DelBello (2014).pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"Moderate or severe Major Depressive Disorder. [{'ItemDocumentId': 1050660, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""moderate or severe MDD.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'DelBello (2014).pdf', 'ItemArm': ''}]",None,na,na,None,na,na,na,na,na,na,na,na,na,na,na,na,na,93.00,na,na,15.00,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,12 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,"DelBello, 2014;Nakonezny, 2015",na,na,na,na,na,na,na,na,na,na,na,37241,Selegiline,tick,na,tick,na,14.80,na,na,152,na,na,93,na,na,Caucasian=69;Black=46;Hispanic=32;Asian=1;Native;American=1;Mixed race=3,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,tick,na,na,51,na,na,10,na,na,na,tick,tick,tick,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,"Gastrointestinal disorders=31;Abdominal pain=3;Abdominal pain upper=4;Diarrhea=5;Nausea=11;Vomiting=7;General disorders & administration site conditions=42
Application site reaction=37;Fatigue=4;Infections and infestations=18;Nasopharyngitis=6;Metabolism and nutrition disorders=6;Decreased appetite =5;Musculoskeletal & connective tissue disorders=13;Back pain=4;Nervous system disorders=41;Dizziness=8;Headache=26;Somnolence=7;Psychiatric disorders=24;Agitation=4;Anxiety=4;Insomnia=9;Irritability=2;Suicidal ideation=4;Respiratory, thoracic & mediastinal disorders=25;Pharyngolaryngeal pain=4;Upper respiratory tract infection=11",na,tick,tick,tick,12 weeks,6.00mg,12.00mg,na,na,na,na,na,na,tick,na,tick,na,tick,na,1 per day,na,na,na,na,na,na,na,na,na,"medication-induced agitation;agitation;uncontrollable screaming;vomiting;loss of consciousness;hospitalization for
mood swings;suicidal ideation;gastritis;anxiety;syn-
cope;orthostatic hypotension;psychotic break",na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,1.62,na,na,na,95,na,na,tick,na,tick,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999240,"An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.",Archives of general psychiatry,Davidson (1988),1988,"Davidson J R, Giller E L, Zisook S, and Overall J E (1988) An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.. Archives of general psychiatry 45(2), 120-7","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Davidson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1988[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 8:\n[¬s]""supported in part by Hoffmann La Roche[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""(1)\nResearch Diagnostic Criteria (RDC) major or minor depression21;\n(2) a minimum score of 20 on the expanded 24-item version of the\nHamilton scale22; (3) a minimum score of 8 on the Covi Anxiety\nScale,23 with a minimum score of3 on the somatic component of this\nscale; (4) depression lasting at least four weeks; (5) age between 18\nand 65 years; (6) the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Depression,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Davidson, 1988",na,na,na,na,na,na,na,na,na,na,na,37244,Isocarboxazid,na,na,na,na,41.9,na,na,68,na,na,37,na,na,white=50;black=14;oriental=4,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,39,na,na,10,na,na,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,49.3mg,tick,6 weeks,tick,tick,na,na,tick,na,tick,na,tick,na,na,na,tick,na,tick,na,tick,na,na,tick,tick,tick,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999240.0,Continuous,107707.0,113615477.0,1.0,13669960.0,0.0,13709935.0,Covi Anxiety Scale Total,1845.0,weeks,0,0 weeks,37244.0,0.0,Isocarboxazid,,Davidson (1988),LSMeans,68.0,10.23,99999.0,0.0,Isocarboxazid,*Covi Anxiety Scale Total
87999240,"An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.",Archives of general psychiatry,Davidson (1988),1988,"Davidson J R, Giller E L, Zisook S, and Overall J E (1988) An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.. Archives of general psychiatry 45(2), 120-7","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Davidson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1988[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 8:\n[¬s]""supported in part by Hoffmann La Roche[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""(1)\nResearch Diagnostic Criteria (RDC) major or minor depression21;\n(2) a minimum score of 20 on the expanded 24-item version of the\nHamilton scale22; (3) a minimum score of 8 on the Covi Anxiety\nScale,23 with a minimum score of3 on the somatic component of this\nscale; (4) depression lasting at least four weeks; (5) age between 18\nand 65 years; (6) the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Depression,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Davidson, 1988",na,na,na,na,na,na,na,na,na,na,na,37244,Isocarboxazid,na,na,na,na,41.9,na,na,68,na,na,37,na,na,white=50;black=14;oriental=4,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,39,na,na,10,na,na,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,49.3mg,tick,6 weeks,tick,tick,na,na,tick,na,tick,na,tick,na,na,na,tick,na,tick,na,tick,na,na,tick,tick,tick,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999240.0,Continuous,107708.0,113615477.0,1.0,13669960.0,0.0,13709935.0,Covi Anxiety Scale Total,1846.0,weeks,6,6 weeks,37244.0,0.0,Isocarboxazid,,Davidson (1988),LSMeans,48.0,5.61,99999.0,0.0,Isocarboxazid,*Covi Anxiety Scale Total
87999240,"An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.",Archives of general psychiatry,Davidson (1988),1988,"Davidson J R, Giller E L, Zisook S, and Overall J E (1988) An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.. Archives of general psychiatry 45(2), 120-7","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Davidson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1988[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 8:\n[¬s]""supported in part by Hoffmann La Roche[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""(1)\nResearch Diagnostic Criteria (RDC) major or minor depression21;\n(2) a minimum score of 20 on the expanded 24-item version of the\nHamilton scale22; (3) a minimum score of 8 on the Covi Anxiety\nScale,23 with a minimum score of3 on the somatic component of this\nscale; (4) depression lasting at least four weeks; (5) age between 18\nand 65 years; (6) the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Depression,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Davidson, 1988",na,na,na,na,na,na,na,na,na,na,na,37244,Isocarboxazid,na,na,na,na,41.9,na,na,68,na,na,37,na,na,white=50;black=14;oriental=4,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,39,na,na,10,na,na,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,49.3mg,tick,6 weeks,tick,tick,na,na,tick,na,tick,na,tick,na,na,na,tick,na,tick,na,tick,na,na,tick,tick,tick,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999240.0,Continuous,107711.0,113615477.0,1.0,13669960.0,0.0,13709933.0,SCL-58 Anxiety subscale,1845.0,weeks,0,0 weeks,37244.0,0.0,Isocarboxazid,,Davidson (1988),,52.0,17.1,99999.0,0.0,Isocarboxazid,*SCL-58 Anxiety subscale
87999240,"An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.",Archives of general psychiatry,Davidson (1988),1988,"Davidson J R, Giller E L, Zisook S, and Overall J E (1988) An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.. Archives of general psychiatry 45(2), 120-7","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Davidson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1988[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 8:\n[¬s]""supported in part by Hoffmann La Roche[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""(1)\nResearch Diagnostic Criteria (RDC) major or minor depression21;\n(2) a minimum score of 20 on the expanded 24-item version of the\nHamilton scale22; (3) a minimum score of 8 on the Covi Anxiety\nScale,23 with a minimum score of3 on the somatic component of this\nscale; (4) depression lasting at least four weeks; (5) age between 18\nand 65 years; (6) the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Depression,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Davidson, 1988",na,na,na,na,na,na,na,na,na,na,na,37244,Isocarboxazid,na,na,na,na,41.9,na,na,68,na,na,37,na,na,white=50;black=14;oriental=4,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,39,na,na,10,na,na,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,49.3mg,tick,6 weeks,tick,tick,na,na,tick,na,tick,na,tick,na,na,na,tick,na,tick,na,tick,na,na,tick,tick,tick,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999240.0,Continuous,107712.0,113615477.0,1.0,13669960.0,0.0,13709933.0,SCL-58 Anxiety subscale,1846.0,weeks,6,6 weeks,37244.0,0.0,Isocarboxazid,,Davidson (1988),,52.0,12.6,99999.0,0.0,Isocarboxazid,*SCL-58 Anxiety subscale
87999240,"An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.",Archives of general psychiatry,Davidson (1988),1988,"Davidson J R, Giller E L, Zisook S, and Overall J E (1988) An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.. Archives of general psychiatry 45(2), 120-7","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Davidson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1988[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 8:\n[¬s]""supported in part by Hoffmann La Roche[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""(1)\nResearch Diagnostic Criteria (RDC) major or minor depression21;\n(2) a minimum score of 20 on the expanded 24-item version of the\nHamilton scale22; (3) a minimum score of 8 on the Covi Anxiety\nScale,23 with a minimum score of3 on the somatic component of this\nscale; (4) depression lasting at least four weeks; (5) age between 18\nand 65 years; (6) the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Depression,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Davidson, 1988",na,na,na,na,na,na,na,na,na,na,na,37244,Isocarboxazid,na,na,na,na,41.9,na,na,68,na,na,37,na,na,white=50;black=14;oriental=4,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,39,na,na,10,na,na,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,49.3mg,tick,6 weeks,tick,tick,na,na,tick,na,tick,na,tick,na,na,na,tick,na,tick,na,tick,na,na,tick,tick,tick,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999240.0,Continuous,107713.0,113615477.0,1.0,13669960.0,0.0,13709934.0,SCL-90 Anxiety subscale,1845.0,weeks,0,0 weeks,37244.0,0.0,Isocarboxazid,,Davidson (1988),,16.0,17.1,99999.0,0.0,Isocarboxazid,*SCL-90 Anxiety subscale
87999240,"An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.",Archives of general psychiatry,Davidson (1988),1988,"Davidson J R, Giller E L, Zisook S, and Overall J E (1988) An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.. Archives of general psychiatry 45(2), 120-7","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Davidson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1988[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 8:\n[¬s]""supported in part by Hoffmann La Roche[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""(1)\nResearch Diagnostic Criteria (RDC) major or minor depression21;\n(2) a minimum score of 20 on the expanded 24-item version of the\nHamilton scale22; (3) a minimum score of 8 on the Covi Anxiety\nScale,23 with a minimum score of3 on the somatic component of this\nscale; (4) depression lasting at least four weeks; (5) age between 18\nand 65 years; (6) the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Depression,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Davidson, 1988",na,na,na,na,na,na,na,na,na,na,na,37244,Isocarboxazid,na,na,na,na,41.9,na,na,68,na,na,37,na,na,white=50;black=14;oriental=4,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,39,na,na,10,na,na,na,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,49.3mg,tick,6 weeks,tick,tick,na,na,tick,na,tick,na,tick,na,na,na,tick,na,tick,na,tick,na,na,tick,tick,tick,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999240.0,Continuous,107714.0,113615477.0,1.0,13669960.0,0.0,13709934.0,SCL-90 Anxiety subscale,1846.0,weeks,6,6 weeks,37244.0,0.0,Isocarboxazid,,Davidson (1988),,16.0,6.5,99999.0,0.0,Isocarboxazid,*SCL-90 Anxiety subscale
87999240,"An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.",Archives of general psychiatry,Davidson (1988),1988,"Davidson J R, Giller E L, Zisook S, and Overall J E (1988) An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.. Archives of general psychiatry 45(2), 120-7","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Davidson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1988[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 8:\n[¬s]""supported in part by Hoffmann La Roche[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""(1)\nResearch Diagnostic Criteria (RDC) major or minor depression21;\n(2) a minimum score of 20 on the expanded 24-item version of the\nHamilton scale22; (3) a minimum score of 8 on the Covi Anxiety\nScale,23 with a minimum score of3 on the somatic component of this\nscale; (4) depression lasting at least four weeks; (5) age between 18\nand 65 years; (6) the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Depression,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Davidson, 1988",na,na,na,na,na,na,na,na,na,na,na,37245,Placebo,na,na,na,na,41.9,na,na,62,na,na,35,na,na,white=45;placebo=17;oriental=0,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,52,na,na,2,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,tick,tick,tick,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999240.0,Continuous,107705.0,113615477.0,1.0,13669974.0,0.0,13709935.0,Covi Anxiety Scale Total,1845.0,weeks,0,0 weeks,37245.0,0.0,Placebo,,Davidson (1988),LSMeans,62.0,9.88,99999.0,0.0,Placebo,*Covi Anxiety Scale Total
87999240,"An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.",Archives of general psychiatry,Davidson (1988),1988,"Davidson J R, Giller E L, Zisook S, and Overall J E (1988) An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.. Archives of general psychiatry 45(2), 120-7","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Davidson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1988[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 8:\n[¬s]""supported in part by Hoffmann La Roche[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""(1)\nResearch Diagnostic Criteria (RDC) major or minor depression21;\n(2) a minimum score of 20 on the expanded 24-item version of the\nHamilton scale22; (3) a minimum score of 8 on the Covi Anxiety\nScale,23 with a minimum score of3 on the somatic component of this\nscale; (4) depression lasting at least four weeks; (5) age between 18\nand 65 years; (6) the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Depression,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Davidson, 1988",na,na,na,na,na,na,na,na,na,na,na,37245,Placebo,na,na,na,na,41.9,na,na,62,na,na,35,na,na,white=45;placebo=17;oriental=0,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,52,na,na,2,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,tick,tick,tick,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999240.0,Continuous,107706.0,113615477.0,1.0,13669974.0,0.0,13709935.0,Covi Anxiety Scale Total,1846.0,weeks,6,6 weeks,37245.0,0.0,Placebo,,Davidson (1988),LSMeans,36.0,7.46,99999.0,0.0,Placebo,*Covi Anxiety Scale Total
87999240,"An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.",Archives of general psychiatry,Davidson (1988),1988,"Davidson J R, Giller E L, Zisook S, and Overall J E (1988) An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.. Archives of general psychiatry 45(2), 120-7","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Davidson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1988[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 8:\n[¬s]""supported in part by Hoffmann La Roche[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""(1)\nResearch Diagnostic Criteria (RDC) major or minor depression21;\n(2) a minimum score of 20 on the expanded 24-item version of the\nHamilton scale22; (3) a minimum score of 8 on the Covi Anxiety\nScale,23 with a minimum score of3 on the somatic component of this\nscale; (4) depression lasting at least four weeks; (5) age between 18\nand 65 years; (6) the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Depression,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Davidson, 1988",na,na,na,na,na,na,na,na,na,na,na,37245,Placebo,na,na,na,na,41.9,na,na,62,na,na,35,na,na,white=45;placebo=17;oriental=0,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,52,na,na,2,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,tick,tick,tick,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999240.0,Continuous,107709.0,113615477.0,1.0,13669974.0,0.0,13709933.0,SCL-58 Anxiety subscale,1845.0,weeks,0,0 weeks,37245.0,0.0,Placebo,,Davidson (1988),,48.0,15.6,99999.0,0.0,Placebo,*SCL-58 Anxiety subscale
87999240,"An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.",Archives of general psychiatry,Davidson (1988),1988,"Davidson J R, Giller E L, Zisook S, and Overall J E (1988) An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.. Archives of general psychiatry 45(2), 120-7","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Davidson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1988[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 8:\n[¬s]""supported in part by Hoffmann La Roche[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""(1)\nResearch Diagnostic Criteria (RDC) major or minor depression21;\n(2) a minimum score of 20 on the expanded 24-item version of the\nHamilton scale22; (3) a minimum score of 8 on the Covi Anxiety\nScale,23 with a minimum score of3 on the somatic component of this\nscale; (4) depression lasting at least four weeks; (5) age between 18\nand 65 years; (6) the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Depression,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Davidson, 1988",na,na,na,na,na,na,na,na,na,na,na,37245,Placebo,na,na,na,na,41.9,na,na,62,na,na,35,na,na,white=45;placebo=17;oriental=0,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,52,na,na,2,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,tick,tick,tick,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999240.0,Continuous,107710.0,113615477.0,1.0,13669974.0,0.0,13709933.0,SCL-58 Anxiety subscale,1846.0,weeks,6,6 weeks,37245.0,0.0,Placebo,,Davidson (1988),,48.0,13.4,99999.0,0.0,Placebo,*SCL-58 Anxiety subscale
87999240,"An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.",Archives of general psychiatry,Davidson (1988),1988,"Davidson J R, Giller E L, Zisook S, and Overall J E (1988) An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.. Archives of general psychiatry 45(2), 120-7","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Davidson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1988[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 8:\n[¬s]""supported in part by Hoffmann La Roche[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""(1)\nResearch Diagnostic Criteria (RDC) major or minor depression21;\n(2) a minimum score of 20 on the expanded 24-item version of the\nHamilton scale22; (3) a minimum score of 8 on the Covi Anxiety\nScale,23 with a minimum score of3 on the somatic component of this\nscale; (4) depression lasting at least four weeks; (5) age between 18\nand 65 years; (6) the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Depression,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Davidson, 1988",na,na,na,na,na,na,na,na,na,na,na,37245,Placebo,na,na,na,na,41.9,na,na,62,na,na,35,na,na,white=45;placebo=17;oriental=0,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,52,na,na,2,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,tick,tick,tick,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999240.0,Continuous,107715.0,113615477.0,1.0,13669974.0,0.0,13709934.0,SCL-90 Anxiety subscale,1845.0,weeks,0,0 weeks,37245.0,0.0,Placebo,,Davidson (1988),,14.0,20.8,99999.0,0.0,Placebo,*SCL-90 Anxiety subscale
87999240,"An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.",Archives of general psychiatry,Davidson (1988),1988,"Davidson J R, Giller E L, Zisook S, and Overall J E (1988) An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.. Archives of general psychiatry 45(2), 120-7","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Davidson[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1988[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 8:\n[¬s]""supported in part by Hoffmann La Roche[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""(1)\nResearch Diagnostic Criteria (RDC) major or minor depression21;\n(2) a minimum score of 20 on the expanded 24-item version of the\nHamilton scale22; (3) a minimum score of 8 on the Covi Anxiety\nScale,23 with a minimum score of3 on the somatic component of this\nscale; (4) depression lasting at least four weeks; (5) age between 18\nand 65 years; (6) the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Depression,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]","[{'ItemDocumentId': 1050677, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""the accompaniment of significant anxiety, somatic\ncomplaints, and phobic or\npanic symptoms.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Davidson J R et al. - 1988 - An efficacy study of isocarboxazid and placebo in .pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Davidson, 1988",na,na,na,na,na,na,na,na,na,na,na,37245,Placebo,na,na,na,na,41.9,na,na,62,na,na,35,na,na,white=45;placebo=17;oriental=0,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,52,na,na,2,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,tick,tick,tick,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87999240.0,Continuous,107716.0,113615477.0,1.0,13669974.0,0.0,13709934.0,SCL-90 Anxiety subscale,1846.0,weeks,6,6 weeks,37245.0,0.0,Placebo,,Davidson (1988),,14.0,13.6,99999.0,0.0,Placebo,*SCL-90 Anxiety subscale
87998692,A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.,Clinical therapeutics,Croft (1999),1999,"Croft H, Settle E Jr, Houser T, Batey S R, Donahue R M, and Ascher J A (1999) A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.. Clinical therapeutics 21(4), 643-58","[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Croft,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1999[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 14:\n[¬s]""Glaxo\nWellcome Inc.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""eligible for the study if they had a diag-\nnosis of moderate-to-severe depression\n(based on Diagnostic and Statistical Man-\nual of Mental Disorders, Fourth Edition\n[DSM-ZVJ criteria27 and a score of 2 18 on\nthe first 21 items of the 3 l-item Hamilton\nRating Scale for Depression [HAM-\nD]2829) at screening (day -6) and baseline\n(day 0) and were currently experiencing a\nrecurrent major depressive episode of 8\nweeks’ to 24 months’ duration. They were\nalso required to be in a stable relationship,\nhave normal sexual functioning and sex-\nual activity that could lead to orgasm at\nleast once every 2 weeks, and be willing\nto discuss their sexual functioning with\nthe investigator. Normal sexual function-\ning was defined""\n""as the absence of sexual\narousal disorder, orgasmic dysfunction,\npremature ejaculation, dyspareunia, and\nvaginismus. Because lack of sexual desire\nis common[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were excluded from the study\nif they had a known predisposition to\nseizures or were receiving medications that\nlower the seizure threshold; had a history\nor current diagnosis of anorexia or bu-\nlimia; were pregnant or lactating or did\nnot agree to avoid pregnancy during the\nstudy; had a history of alcohol or sub-\nstance abuse within the past year; had used\nany psychoactive drug within 1 week of\nstudy treatment (2 weeks for monoamine\noxidase inhibitors or protriptyline, 4 weeks\nfor fluoxetine or any investigational drug);\nhad a history of treatment with bupropion\nor sertraline; or were actively suicidal.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""moderate-to-severe depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Croft, 1999",na,na,na,na,na,na,na,na,na,na,na,37235,Placebo,na,na,na,na,37.4,na,na,121,na,na,61,na,na,white=107;black=10;other=4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,41,na,na,0,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,Nausea=12;Diarrhea=13;Dry mouth=14;Headache=36;Insomnia=5;Somnolence=7,na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,19-64,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87998692.0,Continuous,107697.0,113615142.0,1.0,13669974.0,0.0,13671957.0,HAM-A,1841.0,weeks,0,0 weeks,37235.0,0.0,Placebo,,Croft (1999),,121.0,99999.0,99999.0,0.0,Placebo,*HAM-A
87998692,A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.,Clinical therapeutics,Croft (1999),1999,"Croft H, Settle E Jr, Houser T, Batey S R, Donahue R M, and Ascher J A (1999) A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.. Clinical therapeutics 21(4), 643-58","[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Croft,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1999[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 14:\n[¬s]""Glaxo\nWellcome Inc.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""eligible for the study if they had a diag-\nnosis of moderate-to-severe depression\n(based on Diagnostic and Statistical Man-\nual of Mental Disorders, Fourth Edition\n[DSM-ZVJ criteria27 and a score of 2 18 on\nthe first 21 items of the 3 l-item Hamilton\nRating Scale for Depression [HAM-\nD]2829) at screening (day -6) and baseline\n(day 0) and were currently experiencing a\nrecurrent major depressive episode of 8\nweeks’ to 24 months’ duration. They were\nalso required to be in a stable relationship,\nhave normal sexual functioning and sex-\nual activity that could lead to orgasm at\nleast once every 2 weeks, and be willing\nto discuss their sexual functioning with\nthe investigator. Normal sexual function-\ning was defined""\n""as the absence of sexual\narousal disorder, orgasmic dysfunction,\npremature ejaculation, dyspareunia, and\nvaginismus. Because lack of sexual desire\nis common[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were excluded from the study\nif they had a known predisposition to\nseizures or were receiving medications that\nlower the seizure threshold; had a history\nor current diagnosis of anorexia or bu-\nlimia; were pregnant or lactating or did\nnot agree to avoid pregnancy during the\nstudy; had a history of alcohol or sub-\nstance abuse within the past year; had used\nany psychoactive drug within 1 week of\nstudy treatment (2 weeks for monoamine\noxidase inhibitors or protriptyline, 4 weeks\nfor fluoxetine or any investigational drug);\nhad a history of treatment with bupropion\nor sertraline; or were actively suicidal.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""moderate-to-severe depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Croft, 1999",na,na,na,na,na,na,na,na,na,na,na,37235,Placebo,na,na,na,na,37.4,na,na,121,na,na,61,na,na,white=107;black=10;other=4,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,41,na,na,0,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,Nausea=12;Diarrhea=13;Dry mouth=14;Headache=36;Insomnia=5;Somnolence=7,na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,19-64,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,87998692.0,Continuous,107698.0,113615142.0,1.0,13669974.0,0.0,13671957.0,HAM-A,1842.0,weeks,8,8 weeks,37235.0,0.0,Placebo,,Croft (1999),,99999.0,99999.0,99999.0,0.0,Placebo,*HAM-A
87998692,A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.,Clinical therapeutics,Croft (1999),1999,"Croft H, Settle E Jr, Houser T, Batey S R, Donahue R M, and Ascher J A (1999) A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.. Clinical therapeutics 21(4), 643-58","[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Croft,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1999[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 14:\n[¬s]""Glaxo\nWellcome Inc.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""eligible for the study if they had a diag-\nnosis of moderate-to-severe depression\n(based on Diagnostic and Statistical Man-\nual of Mental Disorders, Fourth Edition\n[DSM-ZVJ criteria27 and a score of 2 18 on\nthe first 21 items of the 3 l-item Hamilton\nRating Scale for Depression [HAM-\nD]2829) at screening (day -6) and baseline\n(day 0) and were currently experiencing a\nrecurrent major depressive episode of 8\nweeks’ to 24 months’ duration. They were\nalso required to be in a stable relationship,\nhave normal sexual functioning and sex-\nual activity that could lead to orgasm at\nleast once every 2 weeks, and be willing\nto discuss their sexual functioning with\nthe investigator. Normal sexual function-\ning was defined""\n""as the absence of sexual\narousal disorder, orgasmic dysfunction,\npremature ejaculation, dyspareunia, and\nvaginismus. Because lack of sexual desire\nis common[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were excluded from the study\nif they had a known predisposition to\nseizures or were receiving medications that\nlower the seizure threshold; had a history\nor current diagnosis of anorexia or bu-\nlimia; were pregnant or lactating or did\nnot agree to avoid pregnancy during the\nstudy; had a history of alcohol or sub-\nstance abuse within the past year; had used\nany psychoactive drug within 1 week of\nstudy treatment (2 weeks for monoamine\noxidase inhibitors or protriptyline, 4 weeks\nfor fluoxetine or any investigational drug);\nhad a history of treatment with bupropion\nor sertraline; or were actively suicidal.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""moderate-to-severe depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Croft, 1999",na,na,na,na,na,na,na,na,na,na,na,37236,Bupropion SR,na,na,na,na,35.9,na,na,120,na,na,61,na,na,white=103;black=11;other=6,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,36,na,na,8,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,Nausea=21;Diarrhea=8;Dry mouth=22;Headache=40;Insomnia=15;Somnolence=4,na,127mg,293mg,361mg,8 week,150mg,400,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,Allergic reaction=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,19-70,na,na,tick,tick,na,1,na,na,na,na,na,na,na,na,na,na,87998692.0,Continuous,107699.0,113615142.0,1.0,13687717.0,0.0,13671957.0,HAM-A,1841.0,weeks,0,0 weeks,37236.0,0.0,Bupropion SR,,Croft (1999),,120.0,99999.0,99999.0,0.0,*bupropion SR,*HAM-A
87998692,A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.,Clinical therapeutics,Croft (1999),1999,"Croft H, Settle E Jr, Houser T, Batey S R, Donahue R M, and Ascher J A (1999) A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.. Clinical therapeutics 21(4), 643-58","[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Croft,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1999[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,tick,tick,na,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 14:\n[¬s]""Glaxo\nWellcome Inc.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""eligible for the study if they had a diag-\nnosis of moderate-to-severe depression\n(based on Diagnostic and Statistical Man-\nual of Mental Disorders, Fourth Edition\n[DSM-ZVJ criteria27 and a score of 2 18 on\nthe first 21 items of the 3 l-item Hamilton\nRating Scale for Depression [HAM-\nD]2829) at screening (day -6) and baseline\n(day 0) and were currently experiencing a\nrecurrent major depressive episode of 8\nweeks’ to 24 months’ duration. They were\nalso required to be in a stable relationship,\nhave normal sexual functioning and sex-\nual activity that could lead to orgasm at\nleast once every 2 weeks, and be willing\nto discuss their sexual functioning with\nthe investigator. Normal sexual function-\ning was defined""\n""as the absence of sexual\narousal disorder, orgasmic dysfunction,\npremature ejaculation, dyspareunia, and\nvaginismus. Because lack of sexual desire\nis common[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were excluded from the study\nif they had a known predisposition to\nseizures or were receiving medications that\nlower the seizure threshold; had a history\nor current diagnosis of anorexia or bu-\nlimia; were pregnant or lactating or did\nnot agree to avoid pregnancy during the\nstudy; had a history of alcohol or sub-\nstance abuse within the past year; had used\nany psychoactive drug within 1 week of\nstudy treatment (2 weeks for monoamine\noxidase inhibitors or protriptyline, 4 weeks\nfor fluoxetine or any investigational drug);\nhad a history of treatment with bupropion\nor sertraline; or were actively suicidal.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050665, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""moderate-to-severe depression[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Croft H et al. - 1999 - A placebo-controlled comparison of the antidepress.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Croft, 1999",na,na,na,na,na,na,na,na,na,na,na,37236,Bupropion SR,na,na,na,na,35.9,na,na,120,na,na,61,na,na,white=103;black=11;other=6,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,36,na,na,8,na,na,na,na,na,na,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,na,Nausea=21;Diarrhea=8;Dry mouth=22;Headache=40;Insomnia=15;Somnolence=4,na,127mg,293mg,361mg,8 week,150mg,400,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,Allergic reaction=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,19-70,na,na,tick,tick,na,1,na,na,na,na,na,na,na,na,na,na,87998692.0,Continuous,107700.0,113615142.0,1.0,13687717.0,0.0,13671957.0,HAM-A,1842.0,weeks,8,8 weeks,37236.0,0.0,Bupropion SR,,Croft (1999),,99999.0,99999.0,99999.0,0.0,*bupropion SR,*HAM-A
90044744,"Comparison of praahpexole, fluoxetine, and placebo in patients with major depression",Depression and Anxiety,Corrigan (2000),2000,"Corrigan M H, Denahan A Q, Eugene Wright, C , Ragual R J, and Evans D L (2000) Comparison of praahpexole, fluoxetine, and placebo in patients with major depression. Depression and Anxiety 11(2), 58-65 DOI: 10.1002/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H","[{'ItemDocumentId': 1064831, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Corrigan[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Depression and Anxiety - 2000 - Corrigan.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1064831, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2000[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Depression and Anxiety - 2000 - Corrigan.pdf', 'ItemArm': ''}]",na,USA,na,na,tick,tick,tick,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1064831, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Inclusion criteria\nMet DSM-III-R criteria for major depression, single episode or\nrecurrent episode, with or without melancholia and without\npsychotic features (296.21, 296.22, 296.23, 296.31, 296.32,\nor 296.33).\nBetween ages of 18 and 65 years, inclusive.""\n""Agreed not to start psychotherapy or behavior therapy while\nparticipating in the trial. Patients currently on these types of\ntherapy for at least 3 months were eligible for the study and\ncould continue to receive therapy during the study.\nConsented to participate voluntarily and signed a written Patient\nInformed Consent prior to any study procedures at Screen visit.""\n""discontinuation to obtain relatively uncontaminated baseline\nevaluations.""\n""MAOI, fluoxetine) may have needed longer than 2 weeks post-""\n""Patients on certain antidepressants with prolonged effects (e.g.,""\n""Had a total score of ≥ 18 on the HAM-D (17-item version), and a\nscore of ≥ 2 on the depressed mood item of the HAM-D at the\nscreen visit and at the baseline visit.\nMale or female (post-menopausal LH>50 mIU/ml, or surgically\nsterile, or using a reliable barrier method contraception).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Depression and Anxiety - 2000 - Corrigan.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1064831, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Exclusion criteria\nHistory of clinically relevant medical disease.""\n""Clinically significant changes on the ECG suggestive of ischemia or\nclinically abnormal laboratory value (i.e., one that required further\ninvestigation or treatment of the patient) or positive hepatitis B\nscreen.\nLifetime history of hypomania/mania, psychotic disorder, dementia,\nand borderline or antisocial personality disorders.""\n""History of a serious suicidal attempt in the past 12 months; presence\nof serious suicidal tendencies/potential; the suicide question on the\nHAM-D must not have been rated > 2.""\n""Women who were pregnant or lactating; women taking a low-""\n""estrogen “mini-pill” contraceptive.""\n""Positive urine screen for benzodiazepines, cocaine/cocaine\nmetabolites, cannabinoids, amphetamines, barbiturates, and\nopiates or history of substance abuse (drugs or alcohol, DSM-III-R\ncriteria) within the past 6 months of the screen visit.\nNon-responders to at least two trials of antidepressant treatment in\nthe past.\nUse of fluoxetine (Prozac) in the past 6 months or use of another\ninvestigational drug within 1 month prior to the baseline visit.\nInability to be withdrawn from any psychoactive drug(s) being taken\nat the time of screening.\nEvidence of hypersensitivity, intolerance, or contraindication to\ndopamine agonists (i.e., bromocriptine, selegiline) or lactose.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Depression and Anxiety - 2000 - Corrigan.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depression,tick,tick,na,None,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,9 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,"Corrigan, 2000",na,na,na,na,na,na,na,na,na,na,na,37229,Placebo,tick,na,na,na,tick,tick,na,35,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,11,na,na,4,na,na,na,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,headache=11;nausea=7;somnolence=2;dizziness=3;insomnia=1;infection=6;asthenia=0;anorexia=1;vomiting=2,na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,28,na,na,tick,na,tick,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
90044744,"Comparison of praahpexole, fluoxetine, and placebo in patients with major depression",Depression and Anxiety,Corrigan (2000),2000,"Corrigan M H, Denahan A Q, Eugene Wright, C , Ragual R J, and Evans D L (2000) Comparison of praahpexole, fluoxetine, and placebo in patients with major depression. Depression and Anxiety 11(2), 58-65 DOI: 10.1002/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H","[{'ItemDocumentId': 1064831, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Corrigan[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Depression and Anxiety - 2000 - Corrigan.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1064831, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2000[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Depression and Anxiety - 2000 - Corrigan.pdf', 'ItemArm': ''}]",na,USA,na,na,tick,tick,tick,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1064831, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Inclusion criteria\nMet DSM-III-R criteria for major depression, single episode or\nrecurrent episode, with or without melancholia and without\npsychotic features (296.21, 296.22, 296.23, 296.31, 296.32,\nor 296.33).\nBetween ages of 18 and 65 years, inclusive.""\n""Agreed not to start psychotherapy or behavior therapy while\nparticipating in the trial. Patients currently on these types of\ntherapy for at least 3 months were eligible for the study and\ncould continue to receive therapy during the study.\nConsented to participate voluntarily and signed a written Patient\nInformed Consent prior to any study procedures at Screen visit.""\n""discontinuation to obtain relatively uncontaminated baseline\nevaluations.""\n""MAOI, fluoxetine) may have needed longer than 2 weeks post-""\n""Patients on certain antidepressants with prolonged effects (e.g.,""\n""Had a total score of ≥ 18 on the HAM-D (17-item version), and a\nscore of ≥ 2 on the depressed mood item of the HAM-D at the\nscreen visit and at the baseline visit.\nMale or female (post-menopausal LH>50 mIU/ml, or surgically\nsterile, or using a reliable barrier method contraception).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Depression and Anxiety - 2000 - Corrigan.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1064831, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Exclusion criteria\nHistory of clinically relevant medical disease.""\n""Clinically significant changes on the ECG suggestive of ischemia or\nclinically abnormal laboratory value (i.e., one that required further\ninvestigation or treatment of the patient) or positive hepatitis B\nscreen.\nLifetime history of hypomania/mania, psychotic disorder, dementia,\nand borderline or antisocial personality disorders.""\n""History of a serious suicidal attempt in the past 12 months; presence\nof serious suicidal tendencies/potential; the suicide question on the\nHAM-D must not have been rated > 2.""\n""Women who were pregnant or lactating; women taking a low-""\n""estrogen “mini-pill” contraceptive.""\n""Positive urine screen for benzodiazepines, cocaine/cocaine\nmetabolites, cannabinoids, amphetamines, barbiturates, and\nopiates or history of substance abuse (drugs or alcohol, DSM-III-R\ncriteria) within the past 6 months of the screen visit.\nNon-responders to at least two trials of antidepressant treatment in\nthe past.\nUse of fluoxetine (Prozac) in the past 6 months or use of another\ninvestigational drug within 1 month prior to the baseline visit.\nInability to be withdrawn from any psychoactive drug(s) being taken\nat the time of screening.\nEvidence of hypersensitivity, intolerance, or contraindication to\ndopamine agonists (i.e., bromocriptine, selegiline) or lactose.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Depression and Anxiety - 2000 - Corrigan.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depression,tick,tick,na,None,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,9 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,"Corrigan, 2000",na,na,na,na,na,na,na,na,na,na,na,37230,Pramipexole 0.375mg,tick,na,na,na,tick,tick,na,36,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,9,na,na,3,na,na,na,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,headache=12;nausea=9;somnolence=4;dizziness=5;insomnia=5;infection=5;asthenia=4;anorexia=1;vomiting=0,na,0.375mg,0.375mg,0.375mg,8 weeks,0.375mg,0.375mg,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,34,na,na,tick,na,tick,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
90044744,"Comparison of praahpexole, fluoxetine, and placebo in patients with major depression",Depression and Anxiety,Corrigan (2000),2000,"Corrigan M H, Denahan A Q, Eugene Wright, C , Ragual R J, and Evans D L (2000) Comparison of praahpexole, fluoxetine, and placebo in patients with major depression. Depression and Anxiety 11(2), 58-65 DOI: 10.1002/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H","[{'ItemDocumentId': 1064831, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Corrigan[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Depression and Anxiety - 2000 - Corrigan.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1064831, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2000[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Depression and Anxiety - 2000 - Corrigan.pdf', 'ItemArm': ''}]",na,USA,na,na,tick,tick,tick,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1064831, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Inclusion criteria\nMet DSM-III-R criteria for major depression, single episode or\nrecurrent episode, with or without melancholia and without\npsychotic features (296.21, 296.22, 296.23, 296.31, 296.32,\nor 296.33).\nBetween ages of 18 and 65 years, inclusive.""\n""Agreed not to start psychotherapy or behavior therapy while\nparticipating in the trial. Patients currently on these types of\ntherapy for at least 3 months were eligible for the study and\ncould continue to receive therapy during the study.\nConsented to participate voluntarily and signed a written Patient\nInformed Consent prior to any study procedures at Screen visit.""\n""discontinuation to obtain relatively uncontaminated baseline\nevaluations.""\n""MAOI, fluoxetine) may have needed longer than 2 weeks post-""\n""Patients on certain antidepressants with prolonged effects (e.g.,""\n""Had a total score of ≥ 18 on the HAM-D (17-item version), and a\nscore of ≥ 2 on the depressed mood item of the HAM-D at the\nscreen visit and at the baseline visit.\nMale or female (post-menopausal LH>50 mIU/ml, or surgically\nsterile, or using a reliable barrier method contraception).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Depression and Anxiety - 2000 - Corrigan.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1064831, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Exclusion criteria\nHistory of clinically relevant medical disease.""\n""Clinically significant changes on the ECG suggestive of ischemia or\nclinically abnormal laboratory value (i.e., one that required further\ninvestigation or treatment of the patient) or positive hepatitis B\nscreen.\nLifetime history of hypomania/mania, psychotic disorder, dementia,\nand borderline or antisocial personality disorders.""\n""History of a serious suicidal attempt in the past 12 months; presence\nof serious suicidal tendencies/potential; the suicide question on the\nHAM-D must not have been rated > 2.""\n""Women who were pregnant or lactating; women taking a low-""\n""estrogen “mini-pill” contraceptive.""\n""Positive urine screen for benzodiazepines, cocaine/cocaine\nmetabolites, cannabinoids, amphetamines, barbiturates, and\nopiates or history of substance abuse (drugs or alcohol, DSM-III-R\ncriteria) within the past 6 months of the screen visit.\nNon-responders to at least two trials of antidepressant treatment in\nthe past.\nUse of fluoxetine (Prozac) in the past 6 months or use of another\ninvestigational drug within 1 month prior to the baseline visit.\nInability to be withdrawn from any psychoactive drug(s) being taken\nat the time of screening.\nEvidence of hypersensitivity, intolerance, or contraindication to\ndopamine agonists (i.e., bromocriptine, selegiline) or lactose.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Depression and Anxiety - 2000 - Corrigan.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depression,tick,tick,na,None,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,9 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,"Corrigan, 2000",na,na,na,na,na,na,na,na,na,na,na,37238,Pramipexole 1mg,tick,na,na,na,tick,tick,na,35,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,12,na,na,5,na,na,na,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,headache=15;nausea=16;somnolence=6;dizziness=6;insomnia=4;infection=7;asthenia=2;anorexia=5;vomiting=4,na,1mg,1mg,1mg,8 weeks,1.00mg,1.00mg,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,30,na,na,tick,na,tick,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
90044744,"Comparison of praahpexole, fluoxetine, and placebo in patients with major depression",Depression and Anxiety,Corrigan (2000),2000,"Corrigan M H, Denahan A Q, Eugene Wright, C , Ragual R J, and Evans D L (2000) Comparison of praahpexole, fluoxetine, and placebo in patients with major depression. Depression and Anxiety 11(2), 58-65 DOI: 10.1002/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H","[{'ItemDocumentId': 1064831, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Corrigan[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Depression and Anxiety - 2000 - Corrigan.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1064831, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2000[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Depression and Anxiety - 2000 - Corrigan.pdf', 'ItemArm': ''}]",na,USA,na,na,tick,tick,tick,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1064831, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Inclusion criteria\nMet DSM-III-R criteria for major depression, single episode or\nrecurrent episode, with or without melancholia and without\npsychotic features (296.21, 296.22, 296.23, 296.31, 296.32,\nor 296.33).\nBetween ages of 18 and 65 years, inclusive.""\n""Agreed not to start psychotherapy or behavior therapy while\nparticipating in the trial. Patients currently on these types of\ntherapy for at least 3 months were eligible for the study and\ncould continue to receive therapy during the study.\nConsented to participate voluntarily and signed a written Patient\nInformed Consent prior to any study procedures at Screen visit.""\n""discontinuation to obtain relatively uncontaminated baseline\nevaluations.""\n""MAOI, fluoxetine) may have needed longer than 2 weeks post-""\n""Patients on certain antidepressants with prolonged effects (e.g.,""\n""Had a total score of ≥ 18 on the HAM-D (17-item version), and a\nscore of ≥ 2 on the depressed mood item of the HAM-D at the\nscreen visit and at the baseline visit.\nMale or female (post-menopausal LH>50 mIU/ml, or surgically\nsterile, or using a reliable barrier method contraception).[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Depression and Anxiety - 2000 - Corrigan.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1064831, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Exclusion criteria\nHistory of clinically relevant medical disease.""\n""Clinically significant changes on the ECG suggestive of ischemia or\nclinically abnormal laboratory value (i.e., one that required further\ninvestigation or treatment of the patient) or positive hepatitis B\nscreen.\nLifetime history of hypomania/mania, psychotic disorder, dementia,\nand borderline or antisocial personality disorders.""\n""History of a serious suicidal attempt in the past 12 months; presence\nof serious suicidal tendencies/potential; the suicide question on the\nHAM-D must not have been rated > 2.""\n""Women who were pregnant or lactating; women taking a low-""\n""estrogen “mini-pill” contraceptive.""\n""Positive urine screen for benzodiazepines, cocaine/cocaine\nmetabolites, cannabinoids, amphetamines, barbiturates, and\nopiates or history of substance abuse (drugs or alcohol, DSM-III-R\ncriteria) within the past 6 months of the screen visit.\nNon-responders to at least two trials of antidepressant treatment in\nthe past.\nUse of fluoxetine (Prozac) in the past 6 months or use of another\ninvestigational drug within 1 month prior to the baseline visit.\nInability to be withdrawn from any psychoactive drug(s) being taken\nat the time of screening.\nEvidence of hypersensitivity, intolerance, or contraindication to\ndopamine agonists (i.e., bromocriptine, selegiline) or lactose.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Depression and Anxiety - 2000 - Corrigan.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,Major depression,tick,tick,na,None,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,9 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,"Corrigan, 2000",na,na,na,na,na,na,na,na,na,na,na,37239,Pramipexole 5mg,tick,na,na,na,tick,tick,na,33,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,19,na,na,17,na,na,na,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,headache=10;nausea=25;somnolence=12;dizziness=9;insomnia=5;infection=1;asthenia=5;anorexia=4;vomiting=13,na,5mg,5mg,5mg,8 weeks,5.00mg,5.00mg,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,31,na,na,tick,na,tick,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87998563,A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine.,Clinical therapeutics,Coleman (2001),2001,"Coleman C C, King B R, Bolden-Watson C, Book M J, Segraves R T, Richard N, Ascher J, Batey S, Jamerson B, and Metz A (2001) A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine.. Clinical therapeutics 23(7), 1040-58","[{'ItemDocumentId': 1052917, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Coleman,[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0149291801800904-main.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052917, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""00l[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0149291801800904-main.pdf', 'ItemArm': ''}]",na,tick,na,tick,"[{'ItemDocumentId': 1052917, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 17:\n[¬s]""The research described in this manuscript\nwas funded by Glaxo Wellcome Inc, Re-\nsearch Triangle Park, North Carolina. T[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0149291801800904-main.pdf', 'ItemArm': ''}]",na,Glaxo Welcome Inc AK1A4007,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1052917, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Eligible patients were men and women aged 218 years with a diagnosis of moderate to severe depression (based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition29 [DSM-ZVj criteria and a minimum score of 20 on the 21-item Hamilton Rating Scale for Depression30,31 [HAM-D] at screening [day -71 and base- line [day -11) who were currently experi- encing an episode of recurrent major de- pression lasting from 2 to 24 months. Patients were required to be involved in sexual activity (in a stable relationship or through masturbation) that had the poten-""\n""ial to lead to orgasm on 21 occasion every 2 weeks. They were also requi""\n""ired to have""\n""normal sexual functioning, absence of sexual arousal disorder (erectile difficulties in men and lubrication swelling difficulties in women), orgasm dysfunction (delay or failure to achieve or- gasm), premature ejaculation, dyspareunia, or vaginismus. P""\n""atients had to be willing to discuss their sexual functioning with an in- vestigator or the investigator’s designee.""\n""Because decreased sexual desire is com- mon in depression,29 patients with sexual desire disorder (deficiency of sexual fan- tasies and desire for sexual activity) were eligible for the study as long as they were having sexual activity on 21 occasion every 2 weeks.""\n""defined as the""\n""or[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0149291801800904-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052917, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were excluded from the study if\nthey had received treatment with bupro-\npion or fluoxetine within the past year; had\nnot responded to antidepressant\ntreatment\nfor a previous depressive episode; were ac-\ntively suicidal; had a known predisposition\nto seizures or were receiving medications\nthat lowered the seizure threshold; had""\n""a\nhistory or current diagnosis of anorexia or\nbulimia; were pregnant or lactating, or did\nnot agree to avoid pregnancy during the\nstudy; had a history of alcohol or substance\nabuse within the past year; or had used any\npsychoactive drug within 1 week of treat-\nment with study drug (2 weeks for mono-""\n""amine oxidase inhibitors or protriptyline,""\n"", 4\nweeks for any investigational\ndrug)[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0149291801800904-main.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"Depression. [{'ItemDocumentId': 1052917, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""moderate to\nsevere depression ([¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0149291801800904-main.pdf', 'ItemArm': ''}]",tick,na,tick,tick,tick,na,na,na,na,na,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,8 weeks,na,na,tick,tick,na,8 weeks,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37226,Placebo,na,na,na,na,36.70,na,na,152,na,na,92,na,na,"white=125
black=21
other=6",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,50,na,na,"5
2 worsening condition",na,na,na,na,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Headache=31;
Dry mouth=22;
Nausea=24;
Agitation=21;
Insomnia=10;
Diarrhea=13;
Somnolence=6;",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,19-62.00,na,na,111,na,na,1,na,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87998563,A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine.,Clinical therapeutics,Coleman (2001),2001,"Coleman C C, King B R, Bolden-Watson C, Book M J, Segraves R T, Richard N, Ascher J, Batey S, Jamerson B, and Metz A (2001) A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine.. Clinical therapeutics 23(7), 1040-58","[{'ItemDocumentId': 1052917, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Coleman,[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0149291801800904-main.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1052917, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""00l[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0149291801800904-main.pdf', 'ItemArm': ''}]",na,tick,na,tick,"[{'ItemDocumentId': 1052917, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 17:\n[¬s]""The research described in this manuscript\nwas funded by Glaxo Wellcome Inc, Re-\nsearch Triangle Park, North Carolina. T[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0149291801800904-main.pdf', 'ItemArm': ''}]",na,Glaxo Welcome Inc AK1A4007,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1052917, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Eligible patients were men and women aged 218 years with a diagnosis of moderate to severe depression (based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition29 [DSM-ZVj criteria and a minimum score of 20 on the 21-item Hamilton Rating Scale for Depression30,31 [HAM-D] at screening [day -71 and base- line [day -11) who were currently experi- encing an episode of recurrent major de- pression lasting from 2 to 24 months. Patients were required to be involved in sexual activity (in a stable relationship or through masturbation) that had the poten-""\n""ial to lead to orgasm on 21 occasion every 2 weeks. They were also requi""\n""ired to have""\n""normal sexual functioning, absence of sexual arousal disorder (erectile difficulties in men and lubrication swelling difficulties in women), orgasm dysfunction (delay or failure to achieve or- gasm), premature ejaculation, dyspareunia, or vaginismus. P""\n""atients had to be willing to discuss their sexual functioning with an in- vestigator or the investigator’s designee.""\n""Because decreased sexual desire is com- mon in depression,29 patients with sexual desire disorder (deficiency of sexual fan- tasies and desire for sexual activity) were eligible for the study as long as they were having sexual activity on 21 occasion every 2 weeks.""\n""defined as the""\n""or[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0149291801800904-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1052917, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were excluded from the study if\nthey had received treatment with bupro-\npion or fluoxetine within the past year; had\nnot responded to antidepressant\ntreatment\nfor a previous depressive episode; were ac-\ntively suicidal; had a known predisposition\nto seizures or were receiving medications\nthat lowered the seizure threshold; had""\n""a\nhistory or current diagnosis of anorexia or\nbulimia; were pregnant or lactating, or did\nnot agree to avoid pregnancy during the\nstudy; had a history of alcohol or substance\nabuse within the past year; or had used any\npsychoactive drug within 1 week of treat-\nment with study drug (2 weeks for mono-""\n""amine oxidase inhibitors or protriptyline,""\n"", 4\nweeks for any investigational\ndrug)[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0149291801800904-main.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"Depression. [{'ItemDocumentId': 1052917, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""moderate to\nsevere depression ([¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0149291801800904-main.pdf', 'ItemArm': ''}]",tick,na,tick,tick,tick,na,na,na,na,na,na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,8 weeks,na,na,tick,tick,na,8 weeks,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37227,Bupropion,na,na,na,na,36.60,na,na,150,na,na,95,na,na,"white=125
black=17
other=8",na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,13,na,na,"13
2 worsening condition",na,na,na,na,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,tick,na,na,na,na,na,"Headache=42;
Dry mouth=44;
Nausea=32;
Agitation=17;
Insomnia=21;
Diarrhea=13;
Somnolence=4;",na,tick,tick,tick,8,150.00mg,400.00mg,na,na,na,na,na,na,tick,na,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,18.00-67.00,na,na,114,na,na,3,na,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87998674,Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment.,Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists,Coleman (1999),1999,"Coleman C C, Cunningham L A, Foster V J, Batey S R, Donahue R M, Houser T L, and Ascher J A (1999) Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment.. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 11(4), 205-15","[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Coleman[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1999[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 11:\n[¬s]""The research described in this manuscript was\nfunded by Glaxo Wellcome Inc.[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Men and women at least 18 years of age were\neligible for the study if they had a diagnosis of moder-\nate to severe depression based on DSM-IV criteria\n(26) and a minimum score of 18 on the first 21 items\nof the 31-item Hamilton Rating Scale for Depression""\n""HAM-D) (27,28) at screening (day -6) and baseline\n(day 0), and were currently experiencing a recurrent\nmajor depressive episode with a duration of 2 to\n24 months. Patients were required to be in a stable\nrelationship, have normal sexual functioning and sex-\nual activity that could lead to orgasm at least once\nevery 2 weeks, and be willing to discuss their sexual\nfunctioning with the investigator. Normal sexual\nfunctioning was defined as the absence of sexual\narousal disorder, orgasm dysfunction, premature\nejaculation, dyspareunia, and vaginismus. Because\nlack of sexual desire is common in some patients\nwith underlying depression (26), patients with sexual\ndesire disorder were eligible for the study. The\nstudy protocol was approved by the Institutional\nReview Board for each study site, and written\ninformed consent was obtained from each patient\nafter study procedures and possible adverse effects\nwere explained.[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were excluded from the study if they\nhad a known predisposition to seizure or were receiv-\ning medications that lower the seizure threshold; had\na history or current diagnosis of anorexia or bulimia;\nwere pregnant or lactating, or did not agree to avoid\npregnancy during the study; had a history of alcohol\nor substance abuse within the past year; had used\nany psychoactive drug within 1 week of study drug\ntreatment (2 weeks for monoamine oxidase inhibitors\nor protriptyline, 4 weeks for fluoxetine or any investi-\ngational drug); had a history of prior treatment with\nbupropion or sertraline; or were actively suicidal.[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""f moder-\nate to severe depression b[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 5:\n[¬s]""r recurrent major depression w[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",tick,tick,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Chloral hydrate was permit-\nted for sleep during the first 14 days of the treatment\nphase. T[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 5:\n[¬s]""Six patients (four\non sertraline and one each on placebo and bupropion\nSR) used chloral hydrate for sleep during the first 14\ndays of the treatment phase as permitted by the pro-\ntocol.[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Coleman, 1999",na,na,na,na,na,na,na,na,na,na,na,37223,Placebo,na,na,na,na,38.50,na,na,124,na,na,73,na,na,"white=109
black=11
other=4",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,40,na,na,2,na,na,na,na,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Headache=32;
Nausea=14;
Dry mouth=19;
Diarrhea=17;
Dyspepsia=8;
Insomnia=8;
Agitation=4;
Rhinitis=11;",na,na,tick,na,8 weeks,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,tick,tick,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,18.00-65.00,na,na,tick,tick,na,0,na,na,na,na,na,na,na,na,na,na,87998674.0,Continuous,109234.0,113614872.0,1.0,13669974.0,0.0,13671957.0,HAM-A Total (copy),1836.0,weeks,8,8 weeks,37223.0,0.0,Placebo,,Coleman (1999),,99999.0,99999.0,99999.0,0.0,Placebo,*HAM-A
87998674,Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment.,Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists,Coleman (1999),1999,"Coleman C C, Cunningham L A, Foster V J, Batey S R, Donahue R M, Houser T L, and Ascher J A (1999) Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment.. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 11(4), 205-15","[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Coleman[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1999[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 11:\n[¬s]""The research described in this manuscript was\nfunded by Glaxo Wellcome Inc.[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Men and women at least 18 years of age were\neligible for the study if they had a diagnosis of moder-\nate to severe depression based on DSM-IV criteria\n(26) and a minimum score of 18 on the first 21 items\nof the 31-item Hamilton Rating Scale for Depression""\n""HAM-D) (27,28) at screening (day -6) and baseline\n(day 0), and were currently experiencing a recurrent\nmajor depressive episode with a duration of 2 to\n24 months. Patients were required to be in a stable\nrelationship, have normal sexual functioning and sex-\nual activity that could lead to orgasm at least once\nevery 2 weeks, and be willing to discuss their sexual\nfunctioning with the investigator. Normal sexual\nfunctioning was defined as the absence of sexual\narousal disorder, orgasm dysfunction, premature\nejaculation, dyspareunia, and vaginismus. Because\nlack of sexual desire is common in some patients\nwith underlying depression (26), patients with sexual\ndesire disorder were eligible for the study. The\nstudy protocol was approved by the Institutional\nReview Board for each study site, and written\ninformed consent was obtained from each patient\nafter study procedures and possible adverse effects\nwere explained.[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were excluded from the study if they\nhad a known predisposition to seizure or were receiv-\ning medications that lower the seizure threshold; had\na history or current diagnosis of anorexia or bulimia;\nwere pregnant or lactating, or did not agree to avoid\npregnancy during the study; had a history of alcohol\nor substance abuse within the past year; had used\nany psychoactive drug within 1 week of study drug\ntreatment (2 weeks for monoamine oxidase inhibitors\nor protriptyline, 4 weeks for fluoxetine or any investi-\ngational drug); had a history of prior treatment with\nbupropion or sertraline; or were actively suicidal.[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""f moder-\nate to severe depression b[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 5:\n[¬s]""r recurrent major depression w[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",tick,tick,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Chloral hydrate was permit-\nted for sleep during the first 14 days of the treatment\nphase. T[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 5:\n[¬s]""Six patients (four\non sertraline and one each on placebo and bupropion\nSR) used chloral hydrate for sleep during the first 14\ndays of the treatment phase as permitted by the pro-\ntocol.[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Coleman, 1999",na,na,na,na,na,na,na,na,na,na,na,37223,Placebo,na,na,na,na,38.50,na,na,124,na,na,73,na,na,"white=109
black=11
other=4",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,40,na,na,2,na,na,na,na,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Headache=32;
Nausea=14;
Dry mouth=19;
Diarrhea=17;
Dyspepsia=8;
Insomnia=8;
Agitation=4;
Rhinitis=11;",na,na,tick,na,8 weeks,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,tick,tick,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,18.00-65.00,na,na,tick,tick,na,0,na,na,na,na,na,na,na,na,na,na,87998674.0,Continuous,109438.0,113614872.0,1.0,13669974.0,0.0,13671957.0,HAM-A,1835.0,weeks,0,0 weeks,37223.0,0.0,Placebo,,Coleman (1999),Missing,124.0,99999.0,99999.0,0.0,Placebo,*HAM-A
87998674,Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment.,Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists,Coleman (1999),1999,"Coleman C C, Cunningham L A, Foster V J, Batey S R, Donahue R M, Houser T L, and Ascher J A (1999) Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment.. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 11(4), 205-15","[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Coleman[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1999[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 11:\n[¬s]""The research described in this manuscript was\nfunded by Glaxo Wellcome Inc.[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Men and women at least 18 years of age were\neligible for the study if they had a diagnosis of moder-\nate to severe depression based on DSM-IV criteria\n(26) and a minimum score of 18 on the first 21 items\nof the 31-item Hamilton Rating Scale for Depression""\n""HAM-D) (27,28) at screening (day -6) and baseline\n(day 0), and were currently experiencing a recurrent\nmajor depressive episode with a duration of 2 to\n24 months. Patients were required to be in a stable\nrelationship, have normal sexual functioning and sex-\nual activity that could lead to orgasm at least once\nevery 2 weeks, and be willing to discuss their sexual\nfunctioning with the investigator. Normal sexual\nfunctioning was defined as the absence of sexual\narousal disorder, orgasm dysfunction, premature\nejaculation, dyspareunia, and vaginismus. Because\nlack of sexual desire is common in some patients\nwith underlying depression (26), patients with sexual\ndesire disorder were eligible for the study. The\nstudy protocol was approved by the Institutional\nReview Board for each study site, and written\ninformed consent was obtained from each patient\nafter study procedures and possible adverse effects\nwere explained.[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were excluded from the study if they\nhad a known predisposition to seizure or were receiv-\ning medications that lower the seizure threshold; had\na history or current diagnosis of anorexia or bulimia;\nwere pregnant or lactating, or did not agree to avoid\npregnancy during the study; had a history of alcohol\nor substance abuse within the past year; had used\nany psychoactive drug within 1 week of study drug\ntreatment (2 weeks for monoamine oxidase inhibitors\nor protriptyline, 4 weeks for fluoxetine or any investi-\ngational drug); had a history of prior treatment with\nbupropion or sertraline; or were actively suicidal.[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""f moder-\nate to severe depression b[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 5:\n[¬s]""r recurrent major depression w[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",tick,tick,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Chloral hydrate was permit-\nted for sleep during the first 14 days of the treatment\nphase. T[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 5:\n[¬s]""Six patients (four\non sertraline and one each on placebo and bupropion\nSR) used chloral hydrate for sleep during the first 14\ndays of the treatment phase as permitted by the pro-\ntocol.[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Coleman, 1999",na,na,na,na,na,na,na,na,na,na,na,37224,Bupropion SR,na,na,na,na,38.10,na,na,122,na,na,68,na,na,"white=106
black=13
other=3",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,27,na,na,8,na,na,na,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,tick,"Headache=40;
Nausea=23;
Dry mouth=21;
Diarrhea=14;
Dyspepsia=9;
Insomnia=24;
Agitation=14;
Rhinitis=9;",na,100mg,290mg,365mg,8 weeks,150mg,400mg,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,suicidal ideation=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,18.00-64.00,na,na,tick,tick,na,1,na,na,na,na,na,na,na,na,na,na,87998674.0,Continuous,109233.0,113614872.0,1.0,13687717.0,0.0,13671957.0,HAM-A Total,1836.0,weeks,8,8 weeks,37224.0,0.0,Bupropion SR,,Coleman (1999),,99999.0,99999.0,99999.0,0.0,*bupropion SR,*HAM-A
87998674,Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment.,Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists,Coleman (1999),1999,"Coleman C C, Cunningham L A, Foster V J, Batey S R, Donahue R M, Houser T L, and Ascher J A (1999) Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment.. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 11(4), 205-15","[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Coleman[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1999[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 11:\n[¬s]""The research described in this manuscript was\nfunded by Glaxo Wellcome Inc.[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Men and women at least 18 years of age were\neligible for the study if they had a diagnosis of moder-\nate to severe depression based on DSM-IV criteria\n(26) and a minimum score of 18 on the first 21 items\nof the 31-item Hamilton Rating Scale for Depression""\n""HAM-D) (27,28) at screening (day -6) and baseline\n(day 0), and were currently experiencing a recurrent\nmajor depressive episode with a duration of 2 to\n24 months. Patients were required to be in a stable\nrelationship, have normal sexual functioning and sex-\nual activity that could lead to orgasm at least once\nevery 2 weeks, and be willing to discuss their sexual\nfunctioning with the investigator. Normal sexual\nfunctioning was defined as the absence of sexual\narousal disorder, orgasm dysfunction, premature\nejaculation, dyspareunia, and vaginismus. Because\nlack of sexual desire is common in some patients\nwith underlying depression (26), patients with sexual\ndesire disorder were eligible for the study. The\nstudy protocol was approved by the Institutional\nReview Board for each study site, and written\ninformed consent was obtained from each patient\nafter study procedures and possible adverse effects\nwere explained.[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were excluded from the study if they\nhad a known predisposition to seizure or were receiv-\ning medications that lower the seizure threshold; had\na history or current diagnosis of anorexia or bulimia;\nwere pregnant or lactating, or did not agree to avoid\npregnancy during the study; had a history of alcohol\nor substance abuse within the past year; had used\nany psychoactive drug within 1 week of study drug\ntreatment (2 weeks for monoamine oxidase inhibitors\nor protriptyline, 4 weeks for fluoxetine or any investi-\ngational drug); had a history of prior treatment with\nbupropion or sertraline; or were actively suicidal.[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""f moder-\nate to severe depression b[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 5:\n[¬s]""r recurrent major depression w[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",tick,tick,na,"[{'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Chloral hydrate was permit-\nted for sleep during the first 14 days of the treatment\nphase. T[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1053874, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 5:\n[¬s]""Six patients (four\non sertraline and one each on placebo and bupropion\nSR) used chloral hydrate for sleep during the first 14\ndays of the treatment phase as permitted by the pro-\ntocol.[¬e]""', 'IsFromPDF': True, 'DocTitle': '10401239909147072.pdf', 'ItemArm': ''}]",na,tick,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Coleman, 1999",na,na,na,na,na,na,na,na,na,na,na,37224,Bupropion SR,na,na,na,na,38.10,na,na,122,na,na,68,na,na,"white=106
black=13
other=3",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,27,na,na,8,na,na,na,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,tick,na,na,na,na,tick,"Headache=40;
Nausea=23;
Dry mouth=21;
Diarrhea=14;
Dyspepsia=9;
Insomnia=24;
Agitation=14;
Rhinitis=9;",na,100mg,290mg,365mg,8 weeks,150mg,400mg,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,suicidal ideation=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,18.00-64.00,na,na,tick,tick,na,1,na,na,na,na,na,na,na,na,na,na,87998674.0,Continuous,109437.0,113614872.0,1.0,13687717.0,0.0,13671957.0,HAM-A,1835.0,weeks,0,0 weeks,37224.0,0.0,Bupropion SR,,Coleman (1999),Missing,122.0,99999.0,99999.0,0.0,*bupropion SR,*HAM-A
87999011,Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.,Clinical neuropharmacology,Chouinard (1993),1993,"Chouinard G, Saxena B M, Nair N P, Kutcher S P, Bakish D, Bradwejn J, Kennedy S H, Sharma V, Remick R A, and Kukha-Mohamad S A (1993) Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.. Clinical neuropharmacology 16 Suppl 2, S51-4","[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Chouinard a[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1994)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Canada,""\n""UK[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,tick,tick,na,na,"[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were both men and women aged be-\ntween 18 and 65 years who satisfied the DSM-III-\nR diagnosis\nor recurrent)\nfor Major Depression\nas determined\na checklist\n(American\nwith\nPsychiatric\nby investigators\na semi-structured\nAssociation,\nand Statistical Manual of Mental Disorders,\nton\nScale\n(single episode\nusing\ninterview\nDiagnostic\n3rd.\ned. revised, 1987). Patients were at least moder-\nately depressed,\nPsychiatric\nfor Depression\n(HAM-D 17-item) (Hamilton,\nThese patients\nwith physical\nwith a total score on the Hamil-\nRating\n1960) of at least 18,\nand on item 1 of the HAM-D (depressed mood) a\nscore of at least 3, at the start of double-blind\ntreatment.\ndid not have more than\na 5-point decrease in their HAM-D 17-item total\nscore during the placebo week.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,"Physical illness, depression secondary to another psychiatric disorder or to a current medical illness, chronic or organic brain disease, mental deficiency, alcoholism, epilepsy or drug addiction.",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,Chloral hydrate or temazepam PRN,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1991.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,na,16 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Chouinard, 1994",na,na,na,na,na,na,na,na,na,na,na,37220,placebo,na,na,na,na,40.2,na,na,109,na,na,66,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,52,na,na,7,na,na,na,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,Headache=56;Nausea=28;Dizziness=15;Insomnia=14;Dry mouth=5;Constipation=12;Diarrhea=14;Flatulence=3;Stomach upset=10;Fatigue=5,na,na,na,na,6weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,18-64,na,na,tick,tick,na,tick,tick,na,na,na,na,na,tick,na,na,na,87999011.0,Continuous,109032.0,113613021.0,1.0,13669974.0,0.0,13784117.0,HAM-D Anxiety,1833.0,weeks,0,0 weeks,37220.0,0.0,placebo,,Chouinard (1993),,109.0,7.5,99999.0,0.0,Placebo,HAMD- Anxiety item
87999011,Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.,Clinical neuropharmacology,Chouinard (1993),1993,"Chouinard G, Saxena B M, Nair N P, Kutcher S P, Bakish D, Bradwejn J, Kennedy S H, Sharma V, Remick R A, and Kukha-Mohamad S A (1993) Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.. Clinical neuropharmacology 16 Suppl 2, S51-4","[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Chouinard a[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1994)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Canada,""\n""UK[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,tick,tick,na,na,"[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were both men and women aged be-\ntween 18 and 65 years who satisfied the DSM-III-\nR diagnosis\nor recurrent)\nfor Major Depression\nas determined\na checklist\n(American\nwith\nPsychiatric\nby investigators\na semi-structured\nAssociation,\nand Statistical Manual of Mental Disorders,\nton\nScale\n(single episode\nusing\ninterview\nDiagnostic\n3rd.\ned. revised, 1987). Patients were at least moder-\nately depressed,\nPsychiatric\nfor Depression\n(HAM-D 17-item) (Hamilton,\nThese patients\nwith physical\nwith a total score on the Hamil-\nRating\n1960) of at least 18,\nand on item 1 of the HAM-D (depressed mood) a\nscore of at least 3, at the start of double-blind\ntreatment.\ndid not have more than\na 5-point decrease in their HAM-D 17-item total\nscore during the placebo week.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,"Physical illness, depression secondary to another psychiatric disorder or to a current medical illness, chronic or organic brain disease, mental deficiency, alcoholism, epilepsy or drug addiction.",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,Chloral hydrate or temazepam PRN,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1991.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,na,16 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Chouinard, 1994",na,na,na,na,na,na,na,na,na,na,na,37220,placebo,na,na,na,na,40.2,na,na,109,na,na,66,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,52,na,na,7,na,na,na,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,Headache=56;Nausea=28;Dizziness=15;Insomnia=14;Dry mouth=5;Constipation=12;Diarrhea=14;Flatulence=3;Stomach upset=10;Fatigue=5,na,na,na,na,6weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,18-64,na,na,tick,tick,na,tick,tick,na,na,na,na,na,tick,na,na,na,87999011.0,Continuous,109033.0,113613021.0,1.0,13669974.0,0.0,13784117.0,HAM-D Anxiety,1834.0,weeks,6,6 weeks,37220.0,0.0,placebo,,Chouinard (1993),,109.0,5.0,99999.0,0.0,Placebo,HAMD- Anxiety item
87999011,Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.,Clinical neuropharmacology,Chouinard (1993),1993,"Chouinard G, Saxena B M, Nair N P, Kutcher S P, Bakish D, Bradwejn J, Kennedy S H, Sharma V, Remick R A, and Kukha-Mohamad S A (1993) Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.. Clinical neuropharmacology 16 Suppl 2, S51-4","[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Chouinard a[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1994)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Canada,""\n""UK[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,tick,tick,na,na,"[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were both men and women aged be-\ntween 18 and 65 years who satisfied the DSM-III-\nR diagnosis\nor recurrent)\nfor Major Depression\nas determined\na checklist\n(American\nwith\nPsychiatric\nby investigators\na semi-structured\nAssociation,\nand Statistical Manual of Mental Disorders,\nton\nScale\n(single episode\nusing\ninterview\nDiagnostic\n3rd.\ned. revised, 1987). Patients were at least moder-\nately depressed,\nPsychiatric\nfor Depression\n(HAM-D 17-item) (Hamilton,\nThese patients\nwith physical\nwith a total score on the Hamil-\nRating\n1960) of at least 18,\nand on item 1 of the HAM-D (depressed mood) a\nscore of at least 3, at the start of double-blind\ntreatment.\ndid not have more than\na 5-point decrease in their HAM-D 17-item total\nscore during the placebo week.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,"Physical illness, depression secondary to another psychiatric disorder or to a current medical illness, chronic or organic brain disease, mental deficiency, alcoholism, epilepsy or drug addiction.",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,Chloral hydrate or temazepam PRN,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1991.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,na,16 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Chouinard, 1994",na,na,na,na,na,na,na,na,na,na,na,37221,brofaromine,na,na,na,na,41.2,na,na,111,na,na,57,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,43,na,na,16,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Headache=53;Nausea=41;Dizziness=26;Insomnia=26;Dry mouth=22;Constipation=16;Diarrhea=15;Flatulence=8;Stomach upset=5;Fatigue=5,na,na,tick,tick,6weeks,75mg,150mg,na,na,na,na,na,na,tick,na,tick,na,tick,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,18-64,na,na,tick,tick,na,tick,tick,na,na,na,na,na,tick,tick,na,na,87999011.0,Continuous,109034.0,113613021.0,1.0,13788719.0,0.0,13784117.0,HAM-D Anxiety,1833.0,weeks,0,0 weeks,37221.0,0.0,brofaromine,,Chouinard (1993),,111.0,7.6,99999.0,0.0,*Brofaromine,HAMD- Anxiety item
87999011,Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.,Clinical neuropharmacology,Chouinard (1993),1993,"Chouinard G, Saxena B M, Nair N P, Kutcher S P, Bakish D, Bradwejn J, Kennedy S H, Sharma V, Remick R A, and Kukha-Mohamad S A (1993) Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.. Clinical neuropharmacology 16 Suppl 2, S51-4","[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Chouinard a[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1994)[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Canada,""\n""UK[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,tick,tick,na,na,"[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Patients were both men and women aged be-\ntween 18 and 65 years who satisfied the DSM-III-\nR diagnosis\nor recurrent)\nfor Major Depression\nas determined\na checklist\n(American\nwith\nPsychiatric\nby investigators\na semi-structured\nAssociation,\nand Statistical Manual of Mental Disorders,\nton\nScale\n(single episode\nusing\ninterview\nDiagnostic\n3rd.\ned. revised, 1987). Patients were at least moder-\nately depressed,\nPsychiatric\nfor Depression\n(HAM-D 17-item) (Hamilton,\nThese patients\nwith physical\nwith a total score on the Hamil-\nRating\n1960) of at least 18,\nand on item 1 of the HAM-D (depressed mood) a\nscore of at least 3, at the start of double-blind\ntreatment.\ndid not have more than\na 5-point decrease in their HAM-D 17-item total\nscore during the placebo week.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,"Physical illness, depression secondary to another psychiatric disorder or to a current medical illness, chronic or organic brain disease, mental deficiency, alcoholism, epilepsy or drug addiction.",na,na,na,na,na,na,na,na,na,na,na,na,Depression,tick,tick,na,Chloral hydrate or temazepam PRN,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1070383, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1991.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'choinard.pdf', 'ItemArm': ''}]",na,na,16 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Chouinard, 1994",na,na,na,na,na,na,na,na,na,na,na,37221,brofaromine,na,na,na,na,41.2,na,na,111,na,na,57,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,43,na,na,16,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Headache=53;Nausea=41;Dizziness=26;Insomnia=26;Dry mouth=22;Constipation=16;Diarrhea=15;Flatulence=8;Stomach upset=5;Fatigue=5,na,na,tick,tick,6weeks,75mg,150mg,na,na,na,na,na,na,tick,na,tick,na,tick,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,18-64,na,na,tick,tick,na,tick,tick,na,na,na,na,na,tick,tick,na,na,87999011.0,Continuous,109035.0,113613021.0,1.0,13788719.0,0.0,13784117.0,HAM-D Anxiety,1834.0,weeks,6,6 weeks,37221.0,0.0,brofaromine,,Chouinard (1993),,111.0,4.9,99999.0,0.0,*Brofaromine,HAMD- Anxiety item
87999374,"A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.",Pharmacopsychiatry,Casacchia (1984),1984,"Casacchia M, Carolei A, Barba C, Frontoni M, Rossi A, Meco G, and Zylberman M R (1984) A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.. Pharmacopsychiatry 17(4), 122-5","[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Casacchia[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984""\n""ltaly[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Forty inpatients with manic depressive psychosis, depressive type\n(296.1-ICD9), or neurotic depression (300.4-ICD9), were included\nin the trial. An initial total score of at least 20 on the 24-ltems\nHRSD was aprerequisite.[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Patients with organic brain diseases, drug\naddiction and general organic diseases were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"Unipolar psychotic depression, neurotic depression",tick,tick,na,Benzodiazepines 1-3/day; Flurazepam,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Casacchia, 1984",na,na,na,na,na,na,na,na,na,na,na,37218,Moclobemide,na,na,na,na,49.5,na,na,18,na,na,8,na,na,tick,tick,Unipolar psychotic depression=9;Neurotic depression=9,na,na,na,Benzodiazepines 1-3 tab. (day)=6; Flurazepam-Flunitrazepam (night)=7,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,5,na,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Diurnal somnolence=1;trembling=2;dry mouth=1;constipation=1,na,150mg,297.2mg,450mg,4 weeks,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,na,na,na,tick,12.8,na,na,na,5,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,87999374.0,Continuous,109248.0,113612854.0,1.0,13669968.0,0.0,13720108.0,HRSD - Psychic anxiety,1831.0,weeks,0,0 weeks,37218.0,0.0,Moclobemide,,Casacchia (1984),,18.0,2.77,0.64,0.0,Moclobemide,*HRSD - psychic anxiety item
87999374,"A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.",Pharmacopsychiatry,Casacchia (1984),1984,"Casacchia M, Carolei A, Barba C, Frontoni M, Rossi A, Meco G, and Zylberman M R (1984) A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.. Pharmacopsychiatry 17(4), 122-5","[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Casacchia[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984""\n""ltaly[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Forty inpatients with manic depressive psychosis, depressive type\n(296.1-ICD9), or neurotic depression (300.4-ICD9), were included\nin the trial. An initial total score of at least 20 on the 24-ltems\nHRSD was aprerequisite.[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Patients with organic brain diseases, drug\naddiction and general organic diseases were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"Unipolar psychotic depression, neurotic depression",tick,tick,na,Benzodiazepines 1-3/day; Flurazepam,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Casacchia, 1984",na,na,na,na,na,na,na,na,na,na,na,37218,Moclobemide,na,na,na,na,49.5,na,na,18,na,na,8,na,na,tick,tick,Unipolar psychotic depression=9;Neurotic depression=9,na,na,na,Benzodiazepines 1-3 tab. (day)=6; Flurazepam-Flunitrazepam (night)=7,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,5,na,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Diurnal somnolence=1;trembling=2;dry mouth=1;constipation=1,na,150mg,297.2mg,450mg,4 weeks,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,na,na,na,tick,12.8,na,na,na,5,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,87999374.0,Continuous,109249.0,113612854.0,1.0,13669968.0,0.0,13720108.0,HRSD - Psychic anxiety,1832.0,weeks,4,4 weeks,37218.0,0.0,Moclobemide,,Casacchia (1984),,18.0,1.38,1.0,0.0,Moclobemide,*HRSD - psychic anxiety item
87999374,"A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.",Pharmacopsychiatry,Casacchia (1984),1984,"Casacchia M, Carolei A, Barba C, Frontoni M, Rossi A, Meco G, and Zylberman M R (1984) A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.. Pharmacopsychiatry 17(4), 122-5","[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Casacchia[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984""\n""ltaly[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Forty inpatients with manic depressive psychosis, depressive type\n(296.1-ICD9), or neurotic depression (300.4-ICD9), were included\nin the trial. An initial total score of at least 20 on the 24-ltems\nHRSD was aprerequisite.[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Patients with organic brain diseases, drug\naddiction and general organic diseases were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"Unipolar psychotic depression, neurotic depression",tick,tick,na,Benzodiazepines 1-3/day; Flurazepam,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Casacchia, 1984",na,na,na,na,na,na,na,na,na,na,na,37218,Moclobemide,na,na,na,na,49.5,na,na,18,na,na,8,na,na,tick,tick,Unipolar psychotic depression=9;Neurotic depression=9,na,na,na,Benzodiazepines 1-3 tab. (day)=6; Flurazepam-Flunitrazepam (night)=7,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,5,na,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Diurnal somnolence=1;trembling=2;dry mouth=1;constipation=1,na,150mg,297.2mg,450mg,4 weeks,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,na,na,na,tick,12.8,na,na,na,5,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,87999374.0,Continuous,109252.0,113612854.0,1.0,13669968.0,0.0,13796761.0,HRSD - Somatic anxiety,1831.0,weeks,0,0 weeks,37218.0,0.0,Moclobemide,,Casacchia (1984),,18.0,2.83,0.85,0.0,Moclobemide,*HRSD - somatic anxiety item
87999374,"A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.",Pharmacopsychiatry,Casacchia (1984),1984,"Casacchia M, Carolei A, Barba C, Frontoni M, Rossi A, Meco G, and Zylberman M R (1984) A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.. Pharmacopsychiatry 17(4), 122-5","[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Casacchia[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984""\n""ltaly[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Forty inpatients with manic depressive psychosis, depressive type\n(296.1-ICD9), or neurotic depression (300.4-ICD9), were included\nin the trial. An initial total score of at least 20 on the 24-ltems\nHRSD was aprerequisite.[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Patients with organic brain diseases, drug\naddiction and general organic diseases were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"Unipolar psychotic depression, neurotic depression",tick,tick,na,Benzodiazepines 1-3/day; Flurazepam,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Casacchia, 1984",na,na,na,na,na,na,na,na,na,na,na,37218,Moclobemide,na,na,na,na,49.5,na,na,18,na,na,8,na,na,tick,tick,Unipolar psychotic depression=9;Neurotic depression=9,na,na,na,Benzodiazepines 1-3 tab. (day)=6; Flurazepam-Flunitrazepam (night)=7,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,5,na,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Diurnal somnolence=1;trembling=2;dry mouth=1;constipation=1,na,150mg,297.2mg,450mg,4 weeks,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,na,na,na,tick,12.8,na,na,na,5,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,87999374.0,Continuous,109253.0,113612854.0,1.0,13669968.0,0.0,13796761.0,HRSD - Somatic anxiety,1832.0,weeks,4,4 weeks,37218.0,0.0,Moclobemide,,Casacchia (1984),,18.0,1.33,0.84,0.0,Moclobemide,*HRSD - somatic anxiety item
87999374,"A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.",Pharmacopsychiatry,Casacchia (1984),1984,"Casacchia M, Carolei A, Barba C, Frontoni M, Rossi A, Meco G, and Zylberman M R (1984) A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.. Pharmacopsychiatry 17(4), 122-5","[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Casacchia[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984""\n""ltaly[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Forty inpatients with manic depressive psychosis, depressive type\n(296.1-ICD9), or neurotic depression (300.4-ICD9), were included\nin the trial. An initial total score of at least 20 on the 24-ltems\nHRSD was aprerequisite.[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Patients with organic brain diseases, drug\naddiction and general organic diseases were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"Unipolar psychotic depression, neurotic depression",tick,tick,na,Benzodiazepines 1-3/day; Flurazepam,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Casacchia, 1984",na,na,na,na,na,na,na,na,na,na,na,37219,Placebo,na,na,na,na,49,na,na,16,na,na,11,na,na,tick,tick,Unipolar psychotic depression=10 Neurotic depression=6,na,na,na,Benzodiazepines 1-3 tab. (day)=9; Flurazepam-Flunitrazepam (night)=7,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,9,na,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Sleep disturbances=1;dry mouth=1,na,150mg,212.5mg,400mg,4 weeks,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,na,na,na,tick,11.4,na,na,na,2,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,87999374.0,Continuous,109250.0,113612854.0,1.0,13669974.0,0.0,13720108.0,HRSD - Psychic anxiety,1831.0,weeks,0,0 weeks,37219.0,0.0,Placebo,,Casacchia (1984),,16.0,2.43,1.03,0.0,Placebo,*HRSD - psychic anxiety item
87999374,"A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.",Pharmacopsychiatry,Casacchia (1984),1984,"Casacchia M, Carolei A, Barba C, Frontoni M, Rossi A, Meco G, and Zylberman M R (1984) A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.. Pharmacopsychiatry 17(4), 122-5","[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Casacchia[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984""\n""ltaly[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Forty inpatients with manic depressive psychosis, depressive type\n(296.1-ICD9), or neurotic depression (300.4-ICD9), were included\nin the trial. An initial total score of at least 20 on the 24-ltems\nHRSD was aprerequisite.[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Patients with organic brain diseases, drug\naddiction and general organic diseases were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"Unipolar psychotic depression, neurotic depression",tick,tick,na,Benzodiazepines 1-3/day; Flurazepam,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Casacchia, 1984",na,na,na,na,na,na,na,na,na,na,na,37219,Placebo,na,na,na,na,49,na,na,16,na,na,11,na,na,tick,tick,Unipolar psychotic depression=10 Neurotic depression=6,na,na,na,Benzodiazepines 1-3 tab. (day)=9; Flurazepam-Flunitrazepam (night)=7,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,9,na,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Sleep disturbances=1;dry mouth=1,na,150mg,212.5mg,400mg,4 weeks,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,na,na,na,tick,11.4,na,na,na,2,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,87999374.0,Continuous,109251.0,113612854.0,1.0,13669974.0,0.0,13720108.0,HRSD - Psychic anxiety,1832.0,weeks,4,4 weeks,37219.0,0.0,Placebo,,Casacchia (1984),,16.0,2.06,0.93,0.0,Placebo,*HRSD - psychic anxiety item
87999374,"A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.",Pharmacopsychiatry,Casacchia (1984),1984,"Casacchia M, Carolei A, Barba C, Frontoni M, Rossi A, Meco G, and Zylberman M R (1984) A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.. Pharmacopsychiatry 17(4), 122-5","[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Casacchia[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984""\n""ltaly[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Forty inpatients with manic depressive psychosis, depressive type\n(296.1-ICD9), or neurotic depression (300.4-ICD9), were included\nin the trial. An initial total score of at least 20 on the 24-ltems\nHRSD was aprerequisite.[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Patients with organic brain diseases, drug\naddiction and general organic diseases were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"Unipolar psychotic depression, neurotic depression",tick,tick,na,Benzodiazepines 1-3/day; Flurazepam,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Casacchia, 1984",na,na,na,na,na,na,na,na,na,na,na,37219,Placebo,na,na,na,na,49,na,na,16,na,na,11,na,na,tick,tick,Unipolar psychotic depression=10 Neurotic depression=6,na,na,na,Benzodiazepines 1-3 tab. (day)=9; Flurazepam-Flunitrazepam (night)=7,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,9,na,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Sleep disturbances=1;dry mouth=1,na,150mg,212.5mg,400mg,4 weeks,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,na,na,na,tick,11.4,na,na,na,2,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,87999374.0,Continuous,109254.0,113612854.0,1.0,13669974.0,0.0,13796761.0,HRSD - Somatic anxiety,1831.0,weeks,0,0 weeks,37219.0,0.0,Placebo,,Casacchia (1984),,16.0,2.68,0.87,0.0,Placebo,*HRSD - somatic anxiety item
87999374,"A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.",Pharmacopsychiatry,Casacchia (1984),1984,"Casacchia M, Carolei A, Barba C, Frontoni M, Rossi A, Meco G, and Zylberman M R (1984) A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.. Pharmacopsychiatry 17(4), 122-5","[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Casacchia[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1984""\n""ltaly[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Forty inpatients with manic depressive psychosis, depressive type\n(296.1-ICD9), or neurotic depression (300.4-ICD9), were included\nin the trial. An initial total score of at least 20 on the 24-ltems\nHRSD was aprerequisite.[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1055491, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Patients with organic brain diseases, drug\naddiction and general organic diseases were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 's-2007-1017421.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"Unipolar psychotic depression, neurotic depression",tick,tick,na,Benzodiazepines 1-3/day; Flurazepam,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Casacchia, 1984",na,na,na,na,na,na,na,na,na,na,na,37219,Placebo,na,na,na,na,49,na,na,16,na,na,11,na,na,tick,tick,Unipolar psychotic depression=10 Neurotic depression=6,na,na,na,Benzodiazepines 1-3 tab. (day)=9; Flurazepam-Flunitrazepam (night)=7,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,9,na,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Sleep disturbances=1;dry mouth=1,na,150mg,212.5mg,400mg,4 weeks,tick,tick,na,na,tick,na,tick,na,na,na,na,na,na,na,2x daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,na,na,na,tick,11.4,na,na,na,2,na,na,tick,tick,na,na,na,na,na,na,na,tick,na,87999374.0,Continuous,109255.0,113612854.0,1.0,13669974.0,0.0,13796761.0,HRSD - Somatic anxiety,1832.0,weeks,4,4 weeks,37219.0,0.0,Placebo,,Casacchia (1984),,16.0,2.12,0.88,0.0,Placebo,*HRSD - somatic anxiety item
90051758,"Efficacy and safety of EB-1010, a triple reuptake inhibitor, in the treatment of patients with major depressive disorder","66th Annual Meeting of the Society of Biological Psychiatry. San Francisco, CA United States.",Bymaster (2011),2011,"Bymaster F, Skolnick P, Huang N Y, Bradshaw M, McKinney A, Manthis J, Fava M, and Tran P (2011) Efficacy and safety of EB-1010, a triple reuptake inhibitor, in the treatment of patients with major depressive disorder. 66th Annual Meeting of the Society of Biological Psychiatry. San Francisco, and CA United States. 69(9 SUPPL. 1), 37S-38S DOI: https://dx.doi.org/10.1016/j.biopsych.2011.03.030","[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Tran[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2012[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""t 11 sites in Romania, 2 sites in Serbia,\nand 7 sites in the United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 6:\n[¬s]""DOV Pharmaceuticals[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""Euthymics Bioscience[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,tick,tick,na,na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Adult outpatients or inpatients between ages 18 and 65 years\n(inclusive) were eligible if they were diagnosed with major[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""depressive disorder according to Diagnostic and Statistical Manual\nof Mental Disorders, 4th Edition, Revised (American Psychiatric\nAssociation, 2000) and MINI International Neuropsychiatric Inter-\nview for major depressive disorder (Sheehan et al., 1998). Patients\nwere required to have a history of recurrent depressive episode of\nat least 2 months in duration. They also were required to have\na previous signiﬁcant clinical improvement to at least one antide-\npressant treatment. In addition, they had a 17-item Hamilton\nDepression Rating Scale (HAMD-17; Hamilton, 1960) total\nscore \t 22 with severity score of\t2 on Item 1 at screening, single-\nblind placebo run-in, and baseline; HAMD-17 score reduction \t15%\nbetween placebo run-in and baseline; Hamilton Anxiety Rating\nScale (HAM-A; Hamilton, 1959) total score <17 at screening; body\nmass index \t35 kg/m2 and body weight >45 kg at screening; and\nstudy medication compliance of80%e120% during the single-blind,\nplacebo run-in period. In addition, any patient receiving psycho-""\n""therapy must have been on the same treatment for at least 3\nmonths prior to screening and the therapy must have remained\nunchanged throughout the study. Women of childbearing potential\nwere required to use adequate contraception and to have a negative\nserum pregnancy test at screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Excluded were patients judged to be a suicide risk, including\nthose with a score of4 on the HAMD-17 suicide item. Also excluded\nwere patients with >15% reduction in the HAMD-17 score between\nscreening and the baseline visit, those known to be resistant to\nantidepressant treatment (failed 2 previous antidepressant treat-\nments from different classes given for at least 4 weeks) or elec-\ntroconvulsive therapy, or who had electroconvulsive therapy\nwithin 1 year before screening. Patients with psychotic depression\nor those who had taken ﬂuoxetine within 4 weeks prior to\nscreening or other antidepressants within 2 weeks or 5 half-lives of\nthe antidepressant (whichever was longer) before baseline were\nexcluded. Patients with any other psychiatric disorder including\nsubstance use disorders were excluded. Study participants were\nrequired to be free of major clinically signiﬁcant medical and/or\nother psychiatric illnesses. Patients with a history of signiﬁcant\ndrug or food allergy or hypersensitivity were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depressive disorder[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,8months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Tran, 2012; Bymaster, 2011",na,na,na,na,na,na,na,na,na,na,na,37185,placebo,na,na,na,na,49.50,na,na,29,na,na,19,na,na,Caucasian=28,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,12,na,na,3,na,na,tick,tick,tick,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Headache=3;Abdominal pain=1;Anxiety=1;Diarrhea=1;Irritability=1;Nausea=1;Rash=1;Upper respiratory tract infection=1;,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,6.90,na,na,na,10,na,na,0,na,na,na,tick,na,na,na,na,na,na,90051758.0,Continuous,107589.0,113601770.0,1.0,13669974.0,0.0,13749631.0,MADRS Anhedonia Factor,1811.0,weeks,0,0 weeks,37185.0,0.0,placebo,,Bymaster (2011),LSmeans; convSE,28.0,13.7,1.6,0.0,Placebo,MADRS Anhedonia factor
90051758,"Efficacy and safety of EB-1010, a triple reuptake inhibitor, in the treatment of patients with major depressive disorder","66th Annual Meeting of the Society of Biological Psychiatry. San Francisco, CA United States.",Bymaster (2011),2011,"Bymaster F, Skolnick P, Huang N Y, Bradshaw M, McKinney A, Manthis J, Fava M, and Tran P (2011) Efficacy and safety of EB-1010, a triple reuptake inhibitor, in the treatment of patients with major depressive disorder. 66th Annual Meeting of the Society of Biological Psychiatry. San Francisco, and CA United States. 69(9 SUPPL. 1), 37S-38S DOI: https://dx.doi.org/10.1016/j.biopsych.2011.03.030","[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Tran[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2012[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""t 11 sites in Romania, 2 sites in Serbia,\nand 7 sites in the United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 6:\n[¬s]""DOV Pharmaceuticals[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""Euthymics Bioscience[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,tick,tick,na,na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Adult outpatients or inpatients between ages 18 and 65 years\n(inclusive) were eligible if they were diagnosed with major[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""depressive disorder according to Diagnostic and Statistical Manual\nof Mental Disorders, 4th Edition, Revised (American Psychiatric\nAssociation, 2000) and MINI International Neuropsychiatric Inter-\nview for major depressive disorder (Sheehan et al., 1998). Patients\nwere required to have a history of recurrent depressive episode of\nat least 2 months in duration. They also were required to have\na previous signiﬁcant clinical improvement to at least one antide-\npressant treatment. In addition, they had a 17-item Hamilton\nDepression Rating Scale (HAMD-17; Hamilton, 1960) total\nscore \t 22 with severity score of\t2 on Item 1 at screening, single-\nblind placebo run-in, and baseline; HAMD-17 score reduction \t15%\nbetween placebo run-in and baseline; Hamilton Anxiety Rating\nScale (HAM-A; Hamilton, 1959) total score <17 at screening; body\nmass index \t35 kg/m2 and body weight >45 kg at screening; and\nstudy medication compliance of80%e120% during the single-blind,\nplacebo run-in period. In addition, any patient receiving psycho-""\n""therapy must have been on the same treatment for at least 3\nmonths prior to screening and the therapy must have remained\nunchanged throughout the study. Women of childbearing potential\nwere required to use adequate contraception and to have a negative\nserum pregnancy test at screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Excluded were patients judged to be a suicide risk, including\nthose with a score of4 on the HAMD-17 suicide item. Also excluded\nwere patients with >15% reduction in the HAMD-17 score between\nscreening and the baseline visit, those known to be resistant to\nantidepressant treatment (failed 2 previous antidepressant treat-\nments from different classes given for at least 4 weeks) or elec-\ntroconvulsive therapy, or who had electroconvulsive therapy\nwithin 1 year before screening. Patients with psychotic depression\nor those who had taken ﬂuoxetine within 4 weeks prior to\nscreening or other antidepressants within 2 weeks or 5 half-lives of\nthe antidepressant (whichever was longer) before baseline were\nexcluded. Patients with any other psychiatric disorder including\nsubstance use disorders were excluded. Study participants were\nrequired to be free of major clinically signiﬁcant medical and/or\nother psychiatric illnesses. Patients with a history of signiﬁcant\ndrug or food allergy or hypersensitivity were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depressive disorder[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,8months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Tran, 2012; Bymaster, 2011",na,na,na,na,na,na,na,na,na,na,na,37185,placebo,na,na,na,na,49.50,na,na,29,na,na,19,na,na,Caucasian=28,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,12,na,na,3,na,na,tick,tick,tick,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Headache=3;Abdominal pain=1;Anxiety=1;Diarrhea=1;Irritability=1;Nausea=1;Rash=1;Upper respiratory tract infection=1;,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,6.90,na,na,na,10,na,na,0,na,na,na,tick,na,na,na,na,na,na,90051758.0,Continuous,107591.0,113601770.0,1.0,13669974.0,0.0,13749631.0,MADRS Anhedonia Factor,1812.0,weeks,6,6 weeks,37185.0,0.0,placebo,,Bymaster (2011),LSmeans; convSE,26.0,9.3,1.58,0.0,Placebo,MADRS Anhedonia factor
90051758,"Efficacy and safety of EB-1010, a triple reuptake inhibitor, in the treatment of patients with major depressive disorder","66th Annual Meeting of the Society of Biological Psychiatry. San Francisco, CA United States.",Bymaster (2011),2011,"Bymaster F, Skolnick P, Huang N Y, Bradshaw M, McKinney A, Manthis J, Fava M, and Tran P (2011) Efficacy and safety of EB-1010, a triple reuptake inhibitor, in the treatment of patients with major depressive disorder. 66th Annual Meeting of the Society of Biological Psychiatry. San Francisco, and CA United States. 69(9 SUPPL. 1), 37S-38S DOI: https://dx.doi.org/10.1016/j.biopsych.2011.03.030","[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Tran[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2012[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""t 11 sites in Romania, 2 sites in Serbia,\nand 7 sites in the United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 6:\n[¬s]""DOV Pharmaceuticals[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""Euthymics Bioscience[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,tick,tick,na,na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Adult outpatients or inpatients between ages 18 and 65 years\n(inclusive) were eligible if they were diagnosed with major[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""depressive disorder according to Diagnostic and Statistical Manual\nof Mental Disorders, 4th Edition, Revised (American Psychiatric\nAssociation, 2000) and MINI International Neuropsychiatric Inter-\nview for major depressive disorder (Sheehan et al., 1998). Patients\nwere required to have a history of recurrent depressive episode of\nat least 2 months in duration. They also were required to have\na previous signiﬁcant clinical improvement to at least one antide-\npressant treatment. In addition, they had a 17-item Hamilton\nDepression Rating Scale (HAMD-17; Hamilton, 1960) total\nscore \t 22 with severity score of\t2 on Item 1 at screening, single-\nblind placebo run-in, and baseline; HAMD-17 score reduction \t15%\nbetween placebo run-in and baseline; Hamilton Anxiety Rating\nScale (HAM-A; Hamilton, 1959) total score <17 at screening; body\nmass index \t35 kg/m2 and body weight >45 kg at screening; and\nstudy medication compliance of80%e120% during the single-blind,\nplacebo run-in period. In addition, any patient receiving psycho-""\n""therapy must have been on the same treatment for at least 3\nmonths prior to screening and the therapy must have remained\nunchanged throughout the study. Women of childbearing potential\nwere required to use adequate contraception and to have a negative\nserum pregnancy test at screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Excluded were patients judged to be a suicide risk, including\nthose with a score of4 on the HAMD-17 suicide item. Also excluded\nwere patients with >15% reduction in the HAMD-17 score between\nscreening and the baseline visit, those known to be resistant to\nantidepressant treatment (failed 2 previous antidepressant treat-\nments from different classes given for at least 4 weeks) or elec-\ntroconvulsive therapy, or who had electroconvulsive therapy\nwithin 1 year before screening. Patients with psychotic depression\nor those who had taken ﬂuoxetine within 4 weeks prior to\nscreening or other antidepressants within 2 weeks or 5 half-lives of\nthe antidepressant (whichever was longer) before baseline were\nexcluded. Patients with any other psychiatric disorder including\nsubstance use disorders were excluded. Study participants were\nrequired to be free of major clinically signiﬁcant medical and/or\nother psychiatric illnesses. Patients with a history of signiﬁcant\ndrug or food allergy or hypersensitivity were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depressive disorder[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,8months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Tran, 2012; Bymaster, 2011",na,na,na,na,na,na,na,na,na,na,na,37186,amitifadine,na,na,na,na,48.20,na,na,34,na,na,25,na,na,Caucasian=31;Black=1;Hispanic=1,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,18,na,na,3,na,na,tick,tick,tick,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Headache=3;Abdominal pain=2;Anxiety=2;Diarrhea=2;Irritability=2;Nausea=2;Rash=2;Upper respiratory tract infection=2;emotional disturbance=2,na,25mg,tick,50mg,6 weeks,50mg,50mg,na,na,na,na,na,na,na,na,tick,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,9.40,na,na,na,19,na,na,0,na,na,tick,tick,na,na,na,na,na,na,90051758.0,Continuous,107590.0,113601770.0,1.0,13749630.0,0.0,13749631.0,MADRS Anhedonia Factor,1811.0,weeks,0,0 weeks,37186.0,0.0,amitifadine,,Bymaster (2011),LSmeans; convSE,33.0,12.8,2.1,0.0,Amitifadine,MADRS Anhedonia factor
90051758,"Efficacy and safety of EB-1010, a triple reuptake inhibitor, in the treatment of patients with major depressive disorder","66th Annual Meeting of the Society of Biological Psychiatry. San Francisco, CA United States.",Bymaster (2011),2011,"Bymaster F, Skolnick P, Huang N Y, Bradshaw M, McKinney A, Manthis J, Fava M, and Tran P (2011) Efficacy and safety of EB-1010, a triple reuptake inhibitor, in the treatment of patients with major depressive disorder. 66th Annual Meeting of the Society of Biological Psychiatry. San Francisco, and CA United States. 69(9 SUPPL. 1), 37S-38S DOI: https://dx.doi.org/10.1016/j.biopsych.2011.03.030","[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Tran[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2012[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""t 11 sites in Romania, 2 sites in Serbia,\nand 7 sites in the United States[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 6:\n[¬s]""DOV Pharmaceuticals[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""Euthymics Bioscience[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,tick,tick,na,na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Adult outpatients or inpatients between ages 18 and 65 years\n(inclusive) were eligible if they were diagnosed with major[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}, {'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""depressive disorder according to Diagnostic and Statistical Manual\nof Mental Disorders, 4th Edition, Revised (American Psychiatric\nAssociation, 2000) and MINI International Neuropsychiatric Inter-\nview for major depressive disorder (Sheehan et al., 1998). Patients\nwere required to have a history of recurrent depressive episode of\nat least 2 months in duration. They also were required to have\na previous signiﬁcant clinical improvement to at least one antide-\npressant treatment. In addition, they had a 17-item Hamilton\nDepression Rating Scale (HAMD-17; Hamilton, 1960) total\nscore \t 22 with severity score of\t2 on Item 1 at screening, single-\nblind placebo run-in, and baseline; HAMD-17 score reduction \t15%\nbetween placebo run-in and baseline; Hamilton Anxiety Rating\nScale (HAM-A; Hamilton, 1959) total score <17 at screening; body\nmass index \t35 kg/m2 and body weight >45 kg at screening; and\nstudy medication compliance of80%e120% during the single-blind,\nplacebo run-in period. In addition, any patient receiving psycho-""\n""therapy must have been on the same treatment for at least 3\nmonths prior to screening and the therapy must have remained\nunchanged throughout the study. Women of childbearing potential\nwere required to use adequate contraception and to have a negative\nserum pregnancy test at screening.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 3:\n[¬s]""Excluded were patients judged to be a suicide risk, including\nthose with a score of4 on the HAMD-17 suicide item. Also excluded\nwere patients with >15% reduction in the HAMD-17 score between\nscreening and the baseline visit, those known to be resistant to\nantidepressant treatment (failed 2 previous antidepressant treat-\nments from different classes given for at least 4 weeks) or elec-\ntroconvulsive therapy, or who had electroconvulsive therapy\nwithin 1 year before screening. Patients with psychotic depression\nor those who had taken ﬂuoxetine within 4 weeks prior to\nscreening or other antidepressants within 2 weeks or 5 half-lives of\nthe antidepressant (whichever was longer) before baseline were\nexcluded. Patients with any other psychiatric disorder including\nsubstance use disorders were excluded. Study participants were\nrequired to be free of major clinically signiﬁcant medical and/or\nother psychiatric illnesses. Patients with a history of signiﬁcant\ndrug or food allergy or hypersensitivity were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1071194, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depressive disorder[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0022395611001890-main.pdf', 'ItemArm': ''}]",tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,8months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Tran, 2012; Bymaster, 2011",na,na,na,na,na,na,na,na,na,na,na,37186,amitifadine,na,na,na,na,48.20,na,na,34,na,na,25,na,na,Caucasian=31;Black=1;Hispanic=1,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,18,na,na,3,na,na,tick,tick,tick,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Headache=3;Abdominal pain=2;Anxiety=2;Diarrhea=2;Irritability=2;Nausea=2;Rash=2;Upper respiratory tract infection=2;emotional disturbance=2,na,25mg,tick,50mg,6 weeks,50mg,50mg,na,na,na,na,na,na,na,na,tick,na,na,na,4x daily,na,na,na,na,na,na,na,na,na,N/A,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,9.40,na,na,na,19,na,na,0,na,na,tick,tick,na,na,na,na,na,na,90051758.0,Continuous,107592.0,113601770.0,1.0,13749630.0,0.0,13749631.0,MADRS Anhedonia Factor,1812.0,weeks,6,6 weeks,37186.0,0.0,amitifadine,,Bymaster (2011),LSmeans; convSE,33.0,7.9,2.74,0.0,Amitifadine,MADRS Anhedonia factor
87999081,Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression.,Acta psychiatrica Belgica,Botte (1992),1992,"Botte L, Evrard J L, Gilles C, Stenier P, and Wolfrum C (1992) Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression.. Acta psychiatrica Belgica 92(6), 355-69",Botte,na,na,1992,na,tick,na,tick,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"Patients were selected on the basis of a diagnosis of depression according to the International Classification of Disease (ICD, 1975): unipolar depression (296.1) or neurotic depression (300.4).",na,"Patients with schizophrenia, psycho-organic syndrome, drug or alcohol abuse or clear suicidal risk, severe organic disease were excluded. ",na,na,na,na,na,na,na,na,na,na,na,na,unipolar depression or neurotic depression,tick,tick,na,only hypnotic at a usual dose in the case of severe insomnia,na,na,na,na,na,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37213,Placebo,na,na,na,na,43.33,na,na,24,na,na,16,na,na,tick,tick,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,12,na,na,0,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Dyspepsia=1;
Increased anxiety=1;
Sweating=1;
Hypotension=2;
Tiredness=1;",na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,9.90,23-58,na,na,5,na,na,na,na,na,na,na,na,na,na,na,na,na,87999081.0,Continuous,107639.0,113613446.0,1.0,13669974.0,0.0,13670000.0,HAMD 17 anxiety factor,1829.0,weeks,6,6 weeks,37213.0,0.0,Placebo,,Botte (1992),% reduction from baseline ,24.0,14.0,0.0,0.0,Placebo,HAM-D
87999081,Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression.,Acta psychiatrica Belgica,Botte (1992),1992,"Botte L, Evrard J L, Gilles C, Stenier P, and Wolfrum C (1992) Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression.. Acta psychiatrica Belgica 92(6), 355-69",Botte,na,na,1992,na,tick,na,tick,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"Patients were selected on the basis of a diagnosis of depression according to the International Classification of Disease (ICD, 1975): unipolar depression (296.1) or neurotic depression (300.4).",na,"Patients with schizophrenia, psycho-organic syndrome, drug or alcohol abuse or clear suicidal risk, severe organic disease were excluded. ",na,na,na,na,na,na,na,na,na,na,na,na,unipolar depression or neurotic depression,tick,tick,na,only hypnotic at a usual dose in the case of severe insomnia,na,na,na,na,na,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37213,Placebo,na,na,na,na,43.33,na,na,24,na,na,16,na,na,tick,tick,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,12,na,na,0,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Dyspepsia=1;
Increased anxiety=1;
Sweating=1;
Hypotension=2;
Tiredness=1;",na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,9.90,23-58,na,na,5,na,na,na,na,na,na,na,na,na,na,na,na,na,87999081.0,Continuous,109435.0,113613446.0,1.0,13669974.0,0.0,13670000.0,HAM-D 17 anxiety factor,1828.0,weeks,0,0 weeks,37213.0,0.0,Placebo,,Botte (1992),missing,24.0,99999.0,99999.0,0.0,Placebo,HAM-D
87999081,Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression.,Acta psychiatrica Belgica,Botte (1992),1992,"Botte L, Evrard J L, Gilles C, Stenier P, and Wolfrum C (1992) Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression.. Acta psychiatrica Belgica 92(6), 355-69",Botte,na,na,1992,na,tick,na,tick,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"Patients were selected on the basis of a diagnosis of depression according to the International Classification of Disease (ICD, 1975): unipolar depression (296.1) or neurotic depression (300.4).",na,"Patients with schizophrenia, psycho-organic syndrome, drug or alcohol abuse or clear suicidal risk, severe organic disease were excluded. ",na,na,na,na,na,na,na,na,na,na,na,na,unipolar depression or neurotic depression,tick,tick,na,only hypnotic at a usual dose in the case of severe insomnia,na,na,na,na,na,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37214,Moclobemide,na,na,na,na,51.39,na,na,23,na,na,13,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,3,na,na,1,na,na,na,na,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,"Insomnia=4;
Increased anxiety=2;
Dyspepsia=2;
Diarrhea=2;
Agitation=1;
Weight gain=1;
Dizziness=1;
Headache=1;
Blurred vision=1;
Constipation=1;
Menstrual disturbances=1;",na,200mg,tick,600mg,6 weeks,300.00mg,600.00mg,na,na,na,na,na,na,na,na,tick,na,na,na,3/ day,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,12.69,20-75,na,na,11,na,na,tick,tick,na,na,na,na,na,na,na,na,na,87999081.0,Continuous,107638.0,113613446.0,1.0,13669968.0,0.0,13670000.0,HAMD 17 - anxiety factor,1829.0,weeks,6,6 weeks,37214.0,0.0,Moclobemide,,Botte (1992),% reduction from baseline ,23.0,10.0,0.0,0.0,Moclobemide,HAM-D
87999081,Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression.,Acta psychiatrica Belgica,Botte (1992),1992,"Botte L, Evrard J L, Gilles C, Stenier P, and Wolfrum C (1992) Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression.. Acta psychiatrica Belgica 92(6), 355-69",Botte,na,na,1992,na,tick,na,tick,tick,tick,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"Patients were selected on the basis of a diagnosis of depression according to the International Classification of Disease (ICD, 1975): unipolar depression (296.1) or neurotic depression (300.4).",na,"Patients with schizophrenia, psycho-organic syndrome, drug or alcohol abuse or clear suicidal risk, severe organic disease were excluded. ",na,na,na,na,na,na,na,na,na,na,na,na,unipolar depression or neurotic depression,tick,tick,na,only hypnotic at a usual dose in the case of severe insomnia,na,na,na,na,na,tick,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,37214,Moclobemide,na,na,na,na,51.39,na,na,23,na,na,13,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,3,na,na,1,na,na,na,na,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,"Insomnia=4;
Increased anxiety=2;
Dyspepsia=2;
Diarrhea=2;
Agitation=1;
Weight gain=1;
Dizziness=1;
Headache=1;
Blurred vision=1;
Constipation=1;
Menstrual disturbances=1;",na,200mg,tick,600mg,6 weeks,300.00mg,600.00mg,na,na,na,na,na,na,na,na,tick,na,na,na,3/ day,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,12.69,20-75,na,na,11,na,na,tick,tick,na,na,na,na,na,na,na,na,na,87999081.0,Continuous,109436.0,113613446.0,1.0,13669968.0,0.0,13670000.0,HAM-D 17 anxiety Factor,1828.0,weeks,0,0 weeks,37214.0,0.0,Moclobemide,,Botte (1992),Missing,23.0,99999.0,99999.0,0.0,Moclobemide,HAM-D
89915354,Transdermal selegiline in depression,"155th annual meeting of the american psychiatric association; 2002 may 18-23rd; philadelphia, PA, USA",Bodkin (2002),2002,"Bodkin JA (2002) Transdermal selegiline in depression. 155th annual meeting of the american psychiatric association, 2002 may 18-23rd, philadelphia, PA, and USA ,","[{'ItemDocumentId': 1064373, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Bodkin[¬e]""', 'IsFromPDF': True, 'DocTitle': 'bodkin-amsterdam-2002-transdermal-selegiline-in-major-depression-a-double-blind-placebo-controlled-parallel-group-study.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1064373, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2002;[¬e]""', 'IsFromPDF': True, 'DocTitle': 'bodkin-amsterdam-2002-transdermal-selegiline-in-major-depression-a-double-blind-placebo-controlled-parallel-group-study.pdf', 'ItemArm': ''}]",na,tick,na,tick,"[{'ItemDocumentId': 1064373, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""Supported in part by Somerset Pharmaceuticals, Inc., Tampa, Fla.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'bodkin-amsterdam-2002-transdermal-selegiline-in-major-depression-a-double-blind-placebo-controlled-parallel-group-study.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,tick,na,"adult outpatients, but not of what setting","[{'ItemDocumentId': 1064373, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""ollment. Diagnostic assessment was made us- ing the Structured Clinical Interview for DSM-IV. A score of 20 or higher on the 17-item Hamilton Depression Rating Scale was re- quired at intake; subjects whose Hamilton depression scores de- creased by 20% or more or fell below a total score of 20 during the placebo run-in period were dropped from the trial to eliminate early placebo responders.""\n""Male and female outpatients, 18 to 65 years of age, who met\nDSM-IV criteria for major depressive disorder, single episode or\nrecurrent, and who had no other primary psychiatric diagnosis\nwere eligible for enr[¬e]""', 'IsFromPDF': True, 'DocTitle': 'bodkin-amsterdam-2002-transdermal-selegiline-in-major-depression-a-double-blind-placebo-controlled-parallel-group-study.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1064373, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included failure to respond to more than one\nadequate trial of an approved antidepressant medication for the\ncurrent episode of depression, any previous manic or hypomanic\nepisode (unless clearly secondary to antidepressant therapy), pres-\nence of substance abuse disorder within the previous 6 months,\npresence of a primary psychiatric illness other than major depres-\nsion, and exposure to ECT within 90 days of initiation of the trial.""\n""In addition, pregnant and breast-feeding women were ex-\ncluded, and all women of childbearing age who were included in\nthe study were using an adequate method of birth control. Finally,\npatients were excluded who displayed any medical illness that\ncould compromise their safety or interfere with implementation\nof the protocol or interpretation of study results.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'bodkin-amsterdam-2002-transdermal-selegiline-in-major-depression-a-double-blind-placebo-controlled-parallel-group-study.pdf', 'ItemArm': ''}]",na,na,na,tick,na,177,106.00,na,na,na,na,na,"[{'ItemDocumentId': 1064373, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""met\nDSM-IV criteria for major depressive disorder, single episode or\nrecurrent,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'bodkin-amsterdam-2002-transdermal-selegiline-in-major-depression-a-double-blind-placebo-controlled-parallel-group-study.pdf', 'ItemArm': ''}]",tick,na,tick,"[{'ItemDocumentId': 1064373, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Chloral hydrate, 1000 mg up to four\ntimes weekly, was permitted if needed for insomnia but was not\nallowed the evening before an evaluation.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'bodkin-amsterdam-2002-transdermal-selegiline-in-major-depression-a-double-blind-placebo-controlled-parallel-group-study.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,na,na,na,9,na,na,na,total 9 patients dropped out due to adverse events,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Bodkin, 2002a; Bodkin, 2002b",na,na,na,na,na,na,na,na,na,na,na,37144,Placebo ,na,na,na,na,43.20,na,na,88,na,na,53.00,na,na,"Caucasian=79;
Black=2;
hispanic=4;
asian=3;",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,tick,15,tick,na,5.00,na,na,na,na,"5 dropped out due to adverse events, including worsening depression",tick,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,Any adverse event=69; Body as a whole=36; Headache=19; Infection=2; Back pain=3; Pain=6; Abdominal pain=5; Cardiovascular=6; Hypertension=1; Postural hypotension=2; Palpitations=1; Tachycardia=0; Skin=21; Application site reaction=15; Nervous=28; Dizziness=5; Insomnia=6; Somnolence=4; Depression=5; Digestive=26; Diarrhea=9; Dry mouth=6; Flatulence=2; Dyspepsia=6; Respiratory=16; Pharyngitis=7; Sinusitis=1; Rhinitis=6; Urogenital=10; Urinary tract infection=5; Musculoskeletal=7; Myalgia=5,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,once daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.80,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
89915354,Transdermal selegiline in depression,"155th annual meeting of the american psychiatric association; 2002 may 18-23rd; philadelphia, PA, USA",Bodkin (2002),2002,"Bodkin JA (2002) Transdermal selegiline in depression. 155th annual meeting of the american psychiatric association, 2002 may 18-23rd, philadelphia, PA, and USA ,","[{'ItemDocumentId': 1064373, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Bodkin[¬e]""', 'IsFromPDF': True, 'DocTitle': 'bodkin-amsterdam-2002-transdermal-selegiline-in-major-depression-a-double-blind-placebo-controlled-parallel-group-study.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1064373, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2002;[¬e]""', 'IsFromPDF': True, 'DocTitle': 'bodkin-amsterdam-2002-transdermal-selegiline-in-major-depression-a-double-blind-placebo-controlled-parallel-group-study.pdf', 'ItemArm': ''}]",na,tick,na,tick,"[{'ItemDocumentId': 1064373, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 7:\n[¬s]""Supported in part by Somerset Pharmaceuticals, Inc., Tampa, Fla.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'bodkin-amsterdam-2002-transdermal-selegiline-in-major-depression-a-double-blind-placebo-controlled-parallel-group-study.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,tick,na,tick,na,"adult outpatients, but not of what setting","[{'ItemDocumentId': 1064373, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""ollment. Diagnostic assessment was made us- ing the Structured Clinical Interview for DSM-IV. A score of 20 or higher on the 17-item Hamilton Depression Rating Scale was re- quired at intake; subjects whose Hamilton depression scores de- creased by 20% or more or fell below a total score of 20 during the placebo run-in period were dropped from the trial to eliminate early placebo responders.""\n""Male and female outpatients, 18 to 65 years of age, who met\nDSM-IV criteria for major depressive disorder, single episode or\nrecurrent, and who had no other primary psychiatric diagnosis\nwere eligible for enr[¬e]""', 'IsFromPDF': True, 'DocTitle': 'bodkin-amsterdam-2002-transdermal-selegiline-in-major-depression-a-double-blind-placebo-controlled-parallel-group-study.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1064373, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Exclusion criteria included failure to respond to more than one\nadequate trial of an approved antidepressant medication for the\ncurrent episode of depression, any previous manic or hypomanic\nepisode (unless clearly secondary to antidepressant therapy), pres-\nence of substance abuse disorder within the previous 6 months,\npresence of a primary psychiatric illness other than major depres-\nsion, and exposure to ECT within 90 days of initiation of the trial.""\n""In addition, pregnant and breast-feeding women were ex-\ncluded, and all women of childbearing age who were included in\nthe study were using an adequate method of birth control. Finally,\npatients were excluded who displayed any medical illness that\ncould compromise their safety or interfere with implementation\nof the protocol or interpretation of study results.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'bodkin-amsterdam-2002-transdermal-selegiline-in-major-depression-a-double-blind-placebo-controlled-parallel-group-study.pdf', 'ItemArm': ''}]",na,na,na,tick,na,177,106.00,na,na,na,na,na,"[{'ItemDocumentId': 1064373, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""met\nDSM-IV criteria for major depressive disorder, single episode or\nrecurrent,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'bodkin-amsterdam-2002-transdermal-selegiline-in-major-depression-a-double-blind-placebo-controlled-parallel-group-study.pdf', 'ItemArm': ''}]",tick,na,tick,"[{'ItemDocumentId': 1064373, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Chloral hydrate, 1000 mg up to four\ntimes weekly, was permitted if needed for insomnia but was not\nallowed the evening before an evaluation.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'bodkin-amsterdam-2002-transdermal-selegiline-in-major-depression-a-double-blind-placebo-controlled-parallel-group-study.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,na,na,na,9,na,na,na,total 9 patients dropped out due to adverse events,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Bodkin, 2002a; Bodkin, 2002b",na,na,na,na,na,na,na,na,na,na,na,37145,Selegiline,na,na,na,na,41.40,na,na,89.00,na,na,53.00,na,na,"caucasian=85;
black=2;
hispanic=2;
asian=0;",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,10,tick,na,4.00,na,na,na,tick,4 patients dropped out due to adverse events including due to worsening depression,tick,tick,na,na,na,tick,na,na,na,tick,na,na,na,na,na,na,na,na,Any adverse event=78; Body as a whole=40; Headache=20; Infection=8; Back pain=5; Pain=4; Abdominal pain=3; Cardiovascular=3; Hypertension=0; Postural hypotension=1; Palpitations=0; Tachycardia=1; Skin=39; Application site reaction=32; Nervous=25; Dizziness=7; Insomnia=6; Somnolence=6; Depression=1; Digestive=23; Diarrhea=8; Dry mouth=8; Flatulence=5; Dyspepsia=3; Respiratory=14; Pharyngitis=5; Sinusitis=5; Rhinitis=4; Urogenital=12; Urinary tract infection=6; Musculoskeletal=4; Myalgia=2,na,na,20.00mg,20.00mg,6 weeks,na,20.00mg,na,na,na,na,na,na,na,na,na,na,na,na,once daily,na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.90,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87997624,"Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study.",Journal of neurology,Benes (2011),2011,"Benes Heike, Mattern Wolfgang, Peglau Ines, Dreykluft Tillmann, Bergmann Lars, Hansen Corinna, Kohnen Ralf, Banik Norbert, Schoen S W, and Hornyak Magdolna (2011) Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study.. Journal of neurology 258(6), 1046-54 DOI: https://dx.doi.org/10.1007/s00415-010-5879-7","[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Benes[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2011[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Germany[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 8:\n[¬s]""The study was sponsored by GlaxoSmithKline\nResearch and Development and GlaxoSmithKline Germany.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients aged 18–80 years with moderate to severe idio-\npathic RLS and at least mild depressive symptoms were\nincluded. Diagnosis of RLS was based on the Interna-\ntional RLS Study Group diagnosis criteria [1] as assessed\nwith the RLS Diagnostic Index [24]. Patients had a score\nof C15 on the International RLS Severity Scale (IRLS)\n[25] and of C11 (‘‘deﬁnite persistant RLS’’) on the RLS\nDiagnostic Index [24]. The severity of RLS was rated by\nthe investigators as moderate to severe and the patients\nhad either experienced C15 nights with symptoms of RLS\nin the previous 4 weeks or, if receiving treatment at\nscreening, reported that they had symptoms of this fre-\nquency before treatment. In nights with RLS symptoms,\npatients had slept less than 6 hours per night. All patients\nhad at least mild depressive symptoms indicated by C12\npoints on the Montgomery–Asberg Depression Rating\nScale [26].[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients suffering from secondary RLS (e.g., caused by\nrenal insufﬁciency or iron insufﬁciency with baseline\nserum ferritin level \\10 ng/ml), other movement or pri-\nmary sleep disorders, and patients requiring treatment for\nRLS during the daytime (from 10 a.m. to 6 p.m.) were\nexcluded. At screening, the Mini-International Neuropsy-\nchiatric Interview (MINI) [27] was performed and patients\nwith a clinically relevant DSM-IV psychiatric disorder like\nschizophrenia, bipolar disorder, or substance abuse with the\nexception of a secondary depression (due to RLS as judged\nby the investigator) were excluded. Further exclusion cri-\nteria were current or anamnestic suicidality and shift work.\nPatients who were pregnant, not using effective contra-\nception or suffering from medical conditions that would\naffect assessment (e.g., independent pain syndromes) were\nalso excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,tick,na,na,266,tick,na,na,tick,tick,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""at least mild depressive symptoms[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]","RLS. [{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""moderate to severe idio-\npathic RLS[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""2007[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,18 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,Benes 2011,na,na,na,na,na,na,na,na,na,na,na,37181,Placebo,na,na,na,na,59.5,na,na,67,na,na,45,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,tick,29,na,na,6,na,na,na,na,na,na,na,na,"flexible until week7, then fixed: participants dropped if dose couldn't be tolerated",tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Nausea=5
Headache=9
Fatigue=4
Dizziness=2
Vomiting=0
Abdominal pain=0
Hyperhidrosis=1
Diarrhea=0
Peripheral edema=1",na,na,na,na,12 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1 per day,na,na,na,na,na,na,na,na,na,NA,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.3,na,na,na,26,na,na,0,na,na,na,na,na,na,na,na,na,na,87997624.0,Continuous,106936.0,113308374.0,1.0,13669974.0,0.0,13669990.0,MADRS total score	,1807.0,weeks,0,0 weeks,37181.0,0.0,Placebo,,Benes (2011),,60.0,18.4,4.6,0.0,Placebo,MADRS
87997624,"Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study.",Journal of neurology,Benes (2011),2011,"Benes Heike, Mattern Wolfgang, Peglau Ines, Dreykluft Tillmann, Bergmann Lars, Hansen Corinna, Kohnen Ralf, Banik Norbert, Schoen S W, and Hornyak Magdolna (2011) Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study.. Journal of neurology 258(6), 1046-54 DOI: https://dx.doi.org/10.1007/s00415-010-5879-7","[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Benes[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2011[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Germany[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 8:\n[¬s]""The study was sponsored by GlaxoSmithKline\nResearch and Development and GlaxoSmithKline Germany.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients aged 18–80 years with moderate to severe idio-\npathic RLS and at least mild depressive symptoms were\nincluded. Diagnosis of RLS was based on the Interna-\ntional RLS Study Group diagnosis criteria [1] as assessed\nwith the RLS Diagnostic Index [24]. Patients had a score\nof C15 on the International RLS Severity Scale (IRLS)\n[25] and of C11 (‘‘deﬁnite persistant RLS’’) on the RLS\nDiagnostic Index [24]. The severity of RLS was rated by\nthe investigators as moderate to severe and the patients\nhad either experienced C15 nights with symptoms of RLS\nin the previous 4 weeks or, if receiving treatment at\nscreening, reported that they had symptoms of this fre-\nquency before treatment. In nights with RLS symptoms,\npatients had slept less than 6 hours per night. All patients\nhad at least mild depressive symptoms indicated by C12\npoints on the Montgomery–Asberg Depression Rating\nScale [26].[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients suffering from secondary RLS (e.g., caused by\nrenal insufﬁciency or iron insufﬁciency with baseline\nserum ferritin level \\10 ng/ml), other movement or pri-\nmary sleep disorders, and patients requiring treatment for\nRLS during the daytime (from 10 a.m. to 6 p.m.) were\nexcluded. At screening, the Mini-International Neuropsy-\nchiatric Interview (MINI) [27] was performed and patients\nwith a clinically relevant DSM-IV psychiatric disorder like\nschizophrenia, bipolar disorder, or substance abuse with the\nexception of a secondary depression (due to RLS as judged\nby the investigator) were excluded. Further exclusion cri-\nteria were current or anamnestic suicidality and shift work.\nPatients who were pregnant, not using effective contra-\nception or suffering from medical conditions that would\naffect assessment (e.g., independent pain syndromes) were\nalso excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,tick,na,na,266,tick,na,na,tick,tick,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""at least mild depressive symptoms[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]","RLS. [{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""moderate to severe idio-\npathic RLS[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""2007[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,18 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,Benes 2011,na,na,na,na,na,na,na,na,na,na,na,37181,Placebo,na,na,na,na,59.5,na,na,67,na,na,45,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,tick,29,na,na,6,na,na,na,na,na,na,na,na,"flexible until week7, then fixed: participants dropped if dose couldn't be tolerated",tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Nausea=5
Headache=9
Fatigue=4
Dizziness=2
Vomiting=0
Abdominal pain=0
Hyperhidrosis=1
Diarrhea=0
Peripheral edema=1",na,na,na,na,12 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,1 per day,na,na,na,na,na,na,na,na,na,NA,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.3,na,na,na,26,na,na,0,na,na,na,na,na,na,na,na,na,na,87997624.0,Continuous,106937.0,113308374.0,1.0,13669974.0,0.0,13669990.0,MADRS total score	,1808.0,weeks,12,12 weeks,37181.0,0.0,Placebo,,Benes (2011),,60.0,12.1,7.1,0.0,Placebo,MADRS
87997624,"Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study.",Journal of neurology,Benes (2011),2011,"Benes Heike, Mattern Wolfgang, Peglau Ines, Dreykluft Tillmann, Bergmann Lars, Hansen Corinna, Kohnen Ralf, Banik Norbert, Schoen S W, and Hornyak Magdolna (2011) Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study.. Journal of neurology 258(6), 1046-54 DOI: https://dx.doi.org/10.1007/s00415-010-5879-7","[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Benes[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2011[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Germany[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 8:\n[¬s]""The study was sponsored by GlaxoSmithKline\nResearch and Development and GlaxoSmithKline Germany.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients aged 18–80 years with moderate to severe idio-\npathic RLS and at least mild depressive symptoms were\nincluded. Diagnosis of RLS was based on the Interna-\ntional RLS Study Group diagnosis criteria [1] as assessed\nwith the RLS Diagnostic Index [24]. Patients had a score\nof C15 on the International RLS Severity Scale (IRLS)\n[25] and of C11 (‘‘deﬁnite persistant RLS’’) on the RLS\nDiagnostic Index [24]. The severity of RLS was rated by\nthe investigators as moderate to severe and the patients\nhad either experienced C15 nights with symptoms of RLS\nin the previous 4 weeks or, if receiving treatment at\nscreening, reported that they had symptoms of this fre-\nquency before treatment. In nights with RLS symptoms,\npatients had slept less than 6 hours per night. All patients\nhad at least mild depressive symptoms indicated by C12\npoints on the Montgomery–Asberg Depression Rating\nScale [26].[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients suffering from secondary RLS (e.g., caused by\nrenal insufﬁciency or iron insufﬁciency with baseline\nserum ferritin level \\10 ng/ml), other movement or pri-\nmary sleep disorders, and patients requiring treatment for\nRLS during the daytime (from 10 a.m. to 6 p.m.) were\nexcluded. At screening, the Mini-International Neuropsy-\nchiatric Interview (MINI) [27] was performed and patients\nwith a clinically relevant DSM-IV psychiatric disorder like\nschizophrenia, bipolar disorder, or substance abuse with the\nexception of a secondary depression (due to RLS as judged\nby the investigator) were excluded. Further exclusion cri-\nteria were current or anamnestic suicidality and shift work.\nPatients who were pregnant, not using effective contra-\nception or suffering from medical conditions that would\naffect assessment (e.g., independent pain syndromes) were\nalso excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,tick,na,na,266,tick,na,na,tick,tick,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""at least mild depressive symptoms[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]","RLS. [{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""moderate to severe idio-\npathic RLS[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""2007[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,18 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,Benes 2011,na,na,na,na,na,na,na,na,na,na,na,37182,Ropinirole,na,na,na,na,58.2,na,na,198,na,na,144,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,tick,54,na,na,35,na,na,tick,tick,tick,tick,na,na,"flexible until week7, then fixed: participants dropped if dose couldn't be tolerated",tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Nausea=64
Headache=39
Fatigue=25
Dizziness=17
Vomiting=14
Abdominal pain=7
Hyperhidrosis=7
Diarrhea=6
Peripheral edema=6",na,tick,1.9 mg,tick,12 weeks,0.5 mg,4 mg,na,na,na,na,na,na,tick,na,na,na,tick,na,1 per day,na,na,na,na,na,na,na,na,na,back pain=1; pulmonary embolism=1; nausea=1; vomiting due to overdose=1; bronchitis=1; abortion=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.4,na,na,na,123,na,na,6,na,na,na,na,na,na,na,na,na,na,87997624.0,Continuous,106934.0,113308374.0,1.0,13669979.0,0.0,13669990.0,MADRS total score ,1807.0,weeks,0,0 weeks,37182.0,0.0,Ropinirole,,Benes (2011),,171.0,18.8,5.2,0.0,Ropinirole,MADRS
87997624,"Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study.",Journal of neurology,Benes (2011),2011,"Benes Heike, Mattern Wolfgang, Peglau Ines, Dreykluft Tillmann, Bergmann Lars, Hansen Corinna, Kohnen Ralf, Banik Norbert, Schoen S W, and Hornyak Magdolna (2011) Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study.. Journal of neurology 258(6), 1046-54 DOI: https://dx.doi.org/10.1007/s00415-010-5879-7","[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Benes[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2011[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Germany[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 8:\n[¬s]""The study was sponsored by GlaxoSmithKline\nResearch and Development and GlaxoSmithKline Germany.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients aged 18–80 years with moderate to severe idio-\npathic RLS and at least mild depressive symptoms were\nincluded. Diagnosis of RLS was based on the Interna-\ntional RLS Study Group diagnosis criteria [1] as assessed\nwith the RLS Diagnostic Index [24]. Patients had a score\nof C15 on the International RLS Severity Scale (IRLS)\n[25] and of C11 (‘‘deﬁnite persistant RLS’’) on the RLS\nDiagnostic Index [24]. The severity of RLS was rated by\nthe investigators as moderate to severe and the patients\nhad either experienced C15 nights with symptoms of RLS\nin the previous 4 weeks or, if receiving treatment at\nscreening, reported that they had symptoms of this fre-\nquency before treatment. In nights with RLS symptoms,\npatients had slept less than 6 hours per night. All patients\nhad at least mild depressive symptoms indicated by C12\npoints on the Montgomery–Asberg Depression Rating\nScale [26].[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients suffering from secondary RLS (e.g., caused by\nrenal insufﬁciency or iron insufﬁciency with baseline\nserum ferritin level \\10 ng/ml), other movement or pri-\nmary sleep disorders, and patients requiring treatment for\nRLS during the daytime (from 10 a.m. to 6 p.m.) were\nexcluded. At screening, the Mini-International Neuropsy-\nchiatric Interview (MINI) [27] was performed and patients\nwith a clinically relevant DSM-IV psychiatric disorder like\nschizophrenia, bipolar disorder, or substance abuse with the\nexception of a secondary depression (due to RLS as judged\nby the investigator) were excluded. Further exclusion cri-\nteria were current or anamnestic suicidality and shift work.\nPatients who were pregnant, not using effective contra-\nception or suffering from medical conditions that would\naffect assessment (e.g., independent pain syndromes) were\nalso excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,tick,na,na,266,tick,na,na,tick,tick,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""at least mild depressive symptoms[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]","RLS. [{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""moderate to severe idio-\npathic RLS[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,tick,tick,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,tick,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1063292, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 4:\n[¬s]""2007[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Benes.pdf', 'ItemArm': ''}]",na,na,18 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,Benes 2011,na,na,na,na,na,na,na,na,na,na,na,37182,Ropinirole,na,na,na,na,58.2,na,na,198,na,na,144,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,tick,54,na,na,35,na,na,tick,tick,tick,tick,na,na,"flexible until week7, then fixed: participants dropped if dose couldn't be tolerated",tick,na,na,na,na,na,na,na,na,na,na,na,na,na,"Nausea=64
Headache=39
Fatigue=25
Dizziness=17
Vomiting=14
Abdominal pain=7
Hyperhidrosis=7
Diarrhea=6
Peripheral edema=6",na,tick,1.9 mg,tick,12 weeks,0.5 mg,4 mg,na,na,na,na,na,na,tick,na,na,na,tick,na,1 per day,na,na,na,na,na,na,na,na,na,back pain=1; pulmonary embolism=1; nausea=1; vomiting due to overdose=1; bronchitis=1; abortion=1,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.4,na,na,na,123,na,na,6,na,na,na,na,na,na,na,na,na,na,87997624.0,Continuous,106935.0,113308374.0,1.0,13669979.0,0.0,13669990.0,MADRS total score	,1808.0,weeks,12,12 weeks,37182.0,0.0,Ropinirole,,Benes (2011),,171.0,8.7,6.9,0.0,Ropinirole,MADRS
87999673,Effects of anti-depressant drugs on psychodynamics.,Psychosomatics,Bellak (1966),1966,"Bellak L, and Rosenberg S (1966) Effects of anti-depressant drugs on psychodynamics.. Psychosomatics 7(2), 106-14","[{'ItemDocumentId': 1063072, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""BELLAK[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0033318266721781-main.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1063072, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1966[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0033318266721781-main.pdf', 'ItemArm': ''}]",na,USA,tick,na,"[{'ItemDocumentId': 1063072, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""This studv was carried out with tht\' partial support\nof a grant, MH10994 by the Pharmacology Division,\nNational Institutl\' of Mental Health, Dt\'pt. of Health,\nEducation, & WeUare.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0033318266721781-main.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,"[{'ItemDocumentId': 1063072, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""he or she met certain criteria, as follows:\n1. Age: Between 18 and 55 years.\n2. Extent of depression: Score between 20\nand 40 on the Depth of Depression Inventory,\nDDI, (2) indicating the presence of a moder-\nately deep depression.\n3. No ECT within the preceding six months.\n4. No psychotropic medication within the\npreceding 30 days.\n5. Manifest symptomatology of depression,\nregardless of what other diagnostic group""\n""might be involved, provided that physical\nillness was excluded.\n6. Ability to read and taite in English.\n7. Only patients who, in the normal course\nof events, would have received anti-depres-\nsants as the first choice of treatment were to\nbe included.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0033318266721781-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063072, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""3. No ECT within the preceding six months.\n4. No psychotropic medication within the\npreceding 30 days.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0033318266721781-main.pdf', 'ItemArm': ''}]",tick,na,33.40,na,na,75,41,na,na,tick,tick,na,"[{'ItemDocumentId': 1063072, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""depressed patients[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0033318266721781-main.pdf', 'ItemArm': ''}]",tick,na,tick,none,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,18 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Bellak, 1966",tick,tick,na,na,na,na,na,na,na,na,na,37210,Placebo,na,na,na,na,tick,tick,na,25,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,1,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999673,Effects of anti-depressant drugs on psychodynamics.,Psychosomatics,Bellak (1966),1966,"Bellak L, and Rosenberg S (1966) Effects of anti-depressant drugs on psychodynamics.. Psychosomatics 7(2), 106-14","[{'ItemDocumentId': 1063072, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""BELLAK[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0033318266721781-main.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1063072, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1966[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0033318266721781-main.pdf', 'ItemArm': ''}]",na,USA,tick,na,"[{'ItemDocumentId': 1063072, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""This studv was carried out with tht\' partial support\nof a grant, MH10994 by the Pharmacology Division,\nNational Institutl\' of Mental Health, Dt\'pt. of Health,\nEducation, & WeUare.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0033318266721781-main.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,tick,tick,na,na,na,"[{'ItemDocumentId': 1063072, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""he or she met certain criteria, as follows:\n1. Age: Between 18 and 55 years.\n2. Extent of depression: Score between 20\nand 40 on the Depth of Depression Inventory,\nDDI, (2) indicating the presence of a moder-\nately deep depression.\n3. No ECT within the preceding six months.\n4. No psychotropic medication within the\npreceding 30 days.\n5. Manifest symptomatology of depression,\nregardless of what other diagnostic group""\n""might be involved, provided that physical\nillness was excluded.\n6. Ability to read and taite in English.\n7. Only patients who, in the normal course\nof events, would have received anti-depres-\nsants as the first choice of treatment were to\nbe included.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0033318266721781-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1063072, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""3. No ECT within the preceding six months.\n4. No psychotropic medication within the\npreceding 30 days.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0033318266721781-main.pdf', 'ItemArm': ''}]",tick,na,33.40,na,na,75,41,na,na,tick,tick,na,"[{'ItemDocumentId': 1063072, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""depressed patients[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-S0033318266721781-main.pdf', 'ItemArm': ''}]",tick,na,tick,none,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,18 months,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"Bellak, 1966",tick,tick,na,na,na,na,na,na,na,na,na,37211,Phenelzine,na,na,na,na,tick,tick,na,25,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,0,na,na,0,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,tick,tick,tick,na,tick,tick,tick,na,tick,na,tick,na,tick,na,tick,na,tick,tick,na,tick,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999050,"A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study.",Erratum in: Psychopharmacology (Berl) 1993;111(3):389-90,Bakish (1992),1992,"Bakish D, Bradwejn J, Nair N, McClure J, Remick R, and Bulger L (1992) A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study.. Erratum in: Psychopharmacology (Berl) 1993, and111(3):389-90 106 Suppl, S98-101","[{'ItemDocumentId': 1050650, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Bakish[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Bakish D et al. - 1992 - A comparison of moclobemide, amitriptyline and pla.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050650, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1992[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Bakish D et al. - 1992 - A comparison of moclobemide, amitriptyline and pla.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050650, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Canada[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Bakish D et al. - 1992 - A comparison of moclobemide, amitriptyline and pla.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,Described as outpatients but not sure from which setting,"[{'ItemDocumentId': 1050650, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Out-patients of either sex, aged 18 65 years, suffering from a major\ndepressive episode, according to DSM III-R and scoring a mini-\nmum of 18 points on the 17-item Hamilton Depression Scale\n(HAM-D) were included. Patients had to weigh within 20% of\nthe norm of their height.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Bakish D et al. - 1992 - A comparison of moclobemide, amitriptyline and pla.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050650, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""The main exclusion criteria were high\nsuicidal risk, depression associated with mood-incongruent psy-\nchotic features, manic or acute confusional states, significant or-\nganic disease, alcohol or drug abuse and recent treatment with\nMAO inhibitors (within the past 2 weeks), tricyclic antidepressants\n(within the past week) or electroconvulsive treatment (within the\npast 6 months). Women with childbearing potential who were not\nusing an effective form of contraception (oral contraceptives) and\nwomen who were pregnant or lactating were also excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Bakish D et al. - 1992 - A comparison of moclobemide, amitriptyline and pla.pdf', 'ItemArm': ''}]",na,na,na,na,na,114 for arms of interest (173 in total),na,na,na,na,na,na,"[{'ItemDocumentId': 1050650, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major\ndepression according to DSM III-R criteria[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Bakish D et al. - 1992 - A comparison of moclobemide, amitriptyline and pla.pdf', 'ItemArm': ''}]","1x bipolar disorder 1x dysthymia. [{'ItemDocumentId': 1050650, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""All patients were diagnosed as suffering from major\ndepression according to DSM III-R criteria, with two\nexceptions; one patient with bipolar disorder in the de-\npressive phase and one with a major depressive episode\nsuperimposed on dysthymia.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Bakish D et al. - 1992 - A comparison of moclobemide, amitriptyline and pla.pdf', 'ItemArm': ''}]",na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,"[{'ItemDocumentId': 1050650, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Con-\ncomitant psychotropic medication was prohibited, with the excep-\ntion of occasional use of chloral hydrate or low doses of a short-\nacting benzodiazepine for severe insomnia or agitation.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Bakish D et al. - 1992 - A comparison of moclobemide, amitriptyline and pla.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,Bakish 1992,na,na,na,na,na,na,na,na,na,na,na,37197,moclobemide,na,na,na,na,42,na,na,58,na,na,26,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,17,na,na,3,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,492mg,600mg,6 weeks,tick,600mg,na,na,tick,na,na,na,na,na,na,na,tick,na,"2 capsules, 3 times a day",na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.9,na,na,na,47,na,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999050,"A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study.",Erratum in: Psychopharmacology (Berl) 1993;111(3):389-90,Bakish (1992),1992,"Bakish D, Bradwejn J, Nair N, McClure J, Remick R, and Bulger L (1992) A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study.. Erratum in: Psychopharmacology (Berl) 1993, and111(3):389-90 106 Suppl, S98-101","[{'ItemDocumentId': 1050650, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Bakish[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Bakish D et al. - 1992 - A comparison of moclobemide, amitriptyline and pla.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050650, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1992[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Bakish D et al. - 1992 - A comparison of moclobemide, amitriptyline and pla.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050650, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Canada[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Bakish D et al. - 1992 - A comparison of moclobemide, amitriptyline and pla.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,Described as outpatients but not sure from which setting,"[{'ItemDocumentId': 1050650, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Out-patients of either sex, aged 18 65 years, suffering from a major\ndepressive episode, according to DSM III-R and scoring a mini-\nmum of 18 points on the 17-item Hamilton Depression Scale\n(HAM-D) were included. Patients had to weigh within 20% of\nthe norm of their height.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Bakish D et al. - 1992 - A comparison of moclobemide, amitriptyline and pla.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050650, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""The main exclusion criteria were high\nsuicidal risk, depression associated with mood-incongruent psy-\nchotic features, manic or acute confusional states, significant or-\nganic disease, alcohol or drug abuse and recent treatment with\nMAO inhibitors (within the past 2 weeks), tricyclic antidepressants\n(within the past week) or electroconvulsive treatment (within the\npast 6 months). Women with childbearing potential who were not\nusing an effective form of contraception (oral contraceptives) and\nwomen who were pregnant or lactating were also excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Bakish D et al. - 1992 - A comparison of moclobemide, amitriptyline and pla.pdf', 'ItemArm': ''}]",na,na,na,na,na,114 for arms of interest (173 in total),na,na,na,na,na,na,"[{'ItemDocumentId': 1050650, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major\ndepression according to DSM III-R criteria[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Bakish D et al. - 1992 - A comparison of moclobemide, amitriptyline and pla.pdf', 'ItemArm': ''}]","1x bipolar disorder 1x dysthymia. [{'ItemDocumentId': 1050650, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""All patients were diagnosed as suffering from major\ndepression according to DSM III-R criteria, with two\nexceptions; one patient with bipolar disorder in the de-\npressive phase and one with a major depressive episode\nsuperimposed on dysthymia.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Bakish D et al. - 1992 - A comparison of moclobemide, amitriptyline and pla.pdf', 'ItemArm': ''}]",na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,"[{'ItemDocumentId': 1050650, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Con-\ncomitant psychotropic medication was prohibited, with the excep-\ntion of occasional use of chloral hydrate or low doses of a short-\nacting benzodiazepine for severe insomnia or agitation.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Bakish D et al. - 1992 - A comparison of moclobemide, amitriptyline and pla.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,Bakish 1992,na,na,na,na,na,na,na,na,na,na,na,37198,placebo,na,na,na,na,44,na,na,56,na,na,20,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,27,na,na,5,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"2 capsules, 3 times a day",na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.7,na,na,na,45,na,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87998463,"A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.",The Journal of clinical psychiatry,Amsterdam (2003),2003,"Amsterdam Jay D (2003) A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.. The Journal of clinical psychiatry 64(2), 208-14","[{'ItemDocumentId': 1050661, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Amsterdam,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam Jay D - 2003 - A double-blind, placebo-controlled trial of the sa.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050661, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2002[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam Jay D - 2003 - A double-blind, placebo-controlled trial of the sa.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050661, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""This study was supported by a research grant from Somerset\nPharmaceuticals, Inc., Tampa, Fla.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam Jay D - 2003 - A double-blind, placebo-controlled trial of the sa.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,tick,na,na,na,tick,na,na,na,na,"[{'ItemDocumentId': 1050661, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""All patients had a primary diagnosis of major depressive disorder, single or recurrent episode, as defined by DSM-IV crite- ria.23 A score = 20 on the Hamilton Rating Scale for De- pression (HAM-D)24 was required at intake;""\n""; subjects showing a decrease ≥ 20% or a fall below a total score of 20 during the placebo run-in period were dropped from the trial to eliminate early placebo responders.""\n""Three hundred sixty-five outpatients aged 18 to 65\nyears were screened at 16 investigative sites. A[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam Jay D - 2003 - A double-blind, placebo-controlled trial of the sa.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050661, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""The presence of a current medical illness with the po- tential to compromise subject safety or interfere with implementation of the protocol or interpretation of results was used as an exclusion criterion. Other exclusion crite- ria included the presence of any significant cardiac dis- ease or conduction abnormalities, hypertension (diastolic blood pressure [BP] >95 mm Hg; systolic BP >160 mm Hg), thyroid disease of less than 6 months’ stability, insu- lin-dependent diabetes mellitus, malignancy or chemo- therapy within 2 years, allergy with dermal manifesta- tion, laboratory indicators of hepatic or renal disease, or history within 2 years of head trauma, CNS surgery, or CNS disorder. Pregnant or breastfeeding women were not""\n""included; women of childbearing age were required to comply with a medically acceptable method of birth con- trol.""\n""Patients were required to be free of any psychoactive medications, including herbal preparations with pur- ported CNS activity, for 5 elimination half-lives or 2 weeks prior to study initiation, whichever was longer. Prior use of MAOIs was not allowed within 2 months of study onset.""\n""5\nPatients with a primary\nDSM-IV Axis I or Axis II diagnosis other than major\ndepressive disorder and patients with a history of manic\nor hypomanic episode or psychosis, or a history of sub-\nstance abuse within 6 months were excluded from the\ntrial.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam Jay D - 2003 - A double-blind, placebo-controlled trial of the sa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050661, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depressive disorder,\nsingle or recurrent episode[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam Jay D - 2003 - A double-blind, placebo-controlled trial of the sa.pdf', 'ItemArm': ''}]",None,na,na,"Chloral hydrate or zolpidem PRN max 2 per week
Loratadine",na,na,na,na,na,na,na,na,na,tick,na,"HAM-D-28 scores
HAM-D-17 scores",na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050661, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""8-week clinical trial[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam Jay D - 2003 - A double-blind, placebo-controlled trial of the sa.pdf', 'ItemArm': ''}]",na,"8 weeks. [{'ItemDocumentId': 1050661, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""8-week clinical trial[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam Jay D - 2003 - A double-blind, placebo-controlled trial of the sa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,tick,na,na,na,na,na,tick,na,na,na,"Amsterdam, 2003",na,na,na,na,na,na,na,na,na,na,na,37193,Selegiline,tick,na,na,tick,41.20,na,na,149,na,na,94,na,na,White=114;Black=20;Hispanic=13;Asian=1;Other=1,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,41,na,na,10,na,na,na,tick,tick,tick,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,Body as a whole=25;Asthenia=5;Headache=17;Pain abdominal=1;Cardiovascular=6;Digestive=19;Diarrhea=8.00;Dyspepsia=2;Nausea=6;Metabolic and nutritional=5;Nervous=29;Anxiety=1;Dizziness=6;Dry mouth=8;Insomnia=11;Somnolence=3;Respiratory=5;Skin=56;Application-site reaction=47;Rash=5;Special sense=9;Urogenital=3,na,tick,tick,tick,8 weeks,20.00mg,20.00mg,na,na,na,na,na,na,tick,na,tick,na,tick,na,"1 per day

. [{'ItemDocumentId': 1050661, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were instructed not to remove or change\ntheir patch on the day of study appointments, so that the\noccurrence and severity of any application-site reactions\ncould be assessed[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam Jay D - 2003 - A double-blind, placebo-controlled trial of the sa.pdf', 'ItemArm': 'Selegiline'}]",na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,11.60,19-64,na,na,93,na,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87998463,"A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.",The Journal of clinical psychiatry,Amsterdam (2003),2003,"Amsterdam Jay D (2003) A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.. The Journal of clinical psychiatry 64(2), 208-14","[{'ItemDocumentId': 1050661, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Amsterdam,[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam Jay D - 2003 - A double-blind, placebo-controlled trial of the sa.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1050661, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""2002[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam Jay D - 2003 - A double-blind, placebo-controlled trial of the sa.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1050661, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""This study was supported by a research grant from Somerset\nPharmaceuticals, Inc., Tampa, Fla.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam Jay D - 2003 - A double-blind, placebo-controlled trial of the sa.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,tick,na,na,na,tick,na,na,na,na,"[{'ItemDocumentId': 1050661, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""All patients had a primary diagnosis of major depressive disorder, single or recurrent episode, as defined by DSM-IV crite- ria.23 A score = 20 on the Hamilton Rating Scale for De- pression (HAM-D)24 was required at intake;""\n""; subjects showing a decrease ≥ 20% or a fall below a total score of 20 during the placebo run-in period were dropped from the trial to eliminate early placebo responders.""\n""Three hundred sixty-five outpatients aged 18 to 65\nyears were screened at 16 investigative sites. A[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam Jay D - 2003 - A double-blind, placebo-controlled trial of the sa.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1050661, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""The presence of a current medical illness with the po- tential to compromise subject safety or interfere with implementation of the protocol or interpretation of results was used as an exclusion criterion. Other exclusion crite- ria included the presence of any significant cardiac dis- ease or conduction abnormalities, hypertension (diastolic blood pressure [BP] >95 mm Hg; systolic BP >160 mm Hg), thyroid disease of less than 6 months’ stability, insu- lin-dependent diabetes mellitus, malignancy or chemo- therapy within 2 years, allergy with dermal manifesta- tion, laboratory indicators of hepatic or renal disease, or history within 2 years of head trauma, CNS surgery, or CNS disorder. Pregnant or breastfeeding women were not""\n""included; women of childbearing age were required to comply with a medically acceptable method of birth con- trol.""\n""Patients were required to be free of any psychoactive medications, including herbal preparations with pur- ported CNS activity, for 5 elimination half-lives or 2 weeks prior to study initiation, whichever was longer. Prior use of MAOIs was not allowed within 2 months of study onset.""\n""5\nPatients with a primary\nDSM-IV Axis I or Axis II diagnosis other than major\ndepressive disorder and patients with a history of manic\nor hypomanic episode or psychosis, or a history of sub-\nstance abuse within 6 months were excluded from the\ntrial.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam Jay D - 2003 - A double-blind, placebo-controlled trial of the sa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,na,na,na,na,na,na,"[{'ItemDocumentId': 1050661, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""major depressive disorder,\nsingle or recurrent episode[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam Jay D - 2003 - A double-blind, placebo-controlled trial of the sa.pdf', 'ItemArm': ''}]",None,na,na,"Chloral hydrate or zolpidem PRN max 2 per week
Loratadine",na,na,na,na,na,na,na,na,na,tick,na,"HAM-D-28 scores
HAM-D-17 scores",na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1050661, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""8-week clinical trial[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam Jay D - 2003 - A double-blind, placebo-controlled trial of the sa.pdf', 'ItemArm': ''}]",na,"8 weeks. [{'ItemDocumentId': 1050661, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""8-week clinical trial[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam Jay D - 2003 - A double-blind, placebo-controlled trial of the sa.pdf', 'ItemArm': ''}]",na,na,na,na,na,na,tick,na,na,na,na,na,tick,na,na,na,"Amsterdam, 2003",na,na,na,na,na,na,na,na,na,na,na,37194,Placebo,tick,na,na,tick,43.50,na,na,152,na,na,99,na,na,White=134;Black=8;Hispanic=8;Asian=1;Other=1,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,41,na,na,8,na,na,na,tick,tick,tick,tick,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,Body as a whole=34.00;Asthenia=5;Headache=19.00;Pain abdominal=6;Cardiovascular=4;Digestive=20  ;Diarrhea=9;Dyspepsia=5;Nausea=6;Metabolic and nutritional=6;Nervous=34;Anxiety=7;Dizziness=4;Dry mouth=8;Insomnia=6;Somnolence=5;Respiratory=4;Skin=26;Application-site reaction=23;Rash=1;Special sense=6;Urogenital=5,na,na,na,na,8 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"1 per day
. [{'ItemDocumentId': 1050661, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were instructed not to remove or change\ntheir patch on the day of study appointments, so that the\noccurrence and severity of any application-site reactions\ncould be assessed.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam Jay D - 2003 - A double-blind, placebo-controlled trial of the sa.pdf', 'ItemArm': 'Placebo'}]",na,na,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,10.00,19-65,na,na,76,na,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
90055468,"Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression",Pharmacopsychiatry,Amsterdam (1989),1989,"Amsterdam J D, Dunner D L, Fabre L F, Kiev A, Rush A J, and Goodman L I (1989) Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression. Pharmacopsychiatry 22(4), 137-143 DOI: http://dx.doi.org/10.1055/s-2007-1014596","[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Amsterdam[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1989[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 6:\n[¬s]""This research was partially supported by a grant-in-\naid from Sanofi Research[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""All patients had moderate to severe depression for\nwhich antidepressant medication appeared the treatment of choice.\nAll met DSM III criteria (American Psychiatric Association, 1980) for\nmajor depressive episode. Each had a minimum score > 17 on the 17-\nitem H DRS at baseline and after the drug free elimination period.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded from the study if they had\nsymptoms or a history of schizophrenia, manic-depressive illness,\ndementia, mental retardation, or substance abuse. Additionally, sub\xad\njects with significant medical illness which might contraindicate the\nuse of minaprine therapy, or those with clinically significant hepatic,\nrenal, endocrine or cardiovascular disorder were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,na,na,na,na,tick,na,na,na,tick,tick,na,Major depression,tick,tick,na,Not permitted aside from chloral hydrate when necessary for severe insomnia.,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,Amsterdam  1989,na,na,na,na,na,na,na,na,na,na,na,37344,Minaprine 100mg,na,na,na,na,41,na,na,34,na,na,12,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,14,na,na,4,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,93mg,tick,4 weeks,100mg,400mg,na,na,na,na,tick,na,tick,na,na,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,12,na,na,na,6,na,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
90055468,"Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression",Pharmacopsychiatry,Amsterdam (1989),1989,"Amsterdam J D, Dunner D L, Fabre L F, Kiev A, Rush A J, and Goodman L I (1989) Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression. Pharmacopsychiatry 22(4), 137-143 DOI: http://dx.doi.org/10.1055/s-2007-1014596","[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Amsterdam[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1989[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 6:\n[¬s]""This research was partially supported by a grant-in-\naid from Sanofi Research[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""All patients had moderate to severe depression for\nwhich antidepressant medication appeared the treatment of choice.\nAll met DSM III criteria (American Psychiatric Association, 1980) for\nmajor depressive episode. Each had a minimum score > 17 on the 17-\nitem H DRS at baseline and after the drug free elimination period.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded from the study if they had\nsymptoms or a history of schizophrenia, manic-depressive illness,\ndementia, mental retardation, or substance abuse. Additionally, sub\xad\njects with significant medical illness which might contraindicate the\nuse of minaprine therapy, or those with clinically significant hepatic,\nrenal, endocrine or cardiovascular disorder were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,na,na,na,na,tick,na,na,na,tick,tick,na,Major depression,tick,tick,na,Not permitted aside from chloral hydrate when necessary for severe insomnia.,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,Amsterdam  1989,na,na,na,na,na,na,na,na,na,na,na,37346,Minaprine 200mg,na,na,na,na,37,na,na,39,na,na,25,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,16,na,na,2,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,186mg,tick,4 weeks,100mg,400mg,na,na,na,na,na,na,tick,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,13,na,na,na,22,na,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
90055468,"Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression",Pharmacopsychiatry,Amsterdam (1989),1989,"Amsterdam J D, Dunner D L, Fabre L F, Kiev A, Rush A J, and Goodman L I (1989) Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression. Pharmacopsychiatry 22(4), 137-143 DOI: http://dx.doi.org/10.1055/s-2007-1014596","[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Amsterdam[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1989[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 6:\n[¬s]""This research was partially supported by a grant-in-\naid from Sanofi Research[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""All patients had moderate to severe depression for\nwhich antidepressant medication appeared the treatment of choice.\nAll met DSM III criteria (American Psychiatric Association, 1980) for\nmajor depressive episode. Each had a minimum score > 17 on the 17-\nitem H DRS at baseline and after the drug free elimination period.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded from the study if they had\nsymptoms or a history of schizophrenia, manic-depressive illness,\ndementia, mental retardation, or substance abuse. Additionally, sub\xad\njects with significant medical illness which might contraindicate the\nuse of minaprine therapy, or those with clinically significant hepatic,\nrenal, endocrine or cardiovascular disorder were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,na,na,na,na,tick,na,na,na,tick,tick,na,Major depression,tick,tick,na,Not permitted aside from chloral hydrate when necessary for severe insomnia.,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,Amsterdam  1989,na,na,na,na,na,na,na,na,na,na,na,37347,Minaprine 300mg,na,na,na,na,40,na,na,43,na,na,22,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,23,na,na,1,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,279mg,tick,4 weeks,100mg,400mg,na,na,na,na,na,na,tick,na,na,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,12,na,na,na,22,na,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
90055468,"Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression",Pharmacopsychiatry,Amsterdam (1989),1989,"Amsterdam J D, Dunner D L, Fabre L F, Kiev A, Rush A J, and Goodman L I (1989) Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression. Pharmacopsychiatry 22(4), 137-143 DOI: http://dx.doi.org/10.1055/s-2007-1014596","[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Amsterdam[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1989[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 6:\n[¬s]""This research was partially supported by a grant-in-\naid from Sanofi Research[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""All patients had moderate to severe depression for\nwhich antidepressant medication appeared the treatment of choice.\nAll met DSM III criteria (American Psychiatric Association, 1980) for\nmajor depressive episode. Each had a minimum score > 17 on the 17-\nitem H DRS at baseline and after the drug free elimination period.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded from the study if they had\nsymptoms or a history of schizophrenia, manic-depressive illness,\ndementia, mental retardation, or substance abuse. Additionally, sub\xad\njects with significant medical illness which might contraindicate the\nuse of minaprine therapy, or those with clinically significant hepatic,\nrenal, endocrine or cardiovascular disorder were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,na,na,na,na,tick,na,na,na,tick,tick,na,Major depression,tick,tick,na,Not permitted aside from chloral hydrate when necessary for severe insomnia.,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,Amsterdam  1989,na,na,na,na,na,na,na,na,na,na,na,37348,Minaprine 400mg,na,na,na,na,37,na,na,37,na,na,22,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,14,tick,na,2,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,352mg,tick,4 weeks,100mg,400mg,na,na,na,na,na,na,tick,na,na,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,13,na,na,na,24,na,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
90055468,"Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression",Pharmacopsychiatry,Amsterdam (1989),1989,"Amsterdam J D, Dunner D L, Fabre L F, Kiev A, Rush A J, and Goodman L I (1989) Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression. Pharmacopsychiatry 22(4), 137-143 DOI: http://dx.doi.org/10.1055/s-2007-1014596","[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Amsterdam[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""1989[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,USA,na,na,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 6:\n[¬s]""This research was partially supported by a grant-in-\naid from Sanofi Research[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,tick,tick,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""All patients had moderate to severe depression for\nwhich antidepressant medication appeared the treatment of choice.\nAll met DSM III criteria (American Psychiatric Association, 1980) for\nmajor depressive episode. Each had a minimum score > 17 on the 17-\nitem H DRS at baseline and after the drug free elimination period.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1085387, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 2:\n[¬s]""Patients were excluded from the study if they had\nsymptoms or a history of schizophrenia, manic-depressive illness,\ndementia, mental retardation, or substance abuse. Additionally, sub\xad\njects with significant medical illness which might contraindicate the\nuse of minaprine therapy, or those with clinically significant hepatic,\nrenal, endocrine or cardiovascular disorder were excluded.[¬e]""', 'IsFromPDF': True, 'DocTitle': 'Amsterdam 1989.pdf', 'ItemArm': ''}]",na,na,na,na,na,tick,na,na,na,tick,tick,na,Major depression,tick,tick,na,Not permitted aside from chloral hydrate when necessary for severe insomnia.,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,Amsterdam  1989,na,na,na,na,na,na,na,na,na,na,na,37349,Placebo,na,na,na,na,39,na,na,37,na,na,18,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,12,na,na,tick,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,tick,4 weeks,tick,tick,na,na,tick,na,tick,na,tick,na,tick,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,13,na,na,na,1,na,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999115,Life satisfaction and psychosocial functioning in chronic depression: effect of acute treatment with antidepressants.,Journal of affective disorders,Agosti (1991),1991,"Agosti V, Stewart J W, and Quitkin F M (1991) Life satisfaction and psychosocial functioning in chronic depression: effect of acute treatment with antidepressants.. Journal of affective disorders 23(1), 35-41","Agosti. [{'ItemDocumentId': 1051806, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Agosti""\n""i ‘[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-016503279190033O-main.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1051806, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1991)[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-016503279190033O-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1051806, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""U.S.A.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-016503279190033O-main.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,na,na,tick,tick,na,na,tick,na,na,na,tick,na,tick,na,na,"The subjects were physically healthy, non-melancholic chronically depressed outpatients. DSM-III diagnoses included: dysthymic disorder, major depression without melancholia, and major depression superimposed on dysthymic disorder. Study entrance requirements were  DSM-III depressive disorder and mood reactivity. In order to focus on chronically depressed patients, we chose the subgroup of 61 patients who had an onset prior to age 21 and were rated prospectively by an experienced clinician as depressed either most or virtually all of the time throughout adulthood.",na,tick,tick,na,na,na,na,na,na,na,na,na,tick,na,Non melancholic chronic depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,"Agosti, 1991",na,8.9,na,na,na,na,na,na,na,na,na,37125,Phenelzine,tick,na,na,tick,tick,tick,na,10,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,tick,tick,6 weeks,60.00mg,90.00mg,na,na,na,na,60mg,na,tick,na,tick,na,tick,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999115,Life satisfaction and psychosocial functioning in chronic depression: effect of acute treatment with antidepressants.,Journal of affective disorders,Agosti (1991),1991,"Agosti V, Stewart J W, and Quitkin F M (1991) Life satisfaction and psychosocial functioning in chronic depression: effect of acute treatment with antidepressants.. Journal of affective disorders 23(1), 35-41","Agosti. [{'ItemDocumentId': 1051806, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Agosti""\n""i ‘[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-016503279190033O-main.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1051806, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1991)[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-016503279190033O-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1051806, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""U.S.A.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-016503279190033O-main.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,na,na,tick,tick,na,na,tick,na,na,na,tick,na,tick,na,na,"The subjects were physically healthy, non-melancholic chronically depressed outpatients. DSM-III diagnoses included: dysthymic disorder, major depression without melancholia, and major depression superimposed on dysthymic disorder. Study entrance requirements were  DSM-III depressive disorder and mood reactivity. In order to focus on chronically depressed patients, we chose the subgroup of 61 patients who had an onset prior to age 21 and were rated prospectively by an experienced clinician as depressed either most or virtually all of the time throughout adulthood.",na,tick,tick,na,na,na,na,na,na,na,na,na,tick,na,Non melancholic chronic depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,"Agosti, 1991",na,8.9,na,na,na,na,na,na,na,na,na,37126,Placebo,tick,na,na,tick,tick,tick,na,23,na,na,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
87999115,Life satisfaction and psychosocial functioning in chronic depression: effect of acute treatment with antidepressants.,Journal of affective disorders,Agosti (1991),1991,"Agosti V, Stewart J W, and Quitkin F M (1991) Life satisfaction and psychosocial functioning in chronic depression: effect of acute treatment with antidepressants.. Journal of affective disorders 23(1), 35-41","Agosti. [{'ItemDocumentId': 1051806, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""Agosti""\n""i ‘[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-016503279190033O-main.pdf', 'ItemArm': ''}]",na,na,"[{'ItemDocumentId': 1051806, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""1991)[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-016503279190033O-main.pdf', 'ItemArm': ''}]",na,"[{'ItemDocumentId': 1051806, 'TextFrom': 0, 'TextTo': 0, 'Text': 'Page 1:\n[¬s]""U.S.A.[¬e]""', 'IsFromPDF': True, 'DocTitle': '1-s2.0-016503279190033O-main.pdf', 'ItemArm': ''}]",na,na,tick,tick,tick,tick,na,tick,na,na,tick,tick,na,na,tick,na,na,na,tick,na,tick,na,na,"The subjects were physically healthy, non-melancholic chronically depressed outpatients. DSM-III diagnoses included: dysthymic disorder, major depression without melancholia, and major depression superimposed on dysthymic disorder. Study entrance requirements were  DSM-III depressive disorder and mood reactivity. In order to focus on chronically depressed patients, we chose the subgroup of 61 patients who had an onset prior to age 21 and were rated prospectively by an experienced clinician as depressed either most or virtually all of the time throughout adulthood.",na,tick,tick,na,na,na,na,na,na,na,na,na,tick,na,Non melancholic chronic depression,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,na,na,na,na,"Agosti, 1991",na,8.9,na,na,na,na,na,na,na,na,na,37353,Selegiline (L-deprenyl),tick,na,na,tick,tick,tick,na,12,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,tick,tick,na,tick,tick,na,na,na,na,na,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,40mg,tick,40mg,6 weeks,40.00mg,40.00mg,na,na,na,na,na,na,na,na,tick,na,na,na,tick,na,tick,na,na,na,na,na,na,na,tick,tick,na,tick,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
89915739,"A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder",International clinical psychopharmacology,A multicentre comparative... (1994),1994,"(1994) A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder. International clinical psychopharmacology 9(2), 109‐113",UK moclobemide study group,tick,na,1994,na,United Kingdom,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,na,"Two hundred and forty-nine subjects (111 male, 138 female) aged 18-65 with a diagnosis of a major depressive episode as defined by DSM-III-R criteria entered the study. At entry participants were required to have a minimum score of 16 on the 17-item Hamilton Depression Rating Scale (HDRS).",na,"Patient at risk of suicide, with mood-incongruent symptoms, confusional states or whose depression was due to another psychiatric illness or organic factor were excluded from the trial. Patients with any significant physical disease, or a history of increased intraocular pressure, glaucoma or micturition disturbances were also excluded. Patients who had received electroconvulsive therapy (ECT) or an investigational drug within the last 4 weeks, an MAOI within the last 2 weeks or other marketed antidepressants, lithium or carbamazepine within the last 7 days were excluded.",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive episode as defined by DSM-III-R,None,na,na,"benzodiazepine
temazepam PRN",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"UK moclobemide study group, 1994",na,na,na,na,na,na,na,na,na,na,na,37169,Placebo,na,na,na,tick,tick,tick,na,54,na,na,tick,tick,na,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,29,na,na,6,na,na,na,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Manic=1;Dry mouth=14;Constipation=6;Suicide=1;Sweating=6,na,na,na,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,3 per day,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,
89915739,"A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder",International clinical psychopharmacology,A multicentre comparative... (1994),1994,"(1994) A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder. International clinical psychopharmacology 9(2), 109‐113",UK moclobemide study group,tick,na,1994,na,United Kingdom,na,na,tick,tick,tick,tick,na,tick,na,tick,na,tick,na,na,tick,na,na,na,na,na,na,tick,na,"Two hundred and forty-nine subjects (111 male, 138 female) aged 18-65 with a diagnosis of a major depressive episode as defined by DSM-III-R criteria entered the study. At entry participants were required to have a minimum score of 16 on the 17-item Hamilton Depression Rating Scale (HDRS).",na,"Patient at risk of suicide, with mood-incongruent symptoms, confusional states or whose depression was due to another psychiatric illness or organic factor were excluded from the trial. Patients with any significant physical disease, or a history of increased intraocular pressure, glaucoma or micturition disturbances were also excluded. Patients who had received electroconvulsive therapy (ECT) or an investigational drug within the last 4 weeks, an MAOI within the last 2 weeks or other marketed antidepressants, lithium or carbamazepine within the last 7 days were excluded.",na,na,na,na,na,na,na,na,na,na,na,na,Major depressive episode as defined by DSM-III-R,None,na,na,"benzodiazepine
temazepam PRN",na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,tick,tick,na,6 weeks,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,na,"UK moclobemide study group, 1994",na,na,na,na,na,na,na,na,na,na,na,37170,Moclobemide,tick,na,na,tick,tick,tick,na,56,na,na,tick,tick,na,tick,tick,na,na,tick,na,na,tick,na,na,na,na,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,27,na,na,2,na,na,na,tick,tick,tick,tick,na,na,tick,na,na,na,na,na,na,na,na,na,na,na,na,na,Manic=2;Dry mouth=15;Constipation=7;Suicide=1;Sweating=2,na,tick,tick,450mg,6 weeks,450.00mg,450.00mg,na,na,na,na,na,na,tick,na,tick,na,tick,na,3 per day,na,na,na,na,na,na,na,na,na,tick,na,tick,na,na,na,na,na,na,na,na,na,na,na,tick,na,na,tick,na,tick,na,tick,tick,tick,na,na,na,na,na,na,na,na,na,,,,,,,,,,,,,,,,,,,,,,,,,